{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 248,
   "metadata": {},
   "outputs": [],
   "source": [
    "base_url = 'http://technologies.unc.edu'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 249,
   "metadata": {},
   "outputs": [],
   "source": [
    "url = 'http://technologies.unc.edu/technologies?limit=288'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Read the web page into Python"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 250,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "r = requests.get(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 251,
   "metadata": {},
   "outputs": [],
   "source": [
    "# print the first 500 characters of the HTML\n",
    "#print(r.text[0:500])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Parse the HTML using Beautiful Soup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 252,
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "soup = BeautifulSoup(r.text, 'html.parser')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 253,
   "metadata": {},
   "outputs": [],
   "source": [
    "results = soup.find_all('div', attrs={'class':'technology'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 254,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200"
      ]
     },
     "execution_count": 254,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 255,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<div class=\"technology\" data-images=\"false\" id=\"technology_14919\"><h2><a href=\"/technologies/18-0149_reconstructing-detailed-textured-surface-models-from-endoscopic-videos\">Reconstructing Detailed Textured Surface Models from Endoscopic Videos</a></h2><p><strong>18-0149</strong> – <span> A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning... <a href=\"/technologies/18-0149_reconstructing-detailed-textured-surface-models-from-endoscopic-videos\">Read More</a></span></p></div>,\n",
       " <div class=\"technology\" data-images=\"false\" id=\"technology_14897\"><h2><a href=\"/technologies/19-0022_crosslinked-hyperbranched-poly-aryletherketone-membranes-for-gas-separation-at-elevated-temperature\">Crosslinked Hyperbranched Poly(aryletherketone) Membranes for Gas Separation at Elevated Temperature</a></h2><p><strong>19-0022</strong> – <span> Gas separation techniques currently use energy-intensive condensation methods. While the high chemical and thermal stability of commercially available PAEKs make them promising membrane candidates, poor solubility hinders their processability and low glass transition temperatures (~150°C) limits their applicability for high temperature separations. Soluble, reactive hyperbranched... <a href=\"/technologies/19-0022_crosslinked-hyperbranched-poly-aryletherketone-membranes-for-gas-separation-at-elevated-temperature\">Read More</a></span></p></div>,\n",
       " <div class=\"technology\" data-images=\"false\" id=\"technology_14870\"><h2><a href=\"/technologies/17-0081_microwave-synthesis-of-polymeric-nanoparticles-of-controlled-size-for-drug-delivery\">Microwave Synthesis of Polymeric Nanoparticles of Controlled Size for Drug Delivery</a></h2><p><strong>17-0081</strong> – <span> The use of nanoparticles in enhanced delivery of drugs to cancerous tissue can minimize the toxicity and side effects attributed to chemotherapy. The present method, Zapped Assembly of Polymeric (ZAP) nanoparticles (NP), uses microwave irradiation of block copolymers to produce nanoparticles of controlled size in a scalable manner. Block copolymers, such as poly(lactic-co-glycolic acid)... <a href=\"/technologies/17-0081_microwave-synthesis-of-polymeric-nanoparticles-of-controlled-size-for-drug-delivery\">Read More</a></span></p></div>]"
      ]
     },
     "execution_count": 255,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results[0:3]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## First result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 256,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<div class=\"technology\" data-images=\"false\" id=\"technology_14919\"><h2><a href=\"/technologies/18-0149_reconstructing-detailed-textured-surface-models-from-endoscopic-videos\">Reconstructing Detailed Textured Surface Models from Endoscopic Videos</a></h2><p><strong>18-0149</strong> – <span> A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning... <a href=\"/technologies/18-0149_reconstructing-detailed-textured-surface-models-from-endoscopic-videos\">Read More</a></span></p></div>"
      ]
     },
     "execution_count": 256,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "first_result = results[0]\n",
    "first_result"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Technology Number"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 257,
   "metadata": {},
   "outputs": [],
   "source": [
    "technology_number = first_result.find('strong').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 258,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'18-0149'"
      ]
     },
     "execution_count": 258,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "technology_number"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Title"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 259,
   "metadata": {},
   "outputs": [],
   "source": [
    "title = first_result.find('h2').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 260,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Reconstructing Detailed Textured Surface Models from Endoscopic Videos'"
      ]
     },
     "execution_count": 260,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "title"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Description"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 261,
   "metadata": {},
   "outputs": [],
   "source": [
    "description = first_result.find('span').text[0:-10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 262,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning...'"
      ]
     },
     "execution_count": 262,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "description"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Publication link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 263,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_link = base_url + first_result.find('a')['href']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 264,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'http://technologies.unc.edu/technologies/18-0149_reconstructing-detailed-textured-surface-models-from-endoscopic-videos'"
      ]
     },
     "execution_count": 264,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_link"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## First Url"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 265,
   "metadata": {},
   "outputs": [],
   "source": [
    "first_url = pub_link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 266,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'http://technologies.unc.edu/technologies/18-0149_reconstructing-detailed-textured-surface-models-from-endoscopic-videos'"
      ]
     },
     "execution_count": 266,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "first_url"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 267,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_request = requests.get(first_url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 268,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_soup = BeautifulSoup(pub_request.text, 'html.parser')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_results = pub_soup.find_all('div', attrs={'class':'technology'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 270,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Reconstructing Detailed Textured Surface Models from Endoscopic Videos</h1><em>Technology #18-0149</em></div>,\n",
       " <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0149/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0149.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585179\"><a href=\"/inventors/18585179_stephen-pizer\">Stephen Pizer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186551\"><em>US Patent Pending</em></dd></dl></div><div class=\"content\"><p>A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning radiotherapy for throat cancer and improving colonoscopic screening. The generalizability of the system to other organs in the body also increases its potential. </p><p><b>Related Publications:</b></p><ul>\n",
       " <li><a href=\"https://www.sciencedirect.com/science/article/pii/S0016510718307272\" target=\"_blank\">Missed Colonic Surface Area at Colonoscopy Can Be Calculated with Computerized 3D Reconstruction</a></li>McGill, Sarah K., et al. “Sa1930 MISSED COLONIC SURFACE AREA AT COLONOSCOPY CAN BE CALCULATED WITH COMPUTERIZED 3D RECONSTRUCTION.” Gastrointestinal Endoscopy 87.6 (2018): AB254.</ul></div></div>]"
      ]
     },
     "execution_count": 270,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_results[0:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 325,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>REALMS (Registration Efficiency and Accuracy through Learning Metric on Shape): A Fast, Interpolative Method for 2D/3D Deformable Image Registration</h1><em>Technology #13-0043</em></div>"
      ]
     },
     "execution_count": 325,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_results[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 326,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0043/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0043.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584897\"><a href=\"/inventors/18584897_chen-rui-chou\">Chen-Rui Chou</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186417\"><em><a href=\"http://google.com/patents/US9495746\" target=\"_blank\">US Patent 9,495,746</a></em></dd></dl></div><div class=\"content\"><p>A real-time method for visualizing tumors in the body, allowing for the most accurate and direct delivery of radiation treatment. This approach minimizes the indirect treatment of healthy tissue that can occur as the body moves during respiration and could significantly improve the outcome for patients with terminal prognoses, such as lung cancer.<br/><strong>Advantages:</strong><br/>•  REALMS significantly improves the margin of error that occurs with current 2D/3D deformable image registration methods<br/>•  With a 3D reference image, and a scale space of deformations that occur during respiration, REALMS performs interpolative and extremely fast (a few milliseconds) calculations to accurately predict the relative position of tumors, providing a better quality image with which doctors can improve radiation treatment of cancer via image-guided radiotherapy</p><p><b>Related Publications:</b></p><ul>\n",
       "<li><a href=\"http://link.springer.com/chapter/10.1007/978-3-642-36620-8_1\" target=\"_blank\">Real-Time 2D/3D Deformable Registration Using Metric Learning</a></li>Springer Link: Part of the Lecture Notes in Computer Science book series (LNCS, volume 7766) 10.1007/978-3-642-36620-8_1</ul></div></div>"
      ]
     },
     "execution_count": 326,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_results[1]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Title"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 327,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_title = pub_results[0].find('h1').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 328,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'REALMS (Registration Efficiency and Accuracy through Learning Metric on Shape): A Fast, Interpolative Method for 2D/3D Deformable Image Registration'"
      ]
     },
     "execution_count": 328,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_title"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 329,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_tech_number = pub_results[0].find('em').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 330,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Technology #13-0043'"
      ]
     },
     "execution_count": 330,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_tech_number"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 331,
   "metadata": {},
   "outputs": [],
   "source": [
    "(t, number) = pub_tech_number.split(' ')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 332,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'#13-0043'"
      ]
     },
     "execution_count": 332,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "number"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Full Description"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 280,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_res_1 = pub_results[1].find('div', class_='content').contents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<p>A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning radiotherapy for throat cancer and improving colonoscopic screening. The generalizability of the system to other organs in the body also increases its potential. </p>,\n",
       " <p><b>Related Publications:</b></p>,\n",
       " <ul>\n",
       " <li><a href=\"https://www.sciencedirect.com/science/article/pii/S0016510718307272\" target=\"_blank\">Missed Colonic Surface Area at Colonoscopy Can Be Calculated with Computerized 3D Reconstruction</a></li>McGill, Sarah K., et al. “Sa1930 MISSED COLONIC SURFACE AREA AT COLONOSCOPY CAN BE CALCULATED WITH COMPUTERIZED 3D RECONSTRUCTION.” Gastrointestinal Endoscopy 87.6 (2018): AB254.</ul>]"
      ]
     },
     "execution_count": 281,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_res_1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_full_description = pub_results[1].find('div', class_='content').contents[0].text[0:-1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning radiotherapy for throat cancer and improving colonoscopic screening. The generalizability of the system to other organs in the body also increases its potential.'"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_full_description"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 284,
   "metadata": {},
   "outputs": [],
   "source": [
    "rel_pub_link = pub_results[1].find('div', class_='content').contents[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 285,
   "metadata": {},
   "outputs": [],
   "source": [
    "rel_pub_link = rel_pub_link.find('a')['href']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 286,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://www.sciencedirect.com/science/article/pii/S0016510718307272'"
      ]
     },
     "execution_count": 286,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "rel_pub_link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 287,
   "metadata": {},
   "outputs": [],
   "source": [
    "rel_pub_title = pub_results[1].find('div', class_='content').contents[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 288,
   "metadata": {},
   "outputs": [],
   "source": [
    "rel_pub_title = rel_pub_title.find('li').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 289,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Missed Colonic Surface Area at Colonoscopy Can Be Calculated with Computerized 3D Reconstruction'"
      ]
     },
     "execution_count": 289,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "rel_pub_title"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract Research Inventor"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 290,
   "metadata": {},
   "outputs": [],
   "source": [
    "research_inventor = pub_results[1].find('dd', class_='inventor').find('a').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 291,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Stephen Pizer'"
      ]
     },
     "execution_count": 291,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "research_inventor"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Research Inventor Link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 292,
   "metadata": {},
   "outputs": [],
   "source": [
    "research_inventor_link = base_url + pub_results[1].find('dd', class_='inventor').find('a')['href']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 293,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'http://technologies.unc.edu/inventors/18585179_stephen-pizer'"
      ]
     },
     "execution_count": 293,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "research_inventor_link"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patent Protection"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 294,
   "metadata": {},
   "outputs": [],
   "source": [
    "patent_protection = pub_results[1].find('div', class_='information').find('dl').contents[7].text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 295,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'US Patent Pending'"
      ]
     },
     "execution_count": 295,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patent_protection"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Managed By"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 296,
   "metadata": {},
   "outputs": [],
   "source": [
    "managed_by = pub_results[1].find('dd', class_='manager').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 297,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Peter Liao Commercialization Manager 919.843.5028'"
      ]
     },
     "execution_count": 297,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "managed_by"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Managed By Link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 298,
   "metadata": {},
   "outputs": [],
   "source": [
    "managed_by_link = pub_results[1].find('dd', class_='manager').find('a')['href']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 299,
   "metadata": {},
   "outputs": [],
   "source": [
    "managed_by_link = base_url + managed_by_link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'http://technologies.unc.edu/managers/358_peter-liao'"
      ]
     },
     "execution_count": 300,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "managed_by_link"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Categories"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 301,
   "metadata": {},
   "outputs": [],
   "source": [
    "pub_categories = pub_results[1].find('li', class_='category').text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 302,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Life SciencesImaging'"
      ]
     },
     "execution_count": 302,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pub_categories"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Script"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 303,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4"
      ]
     },
     "execution_count": 303,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "2+2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 304,
   "metadata": {},
   "outputs": [],
   "source": [
    "urls = []\n",
    "for result in results:\n",
    "    url = base_url + result.find('a')['href']\n",
    "    urls.append((url))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 311,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "df_url = pd.DataFrame(urls, columns=['url'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 312,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(200, 1)"
      ]
     },
     "execution_count": 312,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_url.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 313,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>url</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>http://technologies.unc.edu/technologies/18-01...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>http://technologies.unc.edu/technologies/19-00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>http://technologies.unc.edu/technologies/17-00...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>http://technologies.unc.edu/technologies/16-01...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>http://technologies.unc.edu/technologies/18-00...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                 url\n",
       "0  http://technologies.unc.edu/technologies/18-01...\n",
       "1  http://technologies.unc.edu/technologies/19-00...\n",
       "2  http://technologies.unc.edu/technologies/17-00...\n",
       "3  http://technologies.unc.edu/technologies/16-01...\n",
       "4  http://technologies.unc.edu/technologies/18-00..."
      ]
     },
     "execution_count": 313,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_url.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 314,
   "metadata": {},
   "outputs": [],
   "source": [
    "records = []\n",
    "for url in urls:\n",
    "    pub_request = requests.get(url)\n",
    "    pub_soup = BeautifulSoup(pub_request.text, 'html.parser')\n",
    "    pub_results = pub_soup.find_all('div', attrs={'class':'technology'})\n",
    "    \n",
    "    records.append((pub_results))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 315,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Reconstructing Detailed Textured Surface Models from Endoscopic Videos</h1><em>Technology #18-0149</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0149/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0149.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585179\"><a href=\"/inventors/18585179_stephen-pizer\">Stephen Pizer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186551\"><em>US Patent Pending</em></dd></dl></div><div class=\"content\"><p>A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning radiotherapy for throat cancer and improving colonoscopic screening. The generalizability of the system to other organs in the body also increases its potential. </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.sciencedirect.com/science/article/pii/S0016510718307272\" target=\"_blank\">Missed Colonic Surface Area at Colonoscopy Can Be Calculated with Computerized 3D Reconstruction</a></li>McGill, Sarah K., et al. “Sa1930 MISSED COLONIC SURFACE AREA AT COLONOSCOPY CAN BE CALCULATED WITH COMPUTERIZED 3D RECONSTRUCTION.” Gastrointestinal Endoscopy 87.6 (2018): AB254.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Crosslinked Hyperbranched Poly(aryletherketone) Membranes for Gas Separation at Elevated Temperature</h1><em>Technology #19-0022</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/19-0022/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/19-0022.pdf\">Download Printable PDF</a></p><dl><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585261\"><a href=\"/inventors/18585261_theo-dingemans\">Theo Dingemans</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186585\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Gas separation techniques currently use energy-intensive condensation methods. While the high chemical and thermal stability of commercially available PAEKs make them promising membrane candidates, poor solubility hinders their processability and low glass transition temperatures (~150°C) limits their applicability for high temperature separations. Soluble, reactive hyperbranched poly(aryletherketone)s (HBPAEKs) have been developed that are easily processed into thin membranes that demonstrate gas separation at high temperatures over extended periods. Crosslinking of the HBPEAKs increases the glass transition temperatures (~250°C) of the resulting thin films and tunable free volume, enabling their use as gas separation membranes with performance that exceeds current state-of-the-art membranes.<br/><br/><br/>Advantages:<br/>·         H2/CH4, H2/N2, and H2/CO2 separation at or near the Robeson limit<br/>·         Continuous separation of H2/N2 at 200°C for two weeks without a decrease in selectivity or permeability<br/>·         Applicable for industrial in-line gas separation at elevated temperatures<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Microwave Synthesis of Polymeric Nanoparticles of Controlled Size for Drug Delivery</h1><em>Technology #17-0081</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0081/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0081.pdf\">Download Printable PDF</a></p><dl><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585138\"><a href=\"/inventors/18585138_matthew-parrott\">Matthew Parrott</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186538\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>The use of nanoparticles in enhanced delivery of drugs to cancerous tissue can minimize the toxicity and side effects attributed to chemotherapy. The present method, Zapped Assembly of Polymeric (ZAP) nanoparticles (NP), uses microwave irradiation of block copolymers to produce nanoparticles of controlled size in a scalable manner. Block copolymers, such as poly(lactic-co-glycolic acid) (PLGA), rapidly disperse in the solvent at elevated temperatures provided by microwave heating. Upon cooling, the polymers solidify into nanoparticles through nanoprecipitation.  The resulting nanoparticles can be used to encapsulate biologically active molecules such as anti-cancer agents. This microwave-assisted synthetic platform provides the ability to rapidly develop size-specific PLGA NPs for drug delivery applications.<br/> <br/>·         Nanoparticle sizes range from sub-20 nm to 350 nm in diameter<br/>·         Tunable control of nanoparticle sizes based on the reaction parameters in microwave synthesis<br/>·         PLGA copolymer provides a hydrophilic corona with PEG to promote prolonged circulation and evasion of the reticuloendothelial system<br/><strong> </strong><br/><strong>Stage of Development: </strong>This method has been demonstrated in the laboratory. Specifically, stable PLGA5k 25 nm, PLGA10k 50 nm, and PLGA20k 100 nm NPs were synthesized at laboratory scale. The NPs were also loaded with the chemotherapeutic paclitaxel (PXL) and elicited dose-dependent cancer cell cytotoxicity.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://pubs.rsc.org/en/content/articlelanding/2019/nr/c8nr09944h#!divAbstract\" target=\"_blank\">Zapped assembly of polymeric (ZAP) nanoparticles for anti-cancer drug delivery</a></li>Nanoscale, 2019, 11, 1847</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Gamma Secretase Inhibitors Attenuate Vascular Malformations</h1><em>Technology #16-0192</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0192/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0192.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5454\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5454_orphan-rare-diseases\">Orphan &amp; Rare Diseases</a></li><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584997\"><a href=\"/inventors/18584997_julie-blatt\">Julie Blatt</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_370\"><a href=\"/managers/370_jackie-quay\">Jackie Quay</a> <div><em>Director</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186469\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Gamma secretase inhibitors (GSI) have been determined to attenuate vascular malformations by inhibiting NOTCH expression in endothelial cells.  Vascular malformations are developmental abnormalities of venous, arterial, capillary or lymphatic vessels which have significant morbidities such as pain, infection, pulmonary emboli, bleeding and even death. There is growing interest in medical management of vascular malformations, however existing treatments often cannot result in complete lesion resolution and do not produce permanent results, indicating that there is a significant need for alternative therapies. The use of GSI can provide an alternative and potent treatment for vascular formations.<br/> <br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30573741\" target=\"_blank\">Notch signaling pathway is a potential therapeutic target for extracranial vascular malformations</a></li>Sci Rep. 2018 Dec 20;8(1):17987</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Recombinant Antigens for Differential Serological Detection of Remote Zika Infection</h1><em>Technology #18-0017</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0017/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0017.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585233\"><a href=\"/inventors/18585233_aravinda-desilva\">Aravinda Desilva</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186578\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Two novel antigens have been developed for the serological diagnosis of Zika virus. Accurate diagnosis of Zika is critically important to its treatment, prevention, and further clinical research. Antibodies raised in response to other flaviviruses are often cross reactive to Zika virus, complicating serological diagnosis. Our novel recombinant antigens demonstrate lower cross reactivity as compared to other flavivirus-specific antibodies in serum collected from Zika patients, making them candidates for use in a Zika-specific immunosorbent assay.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29263206\" target=\"_blank\">Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection</a></li>J Clin Microbiol. 2018 Feb 22;56(3)</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Highly Specific and Neutralizing Therapeutic Antibodies for Zika Virus</h1><em>Technology #18-0023</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0023/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0023.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5345\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5345_antibodies\">Antibodies</a></li></ul></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585230\"><a href=\"/inventors/18585230_aravinda-desilva\">Aravinda Desilva</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186577\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p><br/>Our investigators have identified two highly specific and neutralizing antibodies isolated from a traveler naïve to all serotypes of Dengue. The antibodies (A9E and G9E) can be used against 7 different Zika virus types and react only to Zika virus and no other flaviviruses.<br/><br/>Applications:<br/>•Diagnosis and treatment of Zika virus infection.<br/>•Antibody sequences for vaccine development.<br/><br/>Advantages:<br/>•Non-reactive to Dangue and other flavivviruses.<br/>•Fully characterized binding site.<br/>•More potent and highly specific than currently available Ziki antibodies.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28978707\" target=\"_blank\">Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans</a></li>J Virol. 2017 Oct 4. pii: JVI.01469-17.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>AAV-Based Gene Therapy for Equine Osteoarthritis</h1><em>Technology #17-0041</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0041/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0041.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585156\"><a href=\"/inventors/18585156_richard-samulski\">Richard Samulski</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186547\"><em><a href=\"http://google.com/patents/WO2018035441\" target=\"_blank\">PCT Patent Application WO 2018/035441</a></em></dd></dl></div><div class=\"content\"><p>An AAV-based gene therapy has been developed to treat equine osteoarthritis (OA). Interleukin receptor antagonist protein (IL-1ra) blocks joint inflammation caused by IL-1b stimulated cells, and for this reason, it has shown promise in the treatment of OA. Our OA gene therapy cassette utilizes an optimized self-complimentary AAV to produce significant levels of IL-1ra <em>in vivo</em>. In equine models of OA, administration of this therapy resulted in the generation of therapeutic levels of IL-1ra that persisted for 8 months and demonstrated minimal to no detrimental effects in joints.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25902762\" target=\"_blank\">scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy</a></li>Gene Ther. 2015 Jul;22(7):536-45</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Light Triggered CRISPR/Cas9 for Spatial and Temporal Control of Genome Editing</h1><em>Technology #16-0095</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0095/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0095.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5313\"><a href=\"/categories/5313_agriculture-horticulture\">Agriculture &amp; Horticulture</a><ul><li class=\"category\" id=\"category_5314\"><a href=\"/categories/5313_agriculture-horticulture/5314_ag-biotech\">Ag Biotech</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585041\"><a href=\"/inventors/18585041_aravind-asokan\">Aravind Asokan</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186498\"><em><a href=\"http://google.com/patents/US20180073002\" target=\"_blank\">US Patent Pending US 2018/0073002</a></em></dd></dl></div><div class=\"content\"><p><br/>A novel, light-activated Cas9 protein has been developed for better special and temporal control of the CRISPR/Cas9 gene editing system.  The addition of a caged lysine residue keeps Cas9 dormant by default, but in the presence of light the lysine caging group falls off and Cas9 springs into action. Unlike standard CRISPR/Cas9, which has full reign over the body, our light-activated system offers precise spatial and temporal control over genetic modifications, thereby reducing the chance of off-target effects and providing exclusive targeting of the tissue of interest.<br/><strong> </strong><br/><strong>Advantages:</strong></p><ul>\n",
       "  <li>Precise spatial and temporal control of CRISPR/Cas9 activity</li>\n",
       "  <li>Reduced toxicity from off-target mutations</li>\n",
       "  </ul><strong>Applications:</strong><ul>\n",
       "  <li>Gene therapy</li>\n",
       "  <li>Genome engineering</li>\n",
       "  <li>Generating novel cell lines</li>\n",
       "  <li>Functional genomic screening</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25905628\" target=\"_blank\">Optical Control of CRISPR/Cas9 Gene Editing.</a></li>J Am Chem Soc. 2015 May 6;137(17):5642-5. doi: 10.1021/ja512664v. Epub 2015 Apr 23.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>BALB/c Latency Mouse Line</h1><em>Technology #19-0023</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/19-0023/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/19-0023.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5345\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5345_antibodies\">Antibodies</a></li><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585258\"><a href=\"/inventors/18585258_dirk-dittmer\">Dirk Dittmer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>BALB/c mice are commonly used for B cell hybridoma development because of their predictable B cell responses to various antigens. Our investigators have developed the tg801 transgenic mouse line, (BALB/c latency mice), as an alternative to the commonly used BALB/c  or BALB/c/FcgR2b KO mouse that are often used for hybridoma development. Our mouse line was created via random insertion of a synthetic transgene rather than a specific knock-out of a known gene. We believe that this mouse line is useful for companies and researchers looking to generate high quality antibodies against an antigen.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30021906\" target=\"_blank\">Kaposi’s Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections</a></li>J Virol. 2018 Sep 12;92(19).</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Wnt1 as a Therapeutic to Enhance Cardiac Repair and Increase Blood Flow in Patients with PVD</h1><em>Technology #11-0002</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0002/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0002.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584866\"><a href=\"/inventors/18584866_arjun-deb\">Arjun Deb</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186389\"><em><a href=\"http://google.com/patents/US9186388\" target=\"_blank\">US Patent US 9186388</a></em></dd></dl></div><div class=\"content\"><p>Wnt-1 has been identified as a potential new therapeutic agent to enhance cardiac repair in patients with heart ailments, and to increase blood flow in patients with peripheral vascular disease. Following acute cardiac injury, Wnt1 orchestrates a critical early repair response and disruption of downstream Wnt1 signaling leads to heart failure and death. Furthermore, studies in mice show that injection of recombinant Wnt1 protein alone or human endothelial progenitor cells (hEPCs) over expressing Wnt1 improve blood flow and capillary formation in ischemic tissues.<br/><br/><strong>Benefits:</strong></p><ul>\n",
       "  <li>Recombinant Wnt1 can be therapeutically employed for augmenting blood flow to ischemic tissues in patients with coronary artery disease, peripheral artery disease and stroke.</li>\n",
       "  <li>Targeting Wnt1 to epicardium and cardiac fibroblasts during acute cardiac injury may enhance wound healing response and reduce mortality in patients.</li>\n",
       "  <li>Approach can be synergistic with current therapies salvaging myocardium after cardiac injury.</li>\n",
       "  <li>hEPCs are already in use in clinical trials for treating heart and vascular diseases and Wnt1 can be used for enhancing the function of hEPCs prior to cell based therapy.</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21321190\" target=\"_blank\">Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner.</a></li>FASEB J. 2011 Jun;25(6):1836-43. doi: 10.1096/fj.10-172981. Epub 2011 Feb 14.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Interactive Sound Propagation in Virtual Environments</h1><em>Technology #13-0038</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0038/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0038.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584901\"><a href=\"/inventors/18584901_lakulish-antani\">Lakulish Antani</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186421\"><em><a href=\"http://google.com/patents/US9398393\" target=\"_blank\">US Patent 9,398,393</a></em></dd></dl></div><div class=\"content\"><p>This technology provides an efficient technique for modeling sound propagation effects in indoor and outdoor scenes for interactive applications. The technique generates immersive directional reverberation and reflection effects, and can easily scale to multi-channel speaker configurations. It is easy to implement and can be easily integrated into any modern game engine without significantly re-architecting the audio pipeline.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://ieeexplore.ieee.org/abstract/document/6479183\" target=\"_blank\">Aural proxies and directionally-varying reverberation for interactive sound propagation in virtual environments</a></li>Antani, Lakulish, and Dinesh Manocha. “Aural proxies and directionally-varying reverberation for interactive sound propagation in virtual environments.” IEEE transactions on visualization and computer graphics 19.4 (2013): 567-575.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Interactive Wave-Based Sound Propagation</h1><em>Technology #13-0080</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0080/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0080.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584892\"><a href=\"/inventors/18584892_ravish-mehra\">Ravish Mehra</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186413\"><em><a href=\"http://google.com/patents/US9560439\" target=\"_blank\">US Patent 9,560,439</a></em></dd></dl></div><div class=\"content\"><p>This technology provides a novel approach for incorporating dynamic source and listener directivity in a general frequency-domain, wave-based sound propagation technique. The UNC approach can automatically model wave-effects from low-frequency directional sources and can handle analytical, data-driven, rotating or dynamic directivity at runtime. The spatial sound based on listener directivity provided here can be used to enhance a user’s immersion in the virtual environment by providing binaural cues corresponding to the direction the sound is coming from, thereby enriching the experience.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://ieeexplore.ieee.org/abstract/document/6777442\" target=\"_blank\">Source and listener directivity for interactive wave-based sound propagation</a></li>Mehra, Ravish, et al. “Source and listener directivity for interactive wave-based sound propagation.” IEEE transactions on visualization and computer graphics 20.4 (2014): 495-503.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Direct-to-Indirect Acoustic Radiance Transfer</h1><em>Technology #11-0048</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0048/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0048.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584862\"><a href=\"/inventors/18584862_dinesh-manocha\">Dinesh Manocha</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186385\"><em><a href=\"http://google.com/patents/US8995675\" target=\"_blank\">US Patent 8,995,675</a></em></dd></dl></div><div class=\"content\"><p>This invention provides an efficient algorithm for simulating diffuse reflections of sound in a static scene. The UNC approach is built on advances in precomputed light transport techniques for visual rendering and uses them to develop an improved acoustic radiance transfer technique. It precomputes a direct-to-indirect acoustic transfer operator for a scene, and uses it to map direct sound incident on the surfaces of the scene to multibounce diffuse indirect sound, which is gathered at the listener to compute the final impulse response. The algorithm decouples the transfer operator from the source position so it can efficiently update the acoustic response at the listener when the source moves. <br/><br/>Video: <a href=\"http://gamma.cs.unc.edu/Sound/diffuse/2010-tvcg-video.mov\" target=\"_blank\">http://gamma.cs.unc.edu/Sound/diffuse/2010-tvcg-video.mov</a></p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://gamma.cs.unc.edu/Sound/diffuse/2010-tvcg.pdf\" target=\"_blank\">Direct-to-Indirect Acoustic Radiance Transfer</a></li>Antani, Lakulish, et al. “Direct-to-indirect acoustic radiance transfer.” IEEE Transactions on Visualization and Computer Graphics 18.2 (2012): 261-269.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Image Analysis with Deep Learning For Molecular Subtyping of Breast Cancer</h1><em>Technology #19-0010</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/19-0010/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/19-0010.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5370\"><a href=\"/categories/5362_software-information-technology/5370_health-it\">Health IT</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585262\"><a href=\"/inventors/18585262_charles-perou\">Charles Perou</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_370\"><a href=\"/managers/370_jackie-quay\">Jackie Quay</a> <div><em>Director</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>RNA-based, multi-gene molecular assays are available and widely used for patients with ER-positive/HER2-negative breast cancers. However, RNA-based genomic tests can be costly and are not available in many countries. Methods for inferring molecular subtype from histologic images may identify patients most likely to benefit from further genomic testing. To identify patients who could benefit from molecular testing based on H&amp;E-stained histologic images, we developed an image analysis approach using deep learning. Our investigators created image-based classifiers for tumor grade, ER status, PAM50 intrinsic subtype, histologic subtype, and risk of recurrence score (ROR-PT). The resulting classifiers were applied to an independent test set, and accuracy, sensitivity, and specificity of each assessed on the test set. Histologic image analysis with deep learning distinguished low-intermediate vs. high tumor grade ER status, Basal-like vs. non-Basal-like, Ductal vs. Lobular, and high vs. low-medium ROR-PT scores with good accuracy. Image-based methods could be promising for identifying patients with a greater need for further genomic testing, or in place of classically scored variables typically accomplished using human-based scoring.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30182055\" target=\"_blank\">Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype.</a></li>NPJ Breast Cancer. 2018 Sep 3;4:30</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Camera Control Unit Communications Breakout Box</h1><em>Technology #18-0145</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0145/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0145.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585181\"><a href=\"/inventors/18585181_kevin-tucker\">Kevin Tucker</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186554\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>In broadcast video technology, a camera control unit is an electronic device, usually in the form of a rack-mounted box, that connects to a video camera and to external video recording, display, and control devices. One problem with connectors provided on camera control units is that many external intercom, program voice, and tally systems require other types of connectors, such as XLR connectors to exchange signals with the CCU. Using multiple adapters can be cumbersome and unwieldy. <br/><br/>This technology provides an improved method for breaking out the signals from a multi-conductor connector of a camera control unit. UNC’s innovation includes a housing for mounting the box to a network equipment rack.<br/><br/>Advantages:</p><ul><li>Provides a self-contained, organized approach for managing multiple connections and adapters</li></ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Conserved Epitopes for Vaccination Against GII.4 Norovirus Strains</h1><em>Technology #17-0144</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0144/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0144.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585103\"><a href=\"/inventors/18585103_ralph-baric\">Ralph Baric</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186522\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Antigenic diversity within the GII.4 genotype of human norovirus is a significant hurdle to the development of cross-protective immunity after natural infection and vaccination. Our investigators have developed a method of identifying conserved GII.4 norovirus epitopes. Using this method, a conserved GII.4 antibody epitope and residues that mediate antibody access to this conserved epitope was discovered. Further development of this epitope could lead to a broadly cross-protective norovirus vaccine.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806210/pdf/mSphere.00518-17.pdf\" target=\"_blank\">Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion</a></li>mSphere. 2018 Feb 7;3(1)</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Tensegrity Wheel with Force-Based Motion</h1><em>Technology #17-0124</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0124/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0124.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5326\"><a href=\"/categories/5317_engineering-physical-sciences/5326_robotics\">Robotics</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585117\"><a href=\"/inventors/18585117_henry-goodell\">Henry Goodell</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186525\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A tensegrity wheel capable of being steered simply by applying force, has been developed. Terrestrial, long distance travel, either on Earth or a celestial body, benefits from overall weight reduction. Tensegrity structures are inherently lightweight and can facilitate weight reduction. The tensegrity wheel invented at UNC Chapel Hill is of much simpler design than previously disclosed tensegrity wheels and this unique design allows for turning simply by moment shifting and allows the structure to change positions from a rolling wheel to a standing pose for inspection or walking.<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>MTAP Inhibitors for Treatment of Airway Inflammation Associated with CF and COPD</h1><em>Technology #16-0020</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0020/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0020.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585073\"><a href=\"/inventors/18585073_charles-esther\">Charles Esther</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186510\"><em><a href=\"http://google.com/patents/US20180353511\" target=\"_blank\">US Patent Pending US 20180353511</a></em></dd></dl></div><div class=\"content\"><p>Small molecules have been identified that decreases inflammation associated with cystic fibrosis (CF) and COPD. Accumulation of the metabolite 5’-methylthioadenosine (MTA) promotes an anti-inflammatory response. However, the direct administration of MTA is not a viable therapeutic strategy due to poor pharmacokinetics. The small molecules we developed increase endogenous MTA levels by the selective inhibition of the enzyme that metabolizes MTA, MTA phosphorylase (MTAP). Our lead inhibitor, MTDIA, increases MTA plasma levels and promotes a sustained anti-inflammatory response in a mouse model of airway disease (Scnn1b-Tg) indicated by decreased levels of airway inflammatory markers (BALF neutrophil counts, KC-1 and TNF-alpha). Contrary to current therapies, this novel mode of action is expected to alleviate inflammation without obstructing host defense.<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Osseous Distractor for Cranial Reconstruction</h1><em>Technology #18-0065</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0065/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0065.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585211\"><a href=\"/inventors/18585211_nathan-davis\">Nathan Davis</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>A novel device for osseous distraction has been invented. Current osseous distractors, particularly those for cranial reconstruction, can cause scarring, skin infections and wound breakdown. These complications are often responsible for treatment failure. UNC researchers have designed a novel device that can eliminate or negate most of these problems. This new distractor has a low profile in contrast to the elevated profile of existing distractors and does not require the use of large exiting distraction screws.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Improves on current techniques by preventing scarring, skin infections, and wound breakdown</li>\n",
       "  <li>Less visible and obtrusive than currently used devices with large exiting distraction screws</li>\n",
       "  <li>Placement is highly customizable</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Using phase-changing nanodroplets to dissolve blood clots with ultrasound</h1><em>Technology #18-0123</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0123/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0123.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5589\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5589_equipment\">Equipment</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585190\"><a href=\"/inventors/18585190_paul-dayton\">Paul Dayton</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Thrombosis, or pathologic blood clot formation, causes many vascular diseases. UNC researchers have developed a new method for using ultrasound to dissolve blood clots which improves on existing thrombosis treatment practices. The technique combines ultrasound with use of nanodroplets which convert from liquid to gas when exposed to ultrasound energy. This phase change enhances the disruption of blood clots within the vasculature of a patient.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Significantly faster clot dissolution</li>\n",
       "  <li>Highly specific delivery of lytic agent</li>\n",
       "  <li>Precise control of lysis through ultrasound-induced phase change</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Nanofiber-based immunotherapeutic drug delivery specifically targeted to the atherosclerotic niche</h1><em>Technology #18-0152</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0152/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0152.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585177\"><a href=\"/inventors/18585177_melina-kibbe\">Melina Kibbe</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>A nanodrug delivery system has been developed which precisely targets controlled immunotherapeutics to the atherosclerotic niche. This system is comprised of therapeutic peptides tethered to nanofibers which self-assemble from peptide amphiphiles. These complexes are targeted specifically to atherosclerotic lesions. In addition to its specificity, the nanofiber-based delivery system stands out over current techniques because it is easily injectable and bioresorbable.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Precise targeting to atherosclerotic lesions</li>\n",
       "  <li>Easily injectable and bioresorbable</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Long-acting injectable multipurpose implants for treatment of osteoporosis</h1><em>Technology #18-0167</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0167/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0167.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5421\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5421_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585173\"><a href=\"/inventors/18585173_soumya-benhabbour\">Soumya Benhabbour</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Osteoporosis, a chronic disease associated with a decrease in bone strength and increase in bone fractures, leads to high rates of morbidity and mortality globally. UNC researchers have developed a novel long-acting, multipurpose implant as a treatment option for osteoporosis which is safer, more effective, and more versatile than current first-line therapies for osteoporosis which require frequent dosing, have severe side effects, and are unable to effectively promote bone fracture healing.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Safer and more effective than current osteoporosis treatments</li>\n",
       "  <li>Reduces need for frequent dosing</li>\n",
       "  <li>Targets a clinically important disease</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Improved removal of stimulation artifacts in intracranial electroencephalography</h1><em>Technology #18-0136</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0136/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0136.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585185\"><a href=\"/inventors/18585185_flavio-frohlich\">Flavio Frohlich</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Cortical oscillations are associated with key cognitive functions and show impairment in many psychiatric disorders. They are most effectively measured using direct cortical stimulation (DCS) in intracranial electroencephalography (iEEG). A new algorithm has been developed to remove artifacts caused by DCS when recording iEEG signal. This technique, which has been validated on simulated and human iEEG datasets, improves on existing methods for artifact removal, providing a more clear and actionable measurement of cortical oscillations.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Improves on existing methods for artifact removal in the time domain and the frequency domain</li>\n",
       "  <li>Employs unsupervised manifold learning to identify and subtract artifacts</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Novel PET tracers for predicting tumor response to immunotherapy</h1><em>Technology #17-0028</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0028/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0028.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585161\"><a href=\"/inventors/18585161_zibo-li\">Zibo Li</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186548\"><em><a href=\"http://google.com/patents/WO2017057595\" target=\"_blank\">PCT Patent Application WO 2017/057595</a></em></dd></dl></div><div class=\"content\"><p>Labeled Positron Emmision Tomography (PET) imaging tracers have been developed which can easily screen tumors for responsiveness to specific immunotherapies. This low-cost screening method prevents application of costly immunotherapy to non-responsive tumors. These novel tracers are also relevant to serotonin pathways important in diabetes and neurophysiology.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Specifically marks tumors with tumor-infiltrating immune cells, predicting response to cancer immunotherapy</li>\n",
       "  <li>Future applications include serotonin pathway research in diabetes, neurology, and insulinoma</li>\n",
       "  <li>Enables efficient, non-invasive screening and diagnosis for guiding cancer therapeutics</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Light catalyzed radiofluorination</h1><em>Technology #17-0133</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0133/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0133.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5318\"><a href=\"/categories/5317_engineering-physical-sciences/5318_chemical\">Chemical</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585112\"><a href=\"/inventors/18585112_zibo-li\">Zibo Li</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This new method of fluorinating biomolecules for PET imaging and other therapeutic applications is catalyzed by light, making it more adaptable than other fluorination methods. This allows easier fluorination of a broader range of molecules including drugs and proteins and avoids the use of potentially hazardous heavy metals.<br/><br/>Advantages:</p><ul>\n",
       "  <li>\n",
       "  <strong>Broad substrate: </strong>applicable to a wide range of drug candidates and other biomolecules</li>\n",
       "  <li>\n",
       "  <strong>Increased safety: </strong>avoiding use of hazardous heavy metals makes process and quality control easier</li>\n",
       "  <li>\n",
       "  <strong>Research potential: </strong>provides a new way to study drug distribution of existing drugs or new candidates</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Combined Acoustic Radiation Force Impulse (ARGI) Ultrasound and Elastography for Improved Tissue Imaging</h1><em>Technology #12-0104</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0104/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0104.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584872\"><a href=\"/inventors/18584872_caterina-gallippi\">Caterina Gallippi</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186394\"><em><a href=\"http://google.com/patents/US9244041\" target=\"_blank\">US Patent 9,244,041</a></em></dd></dl></div><div class=\"content\"><p>Acoustic Radiation Force Impulse (ARFI) ultrasound is a tissue imaging method where a short duration impulse (on the order of microseconds) of relatively high acoustic energy is transmitted into the body. The tissue’s response in terms of its peak displacement and subsequent recovery from displacement is used as an indicator of the tissue’s mechanical properties. The use of ARFI for elastography yields enhanced differentiation of tissue mechanical property. This technique allows for targeted regions of excitation, resulting in increased spatial resolution of mechanical property analysis. Combined ARFI-Elastography would be useful in breast, vascular, cardiac, abdominal, and other ultrasonic imaging applications. Similar principles may be applied to other medical imaging modalities, such as MRI and Optical imaging. Developments in ultrasound imaging, such as ARFI for elastography, will have helped lead the market to a $7 billion USD industry by 2024.<br/> <br/> <br/><strong> </strong><br/>&lt;!–[if !supportLists]–&gt;•   &lt;!–[endif]–&gt;Ability to palpate tissue further than human reach<br/>&lt;!–[if !supportLists]–&gt;•   &lt;!–[endif]–&gt;Accessing mechanical properties of human pathology, particularly at progressing stages of disease development<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Increased Recombinant AAV Vector Yield Using Engineered Assembly Activating Proteins</h1><em>Technology #18-0116</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0116/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0116.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585199\"><a href=\"/inventors/18585199_aravind-asokan\">Aravind Asokan</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186558\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Assembly Acting Proteins (AAPs) are required for adeno-associated viruses (AAVs) capsid formation.  Novel engineered Assembly Activating Proteins (eAAPs) have been developed with enhanced stability that promote viral assembly and enhance vector yields of recombinant AAV by 200% over wildtype AAP.  eAAPs can address some of the manufacturing limitations of AAV needed for gene therapy, gene silencing, and gene editing applications.<br/><br/><strong>Advantages:</strong><br/>-eAAPs can be used to greatly increase the yield of recombinant AAV vectors<br/>-eAAPs can be fluorescently labeled to enable the study of the role(s) of AAPs in capsid assembly<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29695425\" target=\"_blank\">Mapping and Engineering Functional Domains of the Assembly Activating Protein of Adeno-Associated Viruses.</a></li>J Virol. 2018 Apr 25. pii: JVI.00393-18. doi: 10.1128/JVI.00393-18. [Epub ahead of print]</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Novel Cross-Linker and Related Methods of Isotope Tagging for Analysis of Protein Interactions</h1><em>Technology #13-0034</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0034/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0034.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584903\"><a href=\"/inventors/18584903_xian-chen\">Xian Chen</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186423\"><em><a href=\"http://google.com/patents/US9562010\" target=\"_blank\">US Patent US 9562010</a></em></dd></dl></div><div class=\"content\"><p>An isotope labeled cross-linker has been developed to improve the detection of cross-linked peptides. Chemical cross-linking is often used to study protein-protein interactions, however gas-phase dissociation reactions of cross-linkers often lack the sensitivity and specificity to fragment the cross-linker at the desired location. Consequently, there is a need for improved cross-linkers for studying protein interactions. The developed cross-linker (d4-DTSSP) is asymmetric across a single cleavable bond (versus symmetrical like other commercially available DTSSP), and allows for a unique detection strategy that can differentiate cross-linked fragments from non cross-linked fragment ions that can easily be visually differentiated using mass spectrometry. Furthermore, d4-DTSSP uses a simple electron transfer (EDT) dissociation reaction that allows for high efficiency and product yield along with the identification of interacting proteins.  d4-DTSSP has the potential to significantly enhance the utility of chemical cross-linking for the study of protein-protein interactions.<br/><br/>Advantages:<br/><br/>·      Allows for a unique detection strategy that identifies cross-linked from non-cross-linked fragments<br/> <br/>·      May improve throughput in identifying cross-linked fragments by allowing automated peak-picking<br/> <br/>·      Makes cleavage products predictable, easy to visualize, and easily distinguishable from other EDT product ions such as backbone products, side-chain losses, and charged reduced species.<br/><br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Topical Tigecycline to Control Endodontic Infections</h1><em>Technology #18-0031</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0031/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0031.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585219\"><a href=\"/inventors/18585219_ashraf-fouad\">Ashraf Fouad</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186570\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Endodontic infections result from a variety of bacteria and require treatment, which can include tooth extraction. The severity of infection can lead to hospital stay, morbidity, and even mortality, if not cared for properly. Though antibiotics are ideal, some bacteria have developed a resistance, as a result of antibiotic use in both medicine and dentisty. Tigecycline is a promising antibiotic, new to the treatment of infected root canals. This therapeutic is topical treatment for tooth bacteria infections, which would locally deliver tigecycline, a broadly acting antibiotic, during surgical treatment of the root canal.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Local delivery of potent antibiotic, increasing efficacy of drug as compared to IV administration</li>\n",
       "  <li>Topical delivery system will minimize systemic exposure, decreasing drug side-effects</li>\n",
       "  <li>Easy application by dentist will reduce patient recovery, reducing risk of re-visits to dentist</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Side-car Bassinet to Improve Mother and Baby Development Post-delivery</h1><em>Technology #17-0003</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0003/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0003.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li><li class=\"category\" id=\"category_5360\"><a href=\"/categories/5331_life-sciences/5360_other\">Other</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585169\"><a href=\"/inventors/18585169_kristin-tully\">Kristin Tully</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186550\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A side-car bassinet particularly designed for U.S. maternity beds may improve mother-baby development post-delivery. The bassinet locks into maternity beds, when proximity to mother is warranted, but can be disengaged, and converted to a stand-alone bassinet. To promote breast-feeding in the hours after delivery, it is understood that keeping mother and baby together is important. Stand-alone bassinets present unnecessary obstacles for mothers in the moments following labor (as a result of compromised mobility). A mother’s movement becomes particularly worrisome when cesarean birth is necessary. Stand-alone bassinets lead to suboptimal breast-feeding. By designing a bassinet that can lock into hospital beds, mothers can easily reach their baby for feeding. During times when bassinet is disengaged from the bed, a fourth wall is in place for infant security.<br/> <br/> </p><ul>\n",
       "  <li>Improves breast-feeding consistency for mothers post-delivery, as compared to a stand-alone bassinet</li>\n",
       "  <li>By reducing mother’s movement during the time after delivery, less opportunity for the mother to accidently harm the infant</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Synthesis of extremely stable in vivo 18F based radiotracer to conjugate drugs and diagnostic biomolecules</h1><em>Technology #17-0045</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0045/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0045.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585155\"><a href=\"/inventors/18585155_zibo-li\">Zibo Li</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186546\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p><br/>The invention provides a novel approach for synthesis of an 18F based radiotracer, an ideal backbone for a tracer due to its long half-life (~110 mins). Fluorine is commonly found in organic molecules, and thus, is theoretically easy to directly introduce to a molecule of interest. Positron Emission Tomography (PET) is a medical imaging technique that relies on the use of molecular radiotracerss containing positron emitting isotopes. This UNC method results in a radiotracer that is extremely stable <em>in vivo</em> and can be used to conjugate drugs, peptides, proteins, or any other diagnostic biomolecules.<br/> </p><ul>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;&lt;!–[endif]–&gt;<strong>Applicable for sensitive biomolecules</strong>: Direct fluorination of peptides and proteins is challenging as harsh reaction conditions to obtain radiochemical yields may destroy these biomolecules. The mild conditions applied in this method allow radiolabeling of sensitive biomolecules such as proteins.</li>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;<strong>Stable</strong>: Extremely stable <em>in vivo, </em>which allows for application as a conjugate to drugs, peptides, proteins, and diagnostic molecules.</li>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;&lt;!–[endif]–&gt;<strong>Resistant to hydrolysis</strong>: Increased cellular uptake and enhanced image.</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Novel System for Personalized Brain Stimulation to Alleviate Deficiencies in Higher Order Cognitive Function Cloud Infrastructure</h1><em>Technology #17-0050</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0050/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0050.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585153\"><a href=\"/inventors/18585153_flavio-frohlich\">Flavio Frohlich</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>A novel system that provides targeted and personalized brain stimulation to increase sleep spindle oscillations to alleviate deficiencies in higher order cognitive function, allowing for the treatment of psychiatric and neurological impairments. This technology is cloud infrastructure to support transcranial current stimulation device.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Novel System for Personalized Brain Stimulation to Alleviate Deficiencies in Higher Order Cognitive Function Software</h1><em>Technology #17-0051</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0051/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0051.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585152\"><a href=\"/inventors/18585152_flavio-frohlich\">Flavio Frohlich</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>A novel system that provides targeted and personalized brain stimulation to increase sleep spindle oscillations to alleviate deficiencies in higher order cognitive function, allowing for the treatment of psychiatric and neurological impairments. This technology is the firmware written to control transcranial current stimulation device. This piece of software controls the delivery and monitoring of the stimulation current as well as the interaction.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Higher Frame Rate Ultrasound Imaging for Improved Detection of Human Physiological Events</h1><em>Technology #17-0062</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0062/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0062.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585149\"><a href=\"/inventors/18585149_gianmarco-pinton\">Gianmarco Pinton</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186543\"><em><a href=\"http://google.com/patents/WO2018208942\" target=\"_blank\">PCT Patent Application WO 2018/208942</a></em></dd></dl></div><div class=\"content\"><p>Ultrasound imaging at high frame rates (50 Hz or greater) is reliant on plane-wave transmission. Unfortunately, high frame rate imaging is not conducive with compounding, or averaging, of different acoustic signals to improve image quality. With every ultrasound transmit being devoted to image quality, that is one transmission being lost for analysis of temporal changes in the image. As the field of ultrasound progresses with techniques reliant on faster imaging, such as super resolution, it is not only beneficial to image fast, but also to maintain sensitivity. Adaptive multifocus beamforming is a technique that utilizes a unique transmission to focus the beam in multiple locations in the field of view, while mainting the desired high-frame rate. In this manner, high-frame rate ultrasound images possses a signal-to-noise ratio not achievable previously. Not only could this improve signal tracking in even the slowest of capillaries, deeper penetration depths may be reached, providing more information for physiological assessment.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Higher frame rate imaging allows for improved detection of human physiological events</li>\n",
       "  <li>Increases the number of locations the ultrasound beam can be focused in the image enhances the image quality</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Device and Method for Improving Motor Memory and Other Cognitive Functions, a Potential Therapy for Alzheimer’s Disease, Schizophrenia, Autism and ADHD</h1><em>Technology #16-0010</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0010/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0010.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5360\"><a href=\"/categories/5331_life-sciences/5360_other\">Other</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585078\"><a href=\"/inventors/18585078_flavio-frohlich\">Flavio Frohlich</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Research in understanding the role thalamo-cortical oscillations, like sleep spindles, play in cortical network dynamics and cognitive processes in humans has been impeded due to a lack of tools to monitor and selectively enhance rhythmic brain activity in real-time. Further, current treatment options for these disease aim only to help prolong functional capabilities and slow symptom development. Researchers developed this system to combat this growing health concern and overcome these current research limitations. This system provides targeted and personalized brain stimulation to increase sleep spindle oscillations to alleviate deficiencies in higher order cognitive function, allowing for the treatment of psychiatric and neurological impairments. Brain stimulation has gained momentum as an alternative to pharmacological approaches to treat neurological disorders.    <br/> </p><ul>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;Proprietary method to monitor and selectively enhance transient rhythmic brain activity in real time in humans</li>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;&lt;!–[endif]–&gt;&lt;!–[if !supportLists]–&gt;&lt;!–[endif]–&gt;Improves motor sequence consolidation, providing a non-invasive, drug free therapeutic for disorders shown to have reduction in sleep spindles</li>\n",
       "  </ul><br/> \n",
       "  </div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Improved Mechanical Imaging for Internal Organs and Muscles</h1><em>Technology #16-0098</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0098/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0098.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585039\"><a href=\"/inventors/18585039_caterina-gallippi\">Caterina Gallippi</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186497\"><em><a href=\"http://google.com/patents/US2017032745\" target=\"_blank\">PCT Patent Application US 2017/032745</a></em></dd></dl></div><div class=\"content\"><p><br/>Acoustic radiation force impulse (ARFI) imaging is a technique that utilizes ultrasound to characterize the viscoelastic property of tissue. It is understood that certain organ systems have directionally dependent characteristics (property known as anisotropy). Disease progression may change the mechanical response of tissue, and the ability to measure these changes along multiple axes is beneficial. This unique use of ARFI to measure anisotropy has significant advantages in the clinical space. UNC researchers have developed the disclosed technology is capable of quantifying peak displacements in orthogonal dimensions. With this information, the degree of anisotropy of the tissue can be monitored during disease progression, increasing the information one can gather from ultrasound systems. Developments in ultrasound imaging have led to a $7.3 billion USD industry. With such improvements to tissue mechanical property assessment, ultrasound technology continues to expand as a multi-platform modality.<br/> </p><ul>\n",
       "  <li>Ability to palpate tissue further than human reach</li>\n",
       "  <li>Accessing mechanical properties of human pathology, particularly at progressing stages of disease development</li>\n",
       "  <li>Utilizing a multidimensional-ultrasound transducer reduces risk of error from probe adjustment</li>\n",
       "  <li>The ultrasound-platform will enable the combination of the mechanical information gathered from ARFI with anatomical and vascular information inherent to ultrasound systems.</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Detection of Brain Motion with High-frame Rate Ultrasound Imaging</h1><em>Technology #16-0141</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0141/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0141.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585028\"><a href=\"/inventors/18585028_gianmarco-pinton\">Gianmarco Pinton</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186489\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>There is a lack of understanding of the mechanisms at work during a traumatic brain injury (TBI). Though brain motion has been extensively linked to TBI, direct quantifiable measurements are absent, which could aid in progressing understanding and diagnosis of TBI. The Pinton lab has developed an ultrasonic method for detecting the motion of the brain, at frame rates as high as 10,000 images per second. With a novel motion tracking algorithm, the imaging technique can quantify movement of the brain with displacements down to 1 micron. Through the advancement and implementation of this technique, it is anticipated that the detection of brain motion will further the understanding of the mechanism of trauma.</p><ul>\n",
       "  <li>\n",
       "  &lt;!–[endif]–&gt;At 10,000 images per sec, superior motion detection can be achieved, at a spatial sensitivity better than 1 micron.</li>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;Detection of skull motion will lead to improved understanding and diagnosis of brain injury</li>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;3D simulation development of the nonlinear propagation of shear shock waves, a potential source for traumatic brain injury, may enable the improved design of sport helmets and car safety features.</li>\n",
       "  </ul><br/><br/> \n",
       "  </div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Periodontal Profile Class Scoring Model to predict tooth loss and oral disease progression</h1><em>Technology #16-0170</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0170/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0170.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5370\"><a href=\"/categories/5362_software-information-technology/5370_health-it\">Health IT</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585009\"><a href=\"/inventors/18585009_jim-beck\">Jim Beck</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>University of North Carolina Researchers have developed a new application of the latent class analysis (LCA) method to identify groups of patients with differing classes of periodontal disease. This method uses LCA to create classes using clinical indices typically used in a dental exam derived from a dataset of over 6,900 community dwelling subjects. The model defines 7 classes of individuals that can be used to predict tooth loss, disease progression and status relative to a general population. There are currently no standardized methods available for measuring clinical outcomes in dentistry. This system has the potential to be a dental healthcare “learning” system as the dataset increases with utilization.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Adrenomedullin Therapy to Improve Fetal Implantation</h1><em>Technology #15-0097</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0097/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0097.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584966\"><a href=\"/inventors/18584966_kathleen-caron\">Kathleen Caron</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Researchers at the University of North carolina have innovated a short-term treatment of mouse uterine lining with adrenomedullin peptide prior to pregnancy to improve fetal implantation numbers and overall quality of implantation. This simple, cost-effective and minimally-invasive procedure could be used to improve the success of assisted reproductive technologies in humans, which were performed over 150,000 times in the US in 2011. Worldwide, approximately 1.5 million assisted reproductive technology cycles are performed each year, with an estimated 350,000 live births.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Combined Acoustic Radiation Force Impulse (ARGI) Ultrasound and Elastography  for Tissue Imaging</h1><em>Technology #08-0050</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/08-0050/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/08-0050.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584832\"><a href=\"/inventors/18584832_caterina-gallippi\">Caterina Gallippi</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186362\"><em><a href=\"http://google.com/patents/US9043156\" target=\"_blank\">US Patent 9,043,156</a></em></dd></dl></div><div class=\"content\"><p>Acoustic Radiation Force Impulse (ARFI) ultrasound is a tissue imaging method where a short duration impulse (on the order of microseconds) of relatively high acoustic energy is transmitted into the body. The tissue’s response in terms of its peak displacement and subsequent recovery from displacement is used as an indicator of the tissue’s mechanical properties. The use of ARFI for elastography yields enhanced differentiation of tissue mechanical property. This technique allows for targeted regions of excitation, resulting in increased spatial resolution of mechanical property analysis. Combined ARFI-Elastography would be useful in breast, vascular, cardiac, abdominal, and other ultrasonic imaging applications. Similar principles may be applied to other medical imaging modalities, such as MRI and Optical imaging. Developments in ultrasound imaging, such as ARFI for elastography, will have helped lead the market to a $7 billion USD industry by 2024.<br/> <br/><strong> </strong><br/>&lt;!–[if !supportLists]–&gt;•   &lt;!–[endif]–&gt;Ability to palpate tissue further than human reach<br/>&lt;!–[if !supportLists]–&gt;•   &lt;!–[endif]–&gt;Accessing mechanical properties of human pathology, particularly at progressing stages of disease development<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Dry Powder Aerosol Generator, a delivery system for dry powdered aerosol drugs</h1><em>Technology #05-0077</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/05-0077/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/05-0077.pdf\">Download Printable PDF</a></p><dl><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584813\"><a href=\"/inventors/18584813_anthony-hickey\">Anthony Hickey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186351\"><em><a href=\"http://google.com/patents/US8205612\" target=\"_blank\">US Patent 8,205,612</a></em></dd></dl></div><div class=\"content\"><p><br/>A need exists for an improved delivery system of dry powdered aerosol drugs to patients that cannot consciously inhale deeply upon command to facilitate proper delivery of the drugs within the respiratory tract of the patient. The dry powder aerosol generator includes a dispersion chamber having an internal cavity capable of receiving a dry powdered drug.<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Methods of Acoustic Measurement and Control of Pharmaceutical Sprays</h1><em>Technology #04-0112</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/04-0112/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/04-0112.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584808\"><a href=\"/inventors/18584808_anthony-hickey\">Anthony Hickey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186347\"><em><a href=\"http://google.com/patents/US8156829\" target=\"_blank\">US Patent 8,156,829</a></em></dd></dl></div><div class=\"content\"><p><br/>Researchers at the University of North Carolina at Chapel Hill have developed a means to correlate acoustic measurements to spray formation, using that relationship to characterize output spray behavior. The technology uses real-time algorithms to impart disruptive energy to the orifice delivering the spray, in this way the technology can modulate spray formation with the intent of controlling size, distribution, and overall energy.<br/>&lt;!–[if !supportLists]–&gt;</p><ul>\n",
       "  <li>\n",
       "  &lt;!–[endif]–&gt;Enables targeted delivery for local or systemic drug delivery to the lungs</li>\n",
       "  <li>\n",
       "  &lt;!–[if !supportLists]–&gt;&lt;!–[endif]–&gt;Provides continuous throughput spray-drying within narrowly defined output parameters (e.g., mass delivered, size of particles)</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Coated filament for evaporation/condensation aerosol generation of therapeutic agents and methods</h1><em>Technology #04-0113</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/04-0113/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/04-0113.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584807\"><a href=\"/inventors/18584807_anthony-hickey\">Anthony Hickey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186346\"><em><a href=\"http://google.com/search?#q=2008%2F0199161&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">US Patent 2008/0199161</a></em></dd></dl></div><div class=\"content\"><p>Researchers at the University of North Carolina at Chapel Hill have developed<br/>an aerosol generator device for the delivery and administration of therapeutic agents<br/>to the lungs. The technology provides a tunable delivery method capable of<br/>generating aerosols at precise particle sizes and at a wide range of flow rates.</p><ul>\n",
       "  <li>Enables a wide range of delivered doses</li>\n",
       "  <li>Permits the delivery of therapeutics irrespective of their evaporation temperatures and thermal stability</li>\n",
       "  <li>Allows lung deposition patterns to be controlled</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Hinged endoscopic catheter for easier treatment of intestinal obstruction</h1><em>Technology #18-0015</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0015/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0015.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585239\"><a href=\"/inventors/18585239_theodore-james\">Theodore James</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Intestinal obstruction can result from a variety of medical problems, including gastric outlet obstruction, chronic ulcers, and cancer of the stomach or pancreas, and it leads to impaired or blocked digestion of food, numerous gastrointestinal symptoms, and malnutrition. A common solution to these cases is to bypass the obstruction by creating a connection between the stomach and the small intestine through a procedure called a gastrojejunostomy, allowing the contents of the stomach to continue through the digestive tract unimpeded. Researchers at UNC have developed a custom catheter for improving the safety and speed of this commonly performed surgery. The catheter can be manipulated to bring the small intestine closer to the stomach, facilitating easier placement of the connecting tube. It also expands to open the lumen of the small intestine, minimizing the risk of accidental puncture all the way through.<br/><br/><strong>Advantages:</strong><br/>·       Facilitates accurate procedures by pushing the small intestine against the stomach<br/>·       Minimizes the risk of unintended intestinal punctures by opening up the small intestine before needle insertion<br/>·       Increases the overall safety and speed of a routinely performed surgical intervention<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Method for the Inhibition of Anti-PEG Antibodies</h1><em>Technology #18-0025</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0025/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0025.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5421\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5421_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585226\"><a href=\"/inventors/18585226_sam-lai\">Sam Lai</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186576\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A method for inhibiting the action of anti-PEG antibodies (APAs) has been developed, with the goal of enhancing the effectiveness of PEGylated proteins and nanoparticle therapeutics. APAs can be induced by PEGylated therapeutics, or they can be pre-existing due to previous exposure to PEG in everyday hygiene and food products. The presence of circulating APAs can render PEGylated therapeutics non-efficacious and potentially unsafe. We have developed a method of administering free PEG in combination with a PEGylated therapeutic that severely reduces the detrimental effects of APAs. We have demonstrated this technique in mice using PEGylated liposomal doxorubicin (Doxil®). Our data indicated that this method was able to increase Doxil efficacy for 24 hours with minimal toxicity or side effects.<br/><br/><strong>Advantages:</strong><br/>-Can increase the efficacy and circulation of PEGylated therapeutics<br/>-Minimal toxicity associated with this method<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>COPD Diagnostic Tool</h1><em>Technology #17-0117</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0117/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0117.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585120\"><a href=\"/inventors/18585120_mehmet-kesimer\">Mehmet Kesimer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186527\"><em><a href=\"http://google.com/patents/WO2018204598\" target=\"_blank\">PCT Patent Application WO 2018/204598</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707993\"><a href=\"https://www.sciencedaily.com/releases/2017/09/170906221217.htm\" target=\"_blank\">Science Daily</a></dd></dl></div><div class=\"content\"><p>A method for the diagnosis of chronic bronchitis (CB) has been invented. Currently, the diagnosis of CB relies on self-reporting of symptoms and tests such as the classic and St. George’s Respiratory Questionnaires. CB represents an early developmental phase of chronic obstructive pulmonary lung disease (COPD), and therefore a more quantitative approach to CB diagnosis is desired. Our researchers have developed a method of diagnosing CB based on levels of mucin present in sputum samples. This objective test can be used to diagnose CB, define the severity of CB, and help determine the appropriate therapies.<br/><br/><strong>Advantages:</strong><br/>-Provides a quantitative diagnostic for chronic bronchitis (CB)<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nejm.org/doi/full/10.1056/NEJMoa1701632?af=R&amp;rss=currentIssue&amp;page=&amp;sort=oldest\" target=\"_blank\">Airway Mucin Concentration as a Marker of Chronic Bronchitis</a></li>New England Journal of Medicine<li><a href=\"http://news.unchealthcare.org/news/2017/september/new-insights-on-chronic-bronchitis-could-lead-to-first-diagnostic-test-and-better-treatments\" target=\"_blank\">Chronic Bronchitis: New Insights Could Lead to First Diagnostic Test and Better Treatments</a></li>UNC Healthcare News</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Nanoparticles for the Codelivery of Cancer Immunotherapeutics</h1><em>Technology #17-0119</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0119/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0119.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585118\"><a href=\"/inventors/18585118_andrew-wang\">Andrew Wang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186526\"><em><a href=\"http://google.com/patents/US2018938999\" target=\"_blank\">US Patent Pending US 2018/938999</a></em></dd></dl></div><div class=\"content\"><p>Dual immunotherapy nanoparticles (DINPs) that can simultaneously deliver multiple immunotherapeutics have been synthesized. Emerging evidence suggests that administration of certain immunotherapeutics in combination has a synergistic effect. Specifically, an approach that can block checkpoint inhibitor receptors, like PD1, while activating co-stimulatory receptors, like OX40, is desired. This can be done by utilizing our dual immunotherapy nanoparticles (DINPs). Using DINPs enabled simultaneous delivery of anti-PD1 and anti-OX40 antibodies (Abs) to T cells. Data indicates that codelivery of these Abs by DINPs induced a higher immunotherapeutic response than administration of the free Abs in vivo. DINP combination immunotherapy led to 30% cure rate in mice with 83% of cured mice resisting tumor re-challenge.<br/><br/><strong>Advantages:</strong><br/>-Enables codelivery of immunotherapeutics to T cells, enhancing T cell activation<br/>-More effective than free antibodies in in vivo tumor models<br/><br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://onlinelibrary.wiley.com/doi/abs/10.1002/adma.201706098\" target=\"_blank\">A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy</a></li>10.1002/adma.201706098</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Diagnostic Test for Malignant Cutaneous Melanoma</h1><em>Technology #17-0137</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0137/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0137.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585108\"><a href=\"/inventors/18585108_kathleen-dorsey\">Kathleen Dorsey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186523\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>We have developed a novel diagnostic test for the presence of malignant melanoma based on DNA methylation. The current standard for melanoma diagnosis, histopathologic review, is complicated by the similarities in melanoma’s histologic profile to that of benign melanocytic nevi. The result is inaccurate results that often lead to over and/or under treatment of patients. Our diagnostic test is based on differences at the molecular level between melanomas and benign nuclei. Studies indicate that this test can detect melanoma in FFPE specimens with a sensitivity of 96% and a specificity of 100%. In contrast, currently available genetic tests for melanoma have a sensitivity and specificity of 90% and 91% respectively.<br/><br/><strong>Advantages:</strong><br/>-Analysis of DNA methylation allows for early detection of malignant melanoma, avoiding complications arising from histopathologic analysis.<br/>-Can be applied to standard FFPE specimens<br/>-Has a sensitivity of 96% and a specificity of 100%</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Neurosteroid-induced protection against alcoholism, multiple sclerosis, Alzheimer’s disease, and other neuropsychiatric disorders</h1><em>Technology #17-0159</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0159/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0159.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li><li class=\"category\" id=\"category_5335\"><a href=\"/categories/5331_life-sciences/5335_cellular-therapeutics\">Cellular Therapeutics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5420\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5420_neurology\">Neurology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585092\"><a href=\"/inventors/18585092_a-leslie-morrow\">A Leslie Morrow</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Several naturally-occurring neurosteroids have shown protection against alcohol use disorder, depression, multiple sclerosis, Alzheimer’s disease, traumatic brain injury, and other neuropsychiatric disorders in animal models. These disorders affect a large portion of the population, with 6.2% of adults in the United States suffering from alcohol use disorder alone. Protective action of these neurosteroids has been observed, but the mechanism for these benefits has not been shown. Development of these neurosteroids as therapeutics in humans, as well as efforts to find more neurosteroids with protective action, depend on a more complete understanding of how they protect against depression and other disorders. Researchers at UNC have discovered that these neurosteroids inhibit an important signaling pathway in the brain involved in many neuropsychiatric disorders.<br/><br/><br/><strong>Advantages:</strong><br/>·       Increases awareness of neurosteroid action in clinically relevant signaling pathways in animal models<br/>·       Explains therapeutic usefulness of neurosteroids in disorders including alcohol use disorder, depression, multiple sclerosis, Alzheimer’s disease, and traumatic brain injury<br/>·       Tool for development of novel therapeutics for neuropsychiatric disorders<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>The Garland Carver for Carving Dental Composite Restorations</h1><em>Technology #16-0137</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0137/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0137.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li><li class=\"category\" id=\"category_5360\"><a href=\"/categories/5331_life-sciences/5360_other\">Other</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585031\"><a href=\"/inventors/18585031_glenn-garland\">Glenn Garland</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186493\"><em>PCT Patent Application Filed</em></dd></dl></div><div class=\"content\"></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Stretchable RF Coil Array for High-Resolution MRI</h1><em>Technology #16-0187</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0187/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0187.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585001\"><a href=\"/inventors/18585001_weili-lin\">Weili Lin</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186474\"><em><a href=\"http://google.com/patents/WO2018045042\" target=\"_blank\">PCT Patent Application WO 2018/045042</a></em></dd></dl></div><div class=\"content\"><p>In MRI, the closeness of RF coils to the imaging subject determines the quality of images obtained. This stretchable RF coil array greatly increases the resolution of MRI images for tissues, including the brain, where flexible coils are not an option.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Small Molecules for the Treatment of Metabolic Disorders</h1><em>Technology #14-0018</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0018/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0018.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584942\"><a href=\"/inventors/18584942_jay-brenman\">Jay Brenman</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186438\"><em>US Patent Issued</em></dd></dl></div><div class=\"content\"><p>Small molecule therapeutics for metabolic syndromes, such as non-alcoholic fatty liver disease (NAFLD), have been developed. Activation of AMP-activated protein kinase (AMPK) leads to inhibition of cholesterol synthesis, triglyceride synthesis, and lipogenesis, and, significantly, it can stimulate hepatic fatty acid oxidation. We have identified compounds that can activate AMPK more effectively than its endogenous ligand, ADP. These compounds could serve as lead compounds for a program focused on metabolic disorders such as NAFLD or non-alcoholic steatohepatitis (NASH).<br/><br/><strong>Advantages</strong>:<br/>-AMPK activation can increase hepatic fatty acid oxidation<br/>-AMPK activation can inhibit cholesterol synthesis<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://benthamopen.com/ABSTRACT/CCGTM-7-30\" target=\"_blank\">A High Throughput Assay for Discovery of Small Molecules that Bind AMP-activated Protein Kinase (AMPK)</a></li>Sinnett, S.E. et al.; Curr. Chem. Genom. Transl. Med. 2013; 7: 30-38  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Full Jaw Orthodontic Dentition Model by using human CT and microCT data</h1><em>Technology #12-0071</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0071/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0071.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584879\"><a href=\"/inventors/18584879_ching-chang-ko\">Ching-Chang Ko</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Recombinant Factor IX Proteins with Enhanced Specific Activity and Half-Life for Treatment of Hemophilia</h1><em>Technology #12-0087</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0087/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0087.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584877\"><a href=\"/inventors/18584877_darrel-stafford\">Darrel Stafford</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186398\"><em><a href=\"http://google.com/patents/US20150307863\" target=\"_blank\">US Patent Pending US 2015/0307863</a></em></dd></dl></div><div class=\"content\"><p>Factor IX (FIX) deficiency, or hemophilia B, is an X-linked inherited bleeding disorder that is due to a missing clotting protein.  Data suggests that sequestration of FIX by collagen IV localizes FIX in the areas needed for coagulation.  A modified recombinant FIX protein has been developed that has a Gla domain that binds more tightly to collagen IV and demonstrates a higher specific activity and longer lasting clotting function than the current commercially available recombinant FIX proteins.  In vivo experiments in a hemophilia B mouse model have been used to validate efficacy and functionality of this recombinant FIX protein. <br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>A General and Efficient Self-Assembly System for the Generation of Thermostable Heptameric Targeting Ligands with Significantly Improved Target-Binding Strength</h1><em>Technology #11-0065</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0065/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0065.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584860\"><a href=\"/inventors/18584860_rihe-liu\">Rihe Liu</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186384\"><em><a href=\"http://google.com/patents/US9340616\" target=\"_blank\">US Patent US 9340616</a></em></dd></dl></div><div class=\"content\"><p>A simple and efficient method for the self-assembly of heptameric targeting ligands has been developed. Many developing therapies and diagnostics rely on the use of targeting ligands, such as homing peptides, protein-binding domains, and antibodies. Often, improving the targeting ligand’s affinity for its target is a  time-consuming process, requiring extensive affinity maturation. Our technology allows for an alternative strategy: the creation of multiple binding interactions with the target via a multimeric targeting ligand. In addition to enhanced binding affinity, these multivalent targeting ligands offer improved biodistribution and pharmacokinetic properties when compared to conventional monovalent ligands. Data indicate that these heptamers exhibit 100-1000x greater target-binding strength than their monomeric counterparts. This technology was used to synthesize heptameric antibodies, targeting the EGFR and HER2 receptors, that possessed high stability, enhanced avidity, and low toxicity.<br/><br/><br/><strong>Advantages</strong>:<br/>-Allows for the self-assembly of heptameric target ligands<br/>-Heptameric target ligands show 100-1000x greater binding-strength than monomer target ligands<br/>-Multivalent target ligands possess improved biodistribution and pharmacokinetic properties.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043077\" target=\"_blank\">Heptameric Targeting Ligands against EGFR and HER2 with High Stability and Avidity</a></li>Kim, D. et al.; PLOS ONE. 2012. 7(8): e43077</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Rapid Method for the Assembly of Nanoparticles with Targeting Ligands</h1><em>Technology #11-0136</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0136/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0136.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5324\"><a href=\"/categories/5317_engineering-physical-sciences/5324_nanotechnology\">Nanotechnology</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584855\"><a href=\"/inventors/18584855_rihe-liu\">Rihe Liu</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186381\"><em><a href=\"http://google.com/search?#q=PCT%2FUS2014%2F058257&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">PCT Patent Application PCT/US2014/058257</a></em></dd><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186380\"><em><a href=\"http://google.com/patents/US20160303256\" target=\"_blank\">US Patent Pending US 2016/0303256</a></em></dd></dl></div><div class=\"content\"><p>A rapid and universal method for the synthesis of nano- and microparticles bearing targeting ligands (TLs) had been developed. Nano- and microparticles have use in the fields of drug delivery and diagnostics. A drawback to these technologies is the difficulty of incorporating a TL onto the surface of these particles. A TL (antibody, antigen, etc.) is often required to direct the particles to a specific tissue or cell type. Our researchers have invented a method that allows for the easy incorporation of TLs into these particles. This technology utilizes calmodulin to affix the TL to the surface of the particle, in addition the Ca2+ gradient within cells allows for the release of particle cargo intracellulary.<br/><br/><strong>Advantages:</strong><br/>-Allows for easy incorporation to TLs onto the surface of nano- and micoparticles for use in drug delivery and diagnostic applications<br/>-Calmodulin-based technology allows for facile release of particle cargo intracellularly<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Composition of Novel Cationic Nanoparticles for the Delivery of siRNA Therapeutics in Lung Cancer</h1><em>Technology #08-0038</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/08-0038/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/08-0038.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5324\"><a href=\"/categories/5317_engineering-physical-sciences/5324_nanotechnology\">Nanotechnology</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584833\"><a href=\"/inventors/18584833_leaf-huang\">Leaf   Huang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186363\"><em><a href=\"http://google.com/patents/US8389768\" target=\"_blank\">US Patent US 8389768</a></em></dd></dl></div><div class=\"content\"><p>Cationic nanoparticle formulations have been developed for the delivery of siRNA to tumor cells. siRNA therapeutics are promising treatments for many diseases, but they require delivery vehicles to efficiently transport them to their target cell. We have developed a cationic nanoparticle formulation that efficiently delivers siRNA to H460 human lung carcinoma cells. These nanoparticles were able efficiently deliver siRNA that silenced epidermal growth factor receptor (EFGR) expression. In addition an increase in apoptosis was observed when siRNA was administered in this manner, indicating a synergistic effect between the siRNA and the cationic nanoparticle delivery vehicle.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://pubs.acs.org/doi/abs/10.1021/mp800136v\" target=\"_blank\">Novel Cationic Lipids That Deliver And Enhance Therapeutic Activity of siRNA In Tumor Cells</a></li>Chen Y., et al.; Mol Pharm. 2009 May; 6(3) 696-705</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Method For Improving the Catalytic Activity of Lipases</h1><em>Technology #08-0104</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/08-0104/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/08-0104.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5313\"><a href=\"/categories/5313_agriculture-horticulture\">Agriculture &amp; Horticulture</a><ul><li class=\"category\" id=\"category_5315\"><a href=\"/categories/5313_agriculture-horticulture/5315_food-science-nutrition\">Food Science &amp; Nutrition</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5332\"><a href=\"/categories/5331_life-sciences/5332_ag-biotechnology\">Ag Biotechnology</a></li><li class=\"category\" id=\"category_5341\"><a href=\"/categories/5331_life-sciences/5341_industrial-biotechnology\">Industrial Biotechnology</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584830\"><a href=\"/inventors/18584830_dhiren-thakker\">Dhiren Thakker</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186361\"><em><a href=\"http://google.com/patents/US9416383\" target=\"_blank\">US Patent US 9416383</a></em></dd></dl></div><div class=\"content\"><p>A method of improving the activity of Phospholipase C (PLC) has been discovered. Lipases are the most widely employed industrial biocatalysts. They are used to synthesize compounds for the pharmaceutical, cosmetic, food, chemical and energy industries. As a result, the global market for lipases is in the billions of dollars and growing. Improving the efficiency of lipases allows for the production cheaper products and the ability to apply lipase-based technologies to industries where the current limitations of lipases render them cost inefficient. This technology improves the efficiency of PLC via alkylation of its cysteine residues. We anticipate that this method is applicable to all lipases, creating an opportunity to improve a variety of important industrial processes.<br/><br/><strong>Advantages:</strong><br/>-Improves activity of lipases<br/>-Enables significant cost reductions in the synthesis of select compounds in the pharmaceutical, cosmetic, food, chemical, and energy sectors.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jbc.org/content/286/14/12407.short\" target=\"_blank\">Direct Activation of Human Phospholipase C by Its Well Known Inhibitor U73122</a></li>Klein, R.R. et al. J. Biol. Chem. 2011 Jan; 286, 12407-12416</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Composition of a Polypeptide for the Synthesis of Heparan Sulfate</h1><em>Technology #02-0105</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/02-0105/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/02-0105.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5321\"><a href=\"/categories/5317_engineering-physical-sciences/5321_industrial-biotechnology\">Industrial Biotechnology</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li><li class=\"category\" id=\"category_5421\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5421_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584797\"><a href=\"/inventors/18584797_jian-liu\">Jian Liu</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186339\"><em><a href=\"http://google.com/patents/US7531338\" target=\"_blank\">US Patent US 7531338</a></em></dd></dl></div><div class=\"content\"><p>A novel isoform of 3-O-sulfotransferase that can be used for the synthesis of two separate forms of heparan sulfate (HS) has been discovered. Heparan sulfate can be isolated in many different isoforms that have unique properties and biological roles. The 3-O-sulfotranferase polypeptide sequence developed at UNC-Chapel Hill can be used to synthesize two separate types of HS: one form that can prevent blood clotting, and one subtype that is used by the herpes simplex virus to enter cells. This technology incorporates both the sequence of the polypeptide that can synthesize the two HSs, but also the genetic sequence that encodes it.<br/><br/><strong>Potential Uses:</strong><br/>-Synthesis of anticoagulant therapies<br/>-Development of anti-viral therapies directed against herpes simplex virus<br/>-Potential target for gene therapies modulating heparan sulfate expression<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jbc.org/content/277/40/37912.short\" target=\"_blank\">Heparan Sulfate 3-O-Sulfotransferase Isoform 5 Generates Both an Antithrombin-binding Site and an Entry Receptor for Herpes Simplex Virus, Type 1</a></li>Xia, G., et al.; J. Biol. Chem. 2002 Jul 23; 277 37912-37919</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Composition and Method for Platelet-Based Drug Delivery</h1><em>Technology #00-0110</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/00-0110/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/00-0110.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584792\"><a href=\"/inventors/18584792_thomas-fischer\">Thomas Fischer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_370\"><a href=\"/managers/370_jackie-quay\">Jackie Quay</a> <div><em>Director</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186338\"><em><a href=\"http://google.com/patents/US7901674\" target=\"_blank\">US Patent US 7901674</a></em></dd><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186337\"><em><a href=\"http://google.com/patents/US8492081\" target=\"_blank\">US Patent US 8492081</a></em></dd></dl></div><div class=\"content\"><p>A novel method of drug delivery utilizing rehydrated platelets has been developed. Platelets have long been recognized as potential drug delivery vehicles; however, the need to freshly isolate, modify, and reinfuse them in a short time-span has limited their applicability. Cryopreserved and normally-liquid stored platelets circumvent these problems, but suffer from storage issues and the need to remove cryopreservatives. We have discovered a method for utilizing fixed-dried blood platelets as drug carriers. This technology comprises a method of drying blood platelets, conjugating them to the compound to be delivered, rehydrating the platelets and administering the resulting rehydrated platelets. This technology is anticipated to be particularly effective for therapeutic delivery to the liver, spleen and injured organs.<br/><br/><strong>Advantages:</strong><br/>-Rehydrated platelets avoid storage and purification problems associated with cryopreserved and liquid stored platelets<br/>-Can be used to deliver a variety of compounds to diseased, damaged, and disturbed tissues <em>in vivo</em><br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.pnas.org/content/92/2/397.long\" target=\"_blank\">Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion.</a></li>M.S. Read et al.; P. Natl. Acad. Sci. USA.; 1995 Jan 17; 92(2) 397-401</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Real-time, Automated Software for the Reduction of Ionizing Radiation Dosage for Angiography and Perfusion Analysis</h1><em>Technology #18-0002</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0002/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0002.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585253\"><a href=\"/inventors/18585253_andrew-abumoussa\">Andrew Abumoussa</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186582\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>This software reduces the amount of ionizing radiation required for digital subtraction angiography (DSA), computed tomography perfusion (CTP), and computed tomography angiography, reducing the risk of cancer and other injuries while still maintaining high-resolution capture of blood flow dynamics when imaging internal organs and tissues. Current applications include stroke diagnostics, tumor characterization, and quantification of vasospasm therapeutics. Software developed by physicians at UNC-CH reduces radiation exposures for DSA and CTP by factors of 4 and 20, respectively. <br/><br/><strong>Advantages</strong></p><ul>\n",
       "  <li>Software requires fewer frames to produce high-quality data, reducing necessary exposure to ionizing radiation</li>\n",
       "  <li>Calculations are performed in real-time so as to not interrupt a clinician’s workflow</li>\n",
       "  <li>Automatically performs accurate image segmentation and reconstruction, removing the need for dedicated technicians that manually input parameters.</li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Bitwise Framework for Detection of Complicated Non-Parametric Dependence Structure in Big Data that is Scalable, Easily Interpretable, and Fast</h1><em>Technology #18-0084</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0084/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0084.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li><li class=\"category\" id=\"category_5365\"><a href=\"/categories/5362_software-information-technology/5365_bioinformatics\">Bioinformatics</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585203\"><a href=\"/inventors/18585203_kai-zhang\">Kai Zhang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186560\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Computer-based data analysis often relies on detecting linear associations between variables, which can be problematic and limiting in complex “Big Data” applications. Software, utilizing a novel bitwise statistical algorithm, has been developed to analyze complicated non-parametric dependence structure in Big Data.  Relative to existing methods, our novel software provides enhanced power, interpretability, scalability, and speed.  For example, when compared to distance correlation, the new software processes data up to 1000 times faster.  Potential applications for the new software include genetic data analysis, image/pattern recognition, speech recognition, and medical screening. <br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Novel Algorithm for Artificial Intelligence (AI) Assisted Drug Design</h1><em>Technology #17-0164</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0164/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0164.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585088\"><a href=\"/inventors/18585088_olexandr-isayev\">Olexandr Isayev</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186515\"><em><a href=\"http://google.com/patents/WO2019018780\" target=\"_blank\">PCT Patent Application WO 2019/018780</a></em></dd></dl></div><div class=\"content\"><p>An algorithm that enables artificial intelligence (AI) to generate individual compounds and compound libraries with ideal biochemical and physiological profiles has been developed. Traditional drug discovery programs generally begin with an exhaustive high-throughput screen (HTS) of available compound libraries. However, because there are an estimated 1030-1060 theoretical drug-like molecules, these screens are never, in actuality, exhaustive. This technology has the potential to streamline the process of drug development by identifying lead compounds that already have the desired properties of a marketable drug.<br/><br/><strong>Advantages:</strong><br/>-Can effectively screen more chemical space than high-throughput screening (HTS)<br/>-Allows for fully automated lead compound discovery<br/>-Identifies lead compounds that already have ideal ADME and PK properties<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://arxiv.org/pdf/1711.10907.pdf\" target=\"_blank\">Deep Reinforcement Learning for De-Novo Drug Design</a></li>\n",
       "  <a href=\"https://arxiv.org/abs/1711.10907\" target=\"_blank\">https://arxiv.org/abs/1711.10907</a>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>A Method of Atrial Fibrillation Diagnosis</h1><em>Technology #18-0006</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0006/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0006.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585251\"><a href=\"/inventors/18585251_james-hummel\">James Hummel</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186581\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>By calculating electrogram conformations (Egm-C), UNC clinicians have developed a new methodology that can determine the direction of local activation wavefronts during atrial fibrillation (AF). The calculation of Egm-C allows for recurrence quantification analysis (RQA) to be performed, yielding information about the local dynamics in AF. This information can be used to guide in the diagnosis and treatment of AF, including locating sites for catheter ablation.<br/><br/><strong>Advantages:</strong><br/>-Provides simplification of bipolar recordings during atrial fibrillation<br/>-Can be used to guide catheter ablation of atrial fibrillation</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.sciencedirect.com/science/article/pii/S0010482517302871?via%3Dihub\" target=\"_blank\">A method for quantifying recurrent patterns of local wavefront direction during atrial fibrillation</a></li>Hummel, J.P. et al.; Comput. Biol. Med. 2017 Oct 1; 89, 497-504</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Prevention of Graft-Versus-Host Disease via A Small Molecule Method of CCR7 Inhibition</h1><em>Technology #18-0016</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0016/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0016.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5335\"><a href=\"/categories/5331_life-sciences/5335_cellular-therapeutics\">Cellular Therapeutics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5418\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5418_cell-therapy\">Cell Therapy</a></li><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585238\"><a href=\"/inventors/18585238_james-coghill\">James Coghill</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186580\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>UNC data indicates that treatment of stem cells with cosalane prior to transplantation greatly reduces the incidence of aGVHD, while preserving the GVL effect in several transplant models. Our recent studies demonstrated that knock-out of the cc-chemokine receptor 7 (CCR7), by cosalane, in murine T cells impaired their ability to induce aGVHD. Significantly, these T cells retained their graft-versus-leukemia (GVL) response in mouse stem cell transplant models.<br/><br/><strong>Advantages:</strong><br/>-CCR7 inhibition reduces incidence of graft-versus-host disease<br/>-Cosalane-treated T cells retain graft-versus-leukemia responses</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Predictive Biomarker for Metformin Response in Endometrial Cancer</h1><em>Technology #18-0050</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0050/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0050.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585213\"><a href=\"/inventors/18585213_victoria-bae-jump\">Victoria Bae-Jump</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186562\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>An indicator of therapeutic response to metformin in endometrial cancer (EC) patients has been identified. In a subset of obese patients, preoperative metformin therapy has been linked to decreased tumor proliferation. Differential proteomic analysis of tumor cells collected from EC patient tissue revealed discrepancies in molecular signaling pathways between metformin responder and non-responder patients.  UNC inventors utilized this data to discover a biomarker that can be used to predict the preoperative therapeutic response to metformin treatment in endometrial cancer patients.<br/><br/><strong>Advantages:</strong><br/>-Can predict success of preoperative metformin therapy</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.oncotarget.com/index.php?journal=oncotarget&amp;page=article&amp;op=view&amp;path%5B%5D=20754&amp;pubmed-linkout=1\" target=\"_blank\">Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice.</a></li>Han, J., et al.; Oncotarget. 2017 Sep 8, 8(67): 110965-110982</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Diagnostic Test for the Presence of HPV+ Oropharyngeal Cancers</h1><em>Technology #18-0121</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0121/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0121.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585194\"><a href=\"/inventors/18585194_trevor-hackman\">Trevor Hackman</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186557\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A diagnostic test for HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has been developed. As a result of the high levels of p16 in HPV-driven OPSCC, p16 testing is commonly used as a surrogate test for HPV involvement in OPSCC. However, p16 staining cannot accurately predict lymph node involvement in OPSCC, leading to insufficient treatment of some patients. UNC researchers have developed a diagnostic test for HPV-driven OPSCC that can predict nodal involvement in OPSCC and is as sensitive as p16 staining, but far more specific. This test, based on a proprietary gene signature, has a sensitivity of 88.2% and a specificity of 85.7%.<br/><br/><strong>Advantages</strong><br/>-Can detect lymph node involvement in OPSCC<br/>-Higher sensitivity than p16 staining</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2678979\" target=\"_blank\"> RNA Oncoimmune Phenotyping of HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas by Nodal Status</a></li>Stepp WH, et al.. JAMA Otolaryngol Head Neck Surg. </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Small Molecules for the Treatment of Angelman Syndrome</h1><em>Technology #11-0003</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0003/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0003.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5454\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5454_orphan-rare-diseases\">Orphan &amp; Rare Diseases</a></li><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584865\"><a href=\"/inventors/18584865_ben-philpot\">Ben Philpot</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186388\"><em><a href=\"http://google.com/patents/US2017630664\" target=\"_blank\">US Patent Pending US 2017/630664</a></em></dd><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186387\"><em><a href=\"http://google.com/patents/US9714427\" target=\"_blank\">US Patent US 9714427</a></em></dd></dl></div><div class=\"content\"><p>Small molecules that can unsilence the gene associated with Angelman syndrome have been discovered. Angelman syndrome is a rare neurodevelopmental disorder affecting 1 in 15,000 individuals. Angelman syndrome is caused by a mutation in the maternal copy of the Ube3a allele. UNC researchers have discovered that certain topoisomerase inhibitors can unsilence the paternal copy of the Ube3a allele, restoring normal protein expression. These molecules represent a therapy for Angelman syndrome.  <br/><br/><strong>Advantages:</strong><br/>-Topoisomerase inhibitors are already FDA-approved, allowing for rapid adoption in the clinic<br/>-First small molecule treatment for Angelman syndrome</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.nature.com/articles/nature10726\" target=\"_blank\">Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons</a></li>Huang, H.S., et al.; Nature. 2012 Jan 12; 481 185-189</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Small Molecules That Enhance Efficacy of Therapeutic Oligonucleotides, with Aerosolized Formulation for Lung Indications</h1><em>Technology #18-0134</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0134/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0134.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5454\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5454_orphan-rare-diseases\">Orphan &amp; Rare Diseases</a></li><li class=\"category\" id=\"category_5583\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5583_small-molecule\">Small molecule</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585189\"><a href=\"/inventors/18585189_silvia-kreda\">Silvia Kreda</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186556\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Compounds that enhance the intracellular trafficking of oligonucleotides have been synthesized. Despite the initial clinical success of therapeutic oligonucleotides such as siRNA, antisense nucleotides (ASOs), and splice switching oligonucleotides (SSOs), their full adoption to the clinic has been limited, in part, because of the ineffective delivery of oligonucleotides to their intracellular targets. We have developed small molecules that improve the delivery of therapeutic oligonucleotides to their target sites within the cell. In addition, we have generated a solubilized formulation which demonstrates remarkable activity <em>in vitro</em> in human airway epithelial cells and <em>in vivo</em> in mouse airway cells with a very low effective dose and, therefore, little to no toxicity. Consequently, the aerosolized compound is an excellent candidate for use in delivering therapeutics oligonucleotides to the lung, such as SSOs for the treatment of cystic fibrosis (CF).</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28703575\" target=\"_blank\">A Novel Family of Small Molecules that Enhance the Intracellular Delivery and Pharmacological Effectiveness of Antisense and Splice Switching Oligonucleotides.</a></li>ACS Chem Biol. 2017 Aug 18;12(8):1999-2007. doi: 10.1021/acschembio.7b00242. Epub 2017 Jul 14.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Humanized Antibody for the Treatment of Microvascular Complications of Diabetes</h1><em>Technology #12-0054</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0054/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0054.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584880\"><a href=\"/inventors/18584880_david-clemmons\">David Clemmons</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_366\"><a href=\"/managers/366_jennifer-dean\">Jennifer Dean</a> <div><em></em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186402\"><em><a href=\"http://google.com/patents/US7723483\" target=\"_blank\">US Patent US 7723483</a></em></dd><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186401\"><em><a href=\"http://google.com/patents/US9587024\" target=\"_blank\">US Patent US 9587024</a></em></dd><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186400\"><em><a href=\"http://google.com/patents/US9073996\" target=\"_blank\">US Patent US 9073996</a></em></dd></dl></div><div class=\"content\"><p>A humanized monoclonal antibody has been developed against the alpha V beta 3 integrin. This antibody was developed to block ligand occupancy of the alpha V beta 3 integrin, a receptor that has been shown to be important in predisposing to the development of diabetes complications that are driven by hyperglycemia. Specifically, the antibody has been shown to be effective in animal studies at inhibiting atherosclerotic lesion development, both in the coronary arteries and peripheral blood vessels and in inhibiting the early stages of diabetic nephropathy, including increased urinary albumin excretion and histologic changes in the kidney. This antibody significantly reduced atherosclerosis in all of the coronary arteries and markedly inhibited the development of atherosclerosis in the femoral arteries. Extensive preclinical characterization has been performed, the antibody demonstrated an excellent safety profile in phase I clinical trials, and human clinical studies evaluated this antibody as a therapeutic for a separate indication. Because the antibody is highly effective in atherosclerosis one clinical indication would be patients with coronary artery disease and diabetes who are not responding well to conventional therapy, a substantial number of patients. The second indication that could be pursued is peripheral vascular disease. Biomarkers are available that could be used to inform study enrollment and benefit.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.atherosclerosis-journal.com/article/S0021-9150(17)30032-1/fulltext\" target=\"_blank\">An anti-aVß3 antibody inhibits coronary artery atherosclerosis in diabetic pigs.</a></li>10.1016/j.atherosclerosis.2017.01.030<li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239428/\" target=\"_blank\">Blocking ligand occupancy of the aVß3 integrin inhibits the development of nephropathy in diabetic pigs.</a></li>10.1210/en.2014-1318</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Compositions for Potentiating the Activities of Select Antibiotics Against S. aureus</h1><em>Technology #17-0128</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0128/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0128.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585114\"><a href=\"/inventors/18585114_brian-conlon\">Brian Conlon</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186524\"><em><a href=\"http://google.com/patents/WO2019018594\" target=\"_blank\">PCT Patent Application WO 2019/018594</a></em></dd></dl></div><div class=\"content\"><p>Potentiators of tobramycin against <em>S. aureus</em> have been developed to combat the highly tolerant nature of <em>S. aureus</em> to commonly used antibiotics. We have discovered certain rhamnolipids that, when administered to <em>S. aureus</em>, can facilitate the uptake of tobramycin, leading to a decrease in the minimum inhibitory concentration (MIC) of tobramycin, and an increase in its anti-biofilm activity. Treatment of <em>S. aureus, in vitro,</em> using these potentiators led to colony eradication in less than 3 hours.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29176757\" target=\"_blank\">Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus.</a></li>PLoS Biol. 2017 Nov 27;15(11):e2003981. doi: 10.1371/journal.pbio.2003981. eCollection 2017 Nov</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Aerosolized Formulation of Pyrazinoic Acid for the Treatment of Tuberculosis</h1><em>Technology #17-0068</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0068/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0068.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585147\"><a href=\"/inventors/18585147_miriam-braunstein\">Miriam Braunstein</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186542\"><em><a href=\"http://google.com/patents/WO2018090004\" target=\"_blank\">PCT Patent Application WO 2018/090004</a></em></dd></dl></div><div class=\"content\"><p>Pyrazinamide (PZA) can shorten the treatment time of tuberculosis (TB) by six months and is the only drug deemed irreplaceable in the standard TB treatment regimen, yet approximately fifty percent of multiple drug resistant TB are resistant to PZA. It is believed that the use of the active form of PZA, pyrazinoic acid (POA), instead of PZA to treat TB could circumvent the problem of resistance. However, POA is not effective when administered orally. We have developed novel aerosolized formulations of POA and pyrazinoic acid esters (PAEs) that, when administered in a guinea pig model, significantly decrease the bacterial burden of the lungs. In addition, the above treatment was able to induce host-directed effects against TB, leading to a reduction of bacterial burden in the spleen, liver, and lymph nodes. The use of aerosolized POA/PAEs versus oral PZA circumvents problems with bioavailability and allows for a lower effective dose, thereby decreasing toxicity.  This aerosolized POA represents a novel approach to the treatment of TB.<br/> <br/>Advantages:<br/>-Aerosolized formulation avoids problems associated with oral bioavailability and toxicity<br/>- Requires lower dosage than conventional treatment with PZA<br/>-In addition to the therapeutic effect in the lung, treatment has a systemic effect that increases clearance of TB in the spleen, liver, and lymph nodes<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27351427\" target=\"_blank\">Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.</a></li>Pharm Res. 2016 Oct;33(10):2495-505. doi: 10.1007/s11095-016-1974-5. Epub 2016 Jun 28</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>CRISPR/Cas9 Gene Therapy for Angelman Syndrome</h1><em>Technology #18-0085</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0085/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0085.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li><li class=\"category\" id=\"category_5454\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5454_orphan-rare-diseases\">Orphan &amp; Rare Diseases</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585201\"><a href=\"/inventors/18585201_mark-zylka\">Mark Zylka</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186559\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A potential cure for Angelman syndrome (AS) has been developed utilizing CRISPR/Cas9 gene editing technology. AS is a rare neurodevelopmental disorder that affects approximately 1 in 15,000 people, causing severe intellectual disabilities, seizures, and mutism. AS is caused by a deletion or mutation in the maternal copy of the UBE3A allele.  While individuals inherit one copy of UBE3A from their mother and another from their father, the paternal allele is naturally silenced.  Gene therapy approaches are being developed which deliver a normal copy of UBE3A.  However, this will likely be problematic since overexpression of UBE3A can lead to autism.  We have discovered a means to alter the antisense transcript that is responsible for silencing the paternal copy of UBE3A using CRISPR/Cas9.  This modification eliminates the transcript’s ability to bind with the paternal allele, thereby allowing for expression of functional UBE3A at normal levels from the paternal allele.   <br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: 15-Hydroxyprostaglandin Dehydrogenase (PGDH) Deficient</h1><em>Technology #18-0137</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0137/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0137.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585182\"><a href=\"/inventors/18585182_beverly-koller\">Beverly Koller</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>The ductus arteriosus (DA) is a large vessel in the developing fetus that shunts blood past the pulmonary circulation in the aorta for oxygenation by the placenta. Failure of the DA to close, which is critical to sustain life after birth, is one of the more common congenital heart defects in infants. DA closure is characterized by a fall of Prostaglandin (PG) E2 levels after birth, which is essential for remodeling the DA. 15-Hydroxyprostaglandin dehydrogenase (PGDH) is the primary enzyme regulating PGE2. This mouse line was created by inactivating the gene that encodes the enzyme PGDH (HPGD), which may be useful in the clinical management of diseases where elevated PGE2 levels are beneficial.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/articles/nm0202-91\" target=\"_blank\">Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus.</a></li>Nat Med. 2002 Feb;8(2):91-2.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Robust Chauvenet Rejection (RCR)</h1><em>Technology #17-0086</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0086/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0086.pdf\">Download Printable PDF</a></p><dl><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585132\"><a href=\"/inventors/18585132_daniel-reichart\">Daniel Reichart</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707995\"><a href=\"https://skynet.unc.edu/rcr/calculator\" target=\"_blank\">Software Download</a></dd></dl></div><div class=\"content\"><p>Current methods for data analysis are limited to outlier rejection methods including sigma clipping and Chauvenet’s rejection criterion. These methods require that the sample mean and standard deviation be known prior to outlier rejection. However the measurements used to obtain such information have the potential to introduce the very outliers that are being considered for rejection. This copyrighted, “robust” Chauvenet outlier rejection software addresses these shortcomings and is effective for a variety of strong and significant contaminants while operating under decreased computing times. This software is made freely available for academic research and other non-commercial uses. For commercial applications, please contact OCED.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Image Metrics Software</h1><em>Technology #17-0113</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0113/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0113.pdf\">Download Printable PDF</a></p><dl><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585124\"><a href=\"/inventors/18585124_dorothy-erie\">Dorothy Erie</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707994\"><a href=\"http://im.zimengli.com\" target=\"_blank\">Software Download</a></dd></dl></div><div class=\"content\"><p>In addition to being cost prohibitive, current methods for image processing are limited by the number and types of functions they can implement and their inability to carry out high-throughput analyses. This Image Metrics software addresses these shortcomings, allowing for the easy and customizable processing and analysis of images, including those obtained through scanning probe microscopy. The integrated package allows for the automated, high-throughput processing of data and images with the ability to incorporate custom features. The software, written in MATLAB, can be run as a standalone application on Windows, MacOS, and Linux.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Improved Image and Video Decompression</h1><em>Technology #17-0108</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0108/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0108.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585126\"><a href=\"/inventors/18585126_russell-taylor\">Russell Taylor</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186532\"><em><a href=\"http://google.com/patents/US20190020903\" target=\"_blank\">US Patent Pending US-2019-0020903</a></em></dd></dl></div><div class=\"content\"><p>A technique for image and video decompression has been developed that respects intensity and spatial uncertainty in the encoded stream to significantly improve the perceived quality of final image or video output. This technique avoids spatial and intensity thresholding artifacts by adding noise and spatial blurring into the data stream during the decompression process; these decrease “banding” and “blocking” artifacts that commonly occur upon image reconstruction and detract from overall image quality. The method runs at full video rate on a commodity GPU and is particularly well suited for improving the user experience on high resolution cell phones, televisions, and computers where users commonly stream highly-compressed images or videos that are not well matched to the screen resolution of their device.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Significantly improves image or video output quality of compressed data</li>\n",
       "  <li>Implementable on commodity hardware</li>\n",
       "  <li>Improves user experience when streaming highly-compressed data to high resolution screen </li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>UNC Check-In App</h1><em>Technology #18-0118</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0118/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0118.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5369\"><a href=\"/categories/5362_software-information-technology/5369_education-training\">Education &amp; Training</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585197\"><a href=\"/inventors/18585197_viji-sathy\">Viji Sathy</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd></dl></div><div class=\"content\"><p>ITS Teaching and Learning has partnered with UNC Chapel Hill faculty to create the UNC Check-In app to facilitate taking attendance during classes and other events. The app allows instructors to specify brief time intervals during which students can register attendance when in proximity to designated Bluetooth beacons.<br/><br/>iTunes: <a href=\"https://itunes.apple.com/us/app/unc-check-in/id1296004763\" target=\"_blank\">https://itunes.apple.com/us/app/unc-check-in/id1296004763</a><br/>Google Play: <a href=\"https://play.google.com/store/apps/details?id=comp523.androidbeaconsattendance\" target=\"_blank\">https://play.google.com/store/apps/details?id=comp523.androidbeaconsattendance</a></p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Diabetes Education Board Game</h1><em>Technology #17-0138</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0138/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0138.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5369\"><a href=\"/categories/5362_software-information-technology/5369_education-training\">Education &amp; Training</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585104\"><a href=\"/inventors/18585104_nina-jain\">Nina Jain</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd></dl></div><div class=\"content\"><p>This educational board game leverages expertise from diabetes education, serious gaming, and pediatric endocrinology to create a game designed to teach and assess diabetes care knowledge. The game is designed to be played with a “diabetes master/educator,” patients, and parents. Via gaming, a diabetes educator is able to assess diabetes knowledge and thus tailor further education specific to the patient’s needs. Patient use of actual products in diabetes management is incorporated and future versions could expand the game into all types of diabetes.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Innovation &amp; Entrepreneurship Database</h1><em>Technology #16-0174</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0174/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0174.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5369\"><a href=\"/categories/5362_software-information-technology/5369_education-training\">Education &amp; Training</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585008\"><a href=\"/inventors/18585008_cindy-reifsnider\">Cindy Reifsnider</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd></dl></div><div class=\"content\"><p>The UNC Innovation and Entrepreneurship Database, built on the Salesforce.com platform, is a shared database for information gathering from stakeholders and for report generation for metrics, including being used to produce impact reports.<br/><br/>Database capabilities include:</p><ul>\n",
       "  <li>Tracking of inventors and entrepreneurs</li>\n",
       "  <li>Tracking of startups</li>\n",
       "  <li>Repository for real-time data on startups/spinouts</li>\n",
       "  <li>Tracking of startups/entrepreneurs participation in commercialization support programs and events</li>\n",
       "  <li>Repository of advisors, mentors, subcontractors, and investment specialists</li>\n",
       "  </ul>This system provides a robust database infrastructure for recording, analyzing, and reporting metrics on innovation, entrepreneurship, commercialization and economic development startups and projects from a university.\n",
       "  </div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>COLMAP: Image-based 3D Reconstruction</h1><em>Technology #17-0157</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0157/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0157.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585096\"><a href=\"/inventors/18585096_jan-michael-frahm\">Jan-Michael Frahm</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd></dl></div><div class=\"content\"><p>COLMAP is a general-purpose Structure-from-Motion (SfM) and Multi-View Stereo (MVS) pipeline with a graphical and command-line interface. It offers a wide range of features for reconstruction of ordered and unordered image collections. Image-based 3D reconstruction from images traditionally first recovers a sparse representation of the scene and the camera poses of the input images using Structure-from-Motion. This output then serves as the input to Multi-View Stereo to recover a dense representation of the scene.<br/><br/>Additional information: <a href=\"https://colmap.github.io\" target=\"_blank\">https://colmap.github.io</a></p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://ieeexplore.ieee.org/document/7780814/\" target=\"_blank\">Structure-from-Motion Revisited</a></li>Schonberger, Johannes L., and Jan-Michael Frahm. “Structure-from-motion revisited.” Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition. 2016.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Physics-Inspired Garment Recovery from a Single-View Image</h1><em>Technology #16-0167</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0167/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0167.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585011\"><a href=\"/inventors/18585011_shan-yang\">Shan Yang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186479\"><em><a href=\"http://google.com/patents/US20190043269\" target=\"_blank\">US Patent Pending US-2019-0043269</a></em></dd></dl></div><div class=\"content\"><p>Most recent garment capturing techniques rely on acquiring multiple views of clothing, which may not always be readily available, especially in the case of pre-existing photographs from the web. This technology provides a method that is able to compute a rich and realistic 3D model of a human body and its outfits from a single photograph with little human interaction. The algorithm is not only able to capture the global shape and geometry of the clothing, it can also extract small but important details of cloth, such as occluded wrinkles and folds. Unlike previous methods using full 3D information (i.e. depth, multi-view images, or sampled 3D geometry), this approach achieves detailed garment recovery from a single-view image by using statistical, geometric, and physical priors and a combination of parameter estimation, semantic parsing, shape recovery, and physics- based cloth simulation. The technology has applications in virtual try-on and garment transfer applications, as well as cloth animation for digital characters.<br/><br/>Video: <a href=\"http://www.cs.unc.edu/~alexyang/videos/iccv\" target=\"_blank\">http://www.cs.unc.edu/~alexyang/videos/iccv</a><em>demo.mp4 <p><b>Related Publications:</b></p>\n",
       "  <ul>\n",
       "  <li>&lt;a href=“<a href=\"http://arxiv.org/abs/1608.01250\" target=\"_blank\">http://arxiv.org/abs/1608.01250</a>” target=“</li>\n",
       "  </ul></em>blank”&gt;Detailed Garment Recovery from a Single-View ImagearXiv:1608.01250v4 [cs.CV]</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Efficient Digital Forensics Support Using a Virtualized Environment</h1><em>Technology #11-0094</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0094/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0094.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5373\"><a href=\"/categories/5362_software-information-technology/5373_security\">Security</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584859\"><a href=\"/inventors/18584859_fabian-monrose\">Fabian Monrose</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186383\"><em><a href=\"http://google.com/patents/US9721089\" target=\"_blank\">US Patent 9,721,089</a></em></dd></dl></div><div class=\"content\"><p>This technology provides a forensic platform that transparently monitors and records data access events within a virtualized environment. It accomplishes this using an architecture for efficiently and transparently recording the accesses to monitored objects – the approach monitors accesses to objects on disk and follows the causal chain of these accesses across processes, even after the objects are copied into memory. Its forensic layer records these transactions in a version-based audit log that allows for faithful, and efficient, reconstruction of the recorded events and the changes they induced. This platform can be used to glean insightful information on behavioral profiles of malware activity after a security breach has been detected and reconstruct valuable information about the what, when, and how, after a compromised has been detected.   </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=1866314\" target=\"_blank\">Trail of bytes: efficient support for forensic analysis</a></li>Krishnan, Srinivas, Kevin Z. Snow, and Fabian Monrose. “Trail of bytes: efficient support for forensic analysis.” Proceedings of the 17th ACM conference on Computer and communications security. ACM, 2010.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Acoustic Classification and Optimization for Multi-Modal Rendering of Real-World Scenes</h1><em>Technology #17-0090</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0090/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0090.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585128\"><a href=\"/inventors/18585128_carl-schissler\">Carl Schissler</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186535\"><em><a href=\"http://google.com/patents/US20180232471\" target=\"_blank\">US Patent Pending US 20180232471</a></em></dd></dl></div><div class=\"content\"><p>In order to create realistic augmented, mixed, or virtual reality experiences for applications such as computer aided design, teleconferencing, training, or gaming, 3D models of indoor and outdoor scenes must be augmented with realistic synthetic sound effects. To this end, a novel technique for automatic acoustic material classification and optimization for 3D reconstructions of real-world scenes has been developed. A convolutional neural network classifier is used to predict the material categories for 3D mesh triangles, then iteratively adjusts the reflection coefficients of the materials until simulated impulse response(s) matches corresponding measured impulse response(s). The technique can automatically generate acoustic material properties and plausible sound propagation effects in real-world indoor scenes.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Fast, simple, and practical</li>\n",
       "  <li>Automatically generate acoustic material properties and plausible sound propagation effects</li>\n",
       "  <li>Does not require complicated equipment</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://ieeexplore.ieee.org/document/7849179/\" target=\"_blank\">Acoustic Classification and Optimization for Multi-Modal Rendering of Real-World Scenes</a></li>IEEE Transactions on Visualization and Computer Graphics ( Volume: 24, Issue: 3, March 1 2018 )</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Diagnostic Test for Autism in Infancy</h1><em>Technology #16-0180</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0180/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0180.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585003\"><a href=\"/inventors/18585003_martin-styner\">Martin Styner</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186476\"><em><a href=\"http://google.com/patents/WO2018005820\" target=\"_blank\">PCT Patent Application WO 2018/005820</a></em></dd></dl></div><div class=\"content\"><p>The invention utilizes structural brain characteristics from MRI images for diagnosis of a neurobehavioral disorder and is initially applied to autism. This approach uses imaging data from presymptomatic time points before two years of age, along with preprocessing of data and a machine learning algorithm. Using these elements, clinicians could better identify pediatric patients for whom they might perform an intervention based on the diagnosis.<br/><br/>This could enable diagnosis of autism in high risk infants with high accuracy and at early stage. The target application is for children at high risk for autism spectrum disorder (ASD), including infants with siblings having ASD.<br/><br/>Benefits</p><ul>\n",
       "  <li>Provides new clinical insight as early as 6 months</li>\n",
       "  <li>Enables selection of candidate patients for early intervention much sooner than existing observational approaches</li>\n",
       "  </ul><br/>Stage of Development<ul><li>Prospective study completed using brain imaging and behavioral assessments from over 400 infants.</li></ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.nature.com/articles/nature21369\" target=\"_blank\">Early brain development in infants at high risk for autism spectrum disorder</a></li>Hazlett HC et al. Nature. 2017 Feb; 542, 348–351</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Diagnostic Test for Autism in Infancy</h1><em>Technology #16-0185</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0185/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0185.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585002\"><a href=\"/inventors/18585002_robert-emerson\">Robert Emerson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186475\"><em><a href=\"http://google.com/patents/WO2018005814\" target=\"_blank\">PCT Patent Application WO 2018/005814</a></em></dd></dl></div><div class=\"content\"><p>The invention utilizes functional connectivity brain imaging from MRI images for diagnosis of a neurobehavioral disorder and is initially applied to autism. This approach uses imaging data from presymptomatic time points before two years of age, along with preprocessing of data and a machine learning algorithm. Using these elements, clinicians could better identify pediatric patients for whom they might perform an intervention based on the diagnosis.<br/><br/>This could enable diagnosis of autism in high risk infants with high accuracy and at early stage. The target application is for children at high risk for autism spectrum disorder (ASD), including infants with siblings having ASD.<br/><br/>Benefits</p><ul>\n",
       "  <li>Provides new clinical insight as early as 6 months</li>\n",
       "  <li>Enables selection of candidate patients for early intervention much sooner than existing observational approaches</li>\n",
       "  </ul><br/>Stage of Development<ul><li>Prospective study completed using brain imaging and behavioral assessments from over 400 infants.</li></ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://stm.sciencemag.org/content/9/393/eaag2882\" target=\"_blank\">Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age</a></li>Emerson RW et al. Science Translational Medicine. 2017 Jun;</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Wide Field of View Augmented Reality Head-Mounted Display with Distance Accommodation</h1><em>Technology #16-0189</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0189/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0189.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584998\"><a href=\"/inventors/18584998_henry-fuchs\">Henry Fuchs</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186470\"><em><a href=\"http://google.com/patents/US9983412\" target=\"_blank\">US Patent 9,983,412</a></em></dd></dl></div><div class=\"content\"><p>Provides a variety of designs for achieving a wide field of view head mounted display with optical see-through capability and also dynamically adaptive distance accommodation. This capability would most likely be used to match the optical distance of the computer-generated image to the optical distance of the wearer’s current gaze (the wearer’s current target of interest). The design approach consists of two subsystems: 1) a system near each eye that tracks the horizontal and vertical gaze direction, and 2) an optical system that rapidly changes the optical distance of the display screen on which computer-generated image is presented to the user. This approach provides advantages above existing technology by combining a wide field of view with dynamic focal distance set by tracking the user’s fixation point.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://ieeexplore.ieee.org/abstract/document/7829412/\" target=\"_blank\">Wide field of view varifocal near-eye display using see-through deformable membrane mirrors</a></li>Dunn, David, et al. “Wide field of view varifocal near-eye display using see-through deformable membrane mirrors.” IEEE transactions on visualization and computer graphics 23.4 (2017): 1322-1331.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Topology Aware Geographic Routing</h1><em>Technology #16-0194</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0194/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0194.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5366\"><a href=\"/categories/5362_software-information-technology/5366_communications-networking\">Communications &amp; Networking</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584996\"><a href=\"/inventors/18584996_benjamin-newton\">Benjamin Newton</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186468\"><em><a href=\"http://google.com/patents/US9832705\" target=\"_blank\">US Patent 9,832,705</a></em></dd></dl></div><div class=\"content\"><p>Increasing global internet access is an important goal with both humanitarian and market-growth implications, and much attention has been paid to recent efforts to promote large-scale commercial airborne networks. The major challenge with such networks is the highly dynamic movement of nodes within them, including movement of nodes through varied topologies as well as entry and exit of individual nodes from the network. Efficient routing of network traffic is thus a key problem for large-scale implementation. Using directional data transmission, which is more energy-efficient and longer range than traditional omni-directional transmission, a routing protocol has been developed which takes advantage of local topology information to make strategic forwarding decisions for routing data in continental-scale dynamic networks. Topology Aware Geographic Routing (TAG) outperforms other routing protocols, including other geographic protocols, in theoretical environments and in simulated real-world, continental-scale airborne networks.<br/><br/>Advantages</p><ul>\n",
       "  <li>Considers local topology information to inform forwarding decisions</li>\n",
       "  <li>Decreases number of hops required to deliver a packet compared to other geographic routing protocols</li>\n",
       "  <li>Reliably delivers packets even when topology changes while packet is in flight</li>\n",
       "  <li>Outperforms other geographic routing protocols, including GOAFR+, GFG, and OLSR, in simulations</li>\n",
       "  <li>Increases likelihood of packet delivery even when local topologies violate the often used but unrealistic unit disk graph assumption</li>\n",
       "  <li>No communication overhead except that required to exchange position information among nodes</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://ieeexplore.ieee.org/abstract/document/6980399/\" target=\"_blank\">Analysis of Topology Algorithms for Commercial Airborne Networks</a></li>Newton, Ben, Jay Aikat, and Kevin Jeffay. “Analysis of topology algorithms for commercial airborne networks.” Network Protocols (ICNP), 2014 IEEE 22nd International Conference on. IEEE, 2014.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Interactive Sound Propagation and Rendering for Scenes with High Aural Complexity</h1><em>Technology #15-0003</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0003/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0003.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584995\"><a href=\"/inventors/18584995_carl-schissler\">Carl Schissler</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186467\"><em><a href=\"http://google.com/patents/US9977644\" target=\"_blank\">US Patent 9,977,644</a></em></dd></dl></div><div class=\"content\"><p>Advances in visual rendering have made the generation of extremely complex virtual environments possible. These environments may contain thousands of sound sources (i.e. cars, crowds, machines, etc.) and hundreds or thousands of static and dynamic objects. The scenes may span from a few meters (i.e. a room) to thousands of meters (i.e. an architectural model or outdoor scene). In order to maximize immersion and the realism of these virtual environments, realistic sound generation at interactive rates is crucial. An interactive algorithm for accelerated sound propagation and rendering in complex, dynamic scenes with a large number of sources has been developed. The formulation combines fast backward ray tracing from the listener with sound source clustering to compute propagation paths quickly and efficiently. Furthermore, a novel, hybrid convolution audio rendering algorithm that can render hundreds of thousands of paths at interactive rates is described. The algorithm can be used to generate indoor and outdoor scenes with high aural complexity more quickly than other algorithms.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Implementable on a four-core PC</li>\n",
       "  <li>Compute more than 50 orders of specular or diffuse reflection for tens or hundreds of moving sources at interactive rates</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=2943779\" target=\"_blank\">Interactive Sound Propagation and Rendering for Large Multi-Source Scenes</a></li>Schissler, Carl, and Dinesh Manocha. “Interactive sound propagation and rendering for large multi-source scenes.” ACM Transactions on Graphics (TOG) 36.1 (2017): 2.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>A Parallel ARD-based Wave Simulator for Distributed Memory Architectures</h1><em>Technology #14-0093</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0093/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0093.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584914\"><a href=\"/inventors/18584914_nicolas-morales\">Nicolas Morales</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186430\"><em><a href=\"http://google.com/patents/US9824166\" target=\"_blank\">US Patent 9,824,166</a></em></dd></dl></div><div class=\"content\"><p>Accurate modeling and simulation of indoor (i.e. multi-room environments, automobiles, or aircraft cabins) and outdoor (i.e. urban areas and open landscapes) acoustic spaces is vital to numerous applications spanning from gaming and virtual reality to architectural design and engineering. A new, distributed time-domain simulator has been developed that performs fast, accurate acoustic simulation in large, complex 3D scenes such as outdoor or architectural environments. Acoustic wave propagation in three dimensions is performed using a formulation based on the adaptive rectangular decomposition algorithm. Accelerated and scalable performance is enabled by new algorithms for load balancing and overlapping the computation of pressure field with communication of interface data. The solver can handle the full frequency range of human hearing in scenes with volumes of thousands of cubic meters.<br/><br/>Advantages:</p><ul>\n",
       "  <li>accurate acoustic propagation in large, complex indoor and outdoor environments for full frequency range of human hearing (20 Hz-20 kHz)</li>\n",
       "  <li>near-linear scalability using novel load-balancing scheme and asynchronous communication technique</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.sciencedirect.com/science/article/pii/S0003682X15001024\" target=\"_blank\">A parallel time-domain wave simulator based on rectangular decomposition for distributed memory architectures</a></li>Morales, Nicolas, Ravish Mehra, and Dinesh Manocha. “A parallel time-domain wave simulator based on rectangular decomposition for distributed memory architectures.” Applied Acoustics 97 (2015): 104-114.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>High-Order Diffraction and Diffuse Reflections For Interactive Sound Propagation in Large Environments</h1><em>Technology #14-0094</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0094/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0094.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584912\"><a href=\"/inventors/18584912_carl-schissler\">Carl Schissler</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186429\"><em><a href=\"http://google.com/patents/US20150378019\" target=\"_blank\">US Patent Pending US 2015/0378019</a></em></dd></dl></div><div class=\"content\"><p>Virtual environments such as cities, auditoriums, offices, and factories can span extremely large areas and may be composed of many moving sources and objects. Accurate sound propagation in these environments requires modeling complex acoustic effects such as reflections, scattering between objects, high-order diffractions, late reverberation, echoes, etc. New algorithms to enable interactive geometric sound propagation in complex scenes have been developed that can generate plausible sound effects at interactive rates in large, dynamic scenes that have multiple sound sources. A novel algorithm to compute diffuse reflections and higher order diffraction based on ray-based sound propagation is used that is directly applicable to complex geometric datasets. Furthermore, algorithms for wavelength-dependent simplification and visibility graph computation to accelerate higher-order diffraction at runtime are also described. Together these technologies result in an order-of-magnitude performance increase over prior methods with comparable accuracy. <br/><br/>Advantages:</p><ul>\n",
       "  <li>compute higher-order diffraction and diffuse reflections in complex, dynamic environments to generate plausible sound effects</li>\n",
       "  <li>order-of-magnitude performance improvement over prior methods and the accuracy is comparable to those methods</li>\n",
       "  <li>capable of rendering of large environments (i.e. auditoriums, offices, factories, cities, etc.)</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=2601216\" target=\"_blank\">High-order diffraction and diffuse reflections for interactive sound propagation in large environments</a></li>Schissler, Carl, Ravish Mehra, and Dinesh Manocha. “High-order diffraction and diffuse reflections for interactive sound propagation in large environments.” ACM Transactions on Graphics (TOG) 33.4 (2014): 39.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Sound Propagation in Large Complex Environments Using Wave-Ray Coupling</h1><em>Technology #13-0089</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0089/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0089.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584891\"><a href=\"/inventors/18584891_hengchin-yeh\">Hengchin Yeh</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186412\"><em><a href=\"http://google.com/patents/US20150294041\" target=\"_blank\">US Patent Pending US 2015/0294041</a></em></dd></dl></div><div class=\"content\"><p>Accurate sound propagation has become fundamental to many interactive (i.e. gaming and virtual reality) and offline (i.e. noise prediction in urban scenes, architectural acoustics, and prototyping) applications. Many wave-based techniques for sound propagation are spatially limited and limited to low frequency applications due to computational complexity. On the other hand, geometric techniques for sound propagation are unable to simulate many acoustic effects (i.e. diffraction, interference, and higher-order wave effects) at low frequencies. A new hybrid technique for interactive sound propagation in large, complex indoor and outdoor scenes has been developed that combines the strengths of numerical and geometric acoustic techniques for the different parts of the domain. The more accurate and costly numerical technique is used to model wave phenomena in near-object regions, while the more efficient geometric technique is used to handle propagation in far-field regions and interaction with the environment. The sound pressure field generated by the two techniques is coupled using a novel two-way coupling procedure. The new technique can simulate realistic, high-fidelity acoustic effects using orders of magnitude lower memory than standard wave-based numerical techniques. <br/><br/>Advantages:</p><ul>\n",
       "  <li>Exploits strengths of both geometric and numerical acoustic techniques</li>\n",
       "  <li>Fast, memory-efficient interactive audio rendering that only uses tens to hundreds of megabytes of memory</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=2508420\" target=\"_blank\">Wave-ray coupling for interactive sound propagation in large complex scenes</a></li>Yeh, Hengchin, et al. “Wave-ray coupling for interactive sound propagation in large complex scenes.” ACM Transactions on Graphics (TOG) 32.6 (2013): 165.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Optical See-Through Near-Eye Display Using Point Light Source Backlight</h1><em>Technology #13-0120</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0120/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0120.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584885\"><a href=\"/inventors/18584885_andrew-maimone\">Andrew Maimone</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186407\"><em><a href=\"http://google.com/patents/US20160320620\" target=\"_blank\">US Patent Pending US 2016/0320620</a></em></dd></dl></div><div class=\"content\"><p>The invention is a design for a near-eye display that allows direct viewing through the device (i.e. optical see-through).  The near-eye display uses a series of point light sources to direct light through a spatial light modulator into the eyes. The geometry of the light sources, spatial light modulator, and viewer are arranged so that each pixel on the spatial light modulator is illuminated by a single light source, allowing a clear image to be formed on the eye. The spatial light modulator and backlight are transparent or nearly-transparent, allowing the user’s environment to be seen through the display. This design may be useful to create a wide field of view augmented reality display in a compact, eyeglasses-like form factor.  It may interest makers or investigators of near-eye augmented reality displays, allowing information to be spatially registered and overlaid a user’s natural vision.<br/><br/>The design is untested and performance characteristics are unknown, but may allow a low cost, compact (eye-glasses like) optical see-through near-eye display to be created with a wide field of view. Current optical see-through near eye displays are bulky or have narrow fields of view, limiting their practical use. If the design is successful, it could be used for augmented reality applications, allowing information to be spatially registered and overlaid a user’s natural vision.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=2614080\" target=\"_blank\">Pinlight Displays: Wide Field of View Augmented Reality Eyeglasses Using Defocused Point Light Sources</a></li>Maimone, Andrew, et al. “Pinlight displays: wide field of view augmented reality eyeglasses using defocused point light sources.” ACM SIGGRAPH 2014 Emerging Technologies. ACM, 2014.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Sound Propagation in Large Scenes using Equivalent Sources</h1><em>Technology #12-0052</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0052/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0052.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584881\"><a href=\"/inventors/18584881_ravish-mehra\">Ravish Mehra</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186403\"><em><a href=\"http://google.com/patents/US9711126\" target=\"_blank\">US Patent 9,711,126</a></em></dd></dl></div><div class=\"content\"><p>Interactive, wave-based sound propagation that captures important acoustic phenomena (i.e. interference, diffraction, scattering, sound focusing, and high-order wave effects) for large, open virtual environments or scenes found in simulation and training systems or in video games can take hours of computation and gigabytes of memory even while using state-of-the-art wave simulation methods. A new object-centric algorithm for wave-based sound propagation that captures acoustic effects such as high-order diffraction and scattering using an equivalent source formulation has been developed. During preprocessing, the method uses object-based sound field decomposition to segment a scene into well-separated, rigid objects. The acoustic behavior of the objects and inter-object interactions is expressed by matrix-based transfer functions using an equivalent source formulation that can then be used to compute the acoustic response of the scene to a static source distribution. At runtime, summation of outgoing equivalent sources for all objects is performed at the listener location for real-time sound rendering for a moving listener. Scenes with moving sources and a static listener can be handled by exploiting acoustic reciprocity. The technique can perform accurate sound propagation on large, open scenes in real-time, has a small memory footprint, and allows flexible efficiency-accuracy tradeoffs. <br/><br/>Advantages:</p><ul>\n",
       "  <li>well-suited for quick iterations while authoring scenes</li>\n",
       "  <li>takes orders of magnitude less runtime memory compared to state-of-the-art wave solvers, enabling interactive performance</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=2451245\" target=\"_blank\">Wave-based sound propagation in large open scenes using an equivalent source formulation</a></li>Mehra, Ravish, et al. “Wave-based sound propagation in large open scenes using an equivalent source formulation.” ACM Transactions on Graphics (TOG) 32.2 (2013): 19.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Example-Guided Sound Synthesis</h1><em>Technology #12-0086</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0086/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0086.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584878\"><a href=\"/inventors/18584878_ming-lin\">Ming Lin</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186399\"><em><a href=\"http://google.com/patents/US9401684\" target=\"_blank\">US Patent 9,401,684</a></em></dd></dl></div><div class=\"content\"><p>In order to create truly immersive and compelling virtual environments, high-quality, true-to-life synthesized sound must be generated and closely synchronized with visual renderings. Methods are needed to produce sound effects that precisely capture complex interactions that are not predetermined. To this end, a new method for sound synthesis using estimated material parameters has been developed that recreates realistic audio for virtual objects. Material parameters are estimated from a single pre-recorded audio clip of a material sample based on psychoacoustic principles and feature identification using linear modal analysis. Differences between real-world recordings and synthesized sounds are minimized using a residual compensation method to create the final synthesized audio. The estimated material parameters and the residual compensation naturally transfer to virtual objects of different sizes and shapes.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Data-driven, physically based sound synthesis using a single sound recording</li>\n",
       "  <li>Estimated intrinsic material parameters and residual compensation can be transferred to virtual objects of various sizes and shapes</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://dl.acm.org/citation.cfm?id=2421637\" target=\"_blank\">Example-guided physically based modal sound synthesis</a></li>Ren, Zhimin, Hengchin Yeh, and Ming C. Lin. “Example-guided physically based modal sound synthesis.” ACM Transactions on Graphics (TOG) 32.1 (2013): 1.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Fast Geometric Sound Propagation using Visibility Computations</h1><em>Technology #11-0047</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0047/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0047.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584863\"><a href=\"/inventors/18584863_dinesh-manocha\">Dinesh Manocha</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186386\"><em><a href=\"http://google.com/patents/US8847965\" target=\"_blank\">US Patent 8,847,965</a></em></dd></dl></div><div class=\"content\"><p>In order to create immersive, multimodal virtual reality for use in interactive applications, geometric acoustic algorithms that can quickly and efficiently compute sound propagation paths for complex 3D models and virtual environments at high frame rates on commodity hardware are needed. A new method for simulation of sound propagation has been developed that harnesses geometric acoustics and conservative visibility techniques to quickly and accurately compute sound propagation paths of complex scenes. From a defined sound source position in a given scene, a complex visibility tree can be constructed. This method uses conservative (e.g. occlusion culling) from-region visibility techniques to model sound diffraction and conservative from-point visibility techniques to model specular sound reflections to significantly reduce the complexity of the visibility tree. The new simplified tree can then be used to generate an impulse response for the scene and in turn quickly and accurately simulate sound propagation in the scene.<br/><br/>Advantages:</p><ul><li>Faster and more efficient than approaches using exact from-point visibility algorithms </li></ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://journals.sagepub.com/doi/abs/10.1260/1351-010X.18.1-2.123\" target=\"_blank\">Fast and Accurate Geometric Sound Propagation Using Visibility Computations</a></li>Chandak, Anish, et al. “Fast and accurate geometric sound propagation using visibility computations.” Building Acoustics 18.1-2 (2011): 123-144.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Synthetic polymer networks with tissue-like properties</h1><em>Technology #18-0030</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0030/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0030.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5322\"><a href=\"/categories/5317_engineering-physical-sciences/5322_materials\">Materials</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585224\"><a href=\"/inventors/18585224_sergei-sheiko\">Sergei Sheiko</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186575\"><em>Provisional Patent Application Filed </em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707996\"><a href=\"https://www.nature.com/articles/natrevmats201767\" target=\"_blank\">Biomaterials: Don't stress over it</a></dd></dl></div><div class=\"content\"><p><strong>Technology</strong><br/>Preparation of synthetic materials that mimic properties of biological materials is especially challenging. Current methods to control the properties of these synthetic materials are limited to an Edisonian trial-and-error approach that often requires integration of multiple components into a single material.<br/><br/>The present invention is a design platform that enables the programmable replication of mechanical properties of select biological tissues through rational design of synthetic polymer architecture. This linear-bottlebrush-linear triblock co-polymer architecture allows encoding of specific softness, flexibility, and strain-stiffening properties that can be matched to those of specific tissues such as arteries, muscle, and lung.<br/><br/>Potential application of the resulting materials includes their use in implantable medical devices, tissue engineering, soft robotics, and wearable electronics.<br/><br/><strong>Benefits/Features</strong><br/>•Single component, solvent-free, and moldable networks<br/>•Stimuli-responsive coloration<br/>•Stable at body temperature, resistant to swelling in fluids or drying in air<br/>•Tunable properties achieved without chemical crosslinking or additives<br/><br/><strong>Stage of Development </strong><br/>These materials have been prepared on a laboratory scale.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.nature.com/articles/nature23673\" target=\"_blank\">Mimicking biological stress–strain behaviour with synthetic elastomers</a></li>Nature 2017, 549, 497-501</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>AAV Vector Reprogramming of Adult Striatal Oligodendrocytes into Functional Neurons</h1><em>Technology #16-0079</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0079/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0079.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5339\"><a href=\"/categories/5331_life-sciences/5339_human-health\">Human Health</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li><li class=\"category\" id=\"category_5420\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5420_neurology\">Neurology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585048\"><a href=\"/inventors/18585048_thomas-mccown\">Thomas McCown</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186502\"><em><a href=\"http://google.com/patents/WO2018048877\" target=\"_blank\">PCT Patent Application WO 2018/048877</a></em></dd></dl></div><div class=\"content\"><p>Loss of functional neurons occurs in neuropathologies including Parkinson’s disease, Lou Gehrig’s disease, Huntington’s disease and Alzheimer’s disease.  Many researchers have tried to differentiate neurons from astrocytes or oligodendrocytes in the brain, but studies have always included transgenic mice and are not easily translated into the clinical setting.  A small interfering RNA has been developed that suppresses the polyprimidine tract binding protein, a protein shown to inhibit differentiation of fibroblasts into functional neurons. This siRNA was encapsulated into an AAV2 viral vector and delivered via injection into the brain of rats.  Six weeks following injection, oligodendrocytes had adopted a neuronal morphology. <br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28202388\" target=\"_blank\">Viral Vector Reprogramming of Adult Resident Striatal Oligodendrocytes into Functional Neurons.</a></li>Mol Ther. 2017 Apr 5;25(4):928-934. doi: 10.1016/j.ymthe.2017.01.016. Epub 2017 Feb 13.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Ceria Nanoparticles for the Treatment of Macular Degeneration and Retinoblastoma</h1><em>Technology #16-0108</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0108/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0108.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5421\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5421_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585036\"><a href=\"/inventors/18585036_zongchao-han\">Zongchao Han</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186495\"><em><a href=\"http://google.com/patents/WO2018152283\" target=\"_blank\">PCT Patent Application WO 2018/152283</a></em></dd></dl></div><div class=\"content\"><p>A novel formulation of ceria nanoparticles (nanoceria) has been developed for the treatment of oxidative stress-related disorders. Nanoceria possess unique antioxidant properties at physiological pH that make them candidates for the treatment of oxidative stress-related disorders and have intrinsic oxidase activity at acidic pH which make nanoceria a potential anti-tumor agent within the tumor microenvironment.  However, the poor solubility of nanoceria have historically limited their pharmacological application. We have developed a formulation of nanoceria, using a chitosan derivative, which renders them water soluble and allows for their synthesis in an aqueous environment. The formulation also provides a scaffold for surface engineering to allow for targeted delivery and the attachment of therapeutics, such as anti-cancer agents, for combination therapy.  We have demonstrated that these nanoceria have therapeutic efficacy in a murine model of age-related macular degeneration (AMD) and formulations in hydrogel provide sustained release for 2+ months in the eye. Additionally, our studies indicate that these nanoparticles have a synergistic anti-tumor effect when administered in combination with a chemotherapy agent and tumor-targeting ligand in both a genetic retinoblastoma mouse model and a xenograft retinoblastoma mouse model.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28463509\" target=\"_blank\">Glycol Chitosan Engineered Autoregenerative Antioxidant Significantly Attenuates Pathological Damages in Models of Age-Related Macular Degeneration.</a></li>ACS Nano. 2017 May 23;11(5):4669-4685. doi: 10.1021/acsnano.7b00429. Epub 2017 May 5.<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29752862\" target=\"_blank\">Nanoceria-loaded injectable hydrogels for potential age-related macular degeneration treatment.</a></li>J Biomed Mater Res A. 2018 May 12. doi: 10.1002/jbm.a.36450. [Epub ahead of print]</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Quercetin Prodrug Nanoparticle for Modifying Tumor Microenvironment</h1><em>Technology #16-0156</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0156/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0156.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585024\"><a href=\"/inventors/18585024_leaf-huang\">Leaf Huang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186486\"><em><a href=\"http://google.com/patents/WO2018172942\" target=\"_blank\">PCT Patent Application WO 2018/172942</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707990\"><a href=\"https://pharmacy.unc.edu/news/2017/04/25/huang-receives-2018-drug-targeting-lifetime-achievement-award/\" target=\"_blank\">2018 Drug Targeting Lifetime Achievement Award</a></dd><dd class=\"link\" id=\"link_12707991\"><a href=\"https://pharmacy.unc.edu/news/2015/09/14/unc-researchers-awarded-11-3-million-for-cancer-nanotechnology-research/\" target=\"_blank\">Cancer Nanotechnology Research Award</a></dd></dl></div><div class=\"content\"><p>Quercetin is a naturally occuring flavonoid commonly found in fruits and vegtables.  It has been shown to regulate many biological pathways that lead to apoptosis, angiogenesis inhibition and cellular proliferation.  Quercetin has been examined in several clinical trials as an anti-cancer, anti-tumor agent decades ago however due to poor water solubility and bioavailability has limited its use or approval as a potential anti-cancer therapeutic. Significant research efforts have been committed to overcome the poor physiochemical properties of quercetin without much success.  Therefore, alternative strategies are needed to improve the solubility and bioavailability of this potential therapeutic.<br/><br/>Recently, a novel solution to address the physiochemical properties associated with quercetin has been developed.  Briefly, UNC researchers led by Dr. Leaf Huang has developed a lipid calcium phosphate quercetin prodrug (LCP-QP) nanoparticle formulation which overcomes the aforementioned challenges.  LCP-QP nanoparticle formulation is able to obtain high drug loading capacities while maintaining a small particle size, increased stability, and bioavailability.  Moreover, the LCP-QP formulation results in increased tumor accumulation, cellular uptake, and intracellular release of the quercetin prodrug.  LCP-QP also deploys a tumor-specific targeting molecule to enhance its delivery of the therapeutic payload. Recent preliminary studies have illustrated significantly enhanced antitumor efficiency while mainitaining a favorable toxicity safety profile.  </p><p><b>Related Publications:</b></p><ul><li><a href=\"https://pubs.acs.org/doi/abs/10.1021/acsnano.7b01522\" target=\"_blank\">Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles</a></li></ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Peptidomimetic and Screening Assay Targeting G-alpha-q for the Treatment of Melanoma</h1><em>Technology #12-0098</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/12-0098/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/12-0098.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584873\"><a href=\"/inventors/18584873_john-sondek\">John Sondek</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186395\"><em><a href=\"http://google.com/patents/US9540620\" target=\"_blank\">US Patent US 9540620</a></em></dd></dl></div><div class=\"content\"><p>G-alpha-q proteins play a critical role in the signaling cascade that induces and maintains proliferation in the majority of cells. Mutated G-alpha-q, which is constitutively active, is found in the majority of uveal melanomas, which has a 50% chance of metastasizing to the liver.  Mutated G-alpha-q has also been associated with other cancers, such as breast cancer.  A novel peptidomimetic has been designed that specifically and potently binds to G-alpha-q, thereby inhibiting downstream signaling.  Furthermore, a high-throughput assay has been developed to identify small molecule inhibitors of G-alpha-q using this peptidomimetic. These findings suggest that this peptidomimetic has potential as a potent inhibitor of uveal melanoma growth and as a tool to discover new small molecule inhibitors of G-alpha-q.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Modified HEK293 Cell Line with Enhanced Adherence</h1><em>Technology #03-0030</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/03-0030/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/03-0030.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584799\"><a href=\"/inventors/18584799_john-olsen\">John Olsen</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186340\"><em><a href=\"http://google.com/patents/US7939326\" target=\"_blank\">US Patent US 7939326</a></em></dd></dl></div><div class=\"content\"><p>A modified line of HEK293 cells has been developed that has enhanced adhesion to untreated plastic and glass surfaces. This “sticky” line of HEK293 cells expresses two surface integrins which form a receptor that enables the cells to bind strongly to a wide range of extracellular molecules. In order to enhance the adherence of unmodified HEK293 cells, researchers must use expensive treatments of culture vessels. Therefore, this novel, modified “sticky” line of HEK293 cells will translate into significant savings for a variety of bio-product manufacturing operations.   </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Inhibition of Type I Interferon Signaling to Enhance T Cell Recovery and Reduce HIV-1 Reservoirs During Combined Antiretroviral Therapy</h1><em>Technology #16-0154</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0154/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0154.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585026\"><a href=\"/inventors/18585026_lishan-su\">Lishan Su</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186488\"><em><a href=\"http://google.com/patents/WO2018081197\" target=\"_blank\">PCT Patent Application WO2018/081197</a></em></dd></dl></div><div class=\"content\"><p>Combined antiretroviral therapy (cART) efficiently suppresses HIV-1 replication and enhances the number of immune cells in infected individuals.  However, it does not rescue their immune hyperactivation and dysfunction.  We have demonstrated that treatment of HIV-1  persistently infected humanized mice with an anti-IFN-alpha/beta receptor (IFNAR) antibody in the presence of cART fully reversed HIV-1-induced immune hyeractivation and restored anti-HIV-1 immune responses in T cells from such HIV-1 infected humanized mice.  In addition, treatment of the humanized mice with the anti-IFNAR antibody reduced the size of HIV-1 reservoirs in lymphoid tissues during cART.  Data suggests that this approach could enhance the management of HIV-1 infection since mice treated with the anti-IFNAR antibody demonstrate an enhanced delay of the return of HIV-1 titers after the cessation of cART therapy. </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27941247\" target=\"_blank\">Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.</a></li>J Clin Invest. 2017 Jan 3;127(1):269-279. doi: 10.1172/JCI90745. Epub 2016 Dec 12</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Heterochromatin Gene Repression Inhibitors as Novel Epigenetic Cancer Therapeutics</h1><em>Technology #17-0152</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0152/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0152.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585097\"><a href=\"/inventors/18585097_nate-hathaway\">Nate Hathaway</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186516\"><em><a href=\"http://google.com/patents/WO2019006322\" target=\"_blank\">PCT Patent Application WO 2019/006322</a></em></dd></dl></div><div class=\"content\"><p>Heterochromatin gene repression is a major mammalian regulatory pathway that recently was found dysregulated in multiple human cancers including those of the liver and breast. Research in the Hathaway lab has identified a series of cell-permeable, potent, and specific inhibitors of the HP1-mediated heterochromatin gene repression pathway. Our four lead compounds represent a new class of epigenetic inhibitors capable of inhibiting global heterochromatin gene repression as measured by the signature heterochromatin mark H3K9me3.<br/> <br/><strong>Potential Applications:</strong><br/>Genomic studies have revealed that chromatin-based mechanisms are driver mutations in an expansive set of human malignant diseases and underlie the pathology of many cancers. The precise role of heterochromatin in cancer is complicated and still not entirely clear, this is partially due to the lack of even poor chemical inhibitors of the HP1 pathway. HP1 is overexpressed in human cancers of the breast, prostate, and pancreas. High levels of H3K9me3 (the signature mark of heterochromatin) strongly correlate with mutation rates in human cancers 9. Elevated HP1 levels correlate with decreased survival of patients with breast (HP1a) and prostate cancer (HP1?). Knockdown of one of the HP1 pathway HMT enzymes SetDB1 has antiproliferative on hepatocellular carcinoma <em>in vitro</em> and reduced tumorigenicity in mouse liver cancer models. These lines of evidence demonstrate that disruption of the HP1 pathway is a viable approach to treating multiple types of human cancer.<br/> <br/><strong>Partnering opportunities:</strong><br/>-       Further medicinal chemistry optimization of lead compounds<br/>-       Development in cancer model systems<br/>-       Use of our unique screening platform to identify new heterochromatin inhibitors<br/> </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Human African Trypanosomiasis (HAT) Compounds</h1><em>Technology #16-0082</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0082/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0082.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585044\"><a href=\"/inventors/18585044_richard-tidwell\">Richard Tidwell</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186499\"><em><a href=\"http://google.com/search?#q=PCT%2FUS2017%2F014256&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">PCT Patent Application PCT/US2017/014256</a></em></dd></dl></div><div class=\"content\"><p>Sleeping sickness or human African trypanosomiasis (HAT) is endemic in 37 African countries and around 13 million people are at medium to high risk of being infected.  Sleeping sickness is transmitted by the tsetse fly and is usually fatal without treatment. It occurs in two stages; the early stage (stage 1) with non-specific symptoms, often un- or misdiagnosed - the late stage (stage 2) where the parasite crosses the blood-brain barrier, causing serious neurological disorders including sleep cycle disruptions, neurological manifestations, and progressive mental deterioration.  Until 2009, treatments for stage 2 of the disease were toxic or difficult to administer.  Conventional combination therapy Nifurtimox-Eflornithine (NECT), replaced the toxic arsenic-based treatments for HAT. Although effective in treating stage 2 HAT, NECT has led to a decrease in the disease incidence. The need for new anti-HAT drugs persists, as current drugs are few, antiquated, toxic, prone to resistance, and require parenteral administration.<br/><br/>Research at UNC and collaborators have developed a novel class of oral compounds capable of crossing the blood brain barrier (BBB) with enhanced properties to combat this highly neglected disease.  This work describes the synthesis of analogues that may be effective for the treatment of early and late stage HAT, Chagas disease, and potentially Animal African Trypanosomiasis (AAT). </p><p><b>Related Publications:</b></p><ul><li><a href=\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01163\" target=\"_blank\">Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis.</a></li></ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Fluorogenic Phospholipase C (PLC) Reporter Assay</h1><em>Technology #17-0089</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0089/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0089.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585129\"><a href=\"/inventors/18585129_qisheng-zhang\">Qisheng Zhang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186536\"><em><a href=\"http://google.com/patents/WO2018142365\" target=\"_blank\">PCT Patent Application WO 2018/142365</a></em></dd></dl></div><div class=\"content\"><p>A membrane-associated fluorogenic reporter (XY-69) has been developed that selectively reports phosphatidylinositol-specific phospholipase C (PLC) isozyme activity, both with purified enzymes and in cell lysates. Furthermore, XY-69, but not other soluble fluorogenic PLC reporters, recaptures the direct activation of PLC activity by Gaq, which requires the presence of membranes. Consequently, XY-69 can be used to replace the radiolabeled PIP2 in the traditional PLC assays and has the potential applications to monitor cellular PLC activity with spatiotemporal resolution and to identify both orthosteric and allosteric inhibitors of PLC isozymes in high-throughput screens for testing purposes and drug discovery, particularly in the area of immunological diseases and cancer.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jbc.org/content/early/2017/12/20/jbc.RA117.000926\" target=\"_blank\">A membrane-associated, fluorogenic reporter for mammalian phospholipase C isozymes</a></li>doi: 10.1074/jbc.RA117.000926\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Bi-functional Chemical Epigenetic Modifiers (CEM)s</h1><em>Technology #17-0151</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0151/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0151.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585100\"><a href=\"/inventors/18585100_nate-hathaway\">Nate Hathaway</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186518\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Epigenome editing is a powerful method for life science research and offers great potential for the development of therapeutics for human diseases such as cancers and autoimmune disorders. The underlying mechanisms by which histone-modifying proteins work in concert to properly regulate gene expression still remain largely unkown. UNC inventors have developed a small-molecule platform for specifically inducing gene repression and histone deacetylation at a reporter gene to investigate and manipulate complex epigenetic interactions in live cells.  <br/><br/><strong>C</strong>hromatin <strong>E</strong>pigenetic <strong>M</strong>odifers (CEMs) technology can intricately control gene expression of any mammalian gene.  The technology platform utilizes a new bifunctional small molecules to bind endogenous gene regulatory enzymes and recruit these enzymes to the desired gene using deactivated dCAS9 gene targeting. These novel compounds have been deployed in a dose-dependent and reversible fashion to repress gene expression in a murine stem cell model system. Our fresh approach details a new method of synthetically controlling gene expression programs using the cell’s own machinery and has broad applications in drug discovery research. The advantage of our technique over other currently developed strategies is the use of the bifunctional CEM to control activity. <br/><br/><strong>Potential Applications:</strong><br/>Cancer therapeutics: Our CEM technique can be used to repress key oncogenes driving cancer. Alternatively, it can be used to activate tumor suppressor genes that have been epigenetically silenced in cancer. We are currently testing both approaches in colon and prostate cancer models.<br/><br/>Discovery research: This chemical technology is modular and can be used to study a variety of chromatin regulation pathways, by making CEMs that engage other chromatin enzymes.<br/> <br/><strong>Partnering opportunities:</strong></p><ul>\n",
       "  <li>Further medicinal chemistry optimization of technology</li>\n",
       "  <li>Application as a cancer therapeutic or other human diseases driven by gene misregulation</li>\n",
       "  <li>Application in discovery research</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul><li><a href=\"http://pubs.acs.org/doi/abs/10.1021/acssynbio.7b00295\" target=\"_blank\">Targeted Gene Repression Using Novel Bifunctional Molecules to Harness Endogenous Histone Deacetylation Activity</a></li></ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: FOXJ1-EGFP Transgenic Mouse</h1><em>Technology #18-0013</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0013/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0013.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585243\"><a href=\"/inventors/18585243_lawrence-ostrowski\">Lawrence Ostrowski</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This mouse line expresses the reporter gene EGFP from the promoter of FoxJ1: a transcription factor whose expression is restricted to cells possessing motile cilia or flagella. This promoter has been demonstrated to be highly specific for motile ciliated cells, and transgene-positive mice demonstrate strong EGFP expression in the ciliated cells of tracheal, bronchial, and nasal epithelium. These mice were developed in order to identify a desirable, cell-specific promoter to use in gene therapy for cystic fibrosis as described in the listed publication. In addition to cystic fibrosis, these mice could potentially be used in studies of other diseases that affect ciliated cells such as chronic respiratory infections and polycystic kidney disease.<br/><br/>These mice are available at The Jackson Laboratory and can be found at <a href=\"https://www.jax.org/strain/010827\" target=\"_blank\">https://www.jax.org/strain/010827</a>.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.sciencedirect.com/science/article/pii/S1525001603002211?via%3Dihub\" target=\"_blank\">Targeting Expression of a Transgene to the Airway Surface Epithelium Using a Ciliated Cell-Specific Promoter</a></li>Mol Ther. 2003 Oct;8(4):637-45.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Monoclonal Antibody: Anti-CDC42 Monoclonal Antibody</h1><em>Technology #18-0041</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0041/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0041.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5345\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5345_antibodies\">Antibodies</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585217\"><a href=\"/inventors/18585217_patrick-brennwald\">Patrick Brennwald</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This monoclonal antibody binds equally well to yeast and human Cdc42: a GTPase of the Rho family that helps regulate signaling pathways by orienting the actin and secretory pathways toward a nascent bud site. This antibody can detect Cdc42 by western blot, immunoprecipitation and ELISA, which allows the measurement of Cdc42 in a vast number of studies. Unlike other methods to detect Cdc42 that subject cells to lysis reagents or require another fluorescently tagged protein, the use of this antibody allows quantitative assessment of Cdc42. This antibody was used in a novel <em>in vivo</em> assay to investigate the role of vesicle trafficking in the regulation of Cdc42 polarity in the publication listed below.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953063/\" target=\"_blank\">“The Function of Two Rho Family GTPases Is Determined by Distinct Patterns of Cell Surface Localization”</a></li>Mol Cell Biol. 2010 Nov; 30(21): 5207–5217.<li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159490/\" target=\"_blank\">“The Neural Cell Adhesion Molecule (NCAM) Promotes Clustering and Activation of EphA3 Receptors in GABAergic Interneurons to Induce Ras Homolog Gene Family, Member A (RhoA)/Rho-associated protein kinase (ROCK)-mediated Growth Cone Collapse”</a></li>J Biol Chem. 2016 Dec 16; 291(51): 26262–26272.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Conditional knockout of Dnaic1</h1><em>Technology #18-0012</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0012/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0012.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585248\"><a href=\"/inventors/18585248_lawrence-ostrowski\">Lawrence Ostrowski</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>These mice carry a floxed allele of the Dnaic1 gene and, after recombination with a Cre carrying mouse line, can be used to delete the Dnaic1 gene resulting in immotile cilia and a mouse model of primary ciliary dyskinesia (PCD). Until these mice were developed, studies of PCD had been hampered by the lack of suitable mouse models as disruption of ciliary genes typically results in lethal hydrocephalus. The Cre-mediated deletion of the Dnaic1 gene occurs with high efficiency, and this model of PCD replicates features of the human disease, as mice treated to induce the deletion of the Dnaic1 gene develop rhinosinusitis. This model is useful for studies of the pathogenesis and treatment of PCD and other airway diseases. More information regarding the development and studies utilizing these mice can be found in the listed publications.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.atsjournals.org/doi/abs/10.1165/rcmb.2009-0118OC?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed\" target=\"_blank\">Conditional Deletion of Dnaic1 in a Murine Model of Primary Ciliary Dyskinesia Causes Chronic Rhinosinusitis</a></li>Am J Respir Cell Mol Biol Vol 43. pp 55-63, 2010 <li><a href=\"http://www.nature.com/articles/gt201379\" target=\"_blank\">Restoring ciliary function to differentiated primary ciliary dyskinesia cells with a lentiviral vector</a></li>Gene Therapy (2014) 21, 253-261 (2014)</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Human Factor IX for Treatment of Hemophilia B with Extended Half-life and Enhanced Specific Activity</h1><em>Technology #16-0027</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0027/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0027.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585069\"><a href=\"/inventors/18585069_tal-kafri\">Tal Kafri</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186508\"><em><a href=\"http://google.com/patents/US20180305439\" target=\"_blank\">US Patent Pending US 2018-0305439</a></em></dd></dl></div><div class=\"content\"><p>Codon-optimized Factor IX (FIX) with several modifications have been developed that produce Factor IX with an extended half-life and enhaced specific activity when delivered via gene therapy or when manufactured to deliver protein replacement therapy in hemophilia B patients. <br/> <br/>Features and Advantages<br/>·      FIX proteins have higher specific activity, longer useful clotting function, and longer half-life<br/>·      FIX protein is expressed from a single expression cassette, which facilitates efficient <em>in vivo</em> delivery by viral vectors<br/>·      Can be used to establish human-FIX producing cell lines</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Enhancing Purity and Safety of AAV Vector Preparations for Gene Therapy</h1><em>Technology #15-0118</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0118/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0118.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584955\"><a href=\"/inventors/18584955_aravind-asokan\">Aravind Asokan</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186442\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A novel method has been developed to resolve the mass landscape of whole viral particles, capsid intermediates, and viral genomes present in adeno-associated virus (AAV) vector preparations based on charge detection mass spectrometry (CDMS). CDMS not only provides an accurate analysis of diversity within AAV vector preparations, but it can dramatically shorten the analysis time. CDMS can also enhance current quality control protocols for AAV vector analysis, help identify potential contaminants, and also shed light on AAV capsid dynamics during the infectious pathway.  This method will have a significant impact on clinical AAV vector preparations which often contain variable levels of full or partial-genome containing particles and empty vectors. Consequently,  the composition of these preparations can influence vector dose-related immunotoxicity in patients. This novel method has the potential to greatly increase the efficiency, purity, and safety of AAV therapy.    <br/> <br/><em>Features and Advantages</em><br/>·      Novel method that analyzes the entire landscape of AAV vector preparations<br/>·      Can establish the mass and stoichiometry of AAV capsids complexed with exogenous proteins, nucleic acids, or carbohydrates<br/>·      Determines the purity of recombinant AAV preparations for clinical applications<br/>·      Shortens the analysis time from hours to minutes, and can be seamlessly integrated into current quality control protocols </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27310298\" target=\"_blank\">Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry</a></li>Anal Chem. 2016 Jul 5;88(13):6718-25. doi: 10.1021/acs.analchem.6b00883. Epub 2016 Jun 16.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Enhanced Integration-deficient Lentiviral Vectors that are Resistant to Epigenetic Silencing</h1><em>Technology #14-0070</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0070/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0070.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5460\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5460_gene-therapy\">Gene Therapy</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584921\"><a href=\"/inventors/18584921_tal-kafri\">Tal Kafri</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186432\"><em><a href=\"http://google.com/patents/US20180320198\" target=\"_blank\">US Patent Pending US 2018-0320198</a></em></dd></dl></div><div class=\"content\"><p>Integration deficient lentiviral vectors (IDLVs) efficiently ferry large genetic constructs to both dividing and non-dividing cells <em>in vitro </em>and <em>in vivo</em>. The stable genome of IDLVs allows for successful and long-term gene expression in non-dividing and slowly-dividing cells. In dividing cells, the presence of IDLVs is transient, and is thus used to express potentially toxic proteins whose function is required for a short time such as genome-editing proteins and de-differentiation factors. IDLVs are a promising system for delivery of foreign or native gene sequences, however transcriptional silencing of IDLVs reduces the transgene expression, and overall efficacy of IDLVs.<br/> <br/>IDLVs have been developed that are resistant to epigenetic silencing through a series of mutations, deletions of specific binding sites of host factors, and additions of DNA sequences. Additionally, a method targeting cell conditioning to enhance transgene expression from IDLVs has been developed, which involves the delivery of shRNA expression cassettes, siRNAs, and FDA approved chemicals that inhibit epigenetic silencing. These improvements have the potential to significantly enhance transgene expression from IDLVs, and allow IDLVs to be more widely used as a gene delivery system.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Chimeric VLP for Vaccination Against G11.4 Norovirus Strains</h1><em>Technology #13-0036</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0036/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0036.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584902\"><a href=\"/inventors/18584902_ralph-baric\">Ralph Baric</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_447\"><a href=\"/managers/447_kyle-bartholomew\">Kyle Bartholomew</a> <div><em></em> <em></em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186422\"><em><a href=\"http://google.com/patents/US9975923\" target=\"_blank\">US Patent 9,975,923</a></em></dd></dl></div><div class=\"content\"><p>A virus-like particle (VLP) has been developed in order to induce a more broadly blocking immune response against G11.4 strains of norovirus. This VLP contains multiple epitopes of different strains of norovirus in a backbone of a single strain, and consequently induces a more broadly blocking immune response than single strains alone. G11.4 noroviruses account for the majority of all norovirus outbreaks, however no approved vaccine against this strain of norovirus exists due to the antigenic variation of G11.4 variations. This novel VLP can avoid this problem, and can be used to develop a human norovirus vaccine against current and emerging G11.4 strains. <br/> <br/><strong>Features and Advantages</strong><br/>·      This novel, chimeric VLP induces a broader immune response than single strains of norovirus alone<br/>·      Allows for vaccination despite the heterogeneous nature of G11.4 noroviruses<br/>·      Development of a norovirus vaccine could prevent the annual 21 million norovirus infections, and 200,000 deaths in children under 5 years old worldwide</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24741081\" target=\"_blank\">Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.</a></li>J Virol. 2014 Jul;88(13):7256-66. doi: 10.1128/JVI.00785-14. Epub 2014 Apr 16.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Multivalent Vaccine Antigen that Protects Against Divergent Strains of Coronavirus</h1><em>Technology #13-0091</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0091/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0091.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584890\"><a href=\"/inventors/18584890_ralph-baric\">Ralph Baric</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_366\"><a href=\"/managers/366_jennifer-dean\">Jennifer Dean</a> <div><em></em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186411\"><em><a href=\"http://google.com/patents/US9884895\" target=\"_blank\">US Patent 9,884.895</a></em></dd></dl></div><div class=\"content\"><p>A chimeric antigen has been developed for use in the design of vaccines against coronaviruses, such as SARS-CoV, MERS-CoV, and veterinary strains. This antigen contains spike proteins from three different coronavirus strains and has been shown to provide complete protection against SARS-CoV in a mouse model.  Despite epidemic outbreaks, there are currently no FDA approved vaccines for SARS-CoV or MERS-CoV. Consequently, reemergence of the virus could have a huge impact on public health, biodefense, and the global economy. In addition, the technology could be used to develop more efficacious vaccines against coronaviruses that impact domestic animals and livestock.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Apoe-Flox Mice: Selective Suppression of Apolipoprotein E</h1><em>Technology #18-0066</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0066/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0066.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585206\"><a href=\"/inventors/18585206_nobuyo-maeda\">Nobuyo Maeda</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>These mice possess loxP sites on either side of the <em>Apoe</em> gene which allows for selective, tissue-specific suppression of adipose tissue apolipoprotein E (apoE) expression and normal circulating levels. Unlike mice containing global knockout of apoE, when these mice are bred to mice that express Cre recombinase, the resulting offspring will have exon 3 deleted in only the cre-expressing tissues which can provide better insight in the function of apoE in specific tissues. A primary role of apoE is the mediation of lipid transport throughout various tissues and cells, and consequently these mice can be used in a vast range of studies including metabolism, regulation of the immune system, and neurodegenerative and cardiovascular disease. More information regarding the generation of, and studies using these mice can be found in the listed publication.<br/><br/>These mice are available at The Jackson Laboratory, and can be found at <a href=\"https://www.jax.org/strain/028530\" target=\"_blank\">https://www.jax.org/strain/028530</a>. </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jlr.org/content/56/2/215.long\" target=\"_blank\">Selective suppression of adipose tissue apoE expression impacts systemic metabolic phenotype and adipose tissue inflammation</a></li>J Lipid Res. 2015 Feb; 56(2): 215–226. </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Synthetic Platform for Alkane Functionalization: Site-Selective Aliphatic C-H Dithiocarbonation</h1><em>Technology #16-0005</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0005/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0005.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585083\"><a href=\"/inventors/18585083_erik-alexanian\">Erik Alexanian</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This synthetic platform enables aliphatic C-H bond functionalization and xanthylation using N-xanthylamides and visible light. Unlike other C-H functionalizations which require specific functionality present in the substrate and lack generality in applications to diverse structures, this site-selective transformation facilitates a remarkably efficient and general approach for the introduction of the xanthate functional group into a diverse array or organic small molecules. The requisite N-xanthylamides are easily accessible on scale from the parent N-chloroamides and potassium ethyl xanthate. C-H bond functionalization is a powerful tool for chemical synthesis, and as the xanthate functional group is readily converted to a broad range of valuable synthetic functionality, this approach has a broad utility in organic synthesis. More information regarding this platform can be found in the listed publication below.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://pubs.acs.org/doi/10.1021/jacs.6b09414\" target=\"_blank\">C-H Xanthylation: A Synthetic Platform for Alkane Functionalization</a></li>J Am Chem Soc. 2016, 138 (42), pp 13854-13857. </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Antibody Therapeutic for the Treatment of Lupus</h1><em>Technology #17-0011</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0011/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0011.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585165\"><a href=\"/inventors/18585165_barbara-vilen\">Barbara Vilen</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186549\"><em><a href=\"http://google.com/patents/WO2018064603\" target=\"_blank\">PCT Patent Application WO 2018/064603</a></em></dd></dl></div><div class=\"content\"><p>Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease with underlying genetic and environmental etiologies. Multiple single genes, molecular events, and cell types have been implicated in disease; however, recent therapies targeting single gene products (B-cell Activating Factor, BAFF) or single cells (B cells) have shown marginal therapeutic success. To improve efficacy, we developed a strategy to target immune dysregulation upstream of multiple SLE-associated pathologies. This strategy is based on our findings that lysosomes in lupus-prone mice fail to acidify and degrade immune complexes (IgG autoantibody bound to dead cell debris; IgG-immune complexes). In addition, we show that undegraded IgG-immune complexes promote chronic binding of IgG-immune complexes to particular receptors leading to BAFF and IFNa secretion, B cell activation and autoantibody production, and cell migration and renal disease. To restore lysosome acidification and facilitate the degradation of IgG-immune complexes that are pathognomonic of lupus, we attenuate the lysosome defect and restore degradation of IgG-immune complexes by crosslinking two key surface receptors. Using a PEG-based molecule where intact antibodies binding each receptor were conjugated at differing ratios, we show that crosslinking these receptors restores lysosome acidification, clears the plasma membrane of recycled receptors, and diminishes signal transduction from the target receptors. Future work will focus on designing multivalent, bispecific antibodies to these targets.  This innovation is differentiated from other therapeutics because it targets events in disease that are upstream of multiple disease-related endpoints. We predict this strategy holds potential for better patient outcomes in SLE than targeting single molecules or events.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29866702\" target=\"_blank\">mTORC2 Activity Disrupts Lysosome Acidification in Systemic Lupus Erythematosus by Impairing Caspase-1 Cleavage of Rab39a</a></li>J Immunol. 2018 Jul 15;201(2):371-382</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Diagnostic for ANCA-Associated Vasculitis Relapse</h1><em>Technology #17-0046</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0046/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0046.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585154\"><a href=\"/inventors/18585154_dominic-ciavatta\">Dominic Ciavatta</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186545\"><em><a href=\"http://google.com/patents/WO2018071524\" target=\"_blank\">PCT Patent Application WO 2018/071524</a></em></dd></dl></div><div class=\"content\"><p>ANCA-associated vasculitis (AAV) is an autoimmune disease primarily caused by neutrophil granule proteins encoded by the genes MPO and PRTN3. AAV is characterized by vascular inflammation, and patients cycle between disease remissions interrupted by relapses of active disease. Consequently, many patients are treated with maintenance immunosuppressive drugs that can have cumulative toxic effects including infertility and malignancies after long-term exposure. Therefore, insight about disease prognosis is vital to patient care, and important to determine whether a patient needs maintenance immunosuppressive treatments. Unfortunately the amount of circulating autoantibodies is not an adequate marker of remission or disease state, and there is no reliable biomarker to indicate a state of remission.  DNA methylation in the PRTN3 promoter has been identified as an accurate indicator of remission status in AAV patients. Specifically, DNA methylation of PRTN3 was increased in patients in remission compared to those with activate disease. Importantly, patients with increased levels of DNA methylation had a greater probability of remaining in remission. PRTN3 methylation is a valuable biomarker that can predict the likelihood of disease remission. Using this finding will allow physicians to better understand the disease status of their patients and ultimately make better treatment decisions, such as whether or not maintenance immunosuppressive therapy is necessary. Having a reliable biomarker can significantly improve the treatment for AAV patients.<br/><br/>Advantages:</p><ul>\n",
       "  <li>Methylation state of PRTN3 is a novel biomarker for AAV disease status</li>\n",
       "  <li>Can inform clinicians of disease status of patients, predict the likelihood of stable disease remission, and enhance patient treatment</li>\n",
       "  <li>Can be useful in clinical trials designed to induce or maintain remission</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27821628\" target=\"_blank\">Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis</a></li>J Am Soc Nephrol. 2017 Apr;28(4):1175-1187. doi: 10.1681/ASN.2016050548. Epub 2016 Nov 7.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Recombinant Flavivirus (including Dengue and Zika) Quaternary Epitopes for Vaccines and Diagnostics</h1><em>Technology #16-0047</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0047/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0047.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5452\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5452_infectious-disease\">Infectious Disease</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585062\"><a href=\"/inventors/18585062_aravinda-desilva\">Aravinda Desilva</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186505\"><em><a href=\"http://google.com/patents/US20180280494\" target=\"_blank\">US Patent Pending US 2018-0280494</a></em></dd></dl></div><div class=\"content\"><p>Dengue virus is the causative agent of dengue fever and dengue hemorrhagic fever, but there is currently no approved vaccine for the virus. Research at UNC has identified that a majority of the strongly neutralizing antibodies produced during dengue infection are targeted to the quaternary structure of the envelope E protein. However, since recombinant proteins are secreted as monomers, the key quaternary epitopes targeted by human antibodies are not displayed on recombinant proteins limiting effective vaccine design. A method has been developed to assemble recombinant dengue envelope proteins that display the quaternary structures needed to induce potent neutralizing antibodies. The ability to generate neutralizing antibodies from recombinant quaternary envelope proteins could expedite the development of an effective vaccine against dengue virus.  <br/><br/>Advantages:</p><ul>\n",
       "  <li>Recombinant dengue quaternary envelope proteins provide optimal epitopes for vaccine and diagnostic design</li>\n",
       "  <li>Antibodies against dengue envelope E proteins are more likely to provide to a broad protective response against all four dengue serotypes</li>\n",
       "  <li>Displaying quaternary epitopes on recombinant proteins can be used to develop vaccines against other flaviviruses as well as dengue virus, such as zika.</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/articles/s41598-017-04767-6\" target=\"_blank\">In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers</a></li>Sci Rep. 2017 Jul 3;7(1):4524. </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Use of Tardigrade Proteins to Stabilize Biological Materials, Industrial Enzymes, and Agricultural Products</h1><em>Technology #16-0158</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0158/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0158.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5313\"><a href=\"/categories/5313_agriculture-horticulture\">Agriculture &amp; Horticulture</a><ul><li class=\"category\" id=\"category_5314\"><a href=\"/categories/5313_agriculture-horticulture/5314_ag-biotech\">Ag Biotech</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585022\"><a href=\"/inventors/18585022_gary-pielak\">Gary Pielak</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_371\"><a href=\"/managers/371_kelly-parsons\">Kelly Parsons</a> <div><em>Associate Director, Technology Commercialization</em> <em>919.962.6277</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186482\"><em><a href=\"http://google.com/patents/WO2018034867\" target=\"_blank\">PCT Patent Application WO 2018034867</a></em></dd></dl></div><div class=\"content\"><p>The instability of many high value industrial enzymes and life saving biologics, including vaccines and protein-based pharmaceuticals, require that such materials be produced, transported and stored under refrigerated conditions, which adds difficulty and expense. Lyophilization is an alternate storage method that allows some pharmaceuticals to be stored at room temperature. Unfortunately, many proteins denature and lose activity in the lyophilization process. Additionally, agents currently used to prevent desiccation-induced inactivation do not work for all products. By studying the ability of tardigrade organisms to withstand desiccation, a group of proteins has been identified that maintain the structural and functional integrity of proteins in both hydrated and dry states. Methods to purify these Tardigrade Disordered Proteins (TDPs) have been developed, and studies show that TDPs preserve the functional integrity of proteins exposed to desiccation, which enables the lyophilization process. TDPs can also be utilized at high concentrations without aggregation. This technology has the potential to improve and simplify the production and storage of numerous products, including vaccines, industrial enzymes and seeds. <br/><br/><strong>Advantages</strong>:<br/>·      TDPs stabilize proteins in both hydrated and dry states<br/>·      TDPs protect the functionality of lyophilized proteins<br/>·      Could reduce or eliminate the need to refrigerate sensitive biological materials and enzymes<br/>·      Could be used to increase the drought tolerance of crops<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28306513\" target=\"_blank\">Tardigrades Use Intrinsically Disordered Proteins to Survive Desiccation</a></li>Mol Cell. 2017 Mar 16;65(6):975-984.e5. doi: 10.1016/j.molcel.2017.02.018.<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28901557\" target=\"_blank\">Intrinsically Disordered Proteins and Desiccation Tolerance: Elucidating Functional and Mechanistic Underpinnings of Anhydrobiosis</a></li>Bioessays. 2017 Sep 13. doi: 10.1002/bies.201700119. [Epub ahead of print]</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Method for Detecting Coagulation Inhibitors</h1><em>Technology #13-0032</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0032/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0032.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584904\"><a href=\"/inventors/18584904_dougald-monroe\">Dougald Monroe</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_366\"><a href=\"/managers/366_jennifer-dean\">Jennifer Dean</a> <div><em></em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186424\"><em><a href=\"http://google.com/patents/US9989532\" target=\"_blank\">US Patent 9,989,532</a></em></dd></dl></div><div class=\"content\"><p>An ELISA-like diagnostic test has been developed to identify three commonly used anticoagulants (heparin, rivaroxaban, and dabigatran) in a patient sample. The assay is based on combinations of four different substrates, and can quantitate the amount of anticoagulants as well as identify the type of coagulant(s) present in a patient. This assay detected levels of dabigatran from plasma of mice fed a dabigatran-containing anticoagulant, which demonstrated the functionality and efficacy of the assay. In some situations, such as a patient undergoing an emergency surgery, it may be of critical important for a physician to evaluate levels of circulating anticoagulants to ensure patient safety.<br/><br/>Advantages:<br/>·      Can detect the specific anticoagulants even if other inhibitors are present<br/>·      Will work with newly developed compounds that have the same function<br/>·      A modification of this test could be used to assay for other inhibitors<br/>·      Can also determine the amount of specific anticoagulants </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Nematostella VKOR for the Production of Vitamin K-Dependent Blood Coagulation Factors</h1><em>Technology #09-0107</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/09-0107/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/09-0107.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5333\"><a href=\"/categories/5331_life-sciences/5333_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5453\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5453_biologics\">Biologics</a></li><li class=\"category\" id=\"category_5454\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5454_orphan-rare-diseases\">Orphan &amp; Rare Diseases</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584837\"><a href=\"/inventors/18584837_darrel-stafford\">Darrel Stafford</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_366\"><a href=\"/managers/366_jennifer-dean\">Jennifer Dean</a> <div><em></em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186365\"><em><a href=\"http://google.com/patents/US9631002\" target=\"_blank\">US Patent US 9631002</a></em></dd></dl></div><div class=\"content\"><p>Recombinant Vitamin K-dependent blood coagulation factors such as factors VII, IX , and protein C are clinically important for the treatment of hemophilia and various disorders associated with protein C deficiency.  These factors have to be produced in eukaryotic cells due to their requirement for vitamin K-dependent post-translational modification to be functionally active.  Vitamin K epoxide reductase (VKOR) is the rate limiting factor in eukaryotic cell systems for producing these factors.   It has been identified that <em>Nematostella </em>VKOR can be utilized during vitamin K-dependent protein production to greatly increase the amount of functional, carboxylated vitamin K-dependent proteins produced by the eukaryotic cell systems.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>A System for Photo-induced Protein Dissociation</h1><em>Technology #16-0164</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0164/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0164.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585016\"><a href=\"/inventors/18585016_klaus-hahn\">Klaus Hahn</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>LOVTRAP (LOV2 trap and release of proteins) is an optogenetic system capable of repeatedly and reversibly controlling protein activity with precise kinetics, and is easily applicable to many proteins. This system involves the proteins Zdk and LOV2, and Zdk binds to the dark state of LOV2. When the protein of interest is fused to either Zdk or LOV2, the protein of interest is sequestered away from its site of action in the dark, but is freed to move to its site of action upon irradiation. This approach improves upon previously available methods, as it provides diffusion-limited activation kinetics and deactivation rates can be tuned as described in the listed publication. Additionally, proteins caged by LOVTRAP are not controlled through light-induced delivery to specific subcellular locations; hence, they can act at multiple sites of activation.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/articles/nmeth.3926\" target=\"_blank\">LOVTRAP: an optogenetic system for photoinduced protein dissociation</a></li>Nat Methods. 2016 Sep;13(9):755-8</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Protein: Genetically Encoded Inhibitor of KEAP1</h1><em>Technology #17-0078</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0078/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0078.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585140\"><a href=\"/inventors/18585140_brian-kuhlman\">Brian Kuhlman</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This engineered monobody (R1) is a potent competitive inhibitor of the KEAP1–NRF2 interaction.  Nuclear factor erythroid 2-related factor (NRF2) is a transcription factor that serves as a key modulator of cellular oxidative environment. Under basal conditions, Kelch-like ECH-associated protein 1 (KEAP1) binds NRF2 and promotes its degradation by ubiquitylation. Changes in the redox environment, such as oxidative stress, lead to modification of key cysteines within KEAP1 which results in NRF2 protein accumulation and the subsequent transcription of genes important for restoring the cellular redox state. In human cells, R1 tightly bound KEAP1, and freed NRF2 from KEAP1 resulting in activation of the NRF2 promoter. Unlike cysteine-reactive small molecules that lack protein specificity, R1 is a genetically encoded, reversible inhibitor designed specifically for KEAP1. R1 should prove useful for studying the role of the KEAP1–NRF2 interaction in several disease states such as neurodegenerative diseases, inflammation, cardiovascular disease, diabetes and the initiation of cancer.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://academic.oup.com/peds/article/29/1/1/2364292\" target=\"_blank\">“Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display”</a></li>Protein Eng Des Sel. 2016 Jan;29(1):1-9.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Beta Thalassemia with IVS-2-654 C--&gt;T Mutation</h1><em>Technology #17-0149</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0149/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0149.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585102\"><a href=\"/inventors/18585102_nobuyo-maeda\">Nobuyo Maeda</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>The mice were created using the “plug and socket” method of gene targeting in murine embryonic stem cells to replace the two (cis) murine adult ß globin genes with a single copy of the human ßIVS-2-654 gene. The ßIVS-2-654 C–&gt;T mutation accounts for approximately 20% of ß thalassemia mutations in southern China and causes aberrant RNA splicing and leads to ß0 thalassemia. The generated mice provide an animal model in which the antisense and other types of therapy can be tested in vivo and the first animal model of any disease resulting from a known human splicing mutation.<br/><br/>These mice are available at The Jackson Laboratory and can be found at <a href=\"https://www.jax.org/strain/003250\" target=\"_blank\">https://www.jax.org/strain/003250</a>. </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.bloodjournal.org/content/91/6/2152.long?sso-checked=true\" target=\"_blank\">A common human beta globin splicing mutation modeled in mice.</a></li>Blood (1998) 91(6):2152-6.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Vector System: Hepatitis B Virus cccDNA-based Gene Expression</h1><em>Technology #14-0154</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0154/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0154.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584906\"><a href=\"/inventors/18584906_lishan-su\">Lishan Su</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p> A DNA vector has been developed that efficiently generates Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) that expresses not only HBV genes, but also a reporter gene. In addition to the novel HBV cccDNA-based gene expression vector, infectious HBV reporter viruses and a cell line to study HBV cccDNA generation, maintenance and function have also been developed. Treatment for HBV infection often involves drugs to prevent the reverse transcription activity of HBV which can reduce virus production. Unfortunately, sustained reduction is not achieved due to HBV cccDNA that exists in very low copy numbers in the infected cell, but serves as a template for HBV mRNA transcription and gene expression. Elimination of cccDNA is a promising cure for HBV infection, however studying cccDNA has been limited as it has historically been difficult to detect the cccDNA using available HBV cells lines and existing infection models are not conducive for screening anti-HBV cccDNA drugs. These reagents provide a robust, easy, and suitable system for high-throughput screening, as well as for studying cccDNA-based HBV gene expression.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27819342\" target=\"_blank\">Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs.  </a></li>Sci Rep (2016) 6:36483.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: p16(INK4A) Expression (Luciferase &amp; TdTomato)</h1><em>Technology #11-0105</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/11-0105/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/11-0105.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584858\"><a href=\"/inventors/18584858_norman-sharpless\">Norman Sharpless</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>The p16INK4a tumor suppressor is upregulated and serves to limit proliferation in response to cellular stressors and oncogenic events. Induction of p16INK4a is highly dynamic during tumorigenesis and aging, and is expressed in response to a variety of oncogenic stressors.<br/><br/>The novel knock-in mouse model, p16-LUC, wherein the endogenous p16INK4a promoter drives single-copy expression of firefly luciferase, is an excellent marker of tumorigenesis and aging. p16 induction can be monitored dynamically <em>in vivo</em> following treatment with DNA damaging stressors such as ionizing radiation or can serve as a biomarker in studies investigating oncogenic stress, oncogenic drivers, early tumorigenesis, novel anti-neoplastic therapeutics, toxicities, senescence, and other <em>in vivo</em> stress responses.  This model is available on an albino C57BL/6 background (haired).<br/><br/>The conditional knock-out mouse model, p16-floxed, contains loxP sites in the Cdkn2a gene before the exon 1a start site (left) and in the first intron (right), such that only p16INK4a and not p19ARF is affected by removal of exon 1a. This strain can be crossed with Cre-expressing strains to investigate how the loss of p16INK4a affects early oncogenesis and senescence.  This model is on a mixed C57BL/6 and 129 background.<br/><br/>Please contact Dr. Shenghui He at <a href=\"mailto:shenghui@email.unc.edu\" target=\"_blank\">shenghui@email.unc.edu</a> or Steve Pedroza at <a href=\"mailto:spedroza@email.unc.edu\" target=\"_blank\">spedroza@email.unc.edu</a> to inquire about availibility of this research tool.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.sciencedirect.com/science/article/pii/S0092867412014973\" target=\"_blank\">Monitoring Tumorigenesis and Senescence In Vivo with a p16INK4a-Luciferase Model</a></li>Cell (2013) 152:340-51.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Cell Line: SKOV3-A2</h1><em>Technology #17-0029</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0029/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0029.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585157\"><a href=\"/inventors/18585157_jonathan-serody\">Jonathan Serody</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Ovarian tumor (SKOV3) cells transfected with Human Leukocyte Antigen-A2 (HLA-A2).<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043746\" target=\"_blank\">T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment</a></li>PLoS ONE PLoS ONE (2012) 7(8):e43746</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Connective Tissue Growth Factor Lo and Hi Mutants</h1><em>Technology #17-0070</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0070/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0070.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585144\"><a href=\"/inventors/18585144_nobuyo-maeda\">Nobuyo Maeda</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Increased connective tissue growth factor (CTGF) is associated with fibrosis in chronic organ injury. Studying the role of CTGF in fibrotic disease in vivo, however, has been hampered by perinatal lethality and the limited scope of CTGF mice. In this single mutant mouse strain, replacement with or excision of a modified CTGF allele results in 60% normal CTGF expression (Lo allele) or increased CTGF expression (Hi allele), respectively. Overexpression of CTGF can cause abnormalities, including developmental delay, craniofacial defects, and embryonic death. CTGF Lo-Hi mutant mice should prove useful in further understanding the function of CTGF in fibrotic diseases.<br/><br/>These mice are available at The Jackson Laboratory, and can be found at <a href=\"https://www.jax.org/strain/030767\" target=\"_blank\">https://www.jax.org/strain/030767</a>. Additionally, mice that carry a knock-out of the CTGF gene can be found at <a href=\"https://www.jax.org/strain/030769\" target=\"_blank\">https://www.jax.org/strain/030769</a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012909\" target=\"_blank\">A Mouse Strain Where Basal Connective Tissue Growth Factor Gene Expression Can Be Switched from Low to High</a></li>PLOS ONE (2010) 5(9): e12909</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Monoclonal Antibody: CRY1</h1><em>Technology #17-0074</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0074/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0074.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585142\"><a href=\"/inventors/18585142_aziz-sancar\">Aziz Sancar</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Cryptochrome 1 (Cry1) and cryptochrome 2 (Cry2) proteins are core components of the mammalian circadian rhythm and help keep the circadian clocks in cells in time and in proper rhythm with the 24-hour day, as well as the seasons. Mice mutated in both genes are arrhythmic. This CRY1 hybridoma cell line is derived from Cry1-/-Cry2-/- mice, which allows investigation into cryptochrome knockout and its effects.<br/><br/>This cell line is available for distribution from MilliporeSigma and can be found at <a href=\"http://www.emdmillipore.com/US/en/product/Anti-Cryptochrome-1-Antibody-clone-D46-3361,MM\" target=\"_blank\">http://www.emdmillipore.com/US/en/product/Anti-Cryptochrome-1-Antibody-clone-D46-3361,MM</a><em>NF-MABE1152#.<p><b>Related Publications:</b></p>\n",
       "  <ul>\n",
       "  <li>&lt;a href=“<a href=\"http://cancerres.aacrjournals.org/content/65/15/6828.long\" target=\"_blank\">http://cancerres.aacrjournals.org/content/65/15/6828.long</a>” target=“</li>\n",
       "  </ul></em>blank”&gt;Cryptochrome, Circadian Cycle, Cell Cycle Checkpoints, and CancerAACR Publications, Cancer Research Cancer Res. (2005) 65(15):6828-34.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Humanized NLRP3</h1><em>Technology #17-0083</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/17-0083/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/17-0083.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585136\"><a href=\"/inventors/18585136_beverly-koller\">Beverly Koller</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Mutations in cryopyrin (NLRP3), a large protein functioning as an important immune pathway in human disease, have been identified in most patients with autoinflammatory disorders. The severity of the disease is likely related to the degree a particular mutation alters the protein. This mouse line, in which the NLRP3 locus has been excised and replaced with its human counterpart, shows value as a platform to test therapeutic reagents targeting the human inflammasome. Human NLRP3 proteins function in vivo and demonstrate the human inflammasome’s ability to trigger immune reactions to innate stimuli. Closely related to UNC Ref# 14-0063 (Mouse: NLRP3 Null).<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.sciencedirect.com/science/article/pii/S2211124716316254\" target=\"_blank\">An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice</a></li>Cell Reports 2016 17(11):3077-88.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>RNA Interference Compositions for Inhibiting KRAS in Cancer</h1><em>Technology #16-0006</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0006/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0006.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585080\"><a href=\"/inventors/18585080_chad-pecot\">Chad Pecot</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186514\"><em><a href=\"http://google.com/patents/WO2017127473\" target=\"_blank\">PCT Patent Application WO 2017/127473</a></em></dd></dl></div><div class=\"content\"><p>siRNA sequences have been engineered to simultaneously block expression of multiple mutant KRAS forms in tumors without silencing wild-type KRAS and impacting normal signaling in healthy cells. KRAS mutations are among the most prevalent driver mutations in cancers, and despite extensive research, no effective KRAS inhibitor has been identified and KRAS remains an elusive target for drug development. This novel approach permits the silencing of multiple oncogenic KRAS forms while sparing wild-type expression.<br/><strong>Advantages:</strong><br/>•  Targets a large percentage of human cancers<br/>•  Selectively targets tumor cells while sparing normal cells<br/>•  Effective against an “undruggable” target<br/>•  Compatible with a variety of drug delivery platforms</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25281617\" target=\"_blank\">Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs</a></li>Mol Cancer Ther. 2014 Dec;13(12):2876-85.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Predicting Maximum Heart Rate and Maximum Oxygen Uptake from Submaximal Exercise</h1><em>Technology #16-0007</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0007/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0007.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li><li class=\"category\" id=\"category_5370\"><a href=\"/categories/5362_software-information-technology/5370_health-it\">Health IT</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585079\"><a href=\"/inventors/18585079_claudio-battaglini\">Claudio Battaglini</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186513\"><em><a href=\"http://google.com/patents/US20190009134\" target=\"_blank\">US Patent Pending US-2019-0009134</a></em></dd></dl></div><div class=\"content\"><p>A new method has been developed for accurately estimating maximum heart rate and maximal oxygen uptake from data collected at submaximal intensities. This method accounts for the personal physiology and fitness of an individual and can make predictions with a level of precision and accuracy that is unavailable through conventional submaximal estimation methods. The invention can easily be integrated with existing physiological data collection technologies, including wearable sensors, and has immediate applications in the fitness and medical fields.<br/><strong>Advantages:</strong><br/>•  Provides the accuracy of a maximum cardiopulmonary exercise test without the associated costs or medical risks<br/>•  Accounts for intra-individual (person-specific) physiological variations, rather than population-specific averages, to provide greater accuracy<br/>•  Improves accuracy and utility of training methods that use maximum heart rate and maximum oxygen uptake values to determine training zones<br/>•  Flexible and convenient for collecting data from a variety of exercise methods and from diverse populations, from athletes to clinical patients</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://proceedings.asmedigitalcollection.asme.org/proceeding.aspx?articleid=2483944\" target=\"_blank\">Modeling Heart Rate Dynamics in Response to Changes in Exercise Intensity</a></li>ASME 2017<li><a href=\"https://link.springer.com/article/10.1007/s12283-017-0242-1\" target=\"_blank\">A dynamical systems approach for the submaximal prediction of maximum heart rate and maximal oxygen uptake</a></li>Mazzoleni, Michael J., et al. “A dynamical systems approach for the submaximal prediction of maximum heart rate and maximal oxygen uptake.” Sports Engineering 21.1 (2018): 31-41.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: ARID1A Conditional Inactivation</h1><em>Technology #16-0014</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0014/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0014.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585077\"><a href=\"/inventors/18585077_terry-magnuson\">Terry Magnuson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Ovarian clear-cell carcinoma (OCCC) is an aggressive form of ovarian cancer with high ARID1A mutation rates. ARID1A loss alone does not lead to tumor formation but requires concurrent activation of the phosphoinositide 3-kinase catalytic subunit, PIK3CA.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/articles/ncomms7118\" target=\"_blank\">Coexistent ARID1A?PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling</a></li>Nat. Commun. (2015) 6:6118.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Dynamic Decoding for Multiplexing Bead-Based Assays</h1><em>Technology #16-0015</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0015/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0015.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5323\"><a href=\"/categories/5317_engineering-physical-sciences/5323_microfluidics\">Microfluidics</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585076\"><a href=\"/inventors/18585076_j-ramsey\">J Ramsey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186512\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A methodology has been developed that employs dye stability to distinguish bead populations in bead-based assay systems. This increases multiplexing capabilities beyond current limitations seen with dyes of fixed excitation/emisson wavelengths. Different dyes with similar spectral properties, but different stabilities, adds a dynamic, time-based element that can resolve different bead populations. Related technologies have been developed that increase assay performance and multiplexing capability by utilizing non-cylindrical bead well geometries to improve assay performance and readout (15-0131) and bead-based delivery of reagents to facilitate parallel assays on a multiplexed-in-space microfluidic device (12-0128).<br/><strong>Advantages:</strong><br/>•  Employs the measurement of dye decay to provide additional encoding levels beyond static, single point measurement for distinguishing bead populations<br/>•  Can be used for highly sensitive real-time PCR detection of multiple target sequences on a single chip with or without the use of sequence-specific probes<br/>•  May be used clinically to evaluate the presence of disease causing organisms, gene expression, genotyping, or forensic science applications</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://pubs.rsc.org/en/content/articlehtml/2014/lc/c3lc51303c\" target=\"_blank\">An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples</a></li>Royal Society of Chemistry, Lab on a Chip Lab Chip, 2014, 14, 1087-1098<li><a href=\"http://pubs.rsc.org/en/content/articlehtml/2017/lc/c6lc01415a\" target=\"_blank\">Photobleaching kinetics-based bead encoding for multiplexed bioassays</a></li>Lab Chip, 2017, 17, 1076-1082</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Human DPP4 Expression (MERS Infection)</h1><em>Technology #16-0018</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0018/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0018.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585075\"><a href=\"/inventors/18585075_ralph-baric\">Ralph Baric</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Mice and other small laboratory animals are not susceptible to Middle East Respiratory Syndrome-Coronavirus (MERS) infection. Mice expressing the human host-cell receptor dipeptidyl peptidase 4 are sensitized to infection. These mice are useful for determining immune responses and for evaluation of an anti-MERS vaccine and an antiviral therapy.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/articles/nmicrobiol2016226\" target=\"_blank\">A mouse model for MERS coronavirus-induced acute respiratory distress syndrome</a></li>Nat Microbiol. 2016 Nov 28;2:16226</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Accurate Segmentation of Male Pelvic Organs from CT images via Regression-Based Deformable Models and Iterative Structural Refinement</h1><em>Technology #16-0019</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0019/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0019.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585074\"><a href=\"/inventors/18585074_dinggang-shen\">Dinggang Shen</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186511\"><em><a href=\"http://google.com/patents/WO2017062453\" target=\"_blank\">PCT Patent Application WO 2017/062453</a></em></dd></dl></div><div class=\"content\"><p>This novel method automatically segments male pelvic organs from CT images with robustness to initialization that achieves better results than current deformable models, and could greatly enhance the accuracy of pelvic segmentation consequently preventing more accurate radiotherapy treatments to patients. Segmenting pelvic organs is a prerequisite for prostate cancer radiotherapy, as the efficacy of radiation treatment heavily depends on the segmentation accuracy. However, due to low tissue contrast of CT images, and large shape and appearance variation of pelvic organs, accurate segmentation is challenging. Deformable models aim to alleviate some of these hindrances, but their success greatly depends upon initialization – especially for segmenting organs with large shape variations. This technology is a novel way to guide deformable segmentation, which makes deformable models more robust against arbitrary initializations. By learning an image regressor that predicts the 3D displacement from any image voxel to the target organ boundary, this method overcomes the initialization problem suffered by traditional deformable models. This method has been tested using images from over 300 prostate cancer patients.<br/><strong>Advantages:</strong><br/>•  Accurate, automatic method for segmenting male pelvic organs from CT images<br/>•  Makes deformable models more robust against arbitrary initialization<br/>•  Unlike conventional deformable models, the deformation direction is adaptively determined for optimally driving the shape model onto the target organ<br/>•  Eliminates the need to specify the search range, which is often required in the conventional deformable models </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>3D Printed Intravaginal Rings for Delivery of Therapeutics and Contraceptives</h1><em>Technology #16-0021</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0021/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0021.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585072\"><a href=\"/inventors/18585072_soumya-benhabbour\">Soumya Benhabbour</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186509\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Using state-of-the-art 3D printing technology, intravaginal\n",
       "  rings (IVRs) have been fabricated in a way that cannot be achieved with\n",
       "  conventional engineering. IVRs can be used for the delivery of therapeutics\n",
       "  including contraceptives. Traditional IVR manufacturing uses injection molding\n",
       "  or hot-melt extrusion and complex multistep processes to make reservoir IVRs.\n",
       "  3D printing technology allows for flexibility in starting materials.</p>\n",
       "  <p><b>Advantages:</b></p>\n",
       "  <p>• \n",
       "  Cost effective production process</p>\n",
       "  <p>• \n",
       "  Wide range of starting materials</p>\n",
       "  <p>• \n",
       "  Ability to integrate multiple drugs in one ring\n",
       "  to design multipurpose IVRs</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Cache, Trigger, Impersonate: Enabling Context-Sensitive Honeyclient Analysis On-the-Wire</h1><em>Technology #16-0031</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0031/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0031.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5373\"><a href=\"/categories/5362_software-information-technology/5373_security\">Security</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585067\"><a href=\"/inventors/18585067_fabian-monrose\">Fabian Monrose</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186507\"><em><a href=\"http://google.com/patents/US9992217\" target=\"_blank\">US Patent 9,992,217</a></em></dd></dl></div><div class=\"content\"><p>A novel framework has been developed for adapting honeyclient-based systems (for identifying attacks) to operate on-the-wire at scale. It analyzes web-based exploits inline with network traffic using a cache and replay system, utilizing behavioral-based features. Current techniques only analyze behavioral based features in an offline fashion. The innovation would be used to protect enterprise networks from HTTP-based attacks.<br/><strong>Advantages:</strong><br/>•  Significant operational value<br/>•  A single honeyclient server can readily support massive HTTP traffic volumes with modest hardware, e.g., a large campus deployment</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.internetsociety.org/sites/default/files/blogs-media/cache-trigger-impersonate-enabling-context-sensitive-honeyclient-analysis-wire.pdf\" target=\"_blank\">Cache, Trigger, Impersonate: Enabling Context-Sensitive Honeyclient Analysis On-the-Wire</a></li>PDF</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Plasmid: Porcine Epidemic Diarrhea Virus Infectious Clone</h1><em>Technology #16-0038</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0038/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0038.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585065\"><a href=\"/inventors/18585065_anne-beall\">Anne Beall</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Porcine Epidemic Diarrhea Virus (PEDV) has killed 10% of US farm pigs since 2013; however, there is no rapid reverse genetic platform for manipulating PEDV. This DNA-based PEDV infectious clone system can be used for directed genetic manipulation, both in vitro and in vivo, and to study the genetics, virulence, and transmission of PEDV coronavirus. PEDV containing red fluorescent protein can be used to track virus in both scientific and commercial assays and in vivo. This robust platform may potentially be utilized in the logical design of a live attenuated vaccine for PEDV and therapeutics in a clinical setting.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://mbio.asm.org/content/7/1/e01451-15.abstract\" target=\"_blank\">Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A</a></li>mBio 7(1):e01451 (2015)</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Human CalDAG-GEFIExpression</h1><em>Technology #16-0049</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0049/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0049.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585056\"><a href=\"/inventors/18585056_wolfgang-bergmeier\">Wolfgang Bergmeier</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Ca(2+) and diacylglycerol-regulated guanine nucleotide exchange factor I (CalDAG-GEFI), controls the activation of all 3 integrins in the hematopoietic system. Mice expressing human CalDAG-GEFI produce very low levels of CalDAG-GEFI as compared to expression of the mouse protein.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jci.org/articles/view/30575\" target=\"_blank\">Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III</a></li>J Clin Invest.  2007 Jun;117(6):1699-707.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>No-Execute-After-Read: Preventing Code Disclosure in Commodity Software</h1><em>Technology #16-0058</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0058/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0058.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5373\"><a href=\"/categories/5362_software-information-technology/5373_security\">Security</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585053\"><a href=\"/inventors/18585053_jan-werner\">Jan Werner</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186504\"><em><a href=\"http://google.com/patents/US20170213039\" target=\"_blank\">US Patent Pending US 2017/0213039</a></em></dd></dl></div><div class=\"content\"><p>A novel memory permission primitive, dubbed No-Execute-After-Read (NEAR), has been developed that thwarts just-in-time code reuse attacks by adversaries taking advantage of memory disclosures. Unlike Execute-no-Read, which fails to prevent such attacks, NEAR provides strong security guarantees against just-in-time attacks in commodity binaries. Specifically, NEAR allows the disclosure of all code, but prevents any disclosed code from subsequently being executed, thus fundamentally thwarting just-in-time code reuse. At the same time, commodity binaries with mixed code and data regions still operate correctly, as legitimate data is still readable. The prototype is practical and portable to various platforms and applications, and it has a negligble runtime overhead, making it suitable for practical deployment.<br/><strong>Advantages:</strong><br/>•  A better method than Execute-no-Read in preventing just-in-time code reuse attacks<br/>•  Provides strong security protection against such attacks<br/>•  Practical and portable</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www3.cs.stonybrook.edu/~mikepo/papers/near.asiaccs16.pdf\" target=\"_blank\">No-Execute-After-Read: Preventing Code Disclosure in Commodity Software</a></li>PDF</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Tumor Antigen Capturing Nanoparticle for Cancer Immunotherapy</h1><em>Technology #16-0064</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0064/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0064.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5324\"><a href=\"/categories/5317_engineering-physical-sciences/5324_nanotechnology\">Nanotechnology</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585052\"><a href=\"/inventors/18585052_andrew-wang\">Andrew Wang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186503\"><em><a href=\"http://google.com/search?#q=PCT%2FUS2016%2F062563&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">PCT Patent Application PCT/US2016/062563</a></em></dd></dl></div><div class=\"content\"><p>A biodegradable and biocompatible antigen capturing nanoparticle (AC-NP) has been developed that can improve cancer immunotherapy and induce the abscopal effect - a phenomenon where local tumor treatment causes systemic regression of metastatic lesions. The AC-NPs can deliver captured proteins to antigen-presenting cells and significantly improve the efficacy of treatment in a mouse melanoma model. This nanotechnology represents a novel strategy for improving cancer immunotherapy.<br/><strong>Advantages:</strong><br/>•  Nanoparticle formulation elicits an improved immune response<br/>•  Personalized immunotherapy platform</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://medicalphysicsweb.org/cws/article/research/69608\" target=\"_blank\">Protein-capturing nanoparticles boost immune response to cancer</a></li>\n",
       "  <li><a href=\"https://www.nature.com/articles/nnano.2017.113\" target=\"_blank\">Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy</a></li>\n",
       "  <li><a href=\"https://www.azonano.com/news.aspx?newsID=35659\" target=\"_blank\">Sticky Nanoparticles Enhance the Immune System’s Detection of Cancer Proteins</a></li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Mer Null (B6129SF2/J)</h1><em>Technology #16-0074</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0074/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0074.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585051\"><a href=\"/inventors/18585051_shelton-earp\">Shelton Earp</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Gene-targeted B6129SF2/J mice in which the cytoplasmic kinase domain was replaced with the neomycin-resistant gene. The specific mutation in mer permits functional analyses in signal transduction while avoiding developmental anomalies that may arise from complete ablation of the gene. Mer mice are extremely sensitive to endotoxin (LPS) treatment. These mice exhibit excessive TNF-a production and increased susceptibility to lethal septic shock.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/nature/journal/v398/n6729/full/398723a0.html\" target=\"_blank\">Tyro-3 family receptors are essential regulators of mammalian spermatogenesis</a></li>Nature 398, 723-728 (22 April 1999)</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Mer Null (C57BL/6)</h1><em>Technology #16-0075</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0075/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0075.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585049\"><a href=\"/inventors/18585049_shelton-earp\">Shelton Earp</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Gene-targeted C57BL/6 mice in which the cytoplasmic kinase domain was replaced with the neomycin-resistant gene. The specific mutation in mer permits functional analyses in signal transduction while avoiding developmental anomalies that may arise from complete ablation of the gene. Mer mice are extremely sensitive to endotoxin (LPS) treatment. These mice exhibit excessive TNF-a production and increased susceptibility to lethal septic shock.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jimmunol.org/content/162/6/3498.full\" target=\"_blank\">A Novel Receptor Tyrosine Kinase, Mer, Inhibits TNF-? Production and Lipopolysaccharide-Induced Endotoxic Shock</a></li>J Immunol. 1999;162(6):3498?3503</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Pediatric and Adult Peripheral Cannulation Simulator</h1><em>Technology #16-0080</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0080/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0080.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585045\"><a href=\"/inventors/18585045_jennifer-nelson\">Jennifer Nelson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186500\"><em><a href=\"http://google.com/patents/WO2017127724\" target=\"_blank\">PCT Patent Application WO 2017/127724</a></em></dd></dl></div><div class=\"content\"><p>A pediatric and adult Peripheral Cannulation Simulator has been developed for heart catheterization, medical device placement and mechanical circulatory support. This device incorporates visual feedback and a working pump with fluid-filled, pulsatile venous and arterial vasculature (aka PCS), and uses a human neck, torso, and upper thigh form, combined with pressurized tubing and a pump with variable, controlled pressure and flow direction to allow for the insertion of medical devices, catheters, sheaths, and cannulae of all kinds designed for mechanical circulatory support using Seldinger technique. During and after insertion, the devices may be viewed via a translucent “atrium” within the chest of the simulator in order to facilitate teaching and learning of proper device insertion and positioning, as well as to visualize flow dynamics (if colored fluid or otherwise labeled fluid was used) and the entrainment of air during the use of mechanical circulatory support devices. Because the tubing used to simulate the vasculature is distensible and embedded in silicone molds, it can be visualized with ultrasound during insertion of medical devices. The nature of the connections of the tubing in this device allow for the simulator to be connected to a cardiopulmonary bypass circuit or other mechanical circulatory support pump system and to indefinitely circulate fluid within the vasculature, to the mechanical support system pump, and return to the vasculature via cannula, thus simulating the proper use of the medical device as it might be used in a living person. PCS can be used for training of field/military ECMO, cathlab, ER docs, and nurses.<br/><strong>Advantages:</strong><br/>•  The carotid artery is connected to the femoral artery and both are pulsatile<br/>•  Can be connected to mechanical support and used to achieve continuous, indefinite circulation on the support device<br/>•  Allows for a functional interaction with other devices in a much more high-fidelity, working capacity<br/>•  A pump regulates pressure and flow and changes the pulse rate in a model of a complete AV circulatory loop using a reservoir and atrium</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Large-scale Structure from Motion Software</h1><em>Technology #16-0089</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0089/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0089.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585042\"><a href=\"/inventors/18585042_jan-michael-frahm\">Jan-michael Frahm</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_364\"><a href=\"/managers/364_copyright-materials\">Copyright Materials</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>A new Structure-from-Motion (SfM) technique has been\n",
       "  developed that improves existing incremental Structure-from-Motion strategies\n",
       "  for 3D reconstruction from unordered image collections. The novel SfM\n",
       "  algorithim improves therobustness, accuracy, completeness, and scalability\n",
       "  compared to the current state-of-the-art, and it makes a further step towards a\n",
       "  general-purpose SfM system.</p>\n",
       "  <p><b>Advantages:</b></p>\n",
       "  <p>• \n",
       "  Reliable structure from motion engine</p>\n",
       "  <p></p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://people.inf.ethz.ch/jschoenb/papers/schoenberger2016sfm.pdf\" target=\"_blank\">Structure-from-Motion Revisited</a></li>PDF</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Cell Line: CH Mouse B Cell Lymphoma 27</h1><em>Technology #16-0100</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0100/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0100.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585038\"><a href=\"/inventors/18585038_geoffrey-haughton\">Geoffrey Haughton</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>CH27 is a carcinogen-induced B-cell lymphoma tumor that also expresses IgM/k on its surface.<br/><br/>This cell line is available for distribution from MilliporeSigma at <a href=\"http://www.emdmillipore.com/US/en/product/CH27-Mouse-B-Cell-Lymphoma-Cell-Line,MM_NF-SCC115\" target=\"_blank\">http://www.emdmillipore.com/US/en/product/CH27-Mouse-B-Cell-Lymphoma-Cell-Line,MM<em>NF-SCC115</em></a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li>&lt;a href=“<a href=\"https://onlinelibrary.wiley.com/doi/10.1111/j.1600-065X.1986.tb01501.x\" target=\"_blank\">https://onlinelibrary.wiley.com/doi/10.1111/j.1600-065X.1986.tb01501.x</a>” target=“blank”&gt;The CH Series of Murine B Cell Lymphomas: Neoplastic Analogues of Ly-1+ Normal B Cells</li>Immunol Rev. 1986 Oct;93:35-51.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Exosomal Drug Delivery for Chemotherapy and CNS Disorders</h1><em>Technology #16-0102</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0102/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0102.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585037\"><a href=\"/inventors/18585037_elena-batrakova\">Elena Batrakova</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186496\"><em><a href=\"http://google.com/patents/WO2017173034\" target=\"_blank\">PCT Patent Application WO 2017/173034</a></em></dd></dl></div><div class=\"content\"><p>Novel exosome-based compositions have been developed for the delivery of low molecular weight active ingredients, drugs and macromolecular biotherapeutics to sites of disease associated with inflammation including tumors and the central nervous system. When derived from individual patient exosomes, these vesicles have immune-privileged status which allows them to deliver therapeutic agents to target cells and increase drug efficacy. Delivery of multiple agents has been demonstrated in mouse models.<br/><strong>Advantages:</strong><br/>•  Application-specific, customizable platform technology for the efficient transfer of drugs and genes to target tissues<br/>•  Intranasal or intraveneous delivery of therapeutics<br/>•  High stability, low toxicity and immunogenicity</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26586551\" target=\"_blank\">Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells</a></li>NCBI PubMed Nanomedicine. 2016 Apr;12(3):655-64. doi: 10.1016/j.nano.2015.10.012. Epub 2015 Nov 14</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Fluorescent Reporter of Splice Switching Oligonucleotides (EGFP-654)</h1><em>Technology #16-0111</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0111/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0111.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585035\"><a href=\"/inventors/18585035_ryszard-kole\">Ryszard Kole</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Model designed as a positive readout test for activity, delivery, and distribution of antisense oligomers. The expressed gene (EGFP-654) encoding enhanced green fluorescence protein is interrupted by an aberrantly spliced mutated intron of the human beta-globin gene. Aberrant splicing of this intron prevented expression of EGFP-654 in all tissues, whereas in tissues and organs that took up a splice site-targeted antisense oligomer, correct splicing was restored and EGFP-654 expression upregulated.<br/><br/>This research tool is only available from The Jackson Laboratory at <a href=\"https://www.jax.org/strain/027617\" target=\"_blank\">https://www.jax.org/strain/027617</a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/nbt/journal/v20/n12/full/nbt759.html\" target=\"_blank\">Systemically delivered antisense oligomers upregulate gene expression in mouse tissues</a></li>Nat Biotechnol 2002 Dec;20(12):1228-33.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>BCL6 and SIRT1 as Biomarkers of Endometriosis and Endometrial Dysfunction</h1><em>Technology #16-0123</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0123/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0123.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585033\"><a href=\"/inventors/18585033_steven-young\">Steven Young</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186494\"><em><a href=\"http://google.com/patents/WO2017173250\" target=\"_blank\">PCT Patent Application WO 2017/173250</a></em></dd></dl></div><div class=\"content\"><p>BCL6 and SIRT1 are predictors of endometriosis and endometrial dysfunction, and consequently can be used as diagnostic tools for endometriosis.  Both BCL6 and SIRT1 were found to be elevated in the eutopic endometrium from women with endometriosis.  Furthermore, studies in a baboon animal model of induced endometriosis showed that levels of SIRT1 and BCL6 increased with time after induction.  Once diagnosis of endometriosis is made, there are effective treatments, many of which involve surgery. However, due to the widely varying symptoms of endometriosis and lack of concrete diagnostic tools, many physicians are reluctant to perform these treatments. Consequently, there is often a slow time to diagnosis for patients, and a large number of unnecessary invasive surgeries conducted on patients who have pelvic pain without having endometriosis.  This technology may be developed into a sensitive diagnostic test for endometriosis that will help physicians determine the best course of treatments for patients in a timely fashion, and eliminate potentially unnecessary invasive surgeries.   <br/><strong>Advantages:</strong><br/>•  Novel diagnostic approach for endometriosis<br/>•  Potential avoidance of unnecessary surgery</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Gq-DREADD (hM3Dq)</h1><em>Technology #16-0159</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0159/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0159.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585020\"><a href=\"/inventors/18585020_bryan-roth\">Bryan Roth</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Transgenic mice expressing an evolved G protein-coupled receptor (hM3Dq) selectively activated by the pharmacologically inert, orally bioavailable drug clozapine-N-oxide (CNO). Behavioral correlates of neuronal activation included increased locomotion, stereotypy, and limbic seizures.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.sciencedirect.com/science/article/pii/S089662730900467X\" target=\"_blank\">Remote Control of Neuronal Activity in Transgenic Mice Expressing Evolved G Protein-Coupled Receptors</a></li>Neuron 2009 Jul 16;63(1):27-39.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Gi-DREADD (hM4Di)</h1><em>Technology #16-0160</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0160/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0160.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585017\"><a href=\"/inventors/18585017_bryan-roth\">Bryan Roth</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>In neurons, activation of hM4Di induces neuronal silencing. This model can be used to selectively and reversibly suppress hippocampal neuronal activity during synaptic consolidation. Clozapine-N-oxide induces Gi activation and allows in vivo manipulation of neuronal activity in freely moving animals.<br/><br/>This mouse line is available from The Jackson Laboratory and can be found at <a href=\"https://www.jax.org/strain/026219\" target=\"_blank\">https://www.jax.org/strain/026219</a>. </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059896/\" target=\"_blank\">Chemogenetic Inactivation of Ventral Hippocampal Glutamatergic Neurons Disrupts Consolidation of Contextual Fear Memory</a></li>NCBI, Neuropsychopharmacology  2014 Jul;39(8):1880-92</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Polyclonal Antiserum: DDB1</h1><em>Technology #16-0166</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0166/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0166.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5345\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5345_antibodies\">Antibodies</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585014\"><a href=\"/inventors/18585014_yue-xiong\">Yue Xiong</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Damaged DNA binding protein 1 (DDB1) could prevent the replication of damaged DNA, contributing to DNA repair and the maintenance of genomic integrity. These rabbit polyclonal antibodies to DDB1 (N-REKEFNKGPWKQENVE-H) were raised against a synthetic peptide derived from human p127DDB1 coupled to keyhole limpet haemocyanin (KLH). They are useful for evidencing the in vivo association of DDB1 with ROC1, a small RING finger protein that activates an ubiquitin-conjugating enzyme, and CUL4A, a cullin-dependent ligase essential to cell cycle control, genomic stability and development.<br/><br/>This research tool is available from Kerafast and can be found at <a href=\"https://www.kerafast.com/product/3349/anti-ddb1-antibody\" target=\"_blank\">https://www.kerafast.com/product/3349/anti-ddb1-antibody</a>.<br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/ncb/journal/v6/n10/full/ncb1172.html\" target=\"_blank\">Targeted ubiquitination of CDT1 by the DDB1?CUL4A?ROC1 ligase in response to DNA damage</a></li>Nat Cell Biol. 6(10):1003-9 (2004).</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Two Dimensional Electrides as Battery Electrode Materials</h1><em>Technology #16-0168</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0168/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0168.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5322\"><a href=\"/categories/5317_engineering-physical-sciences/5322_materials\">Materials</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585010\"><a href=\"/inventors/18585010_scott-warren\">Scott Warren</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186478\"><em><a href=\"http://google.com/patents/WO2017210587\" target=\"_blank\">PCT Patent Application WO/2017/210587</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707989\"><a href=\"https://phys.org/news/2017-01-scientists-d-electride.html\" target=\"_blank\">Scientists create first 2-D electride</a></dd></dl></div><div class=\"content\"><p>A new class of two-dimensional materials has been developed for battery electrodes that are derived from bulk electride crystals such as Ca2N, Sr2N, Ba2N, and Y2C. Electrides are materials that trap electrons at stoichiometric concentration, such that the electrons themselves serve as counteranions. Despite rapid progress in the last decade to synthesize, isolate, and use electrides, a number of challenges hinder their potential application. For example, the low surface area and limited electron accessibility of bulk electride surfaces inhibit their potential utility as novel catalysts and conductive materials. These materials are synthesized by a liquid exfoliation process in which large pieces of layered electrides are placed in a solvent and subjected to sonication. The resulting nanosheets have a two-dimensional morphology and can be further isolated and separated by centrifugation or solvent removal.   <br/><br/><strong>Advantages:</strong><br/>•  Nanosheets are stable and possess a low work function and a metallic electronic structure<br/>•  Potential application of nanosheets as battery electrode materials<br/>•  Liquid exfoliation method facilitates material transfer and thin film preparation</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://pubs.acs.org/doi/abs/10.1021/jacs.6b10114?journalCode=jacsat&amp;quickLinkVolume=138&amp;quickLinkPage=16089&amp;selectedTab=citation&amp;volume=138\" target=\"_blank\">Experimental Demonstration of an Electride as a 2D Material</a></li>J. Am. Chem. Soc. 2016, 138, 16089-16094</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Cell Line: HeLa EGFP-654(available with EGFP or Luciferase-pLuc/705)</h1><em>Technology #16-0176</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/16-0176/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/16-0176.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585007\"><a href=\"/inventors/18585007_ryszard-kole\">Ryszard Kole</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707988\"><a href=\"http://unclineberger.org/research/core-facilities/tissueculture/contact-information\" target=\"_blank\">LCCC Tissue Culture Facility</a></dd></dl></div><div class=\"content\"><p>Antisense oligonucleotide-mediated down-regulation of genes that cause human diseases such as cancer and viral infections has been accomplished in cellular and animal models. Unfortunately, these oligonucleotides in cell culture and in vivo frequently exhibit non-antisense effects due to sequence-dependent as well as non-specific interactions with proteins. In this cell line, antisense activity of each oligomer is directly proportional to up-regulation of the EGFP reporter. This provides a positive, quantitative readout for sequence-specific antisense effects of the oligomers in the nuclei of individual cells. The signal is positive, easily detectable in individual cells, and of high sensitivity.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the LCCC Tissue Culture Facility (TCF) to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC60237/\" target=\"_blank\">Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs</a></li>Nucleic Acids Res. 2001 Oct 1; 29(19): 3965?3974.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Scientifically-Lossless Video Microscopy Compression</h1><em>Technology #15-0004</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0004/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0004.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584994\"><a href=\"/inventors/18584994_russell-taylor\">Russell Taylor</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186466\"><em><a href=\"http://google.com/search?#q=US+2017%2F0244976&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">US Patent US 2017/0244976</a></em></dd></dl></div><div class=\"content\"><p>A novel compression method has been developed based upon Pearson’s correlation coefficient and mathematical morphology that, for certain data sets, compresses much better than lossless compression with no impact on analysis results. It is “scientifically lossless.” The compressed size scales with the video’s scientific data content, while existing lossy algorithms greatly impacted data analysis at similar compression sizes.<br/><strong>Advantages:</strong><br/>•  Can achieve over 100Ã— compression, enabling high-throughput video-acquisition experiments to be stored in the same space as conventional experiments<br/>•  Achieves a best compressed size that is 25Ã— smaller than the best lossless compression techniques</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26435032\" target=\"_blank\">Analysis-preserving video microscopy compression via correlation and mathematical morphology</a></li>NCBI PubMed Microsc Res Tech. 2015 Dec;78(12):1055-61. doi: 10.1002/jemt.22584. Epub 2015 Oct 5.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Web Page Classification using Anonymized TCP/IP Headers</h1><em>Technology #15-0015</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0015/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0015.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5366\"><a href=\"/categories/5362_software-information-technology/5366_communications-networking\">Communications &amp; Networking</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584993\"><a href=\"/inventors/18584993_sean-sanders\">Sean Sanders</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186465\"><em><a href=\"http://google.com/patents/US20180013639\" target=\"_blank\">US Patent Pending US 2018/0013639</a></em></dd></dl></div><div class=\"content\"><p>A method has been developed that classifies web pages based only on anonymized TCP/IP headers of traffic generated when a web page is visited. The framework can work for a variety of classification labeling schemes including video and mobile. ISPs and Internet measurement companies, as well as academia may have an interest in the procedure. Commercial uses include (1) Behavioral ad-targeting for Internet service providers; and (2) Inference on higher level traffic events/details using minimal information: (i) internet measurement study tool and (ii) tool to help develop models of the web to test capacity limits and new protocols.<br/><strong>Advantages:</strong><br/>•  Honors privacy concerns of users since it uses anonymized TCP/IP headers<br/>•  Usable by entities that do not have application information or state such as Internet service providers and network administrators<br/>•  Robust to noise in webpage measurement due to variation in time and browser</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.cs.unc.edu/~jasleen/papers/infocom15.pdf\" target=\"_blank\">Can Web Pages Be Classified Using Anonymized TCP/IP Headers?</a></li>Read More infocom15.pdf</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Monoclonal Antibody: SMV59 Against Norovirus GII.2.1976</h1><em>Technology #15-0026</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0026/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0026.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5345\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5345_antibodies\">Antibodies</a></li><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584990\"><a href=\"/inventors/18584990_ralph-baric\">Ralph Baric</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>GII.2.1976 Snow Mountain virus (SMV) is the prototype strain of GII.2 noroviruses (NoVs), which cause an estimated 8% of norovirus outbreaks; however, little is known about the immunobiology of these viruses. Uniquely, mouse monoclonal antibody SMV59 reacts outside the GII.2 genocluster by Western blotting and binds to a diverse panel of NoV VLPs, representing GI and GII, strains by enzyme immunoassays. SMV59 is broadly reactive and recognizes a pan-NoV, nonblockade, linear epitope, which likely resides within the shell domain of the major capsid protein. The high degree of cross-reactivity of this antibody makes it potentially useful as a diagnostic reagent.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24173225\" target=\"_blank\">Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects</a></li>J Virol 2014 Jan;88(2):829-37</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: CGRPalpha-GFP Expression</h1><em>Technology #15-0028</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0028/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0028.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584989\"><a href=\"/inventors/18584989_mark-zylka\">Mark Zylka</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Calcitonin gene-related peptide (CGRPα, encoded by Calca) is a classic marker of nociceptive dorsal root ganglia (DRG) neurons. Mice expressing an axonal tracer and a conditional cell ablation construct from the Calca/Cgrpα locus can be used to prospectively identify peptidergic DRG neurons in culture and evaluate response to agonists that evoke sensations of pain and itch.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22563493\" target=\"_blank\">CGRP?-expressing sensory neurons respond to stimuli that evoke sensations of pain and itch</a></li>PLoS One 2012;7(5):e36355</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Biomarkers for Prognostic Subtyping of Pancreatic Cancer</h1><em>Technology #15-0032</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0032/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0032.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5334\"><a href=\"/categories/5331_life-sciences/5334_biomarkers\">Biomarkers</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584988\"><a href=\"/inventors/18584988_jen-jen-yeh\">Jen Jen Yeh</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186462\"><em><a href=\"http://google.com/patents/US20170233827\" target=\"_blank\">US Patent Pending US 2017/0233827</a></em></dd></dl></div><div class=\"content\"><p>By digitally separating tumor, stroma, and normal tissues to remove confounding gene expression two pancreatic cancer subtypes have been identified and validated. A “basal-like” subtype can be identified which has worse outcome (similar to basal tumors in bladder and breast cancer) but showed a strong trend towards better response to adjuvant therapy. Normal and “activated” stromal subtypes were also identified and found to be prognostic.<br/><strong>Advantages:</strong><br/>•  Separates tumor subtypes by biological and clinical relevance<br/>•  Predictive of response to adjuvant therapy   </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/26343385\" target=\"_blank\">Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma</a></li>NCBI PubMed Nat Genet. 2015 Oct;47(10):1168-78. doi: 10.1038/ng.3398. Epub 2015 Sep 7.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Brg1/Brm as Targets for Cardiac Conduction Defects in Heart Failure</h1><em>Technology #15-0037</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0037/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0037.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a></li><li class=\"category\" id=\"category_5360\"><a href=\"/categories/5331_life-sciences/5360_other\">Other</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584987\"><a href=\"/inventors/18584987_monte-willis\">Monte Willis</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186461\"><em><a href=\"http://google.com/patents/US20180140722\" target=\"_blank\">US Patent Pending US 20180140722</a></em></dd></dl></div><div class=\"content\"><p>An alternative therapy has been developed for cardiac conduction defects by altering Brg1/Brm function in regulating ion channels and gap junction proteins at the same time. The primary therapies for cardiac arrhythmias act by interferring with the sodium channel activity (Class 1), potassium efflux (Class 3), calcium channels, and AV node (Class 4), or beta adrenergic receptor blockade (Class II).  SWI/SNF ATPases Brg1 and Brm have now been shown to regulate cardiomyocyte chromatin remodeling to maintain cardiac conduction. Brg1/Brm double-mutant mice exhibited increased mitochondrial biogensis, autophagy, along with evidence of perturbed cardiac mitochondrial dynamics.<br/><strong>Advantages:</strong><br/>•  Alternative therapy to ion channel therapies<br/>•  HDAC inhibitors could be used as anti-arrhythmia therapy  </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22740088\" target=\"_blank\">Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart</a></li>Circ. Res. 2012 Aug 17;111(5):e111-22<li><a href=\"http://link.springer.com/article/10.1007/s11306-015-0786-7\" target=\"_blank\">Non-targeted metabolomics of Brg1/Brm double-mutant cardiomyocytes reveals a novel role for SWI/SNF complexes in metabolic homeostasis</a></li>Metabolomics 2015, Volume 11, Issue 5, pp 1287?1301</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Akita Mice with Human apoE4 and Human LDLR Receptors (E4hAkita)</h1><em>Technology #15-0038</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0038/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0038.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584986\"><a href=\"/inventors/18584986_nobuyo-maeda\">Nobuyo Maeda</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>The E4hAkita mouse provides a novel model of diabetic atherosclerosis in the absence of severe hyperlipidemia, one in which the diabetes-induced proinflammatory changes in the vasculature and the hLDLR-mediated accumulation of cholesterol in macrophages synergistically trigger foam cell lesions. No diet manipulation, such as high cholesterol, high fat, or high cholate, is necessary to induce atherosclerosis.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23204275\" target=\"_blank\">Diabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammation</a></li>J Lipid Res 2013 Feb;54(2):386-96</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Visible Light-Driven Water Splitting</h1><em>Technology #15-0045</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0045/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0045.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5319\"><a href=\"/categories/5317_engineering-physical-sciences/5319_cleantech\">Cleantech</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584984\"><a href=\"/inventors/18584984_thomas-meyer\">Thomas Meyer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_366\"><a href=\"/managers/366_jennifer-dean\">Jennifer Dean</a> <div><em></em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186459\"><em><a href=\"http://google.com/patents/US20170309840\" target=\"_blank\">US Patent Pending US 2017/0309840</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707987\"><a href=\"https://uncnews.unc.edu/2014/01/14/unc-researchers-harness-energy-day-use-night/\" target=\"_blank\">UNC researchers harness sun’s energy during day for use at night</a></dd></dl></div><div class=\"content\"><p>A dye-sensitized photoelectrosynthesis cell (DSPEC) has been developed for splitting water with a core/shell of nanostructured electrodes derivatized with surface-bound chromophore-catalyst assemblies. Artificial photosynthesis research efforts seek to convert solar energy into chemical fuels by splitting water into oxygen and hydrogen or reducing CO2. The assembly can be further stabilized by deposition of protective overlayers of metal oxides via atomic layer deposition. This DSPEC can split water to H2 and O2 using visible light.<br/><strong>Advantages:</strong><br/>•  Core/shell electrode structure and protective overlayers on chromophore-catalyst assembly result in enhanced efficiency and greater stability over previous approaches for visible light-driven water splitting <br/>•  Demonstrated photocurrent densities as high as 1.97 mA/cm2 at pH 7 <br/>•  Chromophore-catalyst assembly combines both a light absorber and a water oxidation catalyst in a single molecule</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.pnas.org/content/110/50/20008.abstract\" target=\"_blank\">Solar water splitting in a molecular photoelectrochemical cell</a></li>PNAS 2013, 110, 20008-20013<li><a href=\"http://www.pnas.org/content/112/19/5899\" target=\"_blank\">Visible photoelectrochemical water splitting into H2 and O2 in a dye-sensitized photoelectrosynthesis cell</a></li>PNAS 2015, 112, 5899-5902</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Cell Line: CWR-R1 Prostate Cancer</h1><em>Technology #15-0053</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0053/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0053.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5346\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5346_cell-lines\">Cell Lines</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584981\"><a href=\"/inventors/18584981_elizabeth-wilson\">Elizabeth Wilson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This cell line was prepared from the castration-recurrent human prostate cancer CWR22 xenograft. Like the CWR22 tumor, CWR-R1 cells have a functional androgen receptor with a single mutation (AR-H874Y) that has a broadened ligand specificity and is activated at low concentrations of testosterone or dihydrotestosterone (DHT). The cell line is a co-culture of epithelial and stromal fibroblasts that grow as a monolayer in defined medium based in DMEM-H. The cells can be propagated for over 50 passages and growth is increased by low levels of DHT.<br/><br/>This cell line is available for distribution from Kerafast at <a href=\"https://www.kerafast.com/product/3333/human-prostate-cancer-cell-line-cwr-r1\" target=\"_blank\">https://www.kerafast.com/product/3333/human-prostate-cancer-cell-line-cwr-r1</a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/11306464\" target=\"_blank\">Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen</a></li>Cancer Res 2001 Apr 1;61(7):2892-8</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Plasmid: HM175/p16 HAV Infectious Molecular Clone, pHM175-p16#12</h1><em>Technology #15-0056</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0056/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0056.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584980\"><a href=\"/inventors/18584980_stanley-lemon\">Stanley Lemon</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>This plasmid contains a full-length infectious molecular cDNA clone of the noncytopathic, low passage, cell culture-adapted HM175/p16 hepatitis A virus genome. Virus rescued from this cDNA clone produces quasi-enveloped eHAV particles in appropriate cell culture types. The virus may be used to assess the efficacy of various methods for inactivating virus in plasma or blood collections.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.nature.com/nature/journal/v496/n7445/full/nature12029.html\" target=\"_blank\">A pathogenic picornavirus acquires an envelope by hijacking cellular membranes</a></li>Nature 2013, 496, 367?371</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Poly-Metformin: A Polymeric Formulation for the Treatment of Metabolic Disorders and Enhanced Gene Delivery</h1><em>Technology #15-0060</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0060/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0060.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li><li class=\"category\" id=\"category_5421\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5421_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584978\"><a href=\"/inventors/18584978_leaf-huang\">Leaf Huang</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186455\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>A polymeric formulation of Metformin has been developed. PolyMetformin (PolyMet) has been successfully synthesized through conjugation of linear polyethylenimine (PEI) with dicyandiamide. The delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity of PEI both in vitro and in vivo. Furthermore, the polycationic properties of PolyMet permit capture of siRNA into a core-membrane structured Lipid-Polycation-Hyaluronic acid (LPH) nanoparticle for systemic gene delivery. Even in the absence of RNAi, LPH-PolyMet nanoparticles act similarly to Metformin and activate the AMPK pathway. AMPK activation causes the inhibition of cholesterol synthesis, triglyceride synthesis, lipogenesis, and can stimulate hepatic fatty acid oxidation. LPH-PolyMet nanoparticles show promise as a therapy for metabolic disorders such as diabetes, nonalcoholic steatohepatitis (NASH), and nonalcoholic fatty liver disease (NAFLD).<br/><strong>Advantages:</strong><br/>•  PolyMet can circulate for a longer time in the body compared to Metformin <br/>•  Dual purpose therapeutic agent<br/>•  Reduced cytotoxicity from conventional nanoparticle formulations <br/> </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897747/\" target=\"_blank\">PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery</a></li>Nat. Commun. Published online 2016 Jun 6</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Next Generation Biomedicine Low Frequency Magnetic Nanoparticles</h1><em>Technology #15-0061</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0061/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0061.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5324\"><a href=\"/categories/5317_engineering-physical-sciences/5324_nanotechnology\">Nanotechnology</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5332\"><a href=\"/categories/5331_life-sciences/5332_ag-biotechnology\">Ag Biotechnology</a></li><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5419\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5419_oncology\">Oncology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584975\"><a href=\"/inventors/18584975_alexander-kabanov\">Alexander Kabanov</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186452\"><em><a href=\"http://google.com/search?#q=PCT%2FUS2017%2F025250&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">PCT Patent Application PCT/US2017/025250</a></em></dd></dl></div><div class=\"content\"><p>Novel polymer-coated magnetic nanoparticles (MNP-polymer complexes) have been developed that can be used in a variety of biomedical, therapeutic, and industrial applications. The iron oxide magnetic nanoparticle cores are synthesized by thermal decomposition yielding a tunable, uniform size. These unique polymer coatings have been shown to promote enhanced uptake into tumor and other cells. The MNP-polymer complexes can be efficiently and remotely actuated by super low frequency AC magnetic field with variety of field strengths which trigger cell death. The novel polymer coating enables loading of therapeutic and contrast imaging agents which can be modified to accommodate various targeting moieties. Proof of concept data has been generated in cancer cell lines.<br/><br/><strong>Advantages:</strong></p><ul>\n",
       "  <li>Customized to a specific application </li>\n",
       "  <li>High safety and biocompatibility profile</li>\n",
       "  <li>Magnetic nanoparticles can be easily and safely scale-up</li>\n",
       "  <li>Prolonged shelf-life</li>\n",
       "  <li>Lyophilization compatible</li>\n",
       "  <li>Robust quality control </li>\n",
       "  </ul><strong>Applications:</strong><ul>\n",
       "  <li>Biomedical Imaging</li>\n",
       "  <li>Therapuetic (Drug Delivery)</li>\n",
       "  <li>Research Tools</li>\n",
       "  <li>Diagnostics</li>\n",
       "  <li>Industrial Ag Biotechnology</li>\n",
       "  </ul><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://pharmacy.unc.edu/unc-nanomedicine-researchers-uncover-high-potential-for-low-frequency-magnetic-fields/\" target=\"_blank\">Recent Publication</a></li>\n",
       "  <li><a href=\"https://www.nature.com/articles/srep33560\" target=\"_blank\">Remote Actuation of Magnetic Nanoparticles For Cancer Cell Selective Treatment Through Cytoskeletal Disruption</a></li>\n",
       "  <li><a href=\"https://link.springer.com/content/pdf/10.1007%2Fs11051-017-3746-5.pdf\" target=\"_blank\">Theranostic multimodal potential of magnetic nanoparticles actuated by non-heating low frequency magnetic field in the new-generation nanomedicine</a></li>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Methods for Preventing and Treating Graft Versus Host Disease</h1><em>Technology #15-0064</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0064/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0064.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584973\"><a href=\"/inventors/18584973_jonathan-serody\">Jonathan Serody</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186451\"><em><a href=\"http://google.com/patents/US20170360907\" target=\"_blank\">US Patent Pending US 2017/0360907</a></em></dd></dl></div><div class=\"content\"><p>Infusion of ILC2 cells that are substantially free of ILC3 and MPP2 cells can be used to treat steroid refractory GvHd. Gastrointestinal tract graft-versus-host disease (GvHD) is relatively common following allogeneic stem cell transplantation however the prognosis is poor for steroid-refractory GvHD due to lack of alternate treatments. Ex vivo expansion and infusion of mouse ILC2 cells at key timepoints have diminished GvHD and provide encouraging results.<br/><strong>Advantages:</strong><br/>•  New treatment for steroid-refractory GvHD<br/>•  Purified ILC2 cells are free of contaminating MPP2 and ILC3 cells <br/>•  Infusion can be from donor or recipient cells </p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Photoredox-Catalyzed Direct C-H Functionalization of Arenes</h1><em>Technology #15-0068</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0068/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0068.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5318\"><a href=\"/categories/5317_engineering-physical-sciences/5318_chemical\">Chemical</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584971\"><a href=\"/inventors/18584971_david-nicewicz\">David Nicewicz</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186450\"><em><a href=\"http://google.com/patents/US20180148414\" target=\"_blank\">US Patent Pending US 20180148414</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707986\"><a href=\"https://cen.acs.org/articles/93/i37/Photoredox-Catalysis-Activates-Aryl-CH.html\" target=\"_blank\">Photoredox Catalysis Activates Aryl C–H Bonds In Amination Reaction</a></dd></dl></div><div class=\"content\"><p>An organic photoredox-based catalysis system has been developed for the C-H functionalization of aromatic compounds. This method is amenable to addition of a variety of functional groups and provides a practical route to the direct, selective transformation of arene C-H bonds.<br/><strong>Advantages:</strong><br/>•  Regioselective addition<br/>•  No prior functionalization required<br/>•  One-step formation of primary anilines and azoles<br/>•  Mild conditions amenable to late-stage functionalization of synthetic targets</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://science.sciencemag.org/content/349/6254/1326.long\" target=\"_blank\">Site-selective arene C-H amination via photoredox catalysis</a></li>Science 2015, 349, 1326-1330</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Streaming-connected Large-scale Structure-from-Motion</h1><em>Technology #15-0088</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0088/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0088.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584968\"><a href=\"/inventors/18584968_jan-michael-frahm\">Jan-michael Frahm</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186446\"><em><a href=\"http://google.com/patents/WO2016154499\" target=\"_blank\">PCT Patent Application WO 2016/154499</a></em></dd></dl></div><div class=\"content\"><p>A novel large-scale structure from motion framework advances the state of the art in data scalability from city-scale modeling (millions of images) to world-scale modeling (several tens of millions of images) using just a single computer. The main enabling technology is the use of a streaming-based framework for connected component discovery. Moreover, the system employs an adaptive online iconic clustering approach based on an augmented bag-of-words representation, in order to balance the goals of registration, comprehensiveness, and data compactness. Useful for a wide range of applications including virtual reality, image-based localization, and autonomous navigation.<br/><strong>Advantages:</strong><br/>•  Novel data association concept overcomes the challenges that the streaming processing posed for the data association required for 3D reconstruction and achieves high model completeness<br/>•  Pushes the scale of reconstructabilty by more than an order of magnitude while achieving highly complete models<br/>•  Efficient<br/>•  Scalable </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://frahm.web.unc.edu/files/2014/08/cvpr2015-heinly.pdf\" target=\"_blank\">Recent Publication</a></li>PDF</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Delivery of Neuroprotective Therapeutic Agents to the CNS</h1><em>Technology #15-0104</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0104/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0104.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5324\"><a href=\"/categories/5317_engineering-physical-sciences/5324_nanotechnology\">Nanotechnology</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5337\"><a href=\"/categories/5331_life-sciences/5337_drug-delivery\">Drug Delivery</a></li><li class=\"category\" id=\"category_5349\"><a href=\"/categories/5331_life-sciences/5349_therapeutics\">Therapeutics</a><ul><li class=\"category\" id=\"category_5420\"><a href=\"/categories/5331_life-sciences/5349_therapeutics/5420_neurology\">Neurology</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584963\"><a href=\"/inventors/18584963_alexander-kabanov\">Alexander Kabanov</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186445\"><em><a href=\"http://google.com/search?#q=PCT%2FUS2017%2F015930&amp;btnI=745&amp;tbm=pts\" target=\"_blank\">PCT Patent Application PCT/US2017/015930</a></em></dd></dl></div><div class=\"content\"><p>Innovative polymer-based formulations have been developed for delivery of neurotrophins to the brain using peripheral and central administration. The anionic block copolymers are used in charge excess with respect to the neurotrophins, so that neurotrophins and block copolymers form a nanoscale size polyion complex, while the free block copolymers are also present in the formulation. The formulation increases serum and mucosal stability and prevents enzymatic degradation of neurotrophins. The excess of the block copolymer inhibits efflux of neurotrophin from the brain, thereby increasing the brain levels of neurotrophin. These novel compositions are used to treat.<br/><strong>Advantages:</strong><br/>•  Rapid and non-invasive delivery of proteins to the brain<br/>•  Targeted delivery within brain compartments<br/>•  Platform technology allows development of formulations based on various therapeutical proteins<br/>•  Reduction of peripheral exposure to therapeutical proteins<br/>•  Significant reduction of rare and costly proteins needed to achieve therapeutically meaningful doses in specific brain regions </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adfm.201703982\" target=\"_blank\">Nanoformulation of Brain-Derived Neurotrophic Factor with Target Receptor-Triggered-Release in the Central Nervous System</a></li>\n",
       "  <a href=\"https://doi.org/10.1002/adfm.201703982\" target=\"_blank\">https://doi.org/10.1002/adfm.201703982</a>\n",
       "  </ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Multi-stage Robot for Transoral Peripheral Lung Access</h1><em>Technology #15-0106</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0106/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0106.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5326\"><a href=\"/categories/5317_engineering-physical-sciences/5326_robotics\">Robotics</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584962\"><a href=\"/inventors/18584962_ron-alterovitz\">Ron Alterovitz</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186444\"><em><a href=\"http://google.com/patents/US20180214010\" target=\"_blank\">US Patent Pending US 20180214010</a></em></dd></dl></div><div class=\"content\"><p>A robotic approach has been developed for image-guided trans-bronchoscopic lung access. The multi-stage robotic system can bring the benefits of transoral access to patients with difficult-to-access peripheral lung nodules, avoiding the drawbacks of percutaneous and transoral bronchoscopic biopsy. It offers the potential to steerably biopsy peripheral lung regions deep in the parenchyma, via a transoral approach.<br/><strong>Advantages:</strong><br/>•  Brings the benefits of transoral access to patients with peripheral lung nodules<br/>•  Access to sites that are traditionally inaccessible transorally<br/>•  Early stage diagnosis of lung disease<br/>•  Potential to reduce the risk of pneumothorax (lung collapse)<br/>•  Gives physicians the option of obtaining a definitive diagnosis when a suspicious nodule is first detected </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492535/\" target=\"_blank\">Tendons, Concentric Tubes, and a Bevel Tip: Three Steerable Robots in One Transoral Lung Access System</a></li>IEEE Int Conf Robot Autom 2015 May; 2015: 5378?5383.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Automatic Obstacle Avoidance During Tentacle-like Robot Teleoperation</h1><em>Technology #15-0107</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0107/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0107.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5326\"><a href=\"/categories/5317_engineering-physical-sciences/5326_robotics\">Robotics</a></li></ul></li><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584958\"><a href=\"/inventors/18584958_ron-alterovitz\">Ron Alterovitz</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"pct_patent_application\" id=\"pct_patent_application_8186443\"><em><a href=\"http://google.com/patents/WO2016191364\" target=\"_blank\">PCT Patent Application WO 2016/191364</a></em></dd></dl></div><div class=\"content\"><p>A motion planning approach for concentric tube robot teleoperation that enables a tentacle-like robot to interactively maneuver its tip to points selected by a user while automatically avoiding sensitive anatomical obstacles (e.g., critical vessels, nerves, and organs) along its shaft. The user specifies goal positions by clicking with a 3D mouse on an augmented reality interface, and the robot automatically moves its tip to the specified goal position while avoiding contact with obstacles. This approach could enable surgeons to perform safer and less invasive surgeries with fewer medical errors by decreasing cognitive load on surgeons during procedures and providing a level of automatic control of the device. The approach has commercial potential for intuitive surgical and other medical robot and device companies.<br/><strong>Advantages:</strong><br/>•  Safe and effective operation of tentacle-like robots for surgical procedures<br/>•  Decreases physicians' mental loads, freeing them to focus on controlling the robot’s tip<br/>•  Less invasive surgeries<br/>•  Reduces the error between the commanded goal position and the robot’s tip position by using tip position sensing to account for kinematic modeling error.  </p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://uncch.pure.elsevier.com/en/publications/a-motion-planning-approach-to-automatic-obstacle-avoidance-during\" target=\"_blank\">A motion planning approach to automatic obstacle avoidance during concentric tube robot teleoperation</a></li>Recent publication</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Polyclonal Antiserum: Antibodies to Melanoma Antigen-A11 (MAGE-A11)</h1><em>Technology #15-0122</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0122/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0122.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5345\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5345_antibodies\">Antibodies</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584954\"><a href=\"/inventors/18584954_elizabeth-wilson\">Elizabeth Wilson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Prostate cancer growth and progression depend on androgen receptor (AR) transcriptional signaling, which is increased by MAGE-A11, an AR coregulator. MAGE-A11 is a cancer-testis antigen that resides predominantly in the nucleus at low levels in normal human reproductive tract tissues and at higher levels in castration-resistant prostate cancer. These antibodies were raised in rabbits against MAGE-A11 and appear to be high affinity as low levels of MAGE-A11 can be detected. The main uses of the MAGE-A11 antibodies are western blot analysis and immunocytochemistry.<br/><br/>These antibodies are available from Kerafast and can be found at <a href=\"https://www.kerafast.com/product/3332/anti-mage-a11-antibodies\" target=\"_blank\">https://www.kerafast.com/product/3332/anti-mage-a11-antibodies</a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.jbc.org/content/290/41/25174.full\" target=\"_blank\">Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor</a></li>J. Biol. Chem. 2015, 290, 25174-25187.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Matrix Gla (MGP) Expression</h1><em>Technology #15-0125</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0125/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0125.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584951\"><a href=\"/inventors/18584951_terete-borras\">Terete Borras</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Matrix Gla (MGP) is a potent mineralization inhibitor secreted by cartilage chondrocytes and arteries' vascular smooth muscle cells. Expression of Cre is under the control of the entire Mgp regulatory regions, and thus its expression represents a true Mgp-tissue specific expression.  Mgp anticalcification/antistiffness gene in the eye is highly expressed in the glaucoma-associated tissues TM, ciliary muscle, and ppSC.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406033/\" target=\"_blank\">A Novel Mgp-Cre Knock-In Mouse Reveals an Anticalcification/Antistiffness Candidate Gene in the Trabecular Meshwork and Peripapillary Scleral Region</a></li>Investigative Ophthalmology &amp; Visual Science (2015): 2203?2214.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Use of Non-cylindrical Bead Well Geometries to Improve Assay Readout in a Compact Microwell Array</h1><em>Technology #15-0131</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0131/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0131.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5323\"><a href=\"/categories/5317_engineering-physical-sciences/5323_microfluidics\">Microfluidics</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584949\"><a href=\"/inventors/18584949_j-ramsey\">J Ramsey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186441\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>Novel, non-cylindrical bead well geometries have been\n",
       "  developed that improve detection in bead-based assays. Well geometries are\n",
       "  fabricated such that one area of the well is optimized for magnetic loading and\n",
       "  bead retention, and another region of the well is used for signal detection.\n",
       "  The two regions of the well are fluidically connected to each other allowing\n",
       "  for reagents or analytes to diffuse or mix. By spatially separating the bead\n",
       "  from the detection region, the contribution of bead background fluorescence to\n",
       "  the signal can be reduced or eliminated, thus improving the signal to noise\n",
       "  ratio. Related technologies have been developed that increase multiplexing\n",
       "  capability by incorporating dye stability as a measurement (16-0015) and\n",
       "  utilize bead-based delivery of reagents to facilitate parallel assays on a\n",
       "  multiplexed-in-space microfluidic device (12-0128).</p>\n",
       "  <p><b>Advantages:</b></p>\n",
       "  <p>• \n",
       "  Applies to a range of volumes from 1 fL up to\n",
       "  several Î¼L with bead diameters from a few hundred nm to mm \n",
       "   </p>\n",
       "  <p>• \n",
       "  Can be used for highly sensitive real-time PCR\n",
       "  detection of multiple target sequences on a single chip with or without the use\n",
       "  of sequence-specific probes</p>\n",
       "  <p>• \n",
       "  May be used clinically to evaluate the presence\n",
       "  of disease causing organisms, gene expression, genotyping, or forensic science\n",
       "  applications</p>\n",
       "  <p></p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://pubs.rsc.org/en/content/articlehtml/2014/lc/c3lc51303c\" target=\"_blank\">An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples</a></li>Royal Society of Chemistry, Lab on a Chip Lab Chip, 2014, 14, 1087-1098</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Use of Ice-Nucleating Proteins to Improve Performance of Freeze-Thaw Valves in Microfluidic Systems</h1><em>Technology #15-0136</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/15-0136/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/15-0136.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5323\"><a href=\"/categories/5317_engineering-physical-sciences/5323_microfluidics\">Microfluidics</a></li></ul></li><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5336\"><a href=\"/categories/5331_life-sciences/5336_diagnostic\">Diagnostic</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584947\"><a href=\"/inventors/18584947_j-ramsey\">J Ramsey</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"provisional_patent_application\" id=\"provisional_patent_application_8186440\"><em>Provisional Patent Application Filed </em></dd></dl></div><div class=\"content\"><p>This methodology utilizes ice-nucleating proteins (INPs) as additives to initiate the freezing of water or aqueous solutions at higher temperatures and improve the performance of freeze-thaw-valves in microfluidic chips. Ice-nucleating proteins are produced by fungi, bacteria, and other organisms, and are capable of inducing ice crystal formation in microfluidic systems at temperatures as warm as -2 °C. In microfluidic systems that utilize multiple liquids or reagents, valves are often necessary to modulate fluid flow. Various valving technologies have been employed, but most require complicated or relatively expensive microstructures and/or external hardware. Freezing can be used to modulate fluid flow on microfluidic devices through freeze-thaw valves (FTVs). FTVs utilize an external cooling source to freeze a plug of fluid in a channel, thus stopping fluid flow in the desired regions of the chip. The channel can then be opened by warming the plug until it thaws. A high degree of supercooling, often to temperatures below -20 °C, is typically needed to freeze water in most microfluidic devices. The ice-nucleating protein, inaZ, from Pseudomonas syringae has been utilized to create a FTV with an internal temperature of -11 °C.<br/><strong>Advantages:</strong><br/>•  Compatible with both elastic/flexible materials and inelastic/inflexible materials<br/>•  INPs significantly reduce the average time water must be held below the freezing point before crystallization occurs<br/>•  Allows precise fluid control with computer-controlled/automated capabilities<br/>•  Uses simple and easy to manufacture chip architectures with no moving parts<br/>•  Reduces the hardware requirements of the system in terms of cooling equipment</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b00556\" target=\"_blank\">Use of Ice-Nucleating Proteins To Improve the Performance of Freeze–Thaw Valves in Microfluidic Devices</a></li>Anal. Chem., 2017, 89 (11), pp 5998–6005</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Acoustic Detection of Activated Ultrasound Phase-Change Contrast Agents</h1><em>Technology #14-0009</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0009/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0009.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584945\"><a href=\"/inventors/18584945_paul-dayton\">Paul Dayton</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186439\"><em><a href=\"http://google.com/patents/US20160262727\" target=\"_blank\">US Patent Pending US 2016/0262727</a></em></dd></dl></div><div class=\"content\"><p>This novel method detects acoustic signatures unique to phase-contrast agents (PCCAs) that can be used to differentiate PCCAs from surrounding tissue and standard microbubble contrast agents. These unique signals are due to over-expansion and oscillating frequencies induced upon oscillation of PCCAs. Once activated by a primary source, the vaporization event can be monitored passively by ultrasound. PCCAs have been gaining increasing attention in recent years as agents for diagnostic and therapeutic applications of ultrasound, and this detection method has the potential to benefit ultrasound technology and result in new therapeutic and diagnostic imaging techniques.<br/><strong>Advantages:</strong><br/>•  This technology allows for the detection of unique acoustic signatures created by PCCAs<br/>•  Detection of these signals can be differentiated from those of standard microbubble contrast agents<br/>•  Detection of these signals allows spatial localization and quantification of PCCA activation, and may be useful for diagnostic and therapeutic applications of ultrasound<br/>•  This method could be used to monitor PCCA therapy in real-time and lead to new transducer detection schemes for diagnostic ultrasound systems.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Visible Light-Driven Water Splitting</h1><em>Technology #14-0019</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0019/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0019.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5319\"><a href=\"/categories/5317_engineering-physical-sciences/5319_cleantech\">Cleantech</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584938\"><a href=\"/inventors/18584938_thomas-meyer\">Thomas Meyer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186437\"><em><a href=\"http://google.com/patents/US20150072852\" target=\"_blank\">US Patent Pending US 2015/0072852</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707985\"><a href=\"https://uncnews.unc.edu/2014/01/14/unc-researchers-harness-energy-day-use-night/\" target=\"_blank\">UNC researchers harness sun’s energy during day for use at night</a></dd></dl></div><div class=\"content\"><p>A dye-sensitized photoelectrosynthesis cell (DSPEC) has been developed for splitting water with a core/shell of nanostructured electrodes derivatized with surface-bound chromophore-catalyst assemblies. Artificial photosynthesis research efforts seek to convert solar energy into chemical fuels by splitting water into oxygen and hydrogen or reducing CO2. The assembly can be further stabilized by deposition of protective overlayers of metal oxides via atomic layer deposition. This DSPEC can split water to H2 and O2 using visible light.<br/><strong>Advantages:</strong><br/>•  Core/shell electrode structure and protective overlayers on chromophore-catalyst assembly result in enhanced efficiency and greater stability over previous approaches for visible light-driven water splitting <br/>•  Demonstrated photocurrent densities as high as 1.97 mA/cm2 at pH 7 <br/>•  Chromophore-catalyst assembly combines both a light absorber and a water oxidation catalyst in a single molecule</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.pnas.org/content/110/50/20008.abstract\" target=\"_blank\">Solar water splitting in a molecular photoelectrochemical cell</a></li>PNAS 2013, 110, 20008-20013<li><a href=\"http://www.pnas.org/content/112/19/5899\" target=\"_blank\">Visible photoelectrochemical water splitting into H2 and O2 in a dye-sensitized photoelectrosynthesis cell</a></li>PNAS 2015, 112, 5899-5902</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Gaze-controlled Photo Taking System</h1><em>Technology #14-0028</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0028/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0028.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584935\"><a href=\"/inventors/18584935_jan-michael-frahm\">Jan-Michael Frahm</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186436\"><em><a href=\"http://google.com/patents/US20160309081\" target=\"_blank\">US Patent Pending US 2016/0309081</a></em></dd></dl></div><div class=\"content\"><p>A gaze-controlled photo taking system allows the photographer to take a clear, focused image while still participating in the photo-scene experience and avoiding the “observer through the viewfinder” feeling. By augmenting currently existing autofocus algorithms and zoom/cropping mechanisms with gaze detection and pose estimation techniques, this “smarter camera” is adapted to observe the user and is capable of detecting the region of the scene which should be focused upon. Commercial applications include cameras, cell phone cameras, AR glasses like Google glasses, video cameras, etc.<br/><strong>Advantages:</strong><br/>•  Referential gaze detection for usage in hands-free autofocus systems<br/>•  A human-camera interaction system which opens the doors to gaze-specific metadata<br/>•  Useful in post-processing (automatic image composure based on the part of the scene that the user was looking at when the photo was taken)</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.cv-foundation.org/openaccess/content_cvpr_2015/html/Perra_Adaptive_Eye-Camera_Calibration_2015_CVPR_paper.html\" target=\"_blank\">Adaptive Eye-Camera Calibration for Head-Worn Devices</a></li>CVPR 2015 Open Access The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2015, pp. 4146-4155</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Vibration-Induced Stem Cell Chondrogenesis and Osteogenesis</h1><em>Technology #14-0030</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0030/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0030.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5342\"><a href=\"/categories/5331_life-sciences/5342_medical-devices\">Medical Devices</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584934\"><a href=\"/inventors/18584934_robert-dennis\">Robert Dennis</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_373\"><a href=\"/managers/373_charlie-shaw\">Charlie Shaw</a> <div><em>Commercialization Manager</em> <em>919.966.3929</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186435\"><em><a href=\"http://google.com/patents/US20160230135\" target=\"_blank\">US Patent Pending US 2016/0230135</a></em></dd></dl></div><div class=\"content\"><p>A surgically implantable bioreactor that induces either\n",
       "  chondrogenesis (cartilage development) or osteogenesis (formation of bone) from\n",
       "  mesenchymal stem cells has been developed. \n",
       "  In vitro studies in which vibratory signals were provided to both human\n",
       "  and porcine mesenchymal stem cells demonstrated that at lower frequencies the cells\n",
       "  differentiate into a cartilage phenotype, and will conversely differentiate\n",
       "  into a bone phenotype at higher frequencies. \n",
       "  Delivery of these vibratory signals in vivo would provide a novel\n",
       "  treatment option for bone and cartilage replacement.  Currently, replacing bone or cartilage in\n",
       "  patients is accomplished with grafts to the site or with chemical induction of\n",
       "  chondrogenesis or osteogenesis. \n",
       "  Unfortunately, the success of these procedures is often unpredictable due\n",
       "  to problems with host rejection or insufficient induction of the correct tissue\n",
       "  type.  This technology avoids these\n",
       "  problems because the bioreactor is able to drive tissue lineage selection of\n",
       "  mesenchymal stem cells simply through vibrational stimulation.  Using the same technology, these researchers\n",
       "  have invented an in vitro device that is able to stimulate stem cells in\n",
       "  culture with vibrational frequencies between 1 and 100 hertz to better study\n",
       "  the mechanical induction of a cartilage or a bone cell lineage. These devices\n",
       "  represent a novel means to direct the development of mesenchymal stem cells and\n",
       "  provide better options for bone and cartilage replacement.  Additionally, this system can help study stem\n",
       "  cell lineage determination induced by vibrational forces in the in vitro cell\n",
       "  culture system.</p>\n",
       "  <p><b>Advantages:</b></p>\n",
       "  <p>• \n",
       "  Eliminates the need for grafting and may\n",
       "  diminish chance of host tissue rejection </p>\n",
       "  <p>• \n",
       "  No pharmacological agents involved </p>\n",
       "  <p>• \n",
       "  Ability to adjust device program to better\n",
       "  direct tissue-specific growth </p>\n",
       "  <p>• \n",
       "  In vitro system allows for study of how\n",
       "  mechanical force drives stem cell lineage</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Plasmid: Infectious Clone of Pipistrellus Bat Coronavirus (BtCoV) Strain HKU5</h1><em>Technology #14-0034</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0034/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0034.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584933\"><a href=\"/inventors/18584933_ralph-baric\">Ralph Baric</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Bat CoV HKU5 is &gt;65% identical to Middle East respiratory syndrome CoV (MER-CoV), which has a ~45% mortality rate. Studies against subgroup 2c Betacoronavirus have been hampered because MER-CoV has no small animal model and BtCoV HKU5 does not replicate in culture. The development of infectious clones and recombinant viruses from emerging zoonotic CoVs will expedite the rapid identification of subgroup specific broad-spectrum antivirals. The synthetically constructed infectious clone of BtCoV HKU5 replicates efficiently in young and aged mice and in cell culture, and provides a robust platform for testing the breadth of activity of group 2c CoV antiviral drugs.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24667706\" target=\"_blank\">A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant</a></li>MBio 2014 Mar 25;5(2):e00047-14</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Human FIX Knock-In (R333Q Mutation)</h1><em>Technology #14-0039</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0039/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0039.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584929\"><a href=\"/inventors/18584929_darrel-stafford\">Darrel Stafford</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Factor IX knockout models of hemophilia B reproduce the bleeding phenotype of human hemophilia B, but because the models produce no factor IX they fail to reproduce the dominant human phenotype. The R333Q-hFIX mouse expresses a missense mutant human factor IX from the mouse FIX promoter. Mutant human factor IX mRNA transcript and circulating human factor IX are detectable throughout development, but factor IX activity is less than 1% and the mouse exhibits the hemophilic phenotype.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/15178576\" target=\"_blank\">Creation of a mouse expressing defective human factor IX</a></li>Blood 2004 Sep 15;104(6):1733-9</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Improved Illumination of Spatial Augmented Reality Objects</h1><em>Technology #14-0051</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0051/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0051.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584928\"><a href=\"/inventors/18584928_henry-fuchs\">Henry Fuchs</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186433\"><em><a href=\"http://google.com/patents/US20160323553\" target=\"_blank\">US Patent Pending US 2016/0323553</a></em></dd></dl></div><div class=\"content\"><p>This methodology improves upon current spatial augmentation reality techniques, where the object of augmentation appears to glow unnaturally, through a combination of an improved projection surface and more accurate calibration for ambient illumination.<br/><strong>Advantages:</strong><br/>•  More realistic images of live humans, recorded humans, or virtual characters into human-size mannequins<br/>•  Applicable to immersive training scenarios, for immersive “teleconferencing”, entertainment, etc.<br/>•  Make other virtual objects projected onto real forms and shapes more realistic – furniture prototyping, interior design, etc.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Plasmid: Infectious cDNA Clone of Genotype 1a Hepatitis C Virus H77D</h1><em>Technology #14-0061</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0061/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0061.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584925\"><a href=\"/inventors/18584925_stanley-lemon\">Stanley Lemon</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Although hepatitis C virus (HCV) is a leading cause of cirrhosis and liver cancer, many details of its replication remain obscure, as most HCV strains replicate poorly in cell culture. Furthermore, no effective vaccines are available to date and the mechanism of HCV persistence and carcinogenesis in vivo remain inadequately understood. This plasmid contains infectious molecular clones of H77D virus, a replication competent genotype 1a variant of HCV. These clones are capable of robust replication in cultured cells and could be used to facilitate drug development and the assessment of viral resistance to therapeutics.<br/><br/>This plasmid is available for distribution from Kerafast and can be found at <a href=\"https://www.kerafast.com/product/3453/\" target=\"_blank\">https://www.kerafast.com/product/3453/</a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126843/\" target=\"_blank\">Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation</a></li>Nat Med 2014 Aug; 20(8): 927?935.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: NLRP3 Null</h1><em>Technology #14-0063</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0063/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0063.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584923\"><a href=\"/inventors/18584923_beverly-koller\">Beverly Koller</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Acute inflammation in response to both exogenous and endogenous danger signals can lead to the assembly of cytoplasmic inflammasomes that stimulate the activation of caspase-1, which facilitates the maturation and release of cytokines and sometimes the induction of cell death by pyroptosis. This mouse line, which allows for study of the role of the inflammasome in the immune response, was generated by targeted mutagenesis in 129 ES cells using a replacement type vector. This removed all NLRP3 exons and replaced the segment of DNA with the neomycin resistance gene. Closely related to UNC Ref# 17-0083 (Mouse: Humanized NLRP3).<br/><br/>This research tool is available from The Jackson Laboratory at <a href=\"https://www.jax.org/strain/021302\" target=\"_blank\">https://www.jax.org/strain/021302</a>.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22753929\" target=\"_blank\">NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice</a></li>J Immunol 2012 Aug 15;189(4):2006-16</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: GPCR Mutation</h1><em>Technology #14-0085</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0085/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0085.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584917\"><a href=\"/inventors/18584917_bryan-roth\">Bryan Roth</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Adora2A-rM3Ds transgenic mice express a fluorescent protein reporter and a mutant G protein-coupled receptor, rM3Ds, directed to D2-dopamine receptor-expressing striatopallidal medium spiny neurons by the Adora2a promoter/enhancer regions of a BAC transgene. The rM3Ds receptor can be activated by clozapine-N-oxide allowing selective and non-invasive modulation of Gαs– signaling in specific neuronal populations in vivo.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23303063\" target=\"_blank\">A G?s DREADD mouse for selective modulation of cAMP production in striatopallidal neurons</a></li>Neuropsychopharmacology 2013 Apr;38(5):854-62</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Mouse: Human IL4/IL13 Receptorand Ligand Expression (I29-1L4R/IL13/IL4)</h1><em>Technology #14-0086</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0086/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0086.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5347\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5347_mice\">Mice</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584916\"><a href=\"/inventors/18584916_beverly-koller\">Beverly Koller</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Mice expressing human type I (IL-4)  and type II (IL-4 and IL-13) receptors.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Skeletal Representations of Objects</h1><em>Technology #14-0106</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0106/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0106.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5363\"><a href=\"/categories/5362_software-information-technology/5363_algorithm\">Algorithm</a></li><li class=\"category\" id=\"category_5374\"><a href=\"/categories/5362_software-information-technology/5374_simulation-modeling\">Simulation &amp; Modeling</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584911\"><a href=\"/inventors/18584911_stephen-pizer\">Stephen Pizer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_364\"><a href=\"/managers/364_copyright-materials\">Copyright Materials</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>S-reps are skeletal models for anatomic objects especially suited for computing probability distributions from populations of these objects. They allow classification and hypothesis testing using their geometric features and physiological features derived from medical images. This novel software fits S-reps to data in the form of signed distance functions and optionally using the composite principle nested spheres statistical analysis approach of Sungkyu Jung to form shape spaces within which the fitting of s-reps to a collection of object distance functions takes place.</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Device for Accurate Syringe Measurement and Dispensing of Liquids</h1><em>Technology #14-0122</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0122/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0122.pdf\">Download Printable PDF</a></p><dl><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584910\"><a href=\"/inventors/18584910_stephen-eckel\">Stephen Eckel</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_369\"><a href=\"/managers/369_leodis-gupton\">Leodis Gupton</a> <div><em>Commercialization Manager</em> <em>919.966.4132</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186428\"><em><a href=\"http://google.com/patents/US20170146381\" target=\"_blank\">US Patent Pending US 2017/0146381</a></em></dd></dl></div><div class=\"content\"><p>A device has been developed for accurate measurement and dispensing when using a syringe. Precise syringe dispensing of drugs has important care and financial considerations. Advantages: • Precise drug delivery for formulation, certain medications and patients • Digital reader is removable, so it can be used more than once • Fits syringe sizes from 1 ml to 60 ml</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Minimal-latency Tracking and Display for Matching Real and Virtual Worlds in Head-worn Displays</h1><em>Technology #14-0139</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0139/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0139.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584909\"><a href=\"/inventors/18584909_henry-fuchs\">Henry Fuchs</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186427\"><em><a href=\"http://google.com/patents/US20170345398\" target=\"_blank\">US Patent Pending US 2017/0345398</a></em></dd></dl></div><div class=\"content\"><p>Methods, systems, and computer readable media have been developed for minimal-latency tracking and display for matching real and virtual worlds in head-worn displays (i.e., opitical see-through glasses). The system includes a display module, a rendering module, and a processing module. This also offers a new method of reducing latency that takes advantage of the principles of bufferless input/output and “minimal-latency” processing throughout all main components of an AR system, i.e., tracking, rendering, and display. The method calculates a user- perceived image, calculates a desired image, calculates an error image, identifies an error portion, and updates a portion of a projected image. The systems and/or methods have the potential to minimize lag-induced registration errors, which are the main effect of high latency in current systems. This technology can be implemented in software in combination with hardware and/or firmware. In addition to education benefits, societal benefits include more hand-eye coordination and augmented imagery anywhere the user looks. The approach can also benefit research, as it is useful for spatial AR and handheld AR devices that rely on low-latency visual feedback in response to moving objects and gestures.<br/><strong>Advantages:</strong><br/>•  Reduces latency</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://ieeexplore.ieee.org/document/7383304/?arnumber=7383304\" target=\"_blank\">From Motion to Photons in 80 Microseconds: Towards Minimal Latency for Virtual and Augmented Reality Sign In or Purchase</a></li>IEEE Xplore Digital Library 14 January 2016 10.1109/TVCG.2016.2518038</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Cloud-Scale Image Compression through Redundancy Reduction</h1><em>Technology #14-0142</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0142/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0142.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584908\"><a href=\"/inventors/18584908_jan-michael-frahm\">Jan-Michael Frahm</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186426\"><em><a href=\"http://google.com/patents/US20170195678\" target=\"_blank\">US Patent Pending US 2017/0195678</a></em></dd></dl></div><div class=\"content\"><p>An efficient cloud-scale digital image compression scheme has been developed for use in cloud image storage systems that leverages pixel-wise redundancy between images to minimize each photo’s memory footprint. This novel image compression technique takes full advantage of redundant image data in the cloud by independently compressing each newly uploaded image with its GIST nearest neighbor taken from a representative set of uncompressed images, and thereby efficiently reuses image content which is already stored server-side.<br/><strong>Advantages:</strong><br/>•  Allows online photo sharing websites to significantly reduce their storage requirements<br/>•  Scales to accommodate large datasets/large-scale image compression<br/>•  Highly parallelizable for cloud computing<br/>•  Algorithm produces competitive image compression rates while reducing the computational effort by at least an order of magnitude (i.e., it can identify and remove duplicate pixel information at significantly higher speeds that enable online operation at cloud-scale)</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.cs.unc.edu/~jmf/publications/PerraFrahmBMVC2014.pdf\" target=\"_blank\">Cloud-Scale Image Compression Through Content Deduplication</a></li>Read More PerraFrahmBMVC2014.pdf</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>IMAGIN: High-definition High-Dynamic-Range Camera Sensor</h1><em>Technology #14-0143</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/14-0143/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/14-0143.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584907\"><a href=\"/inventors/18584907_montek-singh\">Montek Singh</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186425\"><em><a href=\"http://google.com/patents/US20170126991\" target=\"_blank\">US Patent Pending US 2017/0126991</a></em></dd></dl></div><div class=\"content\"><p>A novel image sensing architecture has been developed that boosts the dynamic range as well as the definition of camera images. The innovation lies not in the design of the photodetector (sensor), but in the data encoding and the communication and processing architecture. Tradeoffs between frame rates, electronic shutter speeds, dark current and bright saturation are optimized for various target applications, with enhancements such as Regions Of Interest (ROI) for higher frame rates, and composition of multiple frames with varying exposure times for improved dynamic range. The methods improve the process of data acquisition from a spatially distributed array of analog continuous time sensors. In general, these methods can be applied to any collection of spatially distinct positive-definite continuous-time continuous-level signal sources, the desired outputs of which are to be discretely digitized representations of their respective time integrals.<br/><strong>Advantages:</strong><br/>•  Enables camera sensors to be developed with much higher dynamic range, and much higher definition</p></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Plasmid: Mutant FabI Selection Marker</h1><em>Technology #13-0024</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0024/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0024.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5344\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods\">Research Tools &amp; Methods</a><ul><li class=\"category\" id=\"category_5348\"><a href=\"/categories/5331_life-sciences/5344_research-tools-methods/5348_other\">Other</a></li></ul></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584905\"><a href=\"/inventors/18584905_terry-magnuson\">Terry Magnuson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_363\"><a href=\"/managers/363_tangible-property\">Tangible Property</a> <div><em></em> <em>919.966.3929</em></div></dd></dl></div><div class=\"content\"><p>Usually, plasmids are maintained in E. coli host by antibiotic selection; however, there are only a few antibiotic-resistance markers available in common use. This new selection marker, mutant fabl (mfabI) for plasmid selection in E. coli, which can be used alone or in combination with any existing antibiotic selection, allows for more efficient molecular manipulation and plasmid propagation in E. coli. It can also be incorporated into recombineering vectors to improve the recombineering tool kit for gene-targeting construct production.<br/><br/>If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23437314\" target=\"_blank\">A Novel Selection Marker for Efficient DNA Cloning and Recombineering in E. coli</a></li>PLoS One 2013;8(2):e57075</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Optical See-Through Head Worn Display Using Multiple Light Attenuating Layers</h1><em>Technology #13-0039</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0039/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0039.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5364\"><a href=\"/categories/5362_software-information-technology/5364_augmented-reality-and-virtual-reality\">Augmented Reality and Virtual Reality</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584900\"><a href=\"/inventors/18584900_andrew-maimone\">Andrew Maimone</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186420\"><em><a href=\"http://google.com/patents/US9858721\" target=\"_blank\">US Patent 9,858,721</a></em></dd></dl></div><div class=\"content\"><p>New optical see-through glasses have been developed that integrate virtual imagery with high visual fidelity into a compact slim display that supports a wide field of view. The use of multiple imaging masking layers allows for simultaneous viewing of real-world objects and virtual objects that can be implemented for several purposes in the realm of augmented reality. Companies engaged in augmented reality could develop the current design for use in a variety of purposes, such as telepresence, simulation and training, and navigation.<br/><strong>Advantages:</strong><br/>Likely the only see-through device to support all of the following qualities:<br/>•  Wide field of view<br/>•  Compact design<br/>•  Multiple simultaneous focal distances<br/>•  Occlusion masking of real objects with virtual objects</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://ieeexplore.ieee.org/document/6671761/?arnumber=6671761\" target=\"_blank\">Computational augmented reality eyeglasses</a></li>IEEE Xplore Digital Library 23 December 2013 10.1109/ISMAR.2013.6671761</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>A Synthetic Route to Pactamycin Amenable to Analog Preparation</h1><em>Technology #13-0041</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0041/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0041.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5317\"><a href=\"/categories/5317_engineering-physical-sciences\">Engineering &amp; Physical Sciences</a><ul><li class=\"category\" id=\"category_5318\"><a href=\"/categories/5317_engineering-physical-sciences/5318_chemical\">Chemical</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584899\"><a href=\"/inventors/18584899_jeffrey-johnson\">Jeffrey Johnson</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_365\"><a href=\"/managers/365_john-rainwater\">John Rainwater</a> <div><em>Commercialization Manager</em> <em>919.445.9371</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186419\"><em><a href=\"http://google.com/patents/US9399652\" target=\"_blank\">US Patent US 9399652</a></em></dd><dt class=\"links\">External Links</dt><dd class=\"link\" id=\"link_12707984\"><a href=\"https://www.chemistryworld.com/opinion/pactamycin/6207.article\" target=\"_blank\">Pactamycin</a></dd></dl></div><div class=\"content\"><p>A key intermediate has been developed in a short, asymmetric total synthesis of pactamycin that is amenable to analog preparation. Pactamycin is a natural product that demonstrates potent anti-tumor, anti-microbial, and anti-viral activities, but its development as a drug candidate is hindered by its high cytotoxicity. Recent pactamycin analogues derived from genetic engineering techniques show reduced toxicities, but genetic engineering approaches to generate pactamycin analogues are limited in flexibility and diversity. Conversely, an efficient chemical approach offers the potential for greater scope in the creation of pactamycin analogues. The cyclopentenone core intermediate is prepared from intramolecular aldol condensation of the claimed aldehyde precursor. This intermediate has been used to synthesize pactamycin.<br/><strong>Advantages:</strong><br/>•  Modular total synthesis is 15 steps from commercially available starting materials<br/>•  Amenable to preparation of pactamycin analogues for drug discovery applications</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed?term=((chapel%20hill%5BAffiliation%5D)%20AND%20pactamycin)%20AND%20%22science%22%5BJournal%5D\" target=\"_blank\">Enantioselective synthesis of pactamycin, a complex antitumor antibiotic.</a></li>Science 2013 Apr 12;340(6129):180-2.</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Combating Device Theft With User Notarization</h1><em>Technology #13-0042</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0042/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0042.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5373\"><a href=\"/categories/5362_software-information-technology/5373_security\">Security</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584898\"><a href=\"/inventors/18584898_michael-reiter\">Michael Reiter</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186418\"><em><a href=\"http://google.com/patents/US9660995\" target=\"_blank\">US Patent 9,660,995</a></em></dd></dl></div><div class=\"content\"><p>An anti-theft process for personal mobile devices often vulnerable to theft or loss. Utilizing video chat and a remote “notary” who visually and verbally authenticates the owner of the device, this system would prevent the distribution of personal information to the wrong hands and could provide extra security measures for processes such as mobile banking transactions or communicating healthcare information.<br/><strong>Advantages:</strong><br/>•  Mobile device anti-theft technology<br/>•  Notarization to enable use of passwords and cryptographic credentials</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://www.cs.unc.edu/techreports/13-003.pdf\" target=\"_blank\">Social Security: Combating Device Theft With Community-Based Video Notarization</a></li>PDF</ul></div></div>],\n",
       " [<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>REALMS (Registration Efficiency and Accuracy through Learning Metric on Shape): A Fast, Interpolative Method for 2D/3D Deformable Image Registration</h1><em>Technology #13-0043</em></div>,\n",
       "  <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/13-0043/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/13-0043.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5362\"><a href=\"/categories/5362_software-information-technology\">Software &amp; Information Technology</a><ul><li class=\"category\" id=\"category_5371\"><a href=\"/categories/5362_software-information-technology/5371_image-processing\">Image Processing</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18584897\"><a href=\"/inventors/18584897_chen-rui-chou\">Chen-Rui Chou</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_issued\" id=\"us_patent_issued_8186417\"><em><a href=\"http://google.com/patents/US9495746\" target=\"_blank\">US Patent 9,495,746</a></em></dd></dl></div><div class=\"content\"><p>A real-time method for visualizing tumors in the body, allowing for the most accurate and direct delivery of radiation treatment. This approach minimizes the indirect treatment of healthy tissue that can occur as the body moves during respiration and could significantly improve the outcome for patients with terminal prognoses, such as lung cancer.<br/><strong>Advantages:</strong><br/>•  REALMS significantly improves the margin of error that occurs with current 2D/3D deformable image registration methods<br/>•  With a 3D reference image, and a scale space of deformations that occur during respiration, REALMS performs interpolative and extremely fast (a few milliseconds) calculations to accurately predict the relative position of tumors, providing a better quality image with which doctors can improve radiation treatment of cancer via image-guided radiotherapy</p><p><b>Related Publications:</b></p><ul>\n",
       "  <li><a href=\"http://link.springer.com/chapter/10.1007/978-3-642-36620-8_1\" target=\"_blank\">Real-Time 2D/3D Deformable Registration Using Metric Learning</a></li>Springer Link: Part of the Lecture Notes in Computer Science book series (LNCS, volume 7766) 10.1007/978-3-642-36620-8_1</ul></div></div>]]"
      ]
     },
     "execution_count": 315,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "records"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 335,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<div class=\"technology\" id=\"nouvant-portfolio-header\"><h1>Reconstructing Detailed Textured Surface Models from Endoscopic Videos</h1><em>Technology #18-0149</em></div>,\n",
       " <div class=\"technology\" id=\"nouvant-portfolio-content\"><div class=\"information\"><p class=\"inquiry\"><strong>Questions about this technology?</strong> <a href=\"https://secure.nouvant.com/uncchapelhill/technology/18-0149/inquiry/new\" target=\"_blank\">Ask a Technology Manager</a></p><p class=\"download\"><a href=\"/technologies/18-0149.pdf\">Download Printable PDF</a></p><dl><dt class=\"categories\">Categories</dt><dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd><dt class=\"inventors\">Researchers</dt><dd class=\"inventor\" id=\"inventor_18585179\"><a href=\"/inventors/18585179_stephen-pizer\">Stephen Pizer</a> <div><em></em> </div></dd><dt class=\"managers\">Managed By</dt><dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd><dt class=\"patents\">Patent Protection</dt><dd class=\"us_patent_pending\" id=\"us_patent_pending_8186551\"><em>US Patent Pending</em></dd></dl></div><div class=\"content\"><p>A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning radiotherapy for throat cancer and improving colonoscopic screening. The generalizability of the system to other organs in the body also increases its potential. </p><p><b>Related Publications:</b></p><ul>\n",
       " <li><a href=\"https://www.sciencedirect.com/science/article/pii/S0016510718307272\" target=\"_blank\">Missed Colonic Surface Area at Colonoscopy Can Be Calculated with Computerized 3D Reconstruction</a></li>McGill, Sarah K., et al. “Sa1930 MISSED COLONIC SURFACE AREA AT COLONOSCOPY CAN BE CALCULATED WITH COMPUTERIZED 3D RECONSTRUCTION.” Gastrointestinal Endoscopy 87.6 (2018): AB254.</ul></div></div>]"
      ]
     },
     "execution_count": 335,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "records[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 393,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://www.sciencedirect.com/science/article/pii/S0016510718307272'"
      ]
     },
     "execution_count": 393,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "records[0][1].find('div', class_='content').find('a')['href']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 486,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<dt class=\"categories\">Categories</dt>,\n",
       " <dd class=\"categories\"><ul><li class=\"category\" id=\"category_5331\"><a href=\"/categories/5331_life-sciences\">Life Sciences</a><ul><li class=\"category\" id=\"category_5340\"><a href=\"/categories/5331_life-sciences/5340_imaging\">Imaging</a></li></ul></li></ul></dd>,\n",
       " <dt class=\"inventors\">Researchers</dt>,\n",
       " <dd class=\"inventor\" id=\"inventor_18585179\"><a href=\"/inventors/18585179_stephen-pizer\">Stephen Pizer</a> <div><em></em> </div></dd>,\n",
       " <dt class=\"managers\">Managed By</dt>,\n",
       " <dd class=\"manager\" id=\"manager_358\"><a href=\"/managers/358_peter-liao\">Peter Liao</a> <div><em>Commercialization Manager</em> <em>919.843.5028</em></div></dd>,\n",
       " <dt class=\"patents\">Patent Protection</dt>,\n",
       " <dd class=\"us_patent_pending\" id=\"us_patent_pending_8186551\"><em>US Patent Pending</em></dd>]"
      ]
     },
     "execution_count": 486,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "records[0][1].find('div', class_='information').find_next('dl').contents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 594,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = []\n",
    "for record in records:\n",
    "    pub_title = record[0].find('h1').text\n",
    "    pub_description = ''.join(record[1].find('div', class_='content').text[0:-1].split('\\xa0')[0:-1])\n",
    "    related_pub_title = record[1].find('div', class_='content').find_next('a').contents[0]\n",
    "    related_pub_link = record[1].find('div', class_='content').find_next('a')['href']\n",
    "    research_inventor = record[1].find('dd', class_='inventor').find('a').text\n",
    "    research_inventor_link = base_url + record[1].find('dd', class_='inventor').find('a')['href']\n",
    "    managed_by = record[1].find('dd', class_='manager').text\n",
    "    managed_by_link = base_url + record[1].find('dd', class_='manager').find('a')['href']\n",
    "    patent_protection = record[1].find('div', class_='information').find_next('dl').contents[-1].text\n",
    "    (techy, technology_number) = record[0].find('em').text.split(' ')\n",
    "    data.append((pub_title, \n",
    "                 pub_description, \n",
    "                 related_pub_title, \n",
    "                 related_pub_link, \n",
    "                 research_inventor,\n",
    "                research_inventor_link,\n",
    "                managed_by,\n",
    "                managed_by_link,\n",
    "                patent_protection,\n",
    "                technology_number))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 595,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Reconstructing Detailed Textured Surface Models from Endoscopic Videos',\n",
       "  'A method has been developed for constructing an accurate three-dimensional textured surface from an endoscopic video, and for transferring information from the reconstruction onto images gathered through other modalities such as computed tomography (CT). This technology facilitates more efficient and thorough review by clinicians and researchers and has demonstrated usefulness in planning radiotherapy for throat cancer and improving colonoscopic screening. The generalizability of the system to other organs in the body also increases its potential.',\n",
       "  'Missed Colonic Surface Area at Colonoscopy Can Be Calculated with Computerized 3D Reconstruction',\n",
       "  'https://www.sciencedirect.com/science/article/pii/S0016510718307272',\n",
       "  'Stephen Pizer',\n",
       "  'http://technologies.unc.edu/inventors/18585179_stephen-pizer',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending',\n",
       "  '#18-0149'),\n",
       " ('Crosslinked Hyperbranched Poly(aryletherketone) Membranes for Gas Separation at Elevated Temperature',\n",
       "  'Gas separation techniques currently use energy-intensive condensation methods. While the high chemical and thermal stability of commercially available PAEKs make them promising membrane candidates, poor solubility hinders their processability and low glass transition temperatures (~150°C) limits their applicability for high temperature separations. Soluble, reactive hyperbranched poly(aryletherketone)s (HBPAEKs) have been developed that are easily processed into thin membranes that demonstrate gas separation at high temperatures over extended periods. Crosslinking of the HBPEAKs increases the glass transition temperatures (~250°C) of the resulting thin films and tunable free volume, enabling their use as gas separation membranes with performance that exceeds current state-of-the-art membranes.Advantages:· H2/CH4, H2/N2, and H2/CO2 separation at or near the Robeson limit· Continuous separation of H2/N2 at 200°C for two weeks without a decrease in selectivity or permeability·',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Theo Dingemans',\n",
       "  'http://technologies.unc.edu/inventors/18585261_theo-dingemans',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#19-0022'),\n",
       " ('Microwave Synthesis of Polymeric Nanoparticles of Controlled Size for Drug Delivery',\n",
       "  'The use of nanoparticles in enhanced delivery of drugs to cancerous tissue can minimize the toxicity and side effects attributed to chemotherapy. The present method, Zapped Assembly of Polymeric (ZAP) nanoparticles (NP), uses microwave irradiation of block copolymers to produce nanoparticles of controlled size in a scalable manner. Block copolymers, such as poly(lactic-co-glycolic acid) (PLGA), rapidly disperse in the solvent at elevated temperatures provided by microwave heating. Upon cooling, the polymers solidify into nanoparticles through nanoprecipitation. The resulting nanoparticles can be used to encapsulate biologically active molecules such as anti-cancer agents. This microwave-assisted synthetic platform provides the ability to rapidly develop size-specific PLGA NPs for drug delivery applications.· Nanoparticle sizes range from sub-20 nm to 350 nm in diameter· Tunable control of nanoparticle sizes based on the reaction parameters in microwave synthesis· PLGA copolymer provides a hydrophilic corona with PEG to promote prolonged circulation and evasion of the reticuloendothelial systemStage of Development: This method has been demonstrated in the laboratory. Specifically, stable PLGA5k 25 nm, PLGA10k 50 nm, and PLGA20k 100 nm NPs were synthesized at laboratory scale. The NPs were also loaded with the chemotherapeutic paclitaxel (PXL) and elicited dose-dependent cancer cell cytotoxicity.',\n",
       "  'Zapped assembly of polymeric (ZAP) nanoparticles for anti-cancer drug delivery',\n",
       "  'https://pubs.rsc.org/en/content/articlelanding/2019/nr/c8nr09944h#!divAbstract',\n",
       "  'Matthew Parrott',\n",
       "  'http://technologies.unc.edu/inventors/18585138_matthew-parrott',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0081'),\n",
       " ('Gamma Secretase Inhibitors Attenuate Vascular Malformations',\n",
       "  'Gamma secretase inhibitors (GSI) have been determined to attenuate vascular malformations by inhibiting NOTCH expression in endothelial cells. Vascular malformations are developmental abnormalities of venous, arterial, capillary or lymphatic vessels which have significant morbidities such as pain, infection, pulmonary emboli, bleeding and even death. There is growing interest in medical management of vascular malformations, however existing treatments often cannot result in complete lesion resolution and do not produce permanent results, indicating that there is a significant need for alternative therapies. The use of GSI can provide an alternative and potent treatment for vascular formations.',\n",
       "  'Notch signaling pathway is a potential therapeutic target for extracranial vascular malformations',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/30573741',\n",
       "  'Julie Blatt',\n",
       "  'http://technologies.unc.edu/inventors/18584997_julie-blatt',\n",
       "  'Jackie Quay Director 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/370_jackie-quay',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#16-0192'),\n",
       " ('Recombinant Antigens for Differential Serological Detection of Remote Zika Infection',\n",
       "  'Two novel antigens have been developed for the serological diagnosis of Zika virus. Accurate diagnosis of Zika is critically important to its treatment, prevention, and further clinical research. Antibodies raised in response to other flaviviruses are often cross reactive to Zika virus, complicating serological diagnosis. Our novel recombinant antigens demonstrate lower cross reactivity as compared to other flavivirus-specific antibodies in serum collected from Zika patients, making them candidates for use in a Zika-specific immunosorbent assay.',\n",
       "  'Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/29263206',\n",
       "  'Aravinda Desilva',\n",
       "  'http://technologies.unc.edu/inventors/18585233_aravinda-desilva',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0017'),\n",
       " ('Highly Specific and Neutralizing Therapeutic Antibodies for Zika Virus',\n",
       "  'Our investigators have identified two highly specific and neutralizing antibodies isolated from a traveler naïve to all serotypes of Dengue. The antibodies (A9E and G9E) can be used against 7 different Zika virus types and react only to Zika virus and no other flaviviruses.Applications:•Diagnosis and treatment of Zika virus infection.•Antibody sequences for vaccine development.Advantages:•Non-reactive to Dangue and other flavivviruses.•Fully characterized binding site.•More potent and highly specific than currently available Ziki antibodies.',\n",
       "  'Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/28978707',\n",
       "  'Aravinda Desilva',\n",
       "  'http://technologies.unc.edu/inventors/18585230_aravinda-desilva',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0023'),\n",
       " ('AAV-Based Gene Therapy for Equine Osteoarthritis',\n",
       "  'An AAV-based gene therapy has been developed to treat equine osteoarthritis (OA). Interleukin receptor antagonist protein (IL-1ra) blocks joint inflammation caused by IL-1b stimulated cells, and for this reason, it has shown promise in the treatment of OA. Our OA gene therapy cassette utilizes an optimized self-complimentary AAV to produce significant levels of IL-1ra in vivo. In equine models of OA, administration of this therapy resulted in the generation of therapeutic levels of IL-1ra that persisted for 8 months and demonstrated minimal to no detrimental effects in joints.',\n",
       "  'scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/25902762',\n",
       "  'Richard Samulski',\n",
       "  'http://technologies.unc.edu/inventors/18585156_richard-samulski',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'PCT Patent Application WO 2018/035441',\n",
       "  '#17-0041'),\n",
       " ('Light Triggered CRISPR/Cas9 for Spatial and Temporal Control of Genome Editing',\n",
       "  'A novel, light-activated Cas9 protein has been developed for better special and temporal control of the CRISPR/Cas9 gene editing system. The addition of a caged lysine residue keeps Cas9 dormant by default, but in the presence of light the lysine caging group falls off and Cas9 springs into action. Unlike standard CRISPR/Cas9, which has full reign over the body, our light-activated system offers precise spatial and temporal control over genetic modifications, thereby reducing the chance of off-target effects and providing exclusive targeting of the tissue of interest.',\n",
       "  'Optical Control of CRISPR/Cas9 Gene Editing.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/25905628',\n",
       "  'Aravind Asokan',\n",
       "  'http://technologies.unc.edu/inventors/18585041_aravind-asokan',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent Pending US 2018/0073002',\n",
       "  '#16-0095'),\n",
       " ('BALB/c Latency Mouse Line',\n",
       "  'BALB/c mice are commonly used for B cell hybridoma development because of their predictable B cell responses to various antigens. Our investigators have developed the tg801 transgenic mouse line, (BALB/c latency mice), as an alternative to the commonly used BALB/c or BALB/c/FcgR2b KO mouse that are often used for hybridoma development. Our mouse line was created via random insertion of a synthetic transgene rather than a specific knock-out of a known gene. We believe that this mouse line is useful for companies and researchers looking to generate high quality antibodies against an antigen.',\n",
       "  'Kaposi’s Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/30021906',\n",
       "  'Dirk Dittmer',\n",
       "  'http://technologies.unc.edu/inventors/18585258_dirk-dittmer',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#19-0023'),\n",
       " ('Wnt1 as a Therapeutic to Enhance Cardiac Repair and Increase Blood Flow in Patients with PVD',\n",
       "  '',\n",
       "  'Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/21321190',\n",
       "  'Arjun Deb',\n",
       "  'http://technologies.unc.edu/inventors/18584866_arjun-deb',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'US Patent US 9186388',\n",
       "  '#11-0002'),\n",
       " ('Interactive Sound Propagation in Virtual Environments',\n",
       "  'This technology provides an efficient technique for modelingsound propagation effects in indoor and outdoor scenes for interactive applications.',\n",
       "  'Aural proxies and directionally-varying reverberation for interactive sound propagation in virtual environments',\n",
       "  'https://ieeexplore.ieee.org/abstract/document/6479183',\n",
       "  'Lakulish Antani',\n",
       "  'http://technologies.unc.edu/inventors/18584901_lakulish-antani',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,398,393',\n",
       "  '#13-0038'),\n",
       " ('Interactive Wave-Based Sound Propagation',\n",
       "  '',\n",
       "  'Source and listener directivity for interactive wave-based sound propagation',\n",
       "  'https://ieeexplore.ieee.org/abstract/document/6777442',\n",
       "  'Ravish Mehra',\n",
       "  'http://technologies.unc.edu/inventors/18584892_ravish-mehra',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,560,439',\n",
       "  '#13-0080'),\n",
       " ('Direct-to-Indirect Acoustic Radiance Transfer',\n",
       "  'This invention provides an efficient algorithm for simulating diffuse reflections of sound in a static scene. The UNC approach is built on advances in precomputed light transport techniques for visual rendering and uses them to develop an improved acoustic radiance transfer technique. It precomputes a direct-to-indirect acoustic transfer operator for a scene, and uses it to map direct sound incident on the surfaces of the scene to multibounce diffuse indirect sound, which is gathered at the listener to compute the final impulse response. The algorithm decouples the transfer operator from the source position so it can efficiently update the acoustic response at the listener when the source moves.Video:',\n",
       "  'http://gamma.cs.unc.edu/Sound/diffuse/2010-tvcg-video.mov',\n",
       "  'http://gamma.cs.unc.edu/Sound/diffuse/2010-tvcg-video.mov',\n",
       "  'Dinesh Manocha',\n",
       "  'http://technologies.unc.edu/inventors/18584862_dinesh-manocha',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 8,995,675',\n",
       "  '#11-0048'),\n",
       " ('Image Analysis with Deep Learning For Molecular Subtyping of Breast Cancer',\n",
       "  'RNA-based, multi-gene molecular assays are available and widely used for patients with ER-positive/HER2-negative breast cancers. However, RNA-based genomic tests can be costly and are not available in many countries. Methods for inferring molecular subtype from histologic images may identify patients most likely to benefit from further genomic testing. To identify patients who could benefit from molecular testing based on H&E-stained histologic images, we developed an image analysis approach using deep learning. Our investigators created image-based classifiers for tumor grade, ER status, PAM50 intrinsic subtype, histologic subtype, and risk of recurrence score (ROR-PT). The resulting classifiers were applied to an independent test set, and accuracy, sensitivity, and specificity of each assessed on the test set. Histologic image analysis with deep learning distinguished low-intermediate vs. high tumor grade ER status, Basal-like vs. non-Basal-like, Ductal vs. Lobular, and high vs. low-medium ROR-PT scores with good accuracy. Image-based methods could be promising for identifying patients with a greater need for further genomic testing, or in place of classically scored variables typically accomplished using human-based scoring.',\n",
       "  'Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/30182055',\n",
       "  'Charles Perou',\n",
       "  'http://technologies.unc.edu/inventors/18585262_charles-perou',\n",
       "  'Jackie Quay Director 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/370_jackie-quay',\n",
       "  'Jackie Quay Director 919.966.3929',\n",
       "  '#19-0010'),\n",
       " ('Camera Control Unit Communications Breakout Box',\n",
       "  'In broadcast video technology, a camera control unit is an electronic device, usually in the form of a rack-mounted box, that connects to a video camera and to external video recording, display, and control devices. One problem with connectors provided oncamera control units is that many external intercom, program voice, and tally systems require other types of connectors, such as XLR connectors to exchange signals with the CCU. Using multiple adapters can be cumbersome and unwieldy.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Kevin Tucker',\n",
       "  'http://technologies.unc.edu/inventors/18585181_kevin-tucker',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0145'),\n",
       " ('Conserved Epitopes for Vaccination Against GII.4 Norovirus Strains',\n",
       "  'Antigenic diversity within the GII.4 genotype of human norovirus is a significant hurdle to the development of cross-protective immunity after natural infection and vaccination. Our investigators have developed a method of identifying conserved GII.4 norovirus epitopes. Using this method, a conserved GII.4 antibody epitope and residues that mediate antibody access to this conserved epitope was discovered. Further development of this epitope could lead to a broadly cross-protective norovirus vaccine.',\n",
       "  'Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion',\n",
       "  'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806210/pdf/mSphere.00518-17.pdf',\n",
       "  'Ralph Baric',\n",
       "  'http://technologies.unc.edu/inventors/18585103_ralph-baric',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0144'),\n",
       " ('Tensegrity Wheel with Force-Based Motion',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Henry Goodell',\n",
       "  'http://technologies.unc.edu/inventors/18585117_henry-goodell',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0124'),\n",
       " ('MTAP Inhibitors for Treatment of Airway Inflammation Associated with CF and COPD',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Charles Esther',\n",
       "  'http://technologies.unc.edu/inventors/18585073_charles-esther',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent Pending US 20180353511',\n",
       "  '#16-0020'),\n",
       " ('Osseous Distractor for Cranial Reconstruction',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Nathan Davis',\n",
       "  'http://technologies.unc.edu/inventors/18585211_nathan-davis',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#18-0065'),\n",
       " ('Using phase-changing nanodroplets to dissolve blood clots with ultrasound',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Paul Dayton',\n",
       "  'http://technologies.unc.edu/inventors/18585190_paul-dayton',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#18-0123'),\n",
       " ('Nanofiber-based immunotherapeutic drug delivery specifically targeted to the atherosclerotic niche',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Melina Kibbe',\n",
       "  'http://technologies.unc.edu/inventors/18585177_melina-kibbe',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#18-0152'),\n",
       " ('Long-acting injectable multipurpose implants for treatment of osteoporosis',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Soumya Benhabbour',\n",
       "  'http://technologies.unc.edu/inventors/18585173_soumya-benhabbour',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#18-0167'),\n",
       " ('Improved removal of stimulation artifacts in intracranial electroencephalography',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Flavio Frohlich',\n",
       "  'http://technologies.unc.edu/inventors/18585185_flavio-frohlich',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#18-0136'),\n",
       " ('Novel PET tracers for predicting tumor response to immunotherapy',\n",
       "  'Labeled Positron Emmision Tomography (PET) imaging tracers have been developed which can easily screen tumors for responsiveness to specific immunotherapies. This low-cost screening method prevents application of costly immunotherapy to non-responsive tumors. These novel tracers are also relevant to serotonin pathways important in diabetes and neurophysiology.Advantages:\\nSpecifically marks tumors with tumor-infiltrating immune cells, predicting response to cancer immunotherapy\\nFuture applications include',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Zibo Li',\n",
       "  'http://technologies.unc.edu/inventors/18585161_zibo-li',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application WO 2017/057595',\n",
       "  '#17-0028'),\n",
       " ('Light catalyzed radiofluorination',\n",
       "  'This new method of fluorinating biomolecules for PET imaging and other therapeutic applications is catalyzed by light, making it more adaptable than other fluorination methods. This allows easier fluorination of a broader range of molecules including drugs and proteins and avoids the use of potentially hazardous heavy metals.Advantages:\\n\\nBroad substrate:applicable to a wide range of drug candidates and other biomolecules\\n\\nIncreased safety: avoiding use of hazardous heavy metals makes process and quality control easier\\n\\nResearch potential:',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Zibo Li',\n",
       "  'http://technologies.unc.edu/inventors/18585112_zibo-li',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#17-0133'),\n",
       " ('Combined Acoustic Radiation Force Impulse (ARGI) Ultrasound and Elastography for Improved Tissue Imaging',\n",
       "  'Acoustic Radiation Force Impulse (ARFI) ultrasound is a tissue imaging method where a short duration impulse (on the order of microseconds) of relatively high acoustic energy is transmitted into the body. The tissue’s response in terms of its peak displacement and subsequent recovery from displacement is used as an indicator of the tissue’s mechanical properties. The use of ARFI for elastography yields enhanced differentiation of tissue mechanical property. This technique allows for targeted regions of excitation, resulting in increased spatial resolution of mechanical property analysis. Combined ARFI-Elastography would be useful in breast, vascular, cardiac, abdominal, and other ultrasonic imaging applications. Similar principles may be applied to other medical imaging modalities, such as MRI and Optical imaging. Developments in ultrasound imaging, such as ARFI for elastography, will have helped lead the market to a $7 billion USD industry by 2024.<!–[if !supportLists]–>• <!–[endif]–>Ability to palpate tissue further than human reach<!–[if !supportLists]–>•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Caterina Gallippi',\n",
       "  'http://technologies.unc.edu/inventors/18584872_caterina-gallippi',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent 9,244,041',\n",
       "  '#12-0104'),\n",
       " ('Increased Recombinant AAV Vector Yield Using Engineered Assembly Activating Proteins',\n",
       "  'Assembly Acting Proteins (AAPs) are required for adeno-associated viruses (AAVs) capsid formation. Novel engineered Assembly Activating Proteins (eAAPs) have been developed with enhanced stability that promote viral assembly and enhance vector yields of recombinant AAV by 200% over wildtype AAP. eAAPs can address some of the manufacturing limitations of AAV needed for gene therapy, gene silencing, and gene editing applications.Advantages:-eAAPs can be used to greatly increase the yield of recombinant AAV vectors-eAAPs can be fluorescently labeled to enable the study of the role(s) of AAPs in capsid assembly',\n",
       "  'Mapping and Engineering Functional Domains of the Assembly Activating Protein of Adeno-Associated Viruses.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/29695425',\n",
       "  'Aravind Asokan',\n",
       "  'http://technologies.unc.edu/inventors/18585199_aravind-asokan',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0116'),\n",
       " ('Novel Cross-Linker and Related Methods of Isotope Tagging for Analysis of Protein Interactions',\n",
       "  'An isotope labeled cross-linker has been developed to improve the detection of cross-linked peptides. Chemical cross-linking is often used to study protein-protein interactions, however gas-phase dissociation reactions of cross-linkers often lack the sensitivity and specificity to fragment the cross-linker at the desired location. Consequently, there is a need for improved cross-linkers for studying protein interactions. The developed cross-linker (d4-DTSSP) is asymmetric across a single cleavable bond (versus symmetrical like other commercially available DTSSP), and allows for a unique detection strategy that can differentiate cross-linked fragments from non cross-linked fragment ions that can easily be visually differentiated using mass spectrometry. Furthermore, d4-DTSSP uses a simple electron transfer (EDT) dissociation reaction that allows for high efficiency and product yield along with the identification of interacting proteins. d4-DTSSP has the potential to significantly enhance the utility of chemical cross-linking for the study of protein-protein interactions.Advantages:· Allows for a unique detection strategy that identifies cross-linked from non-cross-linked fragments· May improve throughput in identifying cross-linked fragments by allowing automated peak-picking·',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Xian Chen',\n",
       "  'http://technologies.unc.edu/inventors/18584903_xian-chen',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent US 9562010',\n",
       "  '#13-0034'),\n",
       " ('Topical Tigecycline to Control Endodontic Infections',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Ashraf Fouad',\n",
       "  'http://technologies.unc.edu/inventors/18585219_ashraf-fouad',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0031'),\n",
       " ('Side-car Bassinet to Improve Mother and Baby Development Post-delivery',\n",
       "  'A side-car bassinet particularly designed for U.S. maternity beds may improve mother-baby development post-delivery. The bassinet locks into maternity beds, when proximity to mother is warranted, but can be disengaged, and converted to a stand-alone bassinet. To promote breast-feeding in the hours after delivery, it is understood that keeping mother and baby together is important. Stand-alone bassinets present unnecessary obstacles for mothers in the moments following labor (as a result of compromised mobility). A mother’s movement becomes particularly worrisome when cesarean birth is necessary. Stand-alone bassinets lead to suboptimal breast-feeding. By designing a bassinet that can lock into hospital beds, mothers can easily reach their baby for feeding. During times when bassinet is disengaged from the bed, a fourth wall is in place for infant security.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Kristin Tully',\n",
       "  'http://technologies.unc.edu/inventors/18585169_kristin-tully',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0003'),\n",
       " ('Synthesis of extremely stable in vivo 18F based radiotracer to conjugate drugs and diagnostic biomolecules',\n",
       "  'The invention provides a novel approach for synthesis of an 18F based radiotracer, an ideal backbone for a tracer due to its long half-life (~110 mins). Fluorine is commonly found in organic molecules, and thus, is theoretically easy to directly introduce to a molecule of interest. Positron Emission Tomography (PET) is a medical imaging technique that relies on the use of molecular radiotracerss containing positron emitting isotopes. This UNC method results in a radiotracer that is extremely stable in vivo and can be used to conjugate drugs, peptides, proteins, or any other diagnostic biomolecules.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Zibo Li',\n",
       "  'http://technologies.unc.edu/inventors/18585155_zibo-li',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0045'),\n",
       " ('Novel System for Personalized Brain Stimulation to Alleviate Deficiencies in Higher Order Cognitive Function Cloud Infrastructure',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Flavio Frohlich',\n",
       "  'http://technologies.unc.edu/inventors/18585153_flavio-frohlich',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#17-0050'),\n",
       " ('Novel System for Personalized Brain Stimulation to Alleviate Deficiencies in Higher Order Cognitive Function Software',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Flavio Frohlich',\n",
       "  'http://technologies.unc.edu/inventors/18585152_flavio-frohlich',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#17-0051'),\n",
       " ('Higher Frame Rate Ultrasound Imaging for Improved Detection of Human Physiological Events',\n",
       "  'Ultrasound imaging at high frame rates (50 Hz or greater) is reliant on plane-wave transmission. Unfortunately, high frame rate imaging is not conducive with compounding, or averaging, of different acoustic signals to improve image quality. With every ultrasound transmit being devoted to image quality, that is one transmission being lost for analysis of temporal changes in the image. As the field of ultrasound progresses with techniques reliant on faster imaging, such as super resolution, it is not only beneficial to image fast, but also to maintain sensitivity. Adaptive multifocus beamforming is a technique that utilizes a unique transmission to focus the beam in multiple locations in the field of view, while mainting the desired high-frame rate. In this manner, high-frame rate ultrasound images possses a signal-to-noise ratio not achievable previously. Not only could this improve signal tracking in even the slowest of capillaries, deeper penetration depths may be reached, providing more information for physiological assessment.Advantages:\\nHigher frame rate imaging allows for improved detection of human physiological events\\nIncreases',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Gianmarco Pinton',\n",
       "  'http://technologies.unc.edu/inventors/18585149_gianmarco-pinton',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application WO 2018/208942',\n",
       "  '#17-0062'),\n",
       " ('Device and Method for Improving Motor Memory and Other Cognitive Functions, a Potential Therapy for Alzheimer’s Disease, Schizophrenia, Autism and ADHD',\n",
       "  'Research in understanding the role thalamo-cortical oscillations, like sleep spindles, play in cortical network dynamics and cognitive processes in humans has been impeded due to a lack of tools to monitor and selectively enhance rhythmic brain activity in real-time. Further, current treatment options for these disease aim only to help prolong functional capabilities and slow symptom development. Researchers developed this system to combat this growing health concern and overcome these current research limitations. This system provides targeted and personalized brain stimulation to increase sleep spindle oscillations to alleviate deficiencies in higher order cognitive function, allowing for the treatment of psychiatric and neurological impairments. Brain stimulation has gained momentum as an alternative to pharmacological approaches to treat neurological disorders. \\n\\n<!–[if !supportLists]–>Proprietary method to monitor and selectively enhance transient rhythmic brain activity in real time in humans\\n\\n<!–[if !supportLists]–><!–[endif]–><!–[if !supportLists]–><!–[endif]–>Improves motor sequence consolidation, providing a non-invasive, drug free therapeutic for disorders shown to have reduction in sleep spindles\\n',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Flavio Frohlich',\n",
       "  'http://technologies.unc.edu/inventors/18585078_flavio-frohlich',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#16-0010'),\n",
       " ('Improved Mechanical Imaging for Internal Organs and Muscles',\n",
       "  'Acoustic radiation force impulse (ARFI) imaging is a technique that utilizes ultrasound to characterize the viscoelastic property of tissue. It is understood that certain organ systems have directionally dependent characteristics (property known as anisotropy). Disease progression may change the mechanical response of tissue, and the ability to measure these changes along multiple axes is beneficial. This unique use of ARFI to measure anisotropy has significant advantages in the clinical space. UNC researchers have developed the disclosed technology is capable of quantifying peak displacements in orthogonal dimensions. With this information, the degree of anisotropy of the tissue can be monitored during disease progression, increasing the information one can gather from ultrasound systems. Developments in ultrasound imaging have led to a $7.3 billion USD industry. With such improvements to tissue mechanical property assessment, ultrasound technology continues to expand as a multi-platform modality.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Caterina Gallippi',\n",
       "  'http://technologies.unc.edu/inventors/18585039_caterina-gallippi',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application US 2017/032745',\n",
       "  '#16-0098'),\n",
       " ('Detection of Brain Motion with High-frame Rate Ultrasound Imaging',\n",
       "  'There is a lack of understanding of the mechanisms at work during a traumatic brain injury (TBI). Though brain motion has been extensively linked to TBI, direct quantifiable measurements are absent, which could aid in progressing understanding and diagnosis of TBI. The Pinton lab has developed an ultrasonic method for detecting the motion of the brain, at frame rates as high as 10,000 images per second. With a novel motion tracking algorithm, the imaging technique can quantify movement of the brain with displacements down to 1 micron. Through the advancement and implementation of this technique, it is anticipated that the detection of brain motion will further the understanding of the mechanism of trauma.\\n\\n<!–[endif]–>At 10,000 images per sec, superior motion detection can be achieved, at a spatial sensitivity better than 1 micron.\\n\\n<!–[if !supportLists]–>Detection of skull motion will lead to improved understanding and diagnosis of brain injury\\n\\n<!–[if !supportLists]–>3D simulation development of the nonlinear propagation of shear shock waves, a potential source for traumatic brain injury, may enable the improved design of sport helmets and car safety features.\\n',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Gianmarco Pinton',\n",
       "  'http://technologies.unc.edu/inventors/18585028_gianmarco-pinton',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#16-0141'),\n",
       " ('Periodontal Profile Class Scoring Model to predict tooth loss and oral disease progression',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Jim Beck',\n",
       "  'http://technologies.unc.edu/inventors/18585009_jim-beck',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#16-0170'),\n",
       " ('Adrenomedullin Therapy to Improve Fetal Implantation',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Kathleen Caron',\n",
       "  'http://technologies.unc.edu/inventors/18584966_kathleen-caron',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#15-0097'),\n",
       " ('Combined Acoustic Radiation Force Impulse (ARGI) Ultrasound and Elastography  for Tissue Imaging',\n",
       "  'Acoustic Radiation Force Impulse (ARFI) ultrasound is a tissue imaging method where a short duration impulse (on the order of microseconds) of relatively high acoustic energy is transmitted into the body. The tissue’s response in terms of its peak displacement and subsequent recovery from displacement is used as an indicator of the tissue’s mechanical properties. The use of ARFI for elastography yields enhanced differentiation of tissue mechanical property. This technique allows for targeted regions of excitation, resulting in increased spatial resolution of mechanical property analysis. Combined ARFI-Elastography would be useful in breast, vascular, cardiac, abdominal, and other ultrasonic imaging applications. Similar principles may be applied to other medical imaging modalities, such as MRI and Optical imaging. Developments in ultrasound imaging, such as ARFI for elastography, will have helped lead the market to a $7 billion USD industry by 2024.<!–[if !supportLists]–>• <!–[endif]–>Ability to palpate tissue further than human reach<!–[if !supportLists]–>•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Caterina Gallippi',\n",
       "  'http://technologies.unc.edu/inventors/18584832_caterina-gallippi',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent 9,043,156',\n",
       "  '#08-0050'),\n",
       " ('Dry Powder Aerosol Generator, a delivery system for dry powdered aerosol drugs',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Anthony Hickey',\n",
       "  'http://technologies.unc.edu/inventors/18584813_anthony-hickey',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent 8,205,612',\n",
       "  '#05-0077'),\n",
       " ('Methods of Acoustic Measurement and Control of Pharmaceutical Sprays',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Anthony Hickey',\n",
       "  'http://technologies.unc.edu/inventors/18584808_anthony-hickey',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent 8,156,829',\n",
       "  '#04-0112'),\n",
       " ('Coated filament for evaporation/condensation aerosol generation of therapeutic agents and methods',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Anthony Hickey',\n",
       "  'http://technologies.unc.edu/inventors/18584807_anthony-hickey',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent 2008/0199161',\n",
       "  '#04-0113'),\n",
       " ('Hinged endoscopic catheter for easier treatment of intestinal obstruction',\n",
       "  'Intestinal obstruction can result from a variety of medical problems, including gastric outlet obstruction, chronic ulcers, and cancer of the stomach or pancreas, and it leads to impaired or blocked digestion of food, numerous gastrointestinal symptoms, and malnutrition. A common solution to these cases is to bypass the obstruction by creating a connection between the stomach and the small intestine through a procedure called a gastrojejunostomy, allowing the contents of the stomach to continue through the digestive tract unimpeded. Researchers at UNC have developed a custom catheter for improving the safety and speed of this commonly performed surgery. The catheter can be manipulated to bring the small intestine closer to the stomach, facilitating easier placement of the connecting tube. It also expands to open the lumen of the small intestine, minimizing the risk of accidental puncture all the way through.Advantages:· Facilitates accurate procedures by pushing the small intestine against the stomach· Minimizes the risk of unintended intestinal punctures by opening up the small intestine before needle insertion·',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Theodore James',\n",
       "  'http://technologies.unc.edu/inventors/18585239_theodore-james',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#18-0015'),\n",
       " ('Method for the Inhibition of Anti-PEG Antibodies',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Sam Lai',\n",
       "  'http://technologies.unc.edu/inventors/18585226_sam-lai',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0025'),\n",
       " ('COPD Diagnostic Tool',\n",
       "  'A method for the diagnosis of chronic bronchitis (CB) has been invented. Currently, the diagnosis of CB relies on self-reporting of symptoms and tests such as the classic and St. George’s Respiratory Questionnaires. CB represents an early developmental phase of chronic obstructive pulmonary lung disease (COPD), and therefore a more quantitative approach to CB diagnosis is desired. Our researchers have developed a method of diagnosing CB based on levels of mucin present in sputum samples. This objective test can be used to diagnose CB, define the severity of CB, and help determine the appropriate therapies.Advantages:-Provides a quantitative diagnostic for chronic bronchitis (CB)',\n",
       "  'Airway Mucin Concentration as a Marker of Chronic Bronchitis',\n",
       "  'http://www.nejm.org/doi/full/10.1056/NEJMoa1701632?af=R&rss=currentIssue&page=&sort=oldest',\n",
       "  'Mehmet Kesimer',\n",
       "  'http://technologies.unc.edu/inventors/18585120_mehmet-kesimer',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Science Daily',\n",
       "  '#17-0117'),\n",
       " ('Nanoparticles for the Codelivery of Cancer Immunotherapeutics',\n",
       "  'Dual immunotherapy nanoparticles (DINPs) that can simultaneously deliver multiple immunotherapeutics have been synthesized. Emerging evidence suggests that administration of certain immunotherapeutics in combination has a synergistic effect. Specifically, an approach that can block checkpoint inhibitor receptors, like PD1, while activating co-stimulatory receptors, like OX40, is desired. This can be done by utilizing our dual immunotherapy nanoparticles (DINPs). Using DINPs enabled simultaneous delivery of anti-PD1 and anti-OX40 antibodies (Abs) to T cells. Data indicates that codelivery of these Abs by DINPs induced a higher immunotherapeutic response than administration of the free Abs in vivo. DINP combination immunotherapy led to 30% cure rate in mice with 83% of cured mice resisting tumor re-challenge.Advantages:-Enables codelivery of immunotherapeutics to T cells, enhancing T cell activation-More effective than free antibodies in in vivo tumor models',\n",
       "  'A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy',\n",
       "  'https://onlinelibrary.wiley.com/doi/abs/10.1002/adma.201706098',\n",
       "  'Andrew Wang',\n",
       "  'http://technologies.unc.edu/inventors/18585118_andrew-wang',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent Pending US 2018/938999',\n",
       "  '#17-0119'),\n",
       " ('Diagnostic Test for Malignant Cutaneous Melanoma',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Kathleen Dorsey',\n",
       "  'http://technologies.unc.edu/inventors/18585108_kathleen-dorsey',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0137'),\n",
       " ('Neurosteroid-induced protection against alcoholism, multiple sclerosis, Alzheimer’s disease, and other neuropsychiatric disorders',\n",
       "  'Several naturally-occurring neurosteroids have shown protection against alcohol use disorder, depression, multiple sclerosis, Alzheimer’s disease, traumatic brain injury, and other neuropsychiatric disorders in animal models. These disorders affect a large portion of the population, with 6.2% of adults in the United States suffering from alcohol use disorder alone. Protective action of these neurosteroids has been observed, but the mechanism for these benefits has not been shown. Development of these neurosteroids as therapeutics in humans, as well as efforts to find more neurosteroids with protective action, depend on a more complete understanding of how they protect against depression and other disorders. Researchers at UNC have discovered that these neurosteroids inhibit an important signaling pathway in the brain involved in many neuropsychiatric disorders.Advantages:· Increases awareness of neurosteroid action in clinically relevant signaling pathways in animal models· Explains therapeutic usefulness of neurosteroids in disorders including alcohol use disorder, depression, multiple sclerosis, Alzheimer’s disease, and traumatic brain injury·',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'A Leslie Morrow',\n",
       "  'http://technologies.unc.edu/inventors/18585092_a-leslie-morrow',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#17-0159'),\n",
       " ('The Garland Carver for Carving Dental Composite Restorations',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Glenn Garland',\n",
       "  'http://technologies.unc.edu/inventors/18585031_glenn-garland',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application Filed',\n",
       "  '#16-0137'),\n",
       " ('Stretchable RF Coil Array for High-Resolution MRI',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Weili Lin',\n",
       "  'http://technologies.unc.edu/inventors/18585001_weili-lin',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application WO 2018/045042',\n",
       "  '#16-0187'),\n",
       " ('Small Molecules for the Treatment of Metabolic Disorders',\n",
       "  'Small molecule therapeutics for metabolic syndromes, such as non-alcoholic fatty liver disease (NAFLD), have been developed. Activation of AMP-activated protein kinase (AMPK) leads to inhibition of cholesterol synthesis, triglyceride synthesis, and lipogenesis, and, significantly, it can stimulate hepatic fatty acid oxidation. We have identified compounds that can activate AMPK more effectively than its endogenous ligand, ADP. These compounds could serve as lead compounds for a program focused on metabolic disorders such as NAFLD or non-alcoholic steatohepatitis (NASH).Advantages:-AMPK activation can increase hepatic fatty acid oxidation-AMPK activation can inhibit cholesterol synthesis',\n",
       "  'A High Throughput Assay for Discovery of Small Molecules that Bind AMP-activated Protein Kinase (AMPK)',\n",
       "  'https://benthamopen.com/ABSTRACT/CCGTM-7-30',\n",
       "  'Jay Brenman',\n",
       "  'http://technologies.unc.edu/inventors/18584942_jay-brenman',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent Issued',\n",
       "  '#14-0018'),\n",
       " ('Full Jaw Orthodontic Dentition Model by using human CT and microCT data',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Ching-Chang Ko',\n",
       "  'http://technologies.unc.edu/inventors/18584879_ching-chang-ko',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  '#12-0071'),\n",
       " ('Recombinant Factor IX Proteins with Enhanced Specific Activity and Half-Life for Treatment of Hemophilia',\n",
       "  'Factor IX (FIX) deficiency, or hemophilia B, is an X-linked inherited bleeding disorder that is due to a missing clotting protein. Data suggests that sequestration of FIX by collagen IV localizes FIX in the areas needed for coagulation. A modified recombinant FIX protein has been developed that has a Gla domain that binds more tightly to collagen IV and demonstrates a higher specific activity and longer lasting clotting function than the current commercially available recombinant FIX proteins. In vivo experiments in a hemophilia B mouse model have been used to validate efficacy and functionality of this recombinant FIX protein.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Darrel Stafford',\n",
       "  'http://technologies.unc.edu/inventors/18584877_darrel-stafford',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent Pending US 2015/0307863',\n",
       "  '#12-0087'),\n",
       " ('A General and Efficient Self-Assembly System for the Generation of Thermostable Heptameric Targeting Ligands with Significantly Improved Target-Binding Strength',\n",
       "  'A simple and efficient method for the self-assembly of heptameric targeting ligands has been developed. Many developing therapies and diagnostics rely on the use of targeting ligands, such as homing peptides, protein-binding domains, and antibodies. Often, improving the targeting ligand’s affinity for its target is a time-consuming process, requiring extensive affinity maturation. Our technology allows for an alternative strategy: the creation of multiple binding interactions with the target via a multimeric targeting ligand. In addition to enhanced binding affinity, these multivalent targeting ligands offer improved biodistribution and pharmacokinetic properties when compared to conventional monovalent ligands. Data indicate that these heptamers exhibit 100-1000x greater target-binding strength than their monomeric counterparts. This technology was used to synthesize heptameric antibodies, targeting the EGFR and HER2 receptors, that possessed high stability, enhanced avidity, and low toxicity.Advantages:-Allows for the self-assembly of heptameric target ligands-Heptameric target ligands show 100-1000x greater binding-strength than monomer target ligands-Multivalent target ligands possess improved biodistribution and pharmacokinetic properties.',\n",
       "  'Heptameric Targeting Ligands against EGFR and HER2 with High Stability and Avidity',\n",
       "  'http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043077',\n",
       "  'Rihe Liu',\n",
       "  'http://technologies.unc.edu/inventors/18584860_rihe-liu',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent US 9340616',\n",
       "  '#11-0065'),\n",
       " ('Rapid Method for the Assembly of Nanoparticles with Targeting Ligands',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Rihe Liu',\n",
       "  'http://technologies.unc.edu/inventors/18584855_rihe-liu',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent Pending US 2016/0303256',\n",
       "  '#11-0136'),\n",
       " ('Composition of Novel Cationic Nanoparticles for the Delivery of siRNA Therapeutics in Lung Cancer',\n",
       "  'Cationic nanoparticle formulations have been developed for the delivery of siRNA to tumor cells. siRNA therapeutics are promising treatments for many diseases, but they require delivery vehicles to efficiently transport them to their target cell. We have developed a cationic nanoparticle formulation that efficiently delivers siRNA to H460 human lung carcinoma cells. These nanoparticles were able efficiently deliver siRNA that silenced epidermal growth factor receptor (EFGR) expression. In addition an increase in apoptosis was observed when siRNA was administered in this manner, indicating a synergistic effect between the siRNA and the cationic nanoparticle delivery vehicle.',\n",
       "  'Novel Cationic Lipids That Deliver And Enhance Therapeutic Activity of siRNA In Tumor Cells',\n",
       "  'https://pubs.acs.org/doi/abs/10.1021/mp800136v',\n",
       "  'Leaf   Huang',\n",
       "  'http://technologies.unc.edu/inventors/18584833_leaf-huang',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent US 8389768',\n",
       "  '#08-0038'),\n",
       " ('Method For Improving the Catalytic Activity of Lipases',\n",
       "  'A method of improving the activity of Phospholipase C (PLC) has been discovered. Lipases are the most widely employed industrial biocatalysts. They are used to synthesize compounds for the pharmaceutical, cosmetic, food, chemical and energy industries. As a result, the global market for lipases is in the billions of dollars and growing. Improving the efficiency of lipases allows for the production cheaper products and the ability to apply lipase-based technologies to industries where the current limitations of lipases render them cost inefficient. This technology improves the efficiency of PLC via alkylation of its cysteine residues. We anticipate that this method is applicable to all lipases, creating an opportunity to improve a variety of important industrial processes.Advantages:-Improves activity of lipases-Enables significant cost reductions in the synthesis of select compounds in the pharmaceutical, cosmetic, food, chemical, and energy sectors.',\n",
       "  'Direct Activation of Human Phospholipase C by Its Well Known Inhibitor U73122',\n",
       "  'http://www.jbc.org/content/286/14/12407.short',\n",
       "  'Dhiren Thakker',\n",
       "  'http://technologies.unc.edu/inventors/18584830_dhiren-thakker',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent US 9416383',\n",
       "  '#08-0104'),\n",
       " ('Composition of a Polypeptide for the Synthesis of Heparan Sulfate',\n",
       "  'A novel isoform of 3-O-sulfotransferase that can be used for the synthesis of two separate forms of heparan sulfate (HS) has been discovered. Heparan sulfate can be isolated in many different isoforms that have unique properties and biological roles. The 3-O-sulfotranferase polypeptide sequence developed at UNC-Chapel Hill can be used to synthesize two separate types of HS: one form that can prevent blood clotting, and one subtype that is used by the herpes simplex virus to enter cells. This technology incorporates both the sequence of the polypeptide that can synthesize the two HSs, but also the genetic sequence that encodes it.Potential Uses:-Synthesis of anticoagulant therapies-Development of anti-viral therapies directed against herpes simplex virus-Potential target for gene therapies modulating heparan sulfate expression',\n",
       "  'Heparan Sulfate 3-O-Sulfotransferase Isoform 5 Generates Both an Antithrombin-binding Site and an Entry Receptor for Herpes Simplex Virus, Type 1',\n",
       "  'http://www.jbc.org/content/277/40/37912.short',\n",
       "  'Jian Liu',\n",
       "  'http://technologies.unc.edu/inventors/18584797_jian-liu',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent US 7531338',\n",
       "  '#02-0105'),\n",
       " ('Composition and Method for Platelet-Based Drug Delivery',\n",
       "  'A novel method of drug delivery utilizing rehydrated platelets has been developed. Platelets have long been recognized as potential drug delivery vehicles; however, the need to freshly isolate, modify, and reinfuse them in a short time-span has limited their applicability. Cryopreserved and normally-liquid stored platelets circumvent these problems, but suffer from storage issues and the need to remove cryopreservatives. We have discovered a method for utilizing fixed-dried blood platelets as drug carriers. This technology comprises a method of drying blood platelets, conjugating them to the compound to be delivered, rehydrating the platelets and administering the resulting rehydrated platelets. This technology is anticipated to be particularly effective for therapeutic delivery to the liver, spleen and injured organs.Advantages:-Rehydrated platelets avoid storage and purification problems associated with cryopreserved and liquid stored platelets-Can be used to deliver a variety of compounds to diseased, damaged, and disturbed tissues in vivo',\n",
       "  'Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion.',\n",
       "  'http://www.pnas.org/content/92/2/397.long',\n",
       "  'Thomas Fischer',\n",
       "  'http://technologies.unc.edu/inventors/18584792_thomas-fischer',\n",
       "  'Jackie Quay Director 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/370_jackie-quay',\n",
       "  'US Patent US 8492081',\n",
       "  '#00-0110'),\n",
       " ('Real-time, Automated Software for the Reduction of Ionizing Radiation Dosage for Angiography and Perfusion Analysis',\n",
       "  'This software reduces the amount of ionizing radiation required for digital subtraction angiography (DSA), computed tomography perfusion (CTP), and computed tomography angiography, reducing the risk of cancer and other injuries while still maintaining high-resolution capture of blood flow dynamics when imaging internal organs and tissues. Current applications include stroke diagnostics, tumor characterization, and quantification of vasospasm therapeutics.Software developed by physicians at UNC-CH reduces radiation exposures for DSA and CTP by factors of 4 and 20, respectively.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Andrew Abumoussa',\n",
       "  'http://technologies.unc.edu/inventors/18585253_andrew-abumoussa',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0002'),\n",
       " ('Bitwise Framework for Detection of Complicated Non-Parametric Dependence Structure in Big Data that is Scalable, Easily Interpretable, and Fast',\n",
       "  'Computer-based data analysis often relies on detecting linear associations between variables, which can be problematic and limiting in complex “Big Data” applications. Software, utilizing a novel bitwise statistical algorithm, has been developed to analyze complicated non-parametric dependence structure in Big Data. Relative to existing methods, our novel software provides enhanced power, interpretability, scalability, and speed. For example, when compared to distance correlation, the new software processes data up to 1000 times faster. Potential applications for the new software include genetic data analysis, image/pattern recognition, speech recognition, and medical screening.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Kai Zhang',\n",
       "  'http://technologies.unc.edu/inventors/18585203_kai-zhang',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0084'),\n",
       " ('Novel Algorithm for Artificial Intelligence (AI) Assisted Drug Design',\n",
       "  'An algorithm that enables artificial intelligence (AI) to generate individual compounds and compound libraries with ideal biochemical and physiological profiles has been developed. Traditional drug discovery programs generally begin with an exhaustive high-throughput screen (HTS) of available compound libraries. However, because there are an estimated 1030-1060 theoretical drug-like molecules, these screens are never, in actuality, exhaustive. This technology has the potential to streamline the process of drug development by identifying lead compounds that already have the desired properties of a marketable drug.Advantages:-Can effectively screen more chemical space than high-throughput screening (HTS)-Allows for fully automated lead compound discovery-Identifies lead compounds that already have ideal ADME and PK properties',\n",
       "  'Deep Reinforcement Learning for De-Novo Drug Design',\n",
       "  'https://arxiv.org/pdf/1711.10907.pdf',\n",
       "  'Olexandr Isayev',\n",
       "  'http://technologies.unc.edu/inventors/18585088_olexandr-isayev',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application WO 2019/018780',\n",
       "  '#17-0164'),\n",
       " ('A Method of Atrial Fibrillation Diagnosis',\n",
       "  '',\n",
       "  'A method for quantifying recurrent patterns of local wavefront direction during atrial fibrillation',\n",
       "  'https://www.sciencedirect.com/science/article/pii/S0010482517302871?via%3Dihub',\n",
       "  'James Hummel',\n",
       "  'http://technologies.unc.edu/inventors/18585251_james-hummel',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0006'),\n",
       " ('Prevention of Graft-Versus-Host Disease via A Small Molecule Method of CCR7 Inhibition',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'James Coghill',\n",
       "  'http://technologies.unc.edu/inventors/18585238_james-coghill',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0016'),\n",
       " ('Predictive Biomarker for Metformin Response in Endometrial Cancer',\n",
       "  'An indicator of therapeutic response to metformin in endometrial cancer (EC) patients has been identified. In a subset of obese patients, preoperative metformin therapy has been linked to decreased tumor proliferation. Differential proteomic analysis of tumor cells collected from EC patient tissue revealed discrepancies in molecular signaling pathways between metformin responder and non-responder patients.',\n",
       "  'Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice.',\n",
       "  'http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=20754&pubmed-linkout=1',\n",
       "  'Victoria Bae-Jump',\n",
       "  'http://technologies.unc.edu/inventors/18585213_victoria-bae-jump',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0050'),\n",
       " ('Diagnostic Test for the Presence of HPV+ Oropharyngeal Cancers',\n",
       "  '',\n",
       "  ' RNA Oncoimmune Phenotyping of HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas by Nodal Status',\n",
       "  'https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2678979',\n",
       "  'Trevor Hackman',\n",
       "  'http://technologies.unc.edu/inventors/18585194_trevor-hackman',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0121'),\n",
       " ('Small Molecules for the Treatment of Angelman Syndrome',\n",
       "  'Small molecules that can unsilence the gene associated with Angelman syndrome have been discovered. Angelman syndrome is a rare neurodevelopmental disorder affecting 1 in 15,000 individuals. Angelman syndrome is caused by a mutation in the maternal copy of the Ube3a allele. UNC researchers have discovered that certain topoisomerase inhibitors can unsilence the paternal copy of the Ube3a allele, restoring normal protein expression. These molecules represent a therapy for Angelman syndrome. ',\n",
       "  'Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons',\n",
       "  'https://www.nature.com/articles/nature10726',\n",
       "  'Ben Philpot',\n",
       "  'http://technologies.unc.edu/inventors/18584865_ben-philpot',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent US 9714427',\n",
       "  '#11-0003'),\n",
       " ('Small Molecules That Enhance Efficacy of Therapeutic Oligonucleotides, with Aerosolized Formulation for Lung Indications',\n",
       "  '',\n",
       "  'A Novel Family of Small Molecules that Enhance the Intracellular Delivery and Pharmacological Effectiveness of Antisense and Splice Switching Oligonucleotides.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/28703575',\n",
       "  'Silvia Kreda',\n",
       "  'http://technologies.unc.edu/inventors/18585189_silvia-kreda',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0134'),\n",
       " ('Humanized Antibody for the Treatment of Microvascular Complications of Diabetes',\n",
       "  '',\n",
       "  'An anti-aVß3 antibody inhibits coronary artery atherosclerosis in diabetic pigs.',\n",
       "  'https://www.atherosclerosis-journal.com/article/S0021-9150(17)30032-1/fulltext',\n",
       "  'David Clemmons',\n",
       "  'http://technologies.unc.edu/inventors/18584880_david-clemmons',\n",
       "  'Jennifer Dean  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/366_jennifer-dean',\n",
       "  'US Patent US 9073996',\n",
       "  '#12-0054'),\n",
       " ('Compositions for Potentiating the Activities of Select Antibiotics Against S. aureus',\n",
       "  'Potentiators of tobramycin against S. aureus have been developed to combat the highly tolerant nature of S. aureus to commonly used antibiotics. We have discovered certain rhamnolipids that, when administered to S. aureus, can facilitate the uptake of tobramycin, leading to a decrease in the minimum inhibitory concentration (MIC) of tobramycin, and an increase in its anti-biofilm activity. Treatment of S. aureus, in vitro, using these potentiators led to colony eradication in less than 3 hours.',\n",
       "  'Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/29176757',\n",
       "  'Brian Conlon',\n",
       "  'http://technologies.unc.edu/inventors/18585114_brian-conlon',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'PCT Patent Application WO 2019/018594',\n",
       "  '#17-0128'),\n",
       " ('Aerosolized Formulation of Pyrazinoic Acid for the Treatment of Tuberculosis',\n",
       "  'Pyrazinamide (PZA) can shorten the treatment time of tuberculosis (TB) by six months and is the only drug deemed irreplaceable in the standard TB treatment regimen, yet approximately fifty percent of multiple drug resistant TB are resistant to PZA. It is believed that the use of the active form of PZA, pyrazinoic acid (POA), instead of PZA to treat TB could circumvent the problem of resistance. However, POA is not effective when administered orally. We have developed novel aerosolized formulations of POA and pyrazinoic acid esters (PAEs) that, when administered in a guinea pig model, significantly decrease the bacterial burden of the lungs. In addition, the above treatment was able to induce host-directed effects against TB, leading to a reduction of bacterial burden in the spleen, liver, and lymph nodes. The use of aerosolized POA/PAEs versus oral PZA circumvents problems with bioavailability and allows for a lower effective dose, thereby decreasing toxicity. This aerosolized POA represents a novel approach to the treatment of TB.Advantages:-Aerosolized formulation avoids problems associated with oral bioavailability and toxicity- Requires lower dosage than conventional treatment with PZA-In addition to the therapeutic effect in the lung, treatment has a systemic effect that increases clearance of TB in the spleen, liver, and lymph nodes',\n",
       "  'Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/27351427',\n",
       "  'Miriam Braunstein',\n",
       "  'http://technologies.unc.edu/inventors/18585147_miriam-braunstein',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'PCT Patent Application WO 2018/090004',\n",
       "  '#17-0068'),\n",
       " ('CRISPR/Cas9 Gene Therapy for Angelman Syndrome',\n",
       "  'A potential cure for Angelman syndrome (AS) has been developed utilizing CRISPR/Cas9 gene editing technology. AS is a rare neurodevelopmental disorder that affects approximately 1 in 15,000 people, causing severe intellectual disabilities, seizures, and mutism. AS is caused by a deletion or mutation in the maternal copy of the UBE3A allele. While individuals inherit one copy of UBE3A from their mother and another from their father, the paternal allele is naturally silenced. Gene therapy approaches are being developed which deliver a normal copy of UBE3A. However, this will likely be problematic since overexpression of UBE3A can lead to autism. We have discovered a means to alter the antisense transcript that is responsible for silencing the paternal copy of UBE3A using CRISPR/Cas9. This modification eliminates the transcript’s ability to bind with the paternal allele, thereby allowing for expression of functional UBE3A at normal levels from the paternal allele.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Mark Zylka',\n",
       "  'http://technologies.unc.edu/inventors/18585201_mark-zylka',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#18-0085'),\n",
       " ('Mouse: 15-Hydroxyprostaglandin Dehydrogenase (PGDH) Deficient',\n",
       "  '',\n",
       "  'Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus.',\n",
       "  'http://www.nature.com/articles/nm0202-91',\n",
       "  'Beverly Koller',\n",
       "  'http://technologies.unc.edu/inventors/18585182_beverly-koller',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#18-0137'),\n",
       " ('Robust Chauvenet Rejection (RCR)',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Daniel Reichart',\n",
       "  'http://technologies.unc.edu/inventors/18585132_daniel-reichart',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Software Download',\n",
       "  '#17-0086'),\n",
       " ('Image Metrics Software',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Dorothy Erie',\n",
       "  'http://technologies.unc.edu/inventors/18585124_dorothy-erie',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Software Download',\n",
       "  '#17-0113'),\n",
       " ('Improved Image and Video Decompression',\n",
       "  'A technique for image and video decompression has been developed that respects intensity and spatial uncertainty in the encoded stream to significantly improve the perceived quality of final image or video output. This technique avoids spatial and intensity thresholding artifacts by adding noise and spatial blurring into the data stream during the decompression process; these decrease “banding” and “blocking” artifacts that commonly occur upon image reconstruction and detract from overall image quality. The method runs at full video rate on a commodity GPU and is particularly well suited for improving the user experience on high resolution cell phones, televisions, and computers where users commonly stream highly-compressed images or videos that are not well matched to the screen resolution of their device.Advantages:\\nSignificantly improves image or video output quality of compressed data\\nImplementable on commodity hardware\\nImproves user experience when streaming highly-compressed data to high resolution screen',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Russell Taylor',\n",
       "  'http://technologies.unc.edu/inventors/18585126_russell-taylor',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US-2019-0020903',\n",
       "  '#17-0108'),\n",
       " ('UNC Check-In App',\n",
       "  'ITS Teaching and Learning has partnered with UNC Chapel Hill faculty to create the UNC Check-In app to facilitate taking attendance during classes and other events. The app allows instructors to specify brief time intervals during which students can register attendance when in proximity to designated Bluetooth beacons.iTunes:https://itunes.apple.com/us/app/unc-check-in/id1296004763Google Play:',\n",
       "  'https://itunes.apple.com/us/app/unc-check-in/id1296004763',\n",
       "  'https://itunes.apple.com/us/app/unc-check-in/id1296004763',\n",
       "  'Viji Sathy',\n",
       "  'http://technologies.unc.edu/inventors/18585197_viji-sathy',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  '#18-0118'),\n",
       " ('Diabetes Education Board Game',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Nina Jain',\n",
       "  'http://technologies.unc.edu/inventors/18585104_nina-jain',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  '#17-0138'),\n",
       " ('Innovation & Entrepreneurship Database',\n",
       "  'The UNC Innovation and Entrepreneurship Database, built on the Salesforce.com platform, is a shared database for information gathering from stakeholders and for report generation for metrics, including being used to produce impact reports.Database capabilities include:\\nTracking of inventors and entrepreneurs\\nTracking of startups\\nRepository for real-time data on startups/spinouts\\nTracking of startups/entrepreneurs participation in commercialization support programs and events\\nRepository of advisors, mentors, subcontractors, and investment specialists\\nThis system provides',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Cindy Reifsnider',\n",
       "  'http://technologies.unc.edu/inventors/18585008_cindy-reifsnider',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  '#16-0174'),\n",
       " ('COLMAP: Image-based 3D Reconstruction',\n",
       "  'COLMAP is a general-purpose Structure-from-Motion (SfM) and Multi-View Stereo (MVS) pipeline with a graphical and command-line interface. It offers a wide range of features for reconstruction of ordered and unordered image collections.Image-based 3D reconstruction from images traditionally first recovers a sparse representation of the scene and the camera poses of the input images using Structure-from-Motion. This output then serves as the input to Multi-View Stereo to recover a dense representation of the scene.Additional information:',\n",
       "  'https://colmap.github.io',\n",
       "  'https://colmap.github.io',\n",
       "  'Jan-Michael Frahm',\n",
       "  'http://technologies.unc.edu/inventors/18585096_jan-michael-frahm',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  '#17-0157'),\n",
       " ('Physics-Inspired Garment Recovery from a Single-View Image',\n",
       "  'Most recent garment capturing techniques rely on acquiring multiple views of clothing, which may not always be readily available, especially in the case of pre-existing photographs from the web. This technology provides a method that is able to compute a rich and realistic 3D model of a human body and its outfits from a single photograph with little human interaction. The algorithm is not only able to capture the global shape and geometry of the clothing, it can also extract small but important details of cloth, such as occluded wrinkles and folds. Unlike previous methods using full 3D information (i.e. depth, multi-view images, or sampled 3D geometry), this approach achieves detailed garment recovery from a single-view image by using statistical, geometric, and physical priors and a combination of parameter estimation, semantic parsing, shape recovery, and physics- based cloth simulation. The technology has applications in virtual try-on and garment transfer applications, as well as cloth animation for digital characters.Video: http://www.cs.unc.edu/~alexyang/videos/iccvdemo.mp4',\n",
       "  'http://www.cs.unc.edu/~alexyang/videos/iccv',\n",
       "  'http://www.cs.unc.edu/~alexyang/videos/iccv',\n",
       "  'Shan Yang',\n",
       "  'http://technologies.unc.edu/inventors/18585011_shan-yang',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US-2019-0043269',\n",
       "  '#16-0167'),\n",
       " ('Efficient Digital Forensics Support Using a Virtualized Environment',\n",
       "  'This technology provides a forensic platform that transparently monitors and records data access events within a virtualized environment. It accomplishes this using an architecture for efficiently and transparently recording the accesses to monitored objects – the approach monitors accesses to objects on disk and follows the causal chain of these accesses across processes, even after the objects are copied into memory. Its forensic layer records these transactions in a version-based audit log that allows for faithful, and efficient, reconstruction of the recorded events and the changes they induced. This platform can be used to glean insightful information on behavioral profiles of malware activity after a security breach has been detected and reconstruct valuable information about the what, when, and how, after a compromised has been detected. ',\n",
       "  'Trail of bytes: efficient support for forensic analysis',\n",
       "  'https://dl.acm.org/citation.cfm?id=1866314',\n",
       "  'Fabian Monrose',\n",
       "  'http://technologies.unc.edu/inventors/18584859_fabian-monrose',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,721,089',\n",
       "  '#11-0094'),\n",
       " ('Acoustic Classification and Optimization for Multi-Modal Rendering of Real-World Scenes',\n",
       "  '',\n",
       "  'Acoustic Classification and Optimization for Multi-Modal Rendering of Real-World Scenes',\n",
       "  'http://ieeexplore.ieee.org/document/7849179/',\n",
       "  'Carl Schissler',\n",
       "  'http://technologies.unc.edu/inventors/18585128_carl-schissler',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 20180232471',\n",
       "  '#17-0090'),\n",
       " ('Diagnostic Test for Autism in Infancy',\n",
       "  '',\n",
       "  'Early brain development in infants at high risk for autism spectrum disorder',\n",
       "  'https://www.nature.com/articles/nature21369',\n",
       "  'Martin Styner',\n",
       "  'http://technologies.unc.edu/inventors/18585003_martin-styner',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'PCT Patent Application WO 2018/005820',\n",
       "  '#16-0180'),\n",
       " ('Diagnostic Test for Autism in Infancy',\n",
       "  '',\n",
       "  'Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age',\n",
       "  'http://stm.sciencemag.org/content/9/393/eaag2882',\n",
       "  'Robert Emerson',\n",
       "  'http://technologies.unc.edu/inventors/18585002_robert-emerson',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'PCT Patent Application WO 2018/005814',\n",
       "  '#16-0185'),\n",
       " ('Wide Field of View Augmented Reality Head-Mounted Display with Distance Accommodation',\n",
       "  '',\n",
       "  'Wide field of view varifocal near-eye display using see-through deformable membrane mirrors',\n",
       "  'http://ieeexplore.ieee.org/abstract/document/7829412/',\n",
       "  'Henry Fuchs',\n",
       "  'http://technologies.unc.edu/inventors/18584998_henry-fuchs',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,983,412',\n",
       "  '#16-0189'),\n",
       " ('Topology Aware Geographic Routing',\n",
       "  '',\n",
       "  'Analysis of Topology Algorithms for Commercial Airborne Networks',\n",
       "  'http://ieeexplore.ieee.org/abstract/document/6980399/',\n",
       "  'Benjamin Newton',\n",
       "  'http://technologies.unc.edu/inventors/18584996_benjamin-newton',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,832,705',\n",
       "  '#16-0194'),\n",
       " ('Interactive Sound Propagation and Rendering for Scenes with High Aural Complexity',\n",
       "  '',\n",
       "  'Interactive Sound Propagation and Rendering for Large Multi-Source Scenes',\n",
       "  'https://dl.acm.org/citation.cfm?id=2943779',\n",
       "  'Carl Schissler',\n",
       "  'http://technologies.unc.edu/inventors/18584995_carl-schissler',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,977,644',\n",
       "  '#15-0003'),\n",
       " ('A Parallel ARD-based Wave Simulator for Distributed Memory Architectures',\n",
       "  '',\n",
       "  'A parallel time-domain wave simulator based on rectangular decomposition for distributed memory architectures',\n",
       "  'https://www.sciencedirect.com/science/article/pii/S0003682X15001024',\n",
       "  'Nicolas Morales',\n",
       "  'http://technologies.unc.edu/inventors/18584914_nicolas-morales',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,824,166',\n",
       "  '#14-0093'),\n",
       " ('High-Order Diffraction and Diffuse Reflections For Interactive Sound Propagation in Large Environments',\n",
       "  'Virtual environments such as cities, auditoriums, offices, and factories can span extremely large areas and may be composed of many moving sources and objects. Accurate sound propagation in these environments requires modeling complex acoustic effects such as reflections, scattering between objects, high-order diffractions, late reverberation, echoes, etc. New algorithms to enable interactive geometric sound propagation in complex scenes have been developed that can generate plausible sound effects at interactive rates in large, dynamic scenes that have multiple sound sources. A novel algorithm to compute diffuse reflections and higher order diffraction based on ray-based sound propagation is used that is directly applicable to complex geometric datasets. Furthermore, algorithms for wavelength-dependent simplification and visibility graph computation to accelerate higher-order diffraction at runtime are also described. Together these technologies result in an order-of-magnitude performance increase over prior methods with comparable accuracy.',\n",
       "  'High-order diffraction and diffuse reflections for interactive sound propagation in large environments',\n",
       "  'https://dl.acm.org/citation.cfm?id=2601216',\n",
       "  'Carl Schissler',\n",
       "  'http://technologies.unc.edu/inventors/18584912_carl-schissler',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2015/0378019',\n",
       "  '#14-0094'),\n",
       " ('Sound Propagation in Large Complex Environments Using Wave-Ray Coupling',\n",
       "  'Accurate sound propagation has become fundamental to many interactive (i.e. gaming and virtual reality) and offline (i.e. noise prediction in urban scenes, architectural acoustics, and prototyping) applications. Many wave-based techniques for sound propagation are spatially limited and limited to low frequency applications due to computational complexity. On the other hand, geometric techniques for sound propagation are unable to simulate many acoustic effects (i.e. diffraction, interference, and higher-order wave effects) at low frequencies. A new hybrid technique for interactive sound propagation in large, complex indoor and outdoor scenes has been developed that combines the strengths of numerical and geometric acoustic techniques for the different parts of the domain. The more accurate and costly numerical technique is used to model wave phenomena in near-object regions, while the more efficient geometric technique is used to handle propagation in far-field regions and interaction with the environment. The sound pressure field generated by the two techniques is coupled using a novel two-way coupling procedure. The new technique can simulate realistic, high-fidelity acoustic effects using orders of magnitude lower memory than standard wave-based numerical techniques.',\n",
       "  'Wave-ray coupling for interactive sound propagation in large complex scenes',\n",
       "  'https://dl.acm.org/citation.cfm?id=2508420',\n",
       "  'Hengchin Yeh',\n",
       "  'http://technologies.unc.edu/inventors/18584891_hengchin-yeh',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2015/0294041',\n",
       "  '#13-0089'),\n",
       " ('Optical See-Through Near-Eye Display Using Point Light Source Backlight',\n",
       "  'The invention is a design for a near-eye display that allows direct viewing through the device (i.e. optical see-through). The near-eye display uses a series of point light sources to direct light through a spatial light modulator into the eyes. The geometry of the light sources, spatial light modulator, and viewer are arranged so that each pixel on the spatial light modulator is illuminated by a single light source, allowing a clear image to be formed on the eye. The spatial light modulator and backlight are transparent or nearly-transparent, allowing the user’s environment to be seen through the display. This design may be useful to create a wide field of view augmented reality display in a compact, eyeglasses-like form factor. ',\n",
       "  'Pinlight Displays: Wide Field of View Augmented Reality Eyeglasses Using Defocused Point Light Sources',\n",
       "  'https://dl.acm.org/citation.cfm?id=2614080',\n",
       "  'Andrew Maimone',\n",
       "  'http://technologies.unc.edu/inventors/18584885_andrew-maimone',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2016/0320620',\n",
       "  '#13-0120'),\n",
       " ('Sound Propagation in Large Scenes using Equivalent Sources',\n",
       "  'Interactive, wave-based sound propagation that captures important acoustic phenomena (i.e. interference, diffraction, scattering, sound focusing, and high-order wave effects) for large, open virtual environments or scenes found in simulation and training systems or in video games can take hours of computation and gigabytes of memory even while using state-of-the-art wave simulation methods. A new object-centric algorithm for wave-based sound propagation that captures acoustic effects such as high-order diffraction and scattering using an equivalent source formulation has been developed. During preprocessing, the method uses object-based sound field decomposition to segment a scene into well-separated, rigid objects. The acoustic behavior of the objects and inter-object interactions is expressed by matrix-based transfer functions using an equivalent source formulation that can then be used to compute the acoustic response of the scene to a static source distribution. At runtime, summation of outgoing equivalent sources for all objects is performed at the listener location for real-time sound rendering for a moving listener. Scenes with moving sources and a static listener can be handled by exploiting acoustic reciprocity. The technique can perform accurate sound propagation on large, open scenes in real-time, has a small memory footprint, and allows flexible efficiency-accuracy tradeoffs.',\n",
       "  'Wave-based sound propagation in large open scenes using an equivalent source formulation',\n",
       "  'https://dl.acm.org/citation.cfm?id=2451245',\n",
       "  'Ravish Mehra',\n",
       "  'http://technologies.unc.edu/inventors/18584881_ravish-mehra',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,711,126',\n",
       "  '#12-0052'),\n",
       " ('Example-Guided Sound Synthesis',\n",
       "  '',\n",
       "  'Example-guided physically based modal sound synthesis',\n",
       "  'https://dl.acm.org/citation.cfm?id=2421637',\n",
       "  'Ming Lin',\n",
       "  'http://technologies.unc.edu/inventors/18584878_ming-lin',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,401,684',\n",
       "  '#12-0086'),\n",
       " ('Fast Geometric Sound Propagation using Visibility Computations',\n",
       "  'In order to create immersive, multimodal virtual reality for use in interactive applications, geometric acoustic algorithms that can quickly and efficiently compute sound propagation paths for complex 3D models and virtual environments at high frame rates on commodity hardware are needed. A new method for simulation of sound propagation has been developed that harnesses geometric acoustics and conservative visibility techniques to quickly and accurately compute sound propagation paths of complex scenes. From a defined sound source position in a given scene, a complex visibility tree can be constructed. This method uses conservative (e.g. occlusion culling) from-region visibility techniques to model sound diffraction and conservative from-point visibility techniques to model specular sound reflections to significantly reduce the complexity of the visibility tree. The new simplified tree can then be used to generate an impulse response for the scene and in turn quickly and accurately simulate sound propagation in the scene.Advantages:Faster and more efficient than approaches using exact from-point visibility algorithms',\n",
       "  'Fast and Accurate Geometric Sound Propagation Using Visibility Computations',\n",
       "  'http://journals.sagepub.com/doi/abs/10.1260/1351-010X.18.1-2.123',\n",
       "  'Dinesh Manocha',\n",
       "  'http://technologies.unc.edu/inventors/18584863_dinesh-manocha',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 8,847,965',\n",
       "  '#11-0047'),\n",
       " ('Synthetic polymer networks with tissue-like properties',\n",
       "  '',\n",
       "  'Mimicking biological stress–strain behaviour with synthetic elastomers',\n",
       "  'https://www.nature.com/articles/nature23673',\n",
       "  'Sergei Sheiko',\n",
       "  'http://technologies.unc.edu/inventors/18585224_sergei-sheiko',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  \"Biomaterials: Don't stress over it\",\n",
       "  '#18-0030'),\n",
       " ('AAV Vector Reprogramming of Adult Striatal Oligodendrocytes into Functional Neurons',\n",
       "  'Loss of functional neurons occurs in neuropathologies including Parkinson’s disease, Lou Gehrig’s disease, Huntington’s disease and Alzheimer’s disease. Many researchers have tried to differentiate neurons from astrocytes or oligodendrocytes in the brain, but studies have always included transgenic mice and are not easily translated into the clinical setting. A small interfering RNA has been developed that suppresses the polyprimidine tract binding protein, a protein shown to inhibit differentiation of fibroblasts into functional neurons. This siRNAwas encapsulated into an AAV2 viral vector and delivered via injection into the brain of rats. Six weeks followinginjection, oligodendrocytes had adopted a neuronal morphology.',\n",
       "  'Viral Vector Reprogramming of Adult Resident Striatal Oligodendrocytes into Functional Neurons.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/28202388',\n",
       "  'Thomas McCown',\n",
       "  'http://technologies.unc.edu/inventors/18585048_thomas-mccown',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'PCT Patent Application WO 2018/048877',\n",
       "  '#16-0079'),\n",
       " ('Ceria Nanoparticles for the Treatment of Macular Degeneration and Retinoblastoma',\n",
       "  'A novel formulation of ceria nanoparticles (nanoceria) has been developed for the treatment of oxidative stress-related disorders. Nanoceria possess unique antioxidant properties at physiological pH that make them candidates for the treatment of oxidative stress-related disorders and have intrinsic oxidase activity at acidic pH which make nanoceria a potential anti-tumor agent within the tumor microenvironment. However, the poor solubility of nanoceria have historically limited their pharmacological application. We have developed a formulation of nanoceria, using a chitosan derivative, which renders them water soluble and allows for their synthesis in an aqueous environment. The formulation also provides a scaffold for surface engineering to allow for targeted delivery and the attachment of therapeutics, such as anti-cancer agents, for combination therapy. We have demonstrated that these nanoceria have therapeutic efficacy in a murine model of age-related macular degeneration (AMD) and formulations in hydrogel provide sustained release for 2+ months in the eye. Additionally, our studies indicate that these nanoparticles have a synergistic anti-tumor effect when administered in combination with a chemotherapy agent and tumor-targeting ligand in both a genetic retinoblastoma mouse model and a xenograft retinoblastoma mouse model.',\n",
       "  'Glycol Chitosan Engineered Autoregenerative Antioxidant Significantly Attenuates Pathological Damages in Models of Age-Related Macular Degeneration.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/28463509',\n",
       "  'Zongchao Han',\n",
       "  'http://technologies.unc.edu/inventors/18585036_zongchao-han',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'PCT Patent Application WO 2018/152283',\n",
       "  '#16-0108'),\n",
       " ('Quercetin Prodrug Nanoparticle for Modifying Tumor Microenvironment',\n",
       "  'Quercetin is a naturally occuring flavonoid commonly found in fruits and vegtables. It has been shown to regulate many biological pathways that lead to apoptosis, angiogenesis inhibition and cellular proliferation. Quercetin has been examined in several clinical trials as an anti-cancer, anti-tumor agent decades ago however due to poor water solubility and bioavailability has limited its use or approval as a potential anti-cancer therapeutic. Significant research efforts have been committed to overcome the poor physiochemical properties of quercetin without much success. Therefore, alternative strategies are needed to improve the solubility and bioavailability of this potential therapeutic.Recently, a novel solution to address the physiochemical properties associated with quercetin has been developed. Briefly, UNC researchers led by Dr. Leaf Huang has developed a lipid calcium phosphate quercetin prodrug (LCP-QP) nanoparticle formulation which overcomes the aforementioned challenges. LCP-QP nanoparticle formulation is able to obtain high drug loading capacities while maintaining a small particle size, increased stability, and bioavailability. Moreover, the LCP-QP formulation results in increased tumor accumulation, cellular uptake, and intracellular release of the quercetin prodrug. LCP-QP also deploys a tumor-specific targeting molecule to enhance its delivery of the therapeutic payload. Recent preliminary studies have illustrated significantly enhanced antitumor efficiency while mainitaining a favorable toxicity safety profile.',\n",
       "  'Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles',\n",
       "  'https://pubs.acs.org/doi/abs/10.1021/acsnano.7b01522',\n",
       "  'Leaf Huang',\n",
       "  'http://technologies.unc.edu/inventors/18585024_leaf-huang',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Cancer Nanotechnology Research Award',\n",
       "  '#16-0156'),\n",
       " ('Peptidomimetic and Screening Assay Targeting G-alpha-q for the Treatment of Melanoma',\n",
       "  'G-alpha-q proteins play a critical role in the signaling cascade that induces and maintains proliferation in the majority of cells. Mutated G-alpha-q, which is constitutively active, is found in the majority of uveal melanomas, which has a 50% chance of metastasizing to the liver. Mutated G-alpha-q has also been associated with other cancers, such as breast cancer. A novel peptidomimetic has been designed that specifically and potently binds to G-alpha-q, thereby inhibiting downstream signaling. ',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'John Sondek',\n",
       "  'http://technologies.unc.edu/inventors/18584873_john-sondek',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent US 9540620',\n",
       "  '#12-0098'),\n",
       " ('Modified HEK293 Cell Line with Enhanced Adherence',\n",
       "  'A modified line of HEK293 cells has been developed that has enhanced adhesion to untreated plastic and glass surfaces. This “sticky” line of HEK293 cells expresses two surface integrins which form a receptor that enables the cells to bind strongly to a wide range of extracellular molecules. In order to enhance the adherence of unmodified HEK293 cells, researchers must use expensive treatments of culture vessels. Therefore, this novel, modified “sticky” line of HEK293 cells will translate into significant savings for a variety of bio-product manufacturing operations.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'John Olsen',\n",
       "  'http://technologies.unc.edu/inventors/18584799_john-olsen',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent US 7939326',\n",
       "  '#03-0030'),\n",
       " ('Inhibition of Type I Interferon Signaling to Enhance T Cell Recovery and Reduce HIV-1 Reservoirs During Combined Antiretroviral Therapy',\n",
       "  'Combined antiretroviral therapy (cART) efficiently suppresses HIV-1 replication and enhances the number of immune cells in infected individuals. However, it does not rescue their immune hyperactivation and dysfunction. We have demonstrated that treatment of HIV-1 persistently infected humanized mice with an anti-IFN-alpha/beta receptor (IFNAR) antibody in the presence of cART fully reversed HIV-1-induced immune hyeractivation and restored anti-HIV-1 immune responses in T cells from such HIV-1 infected humanized mice. In addition, treatment of the humanized mice with the anti-IFNAR antibody reduced the size of HIV-1 reservoirs in lymphoid tissues during cART. Data suggests that this approach could enhance the management of HIV-1 infection since mice treated with the anti-IFNAR antibody demonstrate an enhanced delay of the return of HIV-1 titers after the cessation of cART therapy.',\n",
       "  'Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/27941247',\n",
       "  'Lishan Su',\n",
       "  'http://technologies.unc.edu/inventors/18585026_lishan-su',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'PCT Patent Application WO2018/081197',\n",
       "  '#16-0154'),\n",
       " ('Heterochromatin Gene Repression Inhibitors as Novel Epigenetic Cancer Therapeutics',\n",
       "  'Heterochromatin gene repression is a major mammalian regulatory pathway that recently was found dysregulated in multiple human cancers including those of the liver and breast. Research in the Hathaway lab has identified a series of cell-permeable, potent, and specific inhibitors of the HP1-mediated heterochromatin gene repression pathway. Our four lead compounds represent a new class of epigenetic inhibitors capable of inhibiting global heterochromatin gene repression as measured by the signature heterochromatin mark H3K9me3.Potential Applications:Genomic studies have revealed that chromatin-based mechanisms are driver mutations in an expansive set of human malignant diseases and underlie the pathology of many cancers. The precise role of heterochromatin in cancer is complicated and still not entirely clear, this is partially due to the lack of even poor chemical inhibitors of the HP1 pathway. HP1 is overexpressed in human cancers of the breast, prostate, and pancreas. High levels of H3K9me3 (the signature mark of heterochromatin) strongly correlate with mutation rates in human cancers 9. Elevated HP1 levels correlate with decreased survival of patients with breast (HP1a) and prostate cancer (HP1?). Knockdown of one of the HP1 pathway HMT enzymes SetDB1 has antiproliferative on hepatocellular carcinoma in vitro and reduced tumorigenicity in mouse liver cancer models. These lines of evidence demonstrate that disruption of the HP1 pathway is a viable approach to treating multiple types of human cancer.Partnering opportunities:- Further medicinal chemistry optimization of lead compounds- Development in cancer model systems-',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Nate Hathaway',\n",
       "  'http://technologies.unc.edu/inventors/18585097_nate-hathaway',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application WO 2019/006322',\n",
       "  '#17-0152'),\n",
       " ('Human African Trypanosomiasis (HAT) Compounds',\n",
       "  'Sleeping sickness or human African trypanosomiasis (HAT) is endemic in 37 African countries and around 13 million people are at medium to high risk of being infected. Sleeping sickness is transmitted by the tsetse fly and is usually fatal without treatment. It occurs in two stages; the early stage (stage 1) with non-specific symptoms, often un- or misdiagnosed - the late stage (stage 2) where the parasite crosses the blood-brain barrier, causing serious neurological disorders including sleep cycle disruptions, neurological manifestations, and progressive mental deterioration.Until 2009, treatments for stage 2 of the disease were toxic or difficult to administer. Conventional combination therapy Nifurtimox-Eflornithine (NECT), replaced the toxic arsenic-based treatments for HAT. Although effective in treating stage 2 HAT, NECT has led to a decrease in the disease incidence. The need for new anti-HAT drugs persists, as current drugs are few, antiquated, toxic, prone to resistance, and require parenteral administration.Research at UNC and collaborators have developed a novel class of oral compounds capable of crossing the blood brain barrier (BBB) with enhanced properties to combat this highly neglected disease. This work describes the synthesis of analogues that may be effective for the treatment of early and late stage HAT, Chagas disease, and potentially Animal African Trypanosomiasis (AAT).',\n",
       "  'Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis.',\n",
       "  'https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01163',\n",
       "  'Richard Tidwell',\n",
       "  'http://technologies.unc.edu/inventors/18585044_richard-tidwell',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application PCT/US2017/014256',\n",
       "  '#16-0082'),\n",
       " ('Fluorogenic Phospholipase C (PLC) Reporter Assay',\n",
       "  'A membrane-associated fluorogenic reporter (XY-69) has been developed that selectively reports phosphatidylinositol-specific phospholipase C (PLC) isozyme activity, both with purified enzymes and in cell lysates. Furthermore, XY-69, but not other soluble fluorogenic PLC reporters, recaptures the direct activation of PLC activity by Gaq, which requires the presence of membranes. Consequently, XY-69 can be used to replace the radiolabeled PIP2',\n",
       "  'A membrane-associated, fluorogenic reporter for mammalian phospholipase C isozymes',\n",
       "  'http://www.jbc.org/content/early/2017/12/20/jbc.RA117.000926',\n",
       "  'Qisheng Zhang',\n",
       "  'http://technologies.unc.edu/inventors/18585129_qisheng-zhang',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application WO 2018/142365',\n",
       "  '#17-0089'),\n",
       " ('Bi-functional Chemical Epigenetic Modifiers (CEM)s',\n",
       "  'Epigenome editing is a powerful method for life science research and offers great potential for the development of therapeutics for human diseases such as cancers and autoimmune disorders.The underlying mechanisms by which histone-modifying proteins work in concert to properly regulate gene expression still remain largely unkown. UNC inventors have developed a small-molecule platform for specifically inducing gene repression and histone deacetylation at a reporter gene to investigate and manipulate complex epigenetic interactions in live cells.Chromatin Epigenetic Modifers (CEMs) technology can intricately control gene expression of any mammalian gene. The technology platform utilizes a new bifunctional small molecules to bind endogenous gene regulatory enzymes and recruit these enzymes to the desired gene using deactivated dCAS9 gene targeting.These novel compounds have been deployed in a dose-dependent and reversible fashion to repress gene expression in a murine stem cell model system. Our fresh approach details a new method of synthetically controlling gene expression programs using the cell’s own machinery and has broad applications in drug discovery research. The advantage of our technique over other currently developed strategies is the use of the bifunctional CEM to control activity.Potential Applications:Cancer therapeutics: Our CEM technique can be used to repress key oncogenes driving cancer. Alternatively, it can be used to activate tumor suppressor genes that have been epigenetically silenced in cancer. We are currently testing both approaches in colon and prostate cancer models.Discovery research: This chemical technology is modular and can be used to study a variety of chromatin regulation pathways, by making CEMs that engage other chromatin enzymes.',\n",
       "  'Targeted Gene Repression Using Novel Bifunctional Molecules to Harness Endogenous Histone Deacetylation Activity',\n",
       "  'http://pubs.acs.org/doi/abs/10.1021/acssynbio.7b00295',\n",
       "  'Nate Hathaway',\n",
       "  'http://technologies.unc.edu/inventors/18585100_nate-hathaway',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#17-0151'),\n",
       " ('Mouse: FOXJ1-EGFP Transgenic Mouse',\n",
       "  'This mouse line expresses the reporter gene EGFP from the promoter of FoxJ1: a transcription factor whose expression is restricted to cells possessing motile cilia or flagella. This promoter has been demonstrated to be highly specific for motile ciliated cells, and transgene-positive mice demonstrate strong EGFP expression in the ciliated cells of tracheal, bronchial, and nasal epithelium. These mice were developed in order to identify a desirable, cell-specific promoter to use in gene therapy for cystic fibrosis as described in the listed publication. In addition to cystic fibrosis, these mice could potentially be used in studies of other diseases that affect ciliated cells such as chronic respiratory infections and polycystic kidney disease.These mice are available at The Jackson Laboratory and can be found athttps://www.jax.org/strain/010827.',\n",
       "  'https://www.jax.org/strain/010827',\n",
       "  'https://www.jax.org/strain/010827',\n",
       "  'Lawrence Ostrowski',\n",
       "  'http://technologies.unc.edu/inventors/18585243_lawrence-ostrowski',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#18-0013'),\n",
       " ('Monoclonal Antibody: Anti-CDC42 Monoclonal Antibody',\n",
       "  '',\n",
       "  '“The Function of Two Rho Family GTPases Is Determined by Distinct Patterns of Cell Surface Localization”',\n",
       "  'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953063/',\n",
       "  'Patrick Brennwald',\n",
       "  'http://technologies.unc.edu/inventors/18585217_patrick-brennwald',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#18-0041'),\n",
       " ('Mouse: Conditional knockout of Dnaic1',\n",
       "  '',\n",
       "  'Conditional Deletion of Dnaic1 in a Murine Model of Primary Ciliary Dyskinesia Causes Chronic Rhinosinusitis',\n",
       "  'http://www.atsjournals.org/doi/abs/10.1165/rcmb.2009-0118OC?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed',\n",
       "  'Lawrence Ostrowski',\n",
       "  'http://technologies.unc.edu/inventors/18585248_lawrence-ostrowski',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#18-0012'),\n",
       " ('Human Factor IX for Treatment of Hemophilia B with Extended Half-life and Enhanced Specific Activity',\n",
       "  'Codon-optimized Factor IX (FIX) with several modifications have been developed that produce Factor IX with an extended half-life and enhaced specific activity when delivered via gene therapy or when manufactured to deliver protein replacement therapy in hemophilia B patients.Features and Advantages·FIX proteins have higher specific activity, longer useful clotting function, and longer half-life·FIX protein is expressed from a single expression cassette, which facilitates efficientin vivodelivery by viral vectors·',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Tal Kafri',\n",
       "  'http://technologies.unc.edu/inventors/18585069_tal-kafri',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent Pending US 2018-0305439',\n",
       "  '#16-0027'),\n",
       " ('Enhancing Purity and Safety of AAV Vector Preparations for Gene Therapy',\n",
       "  'A novel method has been developed to resolve the mass landscape of whole viral particles, capsid intermediates, and viral genomes present in adeno-associated virus (AAV) vector preparations based on charge detection mass spectrometry (CDMS).CDMS not only provides an accurate analysis of diversity within AAV vector preparations, but it can dramatically shorten the analysis time. CDMS can also enhance current quality control protocols for AAV vector analysis, help identify potential contaminants, and also shed light on AAV capsid dynamics during the infectious pathway. This method will have a significant impact on clinical AAV vector preparations which often contain variable levels of full or partial-genome containing particles and emptyvectors. Consequently,the composition of these preparationscan influence vector dose-related immunotoxicity in patients.This novel method has the potential to greatly increase the efficiency, purity, and safety of AAV therapy.Features and Advantages· Novel method that analyzes the entire landscape of AAV vector preparations· Can establish the mass and stoichiometry of AAV capsids complexed with exogenous proteins, nucleic acids, or carbohydrates· Determines the purity of recombinant AAV preparations for clinical applications· Shortens the analysis time from hours to minutes, and can be seamlessly integrated into current quality control protocols',\n",
       "  'Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/27310298',\n",
       "  'Aravind Asokan',\n",
       "  'http://technologies.unc.edu/inventors/18584955_aravind-asokan',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#15-0118'),\n",
       " ('Enhanced Integration-deficient Lentiviral Vectors that are Resistant to Epigenetic Silencing',\n",
       "  'Integration deficient lentiviral vectors (IDLVs) efficiently ferry large genetic constructs to both dividing and non-dividing cells in vitro and in vivo. The stable genome of IDLVs allows for successful and long-term gene expression in non-dividing and slowly-dividing cells. In dividing cells, the presence of IDLVs is transient, and is thus used to express potentially toxic proteins whose function is required for a short time such as genome-editing proteins and de-differentiation factors. IDLVs are a promising system for delivery of foreign or native gene sequences, however transcriptional silencing of IDLVs reduces the transgene expression, and overall efficacy of IDLVs.',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Tal Kafri',\n",
       "  'http://technologies.unc.edu/inventors/18584921_tal-kafri',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent Pending US 2018-0320198',\n",
       "  '#14-0070'),\n",
       " ('Chimeric VLP for Vaccination Against G11.4 Norovirus Strains',\n",
       "  'A virus-like particle (VLP) has been developed in order to induce a more broadly blocking immune response against G11.4 strains of norovirus. This VLP contains multiple epitopes of different strains of norovirus in a backbone of a single strain, and consequently induces a more broadly blocking immune response than single strains alone. G11.4 noroviruses account for the majority of all norovirus outbreaks, however no approved vaccine against this strain of norovirus exists due to the antigenic variation of G11.4 variations. This novel VLP can avoid this problem, and can be used to develop a human norovirus vaccine against current and emerging G11.4 strains.Features and Advantages· This novel, chimeric VLP induces a broader immune response than single strains of norovirus alone· Allows for vaccination despite the heterogeneous nature of G11.4 noroviruses·',\n",
       "  'Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/24741081',\n",
       "  'Ralph Baric',\n",
       "  'http://technologies.unc.edu/inventors/18584902_ralph-baric',\n",
       "  'Kyle Bartholomew  ',\n",
       "  'http://technologies.unc.edu/managers/447_kyle-bartholomew',\n",
       "  'US Patent 9,975,923',\n",
       "  '#13-0036'),\n",
       " ('Multivalent Vaccine Antigen that Protects Against Divergent Strains of Coronavirus',\n",
       "  'A chimeric antigen has been developed for use in the design of vaccines against coronaviruses, such as SARS-CoV, MERS-CoV, and veterinary strains. This antigen contains spike proteins from three different coronavirus strains and has been shown to provide complete protection against SARS-CoV in a mouse model. ',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Ralph Baric',\n",
       "  'http://technologies.unc.edu/inventors/18584890_ralph-baric',\n",
       "  'Jennifer Dean  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/366_jennifer-dean',\n",
       "  'US Patent 9,884.895',\n",
       "  '#13-0091'),\n",
       " ('Mouse: Apoe-Flox Mice: Selective Suppression of Apolipoprotein E',\n",
       "  'These mice possess loxP sites on either side of the Apoe gene which allows for selective, tissue-specific suppression of adipose tissue apolipoprotein E (apoE) expression and normal circulating levels. Unlike mice containing global knockout of apoE, when these mice are bred to mice that express Cre recombinase, the resulting offspring will have exon 3 deleted in only the cre-expressing tissues which can provide better insight in the function of apoE in specific tissues. A primary role of apoE is the mediation of lipid transport throughout various tissues and cells, and consequently these mice can be used in a vast range of studies including metabolism, regulation of the immune system, and neurodegenerative and cardiovascular disease. More information regarding the generation of, and studies using these mice can be found in the listed publication.These mice are available at The Jackson Laboratory, and can be found athttps://www.jax.org/strain/028530.',\n",
       "  'https://www.jax.org/strain/028530',\n",
       "  'https://www.jax.org/strain/028530',\n",
       "  'Nobuyo Maeda',\n",
       "  'http://technologies.unc.edu/inventors/18585206_nobuyo-maeda',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#18-0066'),\n",
       " ('Synthetic Platform for Alkane Functionalization: Site-Selective Aliphatic C-H Dithiocarbonation',\n",
       "  '',\n",
       "  'C-H Xanthylation: A Synthetic Platform for Alkane Functionalization',\n",
       "  'http://pubs.acs.org/doi/10.1021/jacs.6b09414',\n",
       "  'Erik Alexanian',\n",
       "  'http://technologies.unc.edu/inventors/18585083_erik-alexanian',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0005'),\n",
       " ('Antibody Therapeutic for the Treatment of Lupus',\n",
       "  'Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease with underlying genetic and environmental etiologies. Multiple single genes, molecular events, and cell types have been implicated in disease; however, recent therapies targeting single gene products (B-cell Activating Factor, BAFF) or single cells (B cells) have shown marginal therapeutic success. To improve efficacy, we developed a strategy to target immune dysregulation upstream of multiple SLE-associated pathologies. This strategy is based on our findings that lysosomes in lupus-prone mice fail to acidify and degrade immune complexes (IgG autoantibody bound to dead cell debris; IgG-immune complexes). In addition, we show that undegraded IgG-immune complexes promote chronic binding of IgG-immune complexes to particular receptors leading to BAFF and IFNa secretion, B cell activation and autoantibody production, and cell migration and renal disease. To restore lysosome acidification and facilitate the degradation of IgG-immune complexes that are pathognomonic of lupus, we attenuate the lysosome defect and restore degradation of IgG-immune complexes by crosslinking two key surface receptors. Using a PEG-based molecule where intact antibodies binding each receptor were conjugated at differing ratios, we show that crosslinking these receptors restores lysosome acidification, clears the plasma membrane of recycled receptors, and diminishes signal transduction from the target receptors. Future work will focus on designing multivalent, bispecific antibodies to these targets.',\n",
       "  'mTORC2 Activity Disrupts Lysosome Acidification in Systemic Lupus Erythematosus by Impairing Caspase-1 Cleavage of Rab39a',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/29866702',\n",
       "  'Barbara Vilen',\n",
       "  'http://technologies.unc.edu/inventors/18585165_barbara-vilen',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'PCT Patent Application WO 2018/064603',\n",
       "  '#17-0011'),\n",
       " ('Diagnostic for ANCA-Associated Vasculitis Relapse',\n",
       "  'ANCA-associated vasculitis (AAV) is an autoimmune disease primarily caused by neutrophil granule proteins encoded by the genes MPO and PRTN3. AAV is characterized by vascular inflammation, and patients cycle between disease remissions interrupted by relapses of active disease. Consequently, many patients are treated with maintenance immunosuppressive drugs that can have cumulative toxic effects including infertility and malignancies after long-term exposure. Therefore, insight about disease prognosis is vital to patient care, and important to determine whether a patient needs maintenance immunosuppressive treatments. Unfortunately the amount of circulating autoantibodies is not an adequate marker of remission or disease state, and there is no reliable biomarker to indicate a state of remission. ',\n",
       "  'Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/27821628',\n",
       "  'Dominic Ciavatta',\n",
       "  'http://technologies.unc.edu/inventors/18585154_dominic-ciavatta',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'PCT Patent Application WO 2018/071524',\n",
       "  '#17-0046'),\n",
       " ('Recombinant Flavivirus (including Dengue and Zika) Quaternary Epitopes for Vaccines and Diagnostics',\n",
       "  'Dengue virus is the causative agent of dengue fever and dengue hemorrhagic fever, but there is currently no approved vaccine for the virus. Research at UNC has identified that a majority of the strongly neutralizing antibodies produced during dengue infection are targeted to the quaternary structure of the envelope E protein. However, since recombinant proteins are secreted as monomers, the key quaternary epitopes targeted by human antibodies are not displayed on recombinant proteins limiting effective vaccine design. A method has been developed to assemble recombinant dengue envelope proteins that display the quaternary structures needed to induce potent neutralizing antibodies. The ability to generate neutralizing antibodies from recombinant quaternary envelope proteins could expedite the development of an effective vaccine against dengue virus.',\n",
       "  'In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers',\n",
       "  'http://www.nature.com/articles/s41598-017-04767-6',\n",
       "  'Aravinda Desilva',\n",
       "  'http://technologies.unc.edu/inventors/18585062_aravinda-desilva',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'US Patent Pending US 2018-0280494',\n",
       "  '#16-0047'),\n",
       " ('Use of Tardigrade Proteins to Stabilize Biological Materials, Industrial Enzymes, and Agricultural Products',\n",
       "  'The instability of many high value industrial enzymes and life saving biologics, including vaccines and protein-based pharmaceuticals, require that such materials be produced, transported and stored under refrigerated conditions, which adds difficulty and expense. Lyophilization is an alternate storage method that allows some pharmaceuticals to be stored at room temperature. Unfortunately, many proteins denature and lose activity in the lyophilization process. Additionally, agents currently used to prevent desiccation-induced inactivation do not work for all products.By studying the ability of tardigrade organisms to withstand desiccation, a group of proteins has been identified that maintain the structural and functional integrity of proteins in both hydrated and dry states. Methods to purify these Tardigrade Disordered Proteins (TDPs) have been developed, and studies show that TDPs preserve the functional integrity of proteins exposed to desiccation, which enables the lyophilization process. TDPs can also be utilized at high concentrations without aggregation. This technology has the potential to improve and simplify the production and storage of numerous products, including vaccines, industrial enzymes and seeds.Advantages:· TDPs stabilize proteins in both hydrated and dry states· TDPs protect the functionality of lyophilized proteins· Could reduce or eliminate the need to refrigerate sensitive biological materials and enzymes· Could be used to increase the drought tolerance of crops',\n",
       "  'Tardigrades Use Intrinsically Disordered Proteins to Survive Desiccation',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/28306513',\n",
       "  'Gary Pielak',\n",
       "  'http://technologies.unc.edu/inventors/18585022_gary-pielak',\n",
       "  'Kelly Parsons Associate Director, Technology Commercialization 919.962.6277',\n",
       "  'http://technologies.unc.edu/managers/371_kelly-parsons',\n",
       "  'PCT Patent Application WO 2018034867',\n",
       "  '#16-0158'),\n",
       " ('Method for Detecting Coagulation Inhibitors',\n",
       "  'An ELISA-like diagnostic test has been developed to identify three commonly used anticoagulants (heparin, rivaroxaban, and dabigatran) in a patient sample. The assay is based on combinations of four different substrates, andcan quantitate the amount of anticoagulants as well as identify the type of coagulant(s) present in a patient.This assaydetected levels of dabigatran from plasma of mice fed a dabigatran-containinganticoagulant, whichdemonstrated the functionality and efficacy of the assay.In some situations, such as a patient undergoing an emergency surgery, it may be of critical important for a physician to evaluate levels of circulating anticoagulants to ensure patient safety.Advantages:· Can detect the specific anticoagulants even if other inhibitors are present· Will work with newly developed compounds that have the same function· A modification of this test could be used to assay for other inhibitors·',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Dougald Monroe',\n",
       "  'http://technologies.unc.edu/inventors/18584904_dougald-monroe',\n",
       "  'Jennifer Dean  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/366_jennifer-dean',\n",
       "  'US Patent 9,989,532',\n",
       "  '#13-0032'),\n",
       " ('Nematostella VKOR for the Production of Vitamin K-Dependent Blood Coagulation Factors',\n",
       "  'Recombinant Vitamin K-dependent blood coagulation factors such as factors VII, IX , and protein C are clinically important for the treatment of hemophilia and various disorders associated with protein C deficiency. These factors have to be produced in eukaryotic cells due to their requirement for vitamin K-dependent post-translational modification to be functionally active. Vitamin K epoxide reductase (VKOR) is the rate limiting factor in eukaryotic cell systems for producing these factors. ',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Darrel Stafford',\n",
       "  'http://technologies.unc.edu/inventors/18584837_darrel-stafford',\n",
       "  'Jennifer Dean  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/366_jennifer-dean',\n",
       "  'US Patent US 9631002',\n",
       "  '#09-0107'),\n",
       " ('A System for Photo-induced Protein Dissociation',\n",
       "  '',\n",
       "  'LOVTRAP: an optogenetic system for photoinduced protein dissociation',\n",
       "  'http://www.nature.com/articles/nmeth.3926',\n",
       "  'Klaus Hahn',\n",
       "  'http://technologies.unc.edu/inventors/18585016_klaus-hahn',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0164'),\n",
       " ('Protein: Genetically Encoded Inhibitor of KEAP1',\n",
       "  'This engineered monobody (R1) is a potent competitive inhibitor of the KEAP1–NRF2 interaction.',\n",
       "  '“Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display”',\n",
       "  'https://academic.oup.com/peds/article/29/1/1/2364292',\n",
       "  'Brian Kuhlman',\n",
       "  'http://technologies.unc.edu/inventors/18585140_brian-kuhlman',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#17-0078'),\n",
       " ('Mouse: Beta Thalassemia with IVS-2-654 C-->T Mutation',\n",
       "  'The mice were created using the “plug and socket” method of gene targeting in murine embryonic stem cells to replace the two (cis) murine adult ß globin genes with a single copy of the human ßIVS-2-654 gene. The ßIVS-2-654 C–>T mutation accounts for approximately 20% of ß thalassemia mutations in southern China and causes aberrant RNA splicing and leads to ß0 thalassemia. The generated mice provide an animal model in which the antisense and other types of therapy can be tested in vivo and the first animal model of any disease resulting from a known human splicing mutation.These mice are available at The Jackson Laboratory and can be found athttps://www.jax.org/strain/003250.',\n",
       "  'https://www.jax.org/strain/003250',\n",
       "  'https://www.jax.org/strain/003250',\n",
       "  'Nobuyo Maeda',\n",
       "  'http://technologies.unc.edu/inventors/18585102_nobuyo-maeda',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#17-0149'),\n",
       " ('Vector System: Hepatitis B Virus cccDNA-based Gene Expression',\n",
       "  '',\n",
       "  'Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs.  ',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/27819342',\n",
       "  'Lishan Su',\n",
       "  'http://technologies.unc.edu/inventors/18584906_lishan-su',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0154'),\n",
       " ('Mouse: p16(INK4A) Expression (Luciferase & TdTomato)',\n",
       "  'The p16INK4a tumor suppressor is upregulated and serves to limit proliferation in response to cellular stressors and oncogenic events. Induction of p16INK4a is highly dynamic during tumorigenesis and aging, and is expressed in response to a variety of oncogenic stressors.The novel knock-in mouse model, p16-LUC, wherein the endogenous p16INK4a promoter drives single-copy expression of firefly luciferase, is an excellent marker of tumorigenesis and aging. p16 induction can be monitored dynamically in vivo following treatment with DNA damaging stressors such as ionizing radiation or can serve as a biomarker in studies investigating oncogenic stress, oncogenic drivers, early tumorigenesis, novel anti-neoplastic therapeutics, toxicities, senescence, and other in vivo stress responses. This model is available on an albino C57BL/6 background (haired).The conditional knock-out mouse model, p16-floxed, contains loxP sites in the Cdkn2a gene before the exon 1a start site (left) and in the first intron (right), such that only p16INK4a and not p19ARF is affected by removal of exon 1a. This strain can be crossed with Cre-expressing strains to investigate how the loss of p16INK4a affects early oncogenesis and senescence. This model is on a mixed C57BL/6 and 129 background.Please contact Dr. Shenghui He at shenghui@email.unc.edu',\n",
       "  'shenghui@email.unc.edu',\n",
       "  'mailto:shenghui@email.unc.edu',\n",
       "  'Norman Sharpless',\n",
       "  'http://technologies.unc.edu/inventors/18584858_norman-sharpless',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#11-0105'),\n",
       " ('Cell Line: SKOV3-A2',\n",
       "  '',\n",
       "  'T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment',\n",
       "  'http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043746',\n",
       "  'Jonathan Serody',\n",
       "  'http://technologies.unc.edu/inventors/18585157_jonathan-serody',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#17-0029'),\n",
       " ('Mouse: Connective Tissue Growth Factor Lo and Hi Mutants',\n",
       "  'Increased connective tissue growth factor (CTGF) is associated with fibrosis in chronic organ injury. Studying the role of CTGF in fibrotic disease in vivo, however, has been hampered by perinatal lethality and the limited scope of CTGF mice. In this single mutant mouse strain, replacement with or excision of a modified CTGF allele results in 60% normal CTGF expression (Lo allele) or increased CTGF expression (Hi allele), respectively. Overexpression of CTGF can cause abnormalities, including developmental delay, craniofacial defects, and embryonic death. CTGF Lo-Hi mutant mice should prove useful in further understanding the function of CTGF in fibrotic diseases.These mice are available at The Jackson Laboratory, and can be found at',\n",
       "  'https://www.jax.org/strain/030767',\n",
       "  'https://www.jax.org/strain/030767',\n",
       "  'Nobuyo Maeda',\n",
       "  'http://technologies.unc.edu/inventors/18585144_nobuyo-maeda',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#17-0070'),\n",
       " ('Monoclonal Antibody: CRY1',\n",
       "  '',\n",
       "  'http://www.emdmillipore.com/US/en/product/Anti-Cryptochrome-1-Antibody-clone-D46-3361,MM',\n",
       "  'http://www.emdmillipore.com/US/en/product/Anti-Cryptochrome-1-Antibody-clone-D46-3361,MM',\n",
       "  'Aziz Sancar',\n",
       "  'http://technologies.unc.edu/inventors/18585142_aziz-sancar',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#17-0074'),\n",
       " ('Mouse: Humanized NLRP3',\n",
       "  '',\n",
       "  'An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice',\n",
       "  'http://www.sciencedirect.com/science/article/pii/S2211124716316254',\n",
       "  'Beverly Koller',\n",
       "  'http://technologies.unc.edu/inventors/18585136_beverly-koller',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#17-0083'),\n",
       " ('RNA Interference Compositions for Inhibiting KRAS in Cancer',\n",
       "  'siRNA sequences have been engineered to simultaneously block expression of multiple mutant KRAS forms in tumors without silencing wild-type KRAS and impacting normal signaling in healthy cells. KRAS mutations are among the most prevalent driver mutations in cancers, and despite extensive research, no effective KRAS inhibitor has been identified and KRAS remains an elusive target for drug development. This novel approach permits the silencing of multiple oncogenic KRAS forms while sparing wild-type expression.Advantages:• Targets a large percentage of human cancers• Selectively targets tumor cells while sparing normal cells• Effective against an “undruggable” target•',\n",
       "  'Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/25281617',\n",
       "  'Chad Pecot',\n",
       "  'http://technologies.unc.edu/inventors/18585080_chad-pecot',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application WO 2017/127473',\n",
       "  '#16-0006'),\n",
       " ('Predicting Maximum Heart Rate and Maximum Oxygen Uptake from Submaximal Exercise',\n",
       "  'A new method has been developed for accurately estimating maximum heart rate and maximal oxygen uptake from data collected at submaximal intensities. This method accounts for the personal physiology and fitness of an individual and can make predictions with a level of precision and accuracy that is unavailable through conventional submaximal estimation methods. The invention can easily be integrated with existing physiological data collection technologies, including wearable sensors, and has immediate applications in the fitness and medical fields.Advantages:• Provides the accuracy of a maximum cardiopulmonary exercise test without the associated costs or medical risks• Accounts for intra-individual (person-specific) physiological variations, rather than population-specific averages, to provide greater accuracy• Improves accuracy and utility of training methods that use maximum heart rate and maximum oxygen uptake values to determine training zones•',\n",
       "  'Modeling Heart Rate Dynamics in Response to Changes in Exercise Intensity',\n",
       "  'http://proceedings.asmedigitalcollection.asme.org/proceeding.aspx?articleid=2483944',\n",
       "  'Claudio Battaglini',\n",
       "  'http://technologies.unc.edu/inventors/18585079_claudio-battaglini',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US-2019-0009134',\n",
       "  '#16-0007'),\n",
       " ('Mouse: ARID1A Conditional Inactivation',\n",
       "  '',\n",
       "  'Coexistent ARID1A?PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling',\n",
       "  'http://www.nature.com/articles/ncomms7118',\n",
       "  'Terry Magnuson',\n",
       "  'http://technologies.unc.edu/inventors/18585077_terry-magnuson',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0014'),\n",
       " ('Dynamic Decoding for Multiplexing Bead-Based Assays',\n",
       "  'A methodology has been developed that employs dye stability to distinguish bead populations in bead-based assay systems. This increases multiplexing capabilities beyond current limitations seen with dyes of fixed excitation/emisson wavelengths. Different dyes with similar spectral properties, but different stabilities, adds a dynamic, time-based element that can resolve different bead populations. Related technologies have been developed that increase assay performance and multiplexing capability by utilizing non-cylindrical bead well geometries to improve assay performance and readout (15-0131) and bead-based delivery of reagents to facilitate parallel assays on a multiplexed-in-space microfluidic device (12-0128).Advantages:• Employs the measurement of dye decay to provide additional encoding levels beyond static, single point measurement for distinguishing bead populations• Can be used for highly sensitive real-time PCR detection of multiple target sequences on a single chip with or without the use of sequence-specific probes•',\n",
       "  'An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples',\n",
       "  'http://pubs.rsc.org/en/content/articlehtml/2014/lc/c3lc51303c',\n",
       "  'J Ramsey',\n",
       "  'http://technologies.unc.edu/inventors/18585076_j-ramsey',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#16-0015'),\n",
       " ('Mouse: Human DPP4 Expression (MERS Infection)',\n",
       "  '',\n",
       "  'A mouse model for MERS coronavirus-induced acute respiratory distress syndrome',\n",
       "  'http://www.nature.com/articles/nmicrobiol2016226',\n",
       "  'Ralph Baric',\n",
       "  'http://technologies.unc.edu/inventors/18585075_ralph-baric',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0018'),\n",
       " ('Accurate Segmentation of Male Pelvic Organs from CT images via Regression-Based Deformable Models and Iterative Structural Refinement',\n",
       "  'This novel method automatically segments male pelvic organs from CT images with robustness to initialization that achieves better results than current deformable models, and could greatly enhance the accuracy of pelvic segmentation consequently preventing more accurate radiotherapy treatments to patients. Segmenting pelvic organs is a prerequisite for prostate cancer radiotherapy, as the efficacy of radiation treatment heavily depends on the segmentation accuracy. However, due to low tissue contrast of CT images, and large shape and appearance variation of pelvic organs, accurate segmentation is challenging. Deformable models aim to alleviate some of these hindrances, but their success greatly depends upon initialization – especially for segmenting organs with large shape variations. This technology is a novel way to guide deformable segmentation, which makes deformable models more robust against arbitrary initializations. By learning an image regressor that predicts the 3D displacement from any image voxel to the target organ boundary, this method overcomes the initialization problem suffered by traditional deformable models. This method has been tested using images from over 300 prostate cancer patients.Advantages:• Accurate, automatic method for segmenting male pelvic organs from CT images• Makes deformable models more robust against arbitrary initialization• Unlike conventional deformable models, the deformation direction is adaptively determined for optimally driving the shape model onto the target organ•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Dinggang Shen',\n",
       "  'http://technologies.unc.edu/inventors/18585074_dinggang-shen',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application WO 2017/062453',\n",
       "  '#16-0019'),\n",
       " ('3D Printed Intravaginal Rings for Delivery of Therapeutics and Contraceptives',\n",
       "  'Using state-of-the-art 3D printing technology, intravaginal\\nrings (IVRs) have been fabricated in a way that cannot be achieved with\\nconventional engineering. IVRs can be used for the delivery of therapeutics\\nincluding contraceptives. Traditional IVR manufacturing uses injection molding\\nor hot-melt extrusion and complex multistep processes to make reservoir IVRs.\\n3D printing technology allows for flexibility in starting materials.\\nAdvantages:\\n•\\nCost effective production process\\n•\\nWide range of starting materials\\n•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Soumya Benhabbour',\n",
       "  'http://technologies.unc.edu/inventors/18585072_soumya-benhabbour',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#16-0021'),\n",
       " ('Cache, Trigger, Impersonate: Enabling Context-Sensitive Honeyclient Analysis On-the-Wire',\n",
       "  'A novel framework has been developed for adapting honeyclient-based systems (for identifying attacks) to operate on-the-wire at scale. It analyzes web-based exploits inline with network traffic using a cache and replay system, utilizing behavioral-based features. Current techniques only analyze behavioral based features in an offline fashion. The innovation would be used to protect enterprise networks from HTTP-based attacks.Advantages:• Significant operational value•',\n",
       "  'Cache, Trigger, Impersonate: Enabling Context-Sensitive Honeyclient Analysis On-the-Wire',\n",
       "  'https://www.internetsociety.org/sites/default/files/blogs-media/cache-trigger-impersonate-enabling-context-sensitive-honeyclient-analysis-wire.pdf',\n",
       "  'Fabian Monrose',\n",
       "  'http://technologies.unc.edu/inventors/18585067_fabian-monrose',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,992,217',\n",
       "  '#16-0031'),\n",
       " ('Plasmid: Porcine Epidemic Diarrhea Virus Infectious Clone',\n",
       "  '',\n",
       "  'Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A',\n",
       "  'http://mbio.asm.org/content/7/1/e01451-15.abstract',\n",
       "  'Anne Beall',\n",
       "  'http://technologies.unc.edu/inventors/18585065_anne-beall',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0038'),\n",
       " ('Mouse: Human CalDAG-GEFIExpression',\n",
       "  '',\n",
       "  'Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III',\n",
       "  'http://www.jci.org/articles/view/30575',\n",
       "  'Wolfgang Bergmeier',\n",
       "  'http://technologies.unc.edu/inventors/18585056_wolfgang-bergmeier',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0049'),\n",
       " ('No-Execute-After-Read: Preventing Code Disclosure in Commodity Software',\n",
       "  'A novel memory permission primitive, dubbed No-Execute-After-Read (NEAR), has been developed that thwarts just-in-time code reuse attacks by adversaries taking advantage of memory disclosures. Unlike Execute-no-Read, which fails to prevent such attacks, NEAR provides strong security guarantees against just-in-time attacks in commodity binaries. Specifically, NEAR allows the disclosure of all code, but prevents any disclosed code from subsequently being executed, thus fundamentally thwarting just-in-time code reuse. At the same time, commodity binaries with mixed code and data regions still operate correctly, as legitimate data is still readable. The prototype is practical and portable to various platforms and applications, and it has a negligble runtime overhead, making it suitable for practical deployment.Advantages:• A better method than Execute-no-Read in preventing just-in-time code reuse attacks• Provides strong security protection against such attacks•',\n",
       "  'No-Execute-After-Read: Preventing Code Disclosure in Commodity Software',\n",
       "  'https://www3.cs.stonybrook.edu/~mikepo/papers/near.asiaccs16.pdf',\n",
       "  'Jan Werner',\n",
       "  'http://technologies.unc.edu/inventors/18585053_jan-werner',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2017/0213039',\n",
       "  '#16-0058'),\n",
       " ('Tumor Antigen Capturing Nanoparticle for Cancer Immunotherapy',\n",
       "  'A biodegradable and biocompatible antigen capturing nanoparticle (AC-NP) has been developed that can improve cancer immunotherapy and induce the abscopal effect - a phenomenon where local tumor treatment causes systemic regression of metastatic lesions. The AC-NPs can deliver captured proteins to antigen-presenting cells and significantly improve the efficacy of treatment in a mouse melanoma model. This nanotechnology represents a novel strategy for improving cancer immunotherapy.Advantages:• Nanoparticle formulation elicits an improved immune response•',\n",
       "  'Protein-capturing nanoparticles boost immune response to cancer',\n",
       "  'http://medicalphysicsweb.org/cws/article/research/69608',\n",
       "  'Andrew Wang',\n",
       "  'http://technologies.unc.edu/inventors/18585052_andrew-wang',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application PCT/US2016/062563',\n",
       "  '#16-0064'),\n",
       " ('Mouse: Mer Null (B6129SF2/J)',\n",
       "  '',\n",
       "  'Tyro-3 family receptors are essential regulators of mammalian spermatogenesis',\n",
       "  'http://www.nature.com/nature/journal/v398/n6729/full/398723a0.html',\n",
       "  'Shelton Earp',\n",
       "  'http://technologies.unc.edu/inventors/18585051_shelton-earp',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0074'),\n",
       " ('Mouse: Mer Null (C57BL/6)',\n",
       "  '',\n",
       "  'A Novel Receptor Tyrosine Kinase, Mer, Inhibits TNF-? Production and Lipopolysaccharide-Induced Endotoxic Shock',\n",
       "  'http://www.jimmunol.org/content/162/6/3498.full',\n",
       "  'Shelton Earp',\n",
       "  'http://technologies.unc.edu/inventors/18585049_shelton-earp',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0075'),\n",
       " ('Pediatric and Adult Peripheral Cannulation Simulator',\n",
       "  'A pediatric and adult Peripheral Cannulation Simulator has been developed for heart catheterization, medical device placement and mechanical circulatory support. This device incorporates visual feedback and a working pump with fluid-filled, pulsatile venous and arterial vasculature (aka PCS), and uses a human neck, torso, and upper thigh form, combined with pressurized tubing and a pump with variable, controlled pressure and flow direction to allow for the insertion of medical devices, catheters, sheaths, and cannulae of all kinds designed for mechanical circulatory support using Seldinger technique. During and after insertion, the devices may be viewed via a translucent “atrium” within the chest of the simulator in order to facilitate teaching and learning of proper device insertion and positioning, as well as to visualize flow dynamics (if colored fluid or otherwise labeled fluid was used) and the entrainment of air during the use of mechanical circulatory support devices. Because the tubing used to simulate the vasculature is distensible and embedded in silicone molds, it can be visualized with ultrasound during insertion of medical devices. The nature of the connections of the tubing in this device allow for the simulator to be connected to a cardiopulmonary bypass circuit or other mechanical circulatory support pump system and to indefinitely circulate fluid within the vasculature, to the mechanical support system pump, and return to the vasculature via cannula, thus simulating the proper use of the medical device as it might be used in a living person. PCS can be used for training of field/military ECMO, cathlab, ER docs, and nurses.Advantages:• The carotid artery is connected to the femoral artery and both are pulsatile• Can be connected to mechanical support and used to achieve continuous, indefinite circulation on the support device• Allows for a functional interaction with other devices in a much more high-fidelity, working capacity•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Jennifer Nelson',\n",
       "  'http://technologies.unc.edu/inventors/18585045_jennifer-nelson',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'PCT Patent Application WO 2017/127724',\n",
       "  '#16-0080'),\n",
       " ('Large-scale Structure from Motion Software',\n",
       "  'A new Structure-from-Motion (SfM) technique has been\\ndeveloped that improves existing incremental Structure-from-Motion strategies\\nfor 3D reconstruction from unordered image collections. The novel SfM\\nalgorithim improves therobustness, accuracy, completeness, and scalability\\ncompared to the current state-of-the-art, and it makes a further step towards a\\ngeneral-purpose SfM system.\\nAdvantages:\\n•',\n",
       "  'Structure-from-Motion Revisited',\n",
       "  'https://people.inf.ethz.ch/jschoenb/papers/schoenberger2016sfm.pdf',\n",
       "  'Jan-michael Frahm',\n",
       "  'http://technologies.unc.edu/inventors/18585042_jan-michael-frahm',\n",
       "  'Copyright Materials  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/364_copyright-materials',\n",
       "  'Copyright Materials  919.966.3929',\n",
       "  '#16-0089'),\n",
       " ('Cell Line: CH Mouse B Cell Lymphoma 27',\n",
       "  'CH27 is a carcinogen-induced B-cell lymphoma tumor that also expresses IgM/k on its surface.This cell line is available for distribution',\n",
       "  'http://www.emdmillipore.com/US/en/product/CH27-Mouse-B-Cell-Lymphoma-Cell-Line,MM',\n",
       "  'http://www.emdmillipore.com/US/en/product/CH27-Mouse-B-Cell-Lymphoma-Cell-Line,MM_NF-SCC115',\n",
       "  'Geoffrey Haughton',\n",
       "  'http://technologies.unc.edu/inventors/18585038_geoffrey-haughton',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0100'),\n",
       " ('Exosomal Drug Delivery for Chemotherapy and CNS Disorders',\n",
       "  'Novel exosome-based compositions have been developed for the delivery of low molecular weight active ingredients, drugs and macromolecular biotherapeutics to sites of disease associated with inflammation including tumors and the central nervous system. When derived from individual patient exosomes, these vesicles have immune-privileged status which allows them to deliver therapeutic agents to target cells and increase drug efficacy. Delivery of multiple agents has been demonstrated in mouse models.Advantages:• Application-specific, customizable platform technology for the efficient transfer of drugs and genes to target tissues• Intranasal or intraveneous delivery of therapeutics•',\n",
       "  'Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/26586551',\n",
       "  'Elena Batrakova',\n",
       "  'http://technologies.unc.edu/inventors/18585037_elena-batrakova',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application WO 2017/173034',\n",
       "  '#16-0102'),\n",
       " ('Mouse: Fluorescent Reporter of Splice Switching Oligonucleotides (EGFP-654)',\n",
       "  'Model designed as a positive readout test for activity, delivery, and distribution of antisense oligomers. The expressed gene (EGFP-654) encoding enhanced green fluorescence protein is interrupted by an aberrantly spliced mutated intron of the human beta-globin gene. Aberrant splicing of this intron prevented expression of EGFP-654 in all tissues, whereas in tissues and organs that took up a splice site-targeted antisense oligomer, correct splicing was restored and EGFP-654 expression upregulated.This research tool is only',\n",
       "  'https://www.jax.org/strain/027617',\n",
       "  'https://www.jax.org/strain/027617',\n",
       "  'Ryszard Kole',\n",
       "  'http://technologies.unc.edu/inventors/18585035_ryszard-kole',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0111'),\n",
       " ('BCL6 and SIRT1 as Biomarkers of Endometriosis and Endometrial Dysfunction',\n",
       "  'BCL6 and SIRT1 are predictors of endometriosis and endometrial dysfunction, and consequently can be used as diagnostic tools for endometriosis. Both BCL6 and SIRT1 were found to be elevated in the eutopic endometrium from women with endometriosis. Furthermore, studies in a baboon animal model of induced endometriosis showed that levels of SIRT1 and BCL6 increased with time after induction. Once diagnosis of endometriosis is made, there are effective treatments, many of which involve surgery. However, due to the widely varying symptoms of endometriosis and lack of concrete diagnostic tools, many physicians are reluctant to perform these treatments. Consequently, there is often a slow time to diagnosis for patients, and a large number of unnecessary invasive surgeries conducted on patients who have pelvic pain without having endometriosis. This technology may be developed into a sensitive diagnostic test for endometriosis that will help physicians determine the best course of treatments for patients in a timely fashion, and eliminate potentially unnecessary invasive surgeries. Advantages:• Novel diagnostic approach for endometriosis•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Steven Young',\n",
       "  'http://technologies.unc.edu/inventors/18585033_steven-young',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'PCT Patent Application WO 2017/173250',\n",
       "  '#16-0123'),\n",
       " ('Mouse: Gq-DREADD (hM3Dq)',\n",
       "  '',\n",
       "  'Remote Control of Neuronal Activity in Transgenic Mice Expressing Evolved G Protein-Coupled Receptors',\n",
       "  'http://www.sciencedirect.com/science/article/pii/S089662730900467X',\n",
       "  'Bryan Roth',\n",
       "  'http://technologies.unc.edu/inventors/18585020_bryan-roth',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0159'),\n",
       " ('Mouse: Gi-DREADD (hM4Di)',\n",
       "  'In neurons, activation of hM4Di induces neuronal silencing. This model can be used to selectively and reversibly suppress hippocampal neuronal activity during synaptic consolidation. Clozapine-N-oxide induces Gi activation and allows in vivo manipulation of neuronal activity in freely moving animals.This mouse line is available from The Jackson Laboratory and can be found athttps://www.jax.org/strain/026219.',\n",
       "  'https://www.jax.org/strain/026219',\n",
       "  'https://www.jax.org/strain/026219',\n",
       "  'Bryan Roth',\n",
       "  'http://technologies.unc.edu/inventors/18585017_bryan-roth',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0160'),\n",
       " ('Polyclonal Antiserum: DDB1',\n",
       "  'Damaged DNA binding protein 1 (DDB1) could prevent the replication of damaged DNA, contributing to DNA repair and the maintenance of genomic integrity. These rabbit polyclonal antibodies to DDB1 (N-REKEFNKGPWKQENVE-H) were raised against a synthetic peptide derived from human p127DDB1 coupled to keyhole limpet haemocyanin (KLH). They are useful for evidencing the in vivo association of DDB1 with ROC1, a small RING finger protein that activates an ubiquitin-conjugating enzyme, and CUL4A, a cullin-dependent ligase essential to cell cycle control, genomic stability and development.This research tool is available from Kerafast and can be found athttps://www.kerafast.com/product/3349/anti-ddb1-antibody.',\n",
       "  'https://www.kerafast.com/product/3349/anti-ddb1-antibody',\n",
       "  'https://www.kerafast.com/product/3349/anti-ddb1-antibody',\n",
       "  'Yue Xiong',\n",
       "  'http://technologies.unc.edu/inventors/18585014_yue-xiong',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#16-0166'),\n",
       " ('Two Dimensional Electrides as Battery Electrode Materials',\n",
       "  'A new class of two-dimensional materials has been developed for battery electrodes that are derived from bulk electride crystals such as Ca2N, Sr2N, Ba2N, and Y2C. Electrides are materials that trap electrons at stoichiometric concentration, such that the electrons themselves serve as counteranions. Despite rapid progress in the last decade to synthesize, isolate, and use electrides, a number of challenges hinder their potential application. For example, the low surface area and limited electron accessibility of bulk electride surfaces inhibit their potential utility as novel catalysts and conductive materials. These materials are synthesized by a liquid exfoliation process in which large pieces of layered electrides are placed in a solvent and subjected to sonication. The resulting nanosheets have a two-dimensional morphology and can be further isolated and separated by centrifugation or solvent removal. Advantages:• Nanosheets are stable and possess a low work function and a metallic electronic structure• Potential application of nanosheets as battery electrode materials•',\n",
       "  'Experimental Demonstration of an Electride as a 2D Material',\n",
       "  'https://pubs.acs.org/doi/abs/10.1021/jacs.6b10114?journalCode=jacsat&quickLinkVolume=138&quickLinkPage=16089&selectedTab=citation&volume=138',\n",
       "  'Scott Warren',\n",
       "  'http://technologies.unc.edu/inventors/18585010_scott-warren',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Scientists create first 2-D electride',\n",
       "  '#16-0168'),\n",
       " ('Cell Line: HeLa EGFP-654(available with EGFP or Luciferase-pLuc/705)',\n",
       "  '',\n",
       "  'Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs',\n",
       "  'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC60237/',\n",
       "  'Ryszard Kole',\n",
       "  'http://technologies.unc.edu/inventors/18585007_ryszard-kole',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'LCCC Tissue Culture Facility',\n",
       "  '#16-0176'),\n",
       " ('Scientifically-Lossless Video Microscopy Compression',\n",
       "  'A novel compression method has been developed based upon Pearson’s correlation coefficient and mathematical morphology that, for certain data sets, compresses much better than lossless compression with no impact on analysis results. It is “scientifically lossless.” The compressed size scales with the video’s scientific data content, while existing lossy algorithms greatly impacted data analysis at similar compression sizes.Advantages:• Can achieve over 100Ã— compression, enabling high-throughput video-acquisition experiments to be stored in the same space as conventional experiments•',\n",
       "  'Analysis-preserving video microscopy compression via correlation and mathematical morphology',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/26435032',\n",
       "  'Russell Taylor',\n",
       "  'http://technologies.unc.edu/inventors/18584994_russell-taylor',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent US 2017/0244976',\n",
       "  '#15-0004'),\n",
       " ('Web Page Classification using Anonymized TCP/IP Headers',\n",
       "  'A method has been developed that classifies web pages based only on anonymized TCP/IP headers of traffic generated when a web page is visited. The framework can work for a variety of classification labeling schemes including video and mobile. ISPs and Internet measurement companies, as well as academia may have an interest in the procedure. Commercial uses include (1) Behavioral ad-targeting for Internet service providers; and (2) Inference on higher level traffic events/details using minimal information: (i) internet measurement study tool and (ii) tool to help develop models of the web to test capacity limits and new protocols.Advantages:• Honors privacy concerns of users since it uses anonymized TCP/IP headers• Usable by entities that do not have application information or state such as Internet service providers and network administrators•',\n",
       "  'Can Web Pages Be Classified Using Anonymized TCP/IP Headers?',\n",
       "  'http://www.cs.unc.edu/~jasleen/papers/infocom15.pdf',\n",
       "  'Sean Sanders',\n",
       "  'http://technologies.unc.edu/inventors/18584993_sean-sanders',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2018/0013639',\n",
       "  '#15-0015'),\n",
       " ('Monoclonal Antibody: SMV59 Against Norovirus GII.2.1976',\n",
       "  '',\n",
       "  'Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/24173225',\n",
       "  'Ralph Baric',\n",
       "  'http://technologies.unc.edu/inventors/18584990_ralph-baric',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0026'),\n",
       " ('Mouse: CGRPalpha-GFP Expression',\n",
       "  '',\n",
       "  'CGRP?-expressing sensory neurons respond to stimuli that evoke sensations of pain and itch',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/22563493',\n",
       "  'Mark Zylka',\n",
       "  'http://technologies.unc.edu/inventors/18584989_mark-zylka',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0028'),\n",
       " ('Biomarkers for Prognostic Subtyping of Pancreatic Cancer',\n",
       "  'By digitally separating tumor, stroma, and normal tissues to remove confounding gene expression two pancreatic cancer subtypes have been identified and validated. A “basal-like” subtype can be identified which has worse outcome (similar to basal tumors in bladder and breast cancer) but showed a strong trend towards better response to adjuvant therapy. Normal and “activated” stromal subtypes were also identified and found to be prognostic.Advantages:• Separates tumor subtypes by biological and clinical relevance• Predictive of response to adjuvant therapy ',\n",
       "  'Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma',\n",
       "  'http://www.ncbi.nlm.nih.gov/pubmed/26343385',\n",
       "  'Jen Jen Yeh',\n",
       "  'http://technologies.unc.edu/inventors/18584988_jen-jen-yeh',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent Pending US 2017/0233827',\n",
       "  '#15-0032'),\n",
       " ('Brg1/Brm as Targets for Cardiac Conduction Defects in Heart Failure',\n",
       "  'An alternative therapy has been developed for cardiac conduction defects by altering Brg1/Brm function in regulating ion channels and gap junction proteins at the same time. The primary therapies for cardiac arrhythmias act by interferring with the sodium channel activity (Class 1), potassium efflux (Class 3), calcium channels, and AV node (Class 4), or beta adrenergic receptor blockade (Class II). SWI/SNF ATPases Brg1 and Brm have now been shown to regulate cardiomyocyte chromatin remodeling to maintain cardiac conduction. Brg1/Brm double-mutant mice exhibited increased mitochondrial biogensis, autophagy, along with evidence of perturbed cardiac mitochondrial dynamics.Advantages:• Alternative therapy to ion channel therapies• HDAC inhibitors could be used as anti-arrhythmia therapy ',\n",
       "  'Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/22740088',\n",
       "  'Monte Willis',\n",
       "  'http://technologies.unc.edu/inventors/18584987_monte-willis',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent Pending US 20180140722',\n",
       "  '#15-0037'),\n",
       " ('Mouse: Akita Mice with Human apoE4 and Human LDLR Receptors (E4hAkita)',\n",
       "  '',\n",
       "  'Diabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammation',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/23204275',\n",
       "  'Nobuyo Maeda',\n",
       "  'http://technologies.unc.edu/inventors/18584986_nobuyo-maeda',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0038'),\n",
       " ('Visible Light-Driven Water Splitting',\n",
       "  'A dye-sensitized photoelectrosynthesis cell (DSPEC) has been developed for splitting water with a core/shell of nanostructured electrodes derivatized with surface-bound chromophore-catalyst assemblies. Artificial photosynthesis research efforts seek to convert solar energy into chemical fuels by splitting water into oxygen and hydrogen or reducing CO2. The assembly can be further stabilized by deposition of protective overlayers of metal oxides via atomic layer deposition. This DSPEC can split water to H2 and O2 using visible light.Advantages:• Core/shell electrode structure and protective overlayers on chromophore-catalyst assembly result in enhanced efficiency and greater stability over previous approaches for visible light-driven water splitting• Demonstrated photocurrent densities as high as 1.97 mA/cm2 at pH 7•',\n",
       "  'Solar water splitting in a molecular photoelectrochemical cell',\n",
       "  'http://www.pnas.org/content/110/50/20008.abstract',\n",
       "  'Thomas Meyer',\n",
       "  'http://technologies.unc.edu/inventors/18584984_thomas-meyer',\n",
       "  'Jennifer Dean  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/366_jennifer-dean',\n",
       "  'UNC researchers harness sun’s energy during day for use at night',\n",
       "  '#15-0045'),\n",
       " ('Cell Line: CWR-R1 Prostate Cancer',\n",
       "  '',\n",
       "  'https://www.kerafast.com/product/3333/human-prostate-cancer-cell-line-cwr-r1',\n",
       "  'https://www.kerafast.com/product/3333/human-prostate-cancer-cell-line-cwr-r1',\n",
       "  'Elizabeth Wilson',\n",
       "  'http://technologies.unc.edu/inventors/18584981_elizabeth-wilson',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0053'),\n",
       " ('Plasmid: HM175/p16 HAV Infectious Molecular Clone, pHM175-p16#12',\n",
       "  '',\n",
       "  'A pathogenic picornavirus acquires an envelope by hijacking cellular membranes',\n",
       "  'http://www.nature.com/nature/journal/v496/n7445/full/nature12029.html',\n",
       "  'Stanley Lemon',\n",
       "  'http://technologies.unc.edu/inventors/18584980_stanley-lemon',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0056'),\n",
       " ('Poly-Metformin: A Polymeric Formulation for the Treatment of Metabolic Disorders and Enhanced Gene Delivery',\n",
       "  'A polymeric formulation of Metformin has been developed. PolyMetformin (PolyMet) has been successfully synthesized through conjugation of linear polyethylenimine (PEI) with dicyandiamide. The delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity of PEI both in vitro and in vivo. Furthermore, the polycationic properties of PolyMet permit capture of siRNA into a core-membrane structured Lipid-Polycation-Hyaluronic acid (LPH) nanoparticle for systemic gene delivery. Even in the absence of RNAi, LPH-PolyMet nanoparticles act similarly to Metformin and activate the AMPK pathway. AMPK activation causes the inhibition of cholesterol synthesis, triglyceride synthesis, lipogenesis, and can stimulate hepatic fatty acid oxidation. LPH-PolyMet nanoparticles show promise as a therapy for metabolic disorders such as diabetes, nonalcoholic steatohepatitis (NASH), and nonalcoholic fatty liver disease (NAFLD).Advantages:• PolyMet can circulate for a longer time in the body compared to Metformin• Dual purpose therapeutic agent• Reduced cytotoxicity from conventional nanoparticle formulations',\n",
       "  'PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery',\n",
       "  'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897747/',\n",
       "  'Leaf Huang',\n",
       "  'http://technologies.unc.edu/inventors/18584978_leaf-huang',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#15-0060'),\n",
       " ('Next Generation Biomedicine Low Frequency Magnetic Nanoparticles',\n",
       "  'Novel polymer-coated magnetic nanoparticles (MNP-polymer complexes) have been developed that can be used in a variety of biomedical, therapeutic, and industrial applications. The iron oxide magnetic nanoparticle cores are synthesized by thermal decomposition yielding a tunable, uniform size. These unique polymer coatings have been shown to promote enhanced uptake into tumor and other cells. The MNP-polymer complexes can be efficiently and remotely actuated by super low frequency AC magnetic field with variety of field strengths which trigger cell death. The novel polymer coating enables loading of therapeutic and contrast imaging agents which can be modified to accommodate various targeting moieties. Proof of concept data has been generated in cancer cell lines.Advantages:\\nCustomized to a specific application\\nHigh safety and biocompatibility profile\\nMagnetic nanoparticles can be easily and safely scale-up\\nProlonged shelf-life\\nLyophilization compatible\\nRobust quality control',\n",
       "  'Recent Publication',\n",
       "  'https://pharmacy.unc.edu/unc-nanomedicine-researchers-uncover-high-potential-for-low-frequency-magnetic-fields/',\n",
       "  'Alexander Kabanov',\n",
       "  'http://technologies.unc.edu/inventors/18584975_alexander-kabanov',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application PCT/US2017/025250',\n",
       "  '#15-0061'),\n",
       " ('Methods for Preventing and Treating Graft Versus Host Disease',\n",
       "  'Infusion of ILC2 cells that are substantially free of ILC3 and MPP2 cells can be used to treat steroid refractory GvHd. Gastrointestinal tract graft-versus-host disease (GvHD) is relatively common following allogeneic stem cell transplantation however the prognosis is poor for steroid-refractory GvHD due to lack of alternate treatments. Ex vivo expansion and infusion of mouse ILC2 cells at key timepoints have diminished GvHD and provide encouraging results.Advantages:• New treatment for steroid-refractory GvHD• Purified ILC2 cells are free of contaminating MPP2 and ILC3 cells•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Jonathan Serody',\n",
       "  'http://technologies.unc.edu/inventors/18584973_jonathan-serody',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent Pending US 2017/0360907',\n",
       "  '#15-0064'),\n",
       " ('Photoredox-Catalyzed Direct C-H Functionalization of Arenes',\n",
       "  'An organic photoredox-based catalysis system has been developed for the C-H functionalization of aromatic compounds. This method is amenable to addition of a variety of functional groups and provides a practical route to the direct, selective transformation of arene C-H bonds.Advantages:• Regioselective addition• No prior functionalization required• One-step formation of primary anilines and azoles•',\n",
       "  'Site-selective arene C-H amination via photoredox catalysis',\n",
       "  'http://science.sciencemag.org/content/349/6254/1326.long',\n",
       "  'David Nicewicz',\n",
       "  'http://technologies.unc.edu/inventors/18584971_david-nicewicz',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Photoredox Catalysis Activates Aryl C–H Bonds In Amination Reaction',\n",
       "  '#15-0068'),\n",
       " ('Streaming-connected Large-scale Structure-from-Motion',\n",
       "  'A novel large-scale structure from motion framework advances the state of the art in data scalability from city-scale modeling (millions of images) to world-scale modeling (several tens of millions of images) using just a single computer. The main enabling technology is the use of a streaming-based framework for connected component discovery. Moreover, the system employs an adaptive online iconic clustering approach based on an augmented bag-of-words representation, in order to balance the goals of registration, comprehensiveness, and data compactness. Useful for a wide range of applications including virtual reality, image-based localization, and autonomous navigation.Advantages:• Novel data association concept overcomes the challenges that the streaming processing posed for the data association required for 3D reconstruction and achieves high model completeness• Pushes the scale of reconstructabilty by more than an order of magnitude while achieving highly complete models• Efficient• Scalable',\n",
       "  'Recent Publication',\n",
       "  'http://frahm.web.unc.edu/files/2014/08/cvpr2015-heinly.pdf',\n",
       "  'Jan-michael Frahm',\n",
       "  'http://technologies.unc.edu/inventors/18584968_jan-michael-frahm',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'PCT Patent Application WO 2016/154499',\n",
       "  '#15-0088'),\n",
       " ('Delivery of Neuroprotective Therapeutic Agents to the CNS',\n",
       "  'Innovative polymer-based formulations have been developed for delivery of neurotrophins to the brain using peripheral and central administration. The anionic block copolymers are used in charge excess with respect to the neurotrophins, so that neurotrophins and block copolymers form a nanoscale size polyion complex, while the free block copolymers are also present in the formulation. The formulation increases serum and mucosal stability and prevents enzymatic degradation of neurotrophins. The excess of the block copolymer inhibits efflux of neurotrophin from the brain, thereby increasing the brain levels of neurotrophin. These novel compositions are used to treat.Advantages:• Rapid and non-invasive delivery of proteins to the brain• Targeted delivery within brain compartments• Platform technology allows development of formulations based on various therapeutical proteins• Reduction of peripheral exposure to therapeutical proteins• Significant reduction of rare and costly proteins needed to achieve therapeutically meaningful doses in specific brain regions',\n",
       "  'Nanoformulation of Brain-Derived Neurotrophic Factor with Target Receptor-Triggered-Release in the Central Nervous System',\n",
       "  'https://onlinelibrary.wiley.com/doi/epdf/10.1002/adfm.201703982',\n",
       "  'Alexander Kabanov',\n",
       "  'http://technologies.unc.edu/inventors/18584963_alexander-kabanov',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'PCT Patent Application PCT/US2017/015930',\n",
       "  '#15-0104'),\n",
       " ('Multi-stage Robot for Transoral Peripheral Lung Access',\n",
       "  'A robotic approach has been developed for image-guided trans-bronchoscopic lung access. The multi-stage robotic system can bring the benefits of transoral access to patients with difficult-to-access peripheral lung nodules, avoiding the drawbacks of percutaneous and transoral bronchoscopic biopsy. It offers the potential to steerably biopsy peripheral lung regions deep in the parenchyma, via a transoral approach.Advantages:• Brings the benefits of transoral access to patients with peripheral lung nodules• Access to sites that are traditionally inaccessible transorally• Early stage diagnosis of lung disease• Potential to reduce the risk of pneumothorax (lung collapse)• Gives physicians the option of obtaining a definitive diagnosis when a suspicious nodule is first detected',\n",
       "  'Tendons, Concentric Tubes, and a Bevel Tip: Three Steerable Robots in One Transoral Lung Access System',\n",
       "  'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492535/',\n",
       "  'Ron Alterovitz',\n",
       "  'http://technologies.unc.edu/inventors/18584962_ron-alterovitz',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 20180214010',\n",
       "  '#15-0106'),\n",
       " ('Automatic Obstacle Avoidance During Tentacle-like Robot Teleoperation',\n",
       "  \"A motion planning approach for concentric tube robot teleoperation that enables a tentacle-like robot to interactively maneuver its tip to points selected by a user while automatically avoiding sensitive anatomical obstacles (e.g., critical vessels, nerves, and organs) along its shaft. The user specifies goal positions by clicking with a 3D mouse on an augmented reality interface, and the robot automatically moves its tip to the specified goal position while avoiding contact with obstacles. This approach could enable surgeons to perform safer and less invasive surgeries with fewer medical errors by decreasing cognitive load on surgeons during procedures and providing a level of automatic control of the device. The approach has commercial potential for intuitive surgical and other medical robot and device companies.Advantages:• Safe and effective operation of tentacle-like robots for surgical procedures• Decreases physicians' mental loads, freeing them to focus on controlling the robot’s tip• Less invasive surgeries• Reduces the error between the commanded goal position and the robot’s tip position by using tip position sensing to account for kinematic modeling error. \",\n",
       "  'A motion planning approach to automatic obstacle avoidance during concentric tube robot teleoperation',\n",
       "  'https://uncch.pure.elsevier.com/en/publications/a-motion-planning-approach-to-automatic-obstacle-avoidance-during',\n",
       "  'Ron Alterovitz',\n",
       "  'http://technologies.unc.edu/inventors/18584958_ron-alterovitz',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'PCT Patent Application WO 2016/191364',\n",
       "  '#15-0107'),\n",
       " ('Polyclonal Antiserum: Antibodies to Melanoma Antigen-A11 (MAGE-A11)',\n",
       "  'Prostate cancer growth and progression depend on androgen receptor (AR) transcriptional signaling, which is increased by MAGE-A11, an AR coregulator. MAGE-A11 is a cancer-testis antigen that resides predominantly in the nucleus at low levels in normal human reproductive tract tissues and at higher levels in castration-resistant prostate cancer. These antibodies were raised in rabbits against MAGE-A11 and appear to be high affinity as low levels of MAGE-A11 can be detected. The main uses of the MAGE-A11 antibodies are western blot analysis and immunocytochemistry.These antibodies are available from Kerafast and can be found at',\n",
       "  'https://www.kerafast.com/product/3332/anti-mage-a11-antibodies',\n",
       "  'https://www.kerafast.com/product/3332/anti-mage-a11-antibodies',\n",
       "  'Elizabeth Wilson',\n",
       "  'http://technologies.unc.edu/inventors/18584954_elizabeth-wilson',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0122'),\n",
       " ('Mouse: Matrix Gla (MGP) Expression',\n",
       "  \"Matrix Gla (MGP) is a potent mineralization inhibitor secreted by cartilage chondrocytes and arteries' vascular smooth muscle cells. Expression of Cre is under the control of the entire Mgp regulatory regions, and thus its expression represents a true Mgp-tissue specific expression.\",\n",
       "  'A Novel Mgp-Cre Knock-In Mouse Reveals an Anticalcification/Antistiffness Candidate Gene in the Trabecular Meshwork and Peripapillary Scleral Region',\n",
       "  'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406033/',\n",
       "  'Terete Borras',\n",
       "  'http://technologies.unc.edu/inventors/18584951_terete-borras',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#15-0125'),\n",
       " ('Use of Non-cylindrical Bead Well Geometries to Improve Assay Readout in a Compact Microwell Array',\n",
       "  'Novel, non-cylindrical bead well geometries have been\\ndeveloped that improve detection in bead-based assays. Well geometries are\\nfabricated such that one area of the well is optimized for magnetic loading and\\nbead retention, and another region of the well is used for signal detection.\\nThe two regions of the well are fluidically connected to each other allowing\\nfor reagents or analytes to diffuse or mix. By spatially separating the bead\\nfrom the detection region, the contribution of bead background fluorescence to\\nthe signal can be reduced or eliminated, thus improving the signal to noise\\nratio. Related technologies have been developed that increase multiplexing\\ncapability by incorporating dye stability as a measurement (16-0015) and\\nutilize bead-based delivery of reagents to facilitate parallel assays on a\\nmultiplexed-in-space microfluidic device (12-0128).\\nAdvantages:\\n•\\nApplies to a range of volumes from 1 fL up to\\nseveral Î¼L with bead diameters from a few hundred nm to mm\\n\\n•\\nCan be used for highly sensitive real-time PCR\\ndetection of multiple target sequences on a single chip with or without the use\\nof sequence-specific probes\\n•',\n",
       "  'An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples',\n",
       "  'http://pubs.rsc.org/en/content/articlehtml/2014/lc/c3lc51303c',\n",
       "  'J Ramsey',\n",
       "  'http://technologies.unc.edu/inventors/18584949_j-ramsey',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#15-0131'),\n",
       " ('Use of Ice-Nucleating Proteins to Improve Performance of Freeze-Thaw Valves in Microfluidic Systems',\n",
       "  'This methodology utilizes ice-nucleating proteins (INPs) as additives to initiate the freezing of water or aqueous solutions at higher temperatures and improve the performance of freeze-thaw-valves in microfluidic chips. Ice-nucleating proteins are produced by fungi, bacteria, and other organisms, and are capable of inducing ice crystal formation in microfluidic systems at temperatures as warm as -2 °C. In microfluidic systems that utilize multiple liquids or reagents, valves are often necessary to modulate fluid flow. Various valving technologies have been employed, but most require complicated or relatively expensive microstructures and/or external hardware. Freezing can be used to modulate fluid flow on microfluidic devices through freeze-thaw valves (FTVs). FTVs utilize an external cooling source to freeze a plug of fluid in a channel, thus stopping fluid flow in the desired regions of the chip. The channel can then be opened by warming the plug until it thaws. A high degree of supercooling, often to temperatures below -20 °C, is typically needed to freeze water in most microfluidic devices. The ice-nucleating protein, inaZ, from Pseudomonas syringae has been utilized to create a FTV with an internal temperature of -11 °C.Advantages:• Compatible with both elastic/flexible materials and inelastic/inflexible materials• INPs significantly reduce the average time water must be held below the freezing point before crystallization occurs• Allows precise fluid control with computer-controlled/automated capabilities• Uses simple and easy to manufacture chip architectures with no moving parts•',\n",
       "  'Use of Ice-Nucleating Proteins To Improve the Performance of Freeze–Thaw Valves in Microfluidic Devices',\n",
       "  'https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b00556',\n",
       "  'J Ramsey',\n",
       "  'http://technologies.unc.edu/inventors/18584947_j-ramsey',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Provisional Patent Application Filed ',\n",
       "  '#15-0136'),\n",
       " ('Acoustic Detection of Activated Ultrasound Phase-Change Contrast Agents',\n",
       "  'This novel method detects acoustic signatures unique to phase-contrast agents (PCCAs) that can be used to differentiate PCCAs from surrounding tissue and standard microbubble contrast agents. These unique signals are due to over-expansion and oscillating frequencies induced upon oscillation of PCCAs. Once activated by a primary source, the vaporization event can be monitored passively by ultrasound. PCCAs have been gaining increasing attention in recent years as agents for diagnostic and therapeutic applications of ultrasound, and this detection method has the potential to benefit ultrasound technology and result in new therapeutic and diagnostic imaging techniques.Advantages:• This technology allows for the detection of unique acoustic signatures created by PCCAs• Detection of these signals can be differentiated from those of standard microbubble contrast agents• Detection of these signals allows spatial localization and quantification of PCCA activation, and may be useful for diagnostic and therapeutic applications of ultrasound•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Paul Dayton',\n",
       "  'http://technologies.unc.edu/inventors/18584945_paul-dayton',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent Pending US 2016/0262727',\n",
       "  '#14-0009'),\n",
       " ('Visible Light-Driven Water Splitting',\n",
       "  'A dye-sensitized photoelectrosynthesis cell (DSPEC) has been developed for splitting water with a core/shell of nanostructured electrodes derivatized with surface-bound chromophore-catalyst assemblies. Artificial photosynthesis research efforts seek to convert solar energy into chemical fuels by splitting water into oxygen and hydrogen or reducing CO2. The assembly can be further stabilized by deposition of protective overlayers of metal oxides via atomic layer deposition. This DSPEC can split water to H2 and O2 using visible light.Advantages:• Core/shell electrode structure and protective overlayers on chromophore-catalyst assembly result in enhanced efficiency and greater stability over previous approaches for visible light-driven water splitting• Demonstrated photocurrent densities as high as 1.97 mA/cm2 at pH 7•',\n",
       "  'Solar water splitting in a molecular photoelectrochemical cell',\n",
       "  'http://www.pnas.org/content/110/50/20008.abstract',\n",
       "  'Thomas Meyer',\n",
       "  'http://technologies.unc.edu/inventors/18584938_thomas-meyer',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'UNC researchers harness sun’s energy during day for use at night',\n",
       "  '#14-0019'),\n",
       " ('Gaze-controlled Photo Taking System',\n",
       "  'A gaze-controlled photo taking system allows the photographer to take a clear, focused image while still participating in the photo-scene experience and avoiding the “observer through the viewfinder” feeling. By augmenting currently existing autofocus algorithms and zoom/cropping mechanisms with gaze detection and pose estimation techniques, this “smarter camera” is adapted to observe the user and is capable of detecting the region of the scene which should be focused upon. Commercial applications include cameras, cell phone cameras, AR glasses like Google glasses, video cameras, etc.Advantages:• Referential gaze detection for usage in hands-free autofocus systems• A human-camera interaction system which opens the doors to gaze-specific metadata•',\n",
       "  'Adaptive Eye-Camera Calibration for Head-Worn Devices',\n",
       "  'http://www.cv-foundation.org/openaccess/content_cvpr_2015/html/Perra_Adaptive_Eye-Camera_Calibration_2015_CVPR_paper.html',\n",
       "  'Jan-Michael Frahm',\n",
       "  'http://technologies.unc.edu/inventors/18584935_jan-michael-frahm',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2016/0309081',\n",
       "  '#14-0028'),\n",
       " ('Vibration-Induced Stem Cell Chondrogenesis and Osteogenesis',\n",
       "  'A surgically implantable bioreactor that induces either\\nchondrogenesis (cartilage development) or osteogenesis (formation of bone) from\\nmesenchymal stem cells has been developed.\\nIn vitro studies in which vibratory signals were provided to both human\\nand porcine mesenchymal stem cells demonstrated that at lower frequencies the cells\\ndifferentiate into a cartilage phenotype, and will conversely differentiate\\ninto a bone phenotype at higher frequencies.\\nDelivery of these vibratory signals in vivo would provide a novel\\ntreatment option for bone and cartilage replacement. Currently, replacing bone or cartilage in\\npatients is accomplished with grafts to the site or with chemical induction of\\nchondrogenesis or osteogenesis.\\nUnfortunately, the success of these procedures is often unpredictable due\\nto problems with host rejection or insufficient induction of the correct tissue\\ntype. This technology avoids these\\nproblems because the bioreactor is able to drive tissue lineage selection of\\nmesenchymal stem cells simply through vibrational stimulation. Using the same technology, these researchers\\nhave invented an in vitro device that is able to stimulate stem cells in\\nculture with vibrational frequencies between 1 and 100 hertz to better study\\nthe mechanical induction of a cartilage or a bone cell lineage. These devices\\nrepresent a novel means to direct the development of mesenchymal stem cells and\\nprovide better options for bone and cartilage replacement. Additionally, this system can help study stem\\ncell lineage determination induced by vibrational forces in the in vitro cell\\nculture system.\\nAdvantages:\\n•\\nEliminates the need for grafting and may\\ndiminish chance of host tissue rejection \\n•\\nNo pharmacological agents involved \\n•\\nAbility to adjust device program to better\\ndirect tissue-specific growth \\n•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Robert Dennis',\n",
       "  'http://technologies.unc.edu/inventors/18584934_robert-dennis',\n",
       "  'Charlie Shaw Commercialization Manager 919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/373_charlie-shaw',\n",
       "  'US Patent Pending US 2016/0230135',\n",
       "  '#14-0030'),\n",
       " ('Plasmid: Infectious Clone of Pipistrellus Bat Coronavirus (BtCoV) Strain HKU5',\n",
       "  '',\n",
       "  'A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/24667706',\n",
       "  'Ralph Baric',\n",
       "  'http://technologies.unc.edu/inventors/18584933_ralph-baric',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0034'),\n",
       " ('Mouse: Human FIX Knock-In (R333Q Mutation)',\n",
       "  '',\n",
       "  'Creation of a mouse expressing defective human factor IX',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/15178576',\n",
       "  'Darrel Stafford',\n",
       "  'http://technologies.unc.edu/inventors/18584929_darrel-stafford',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0039'),\n",
       " ('Improved Illumination of Spatial Augmented Reality Objects',\n",
       "  'This methodology improves upon current spatial augmentation reality techniques, where the object of augmentation appears to glow unnaturally, through a combination of an improved projection surface and more accurate calibration for ambient illumination.Advantages:• More realistic images of live humans, recorded humans, or virtual characters into human-size mannequins• Applicable to immersive training scenarios, for immersive “teleconferencing”, entertainment, etc.•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Henry Fuchs',\n",
       "  'http://technologies.unc.edu/inventors/18584928_henry-fuchs',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2016/0323553',\n",
       "  '#14-0051'),\n",
       " ('Plasmid: Infectious cDNA Clone of Genotype 1a Hepatitis C Virus H77D',\n",
       "  'Although hepatitis C virus (HCV) is a leading cause of cirrhosis and liver cancer, many details of its replication remain obscure, as most HCV strains replicate poorly in cell culture. Furthermore, no effective vaccines are available to date and the mechanism of HCV persistence and carcinogenesis in vivo remain inadequately understood. This plasmid contains infectious molecular clones of H77D virus, a replication competent genotype 1a variant of HCV. These clones are capable of robust replication in cultured cells and could be used to facilitate drug development and the assessment of viral resistance to therapeutics.This plasmid isavailable for distribution from Kerafast and can be found at',\n",
       "  'https://www.kerafast.com/product/3453/',\n",
       "  'https://www.kerafast.com/product/3453/',\n",
       "  'Stanley Lemon',\n",
       "  'http://technologies.unc.edu/inventors/18584925_stanley-lemon',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0061'),\n",
       " ('Mouse: NLRP3 Null',\n",
       "  '',\n",
       "  'https://www.jax.org/strain/021302',\n",
       "  'https://www.jax.org/strain/021302',\n",
       "  'Beverly Koller',\n",
       "  'http://technologies.unc.edu/inventors/18584923_beverly-koller',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0063'),\n",
       " ('Mouse: GPCR Mutation',\n",
       "  '',\n",
       "  'A G?s DREADD mouse for selective modulation of cAMP production in striatopallidal neurons',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/23303063',\n",
       "  'Bryan Roth',\n",
       "  'http://technologies.unc.edu/inventors/18584917_bryan-roth',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0085'),\n",
       " ('Mouse: Human IL4/IL13 Receptorand Ligand Expression (I29-1L4R/IL13/IL4)',\n",
       "  'Mice expressing human type I (IL-4)',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Beverly Koller',\n",
       "  'http://technologies.unc.edu/inventors/18584916_beverly-koller',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#14-0086'),\n",
       " ('Skeletal Representations of Objects',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Stephen Pizer',\n",
       "  'http://technologies.unc.edu/inventors/18584911_stephen-pizer',\n",
       "  'Copyright Materials  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/364_copyright-materials',\n",
       "  'Copyright Materials  919.966.3929',\n",
       "  '#14-0106'),\n",
       " ('Device for Accurate Syringe Measurement and Dispensing of Liquids',\n",
       "  '',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Stephen Eckel',\n",
       "  'http://technologies.unc.edu/inventors/18584910_stephen-eckel',\n",
       "  'Leodis Gupton Commercialization Manager 919.966.4132',\n",
       "  'http://technologies.unc.edu/managers/369_leodis-gupton',\n",
       "  'US Patent Pending US 2017/0146381',\n",
       "  '#14-0122'),\n",
       " ('Minimal-latency Tracking and Display for Matching Real and Virtual Worlds in Head-worn Displays',\n",
       "  'Methods, systems, and computer readable media have been developed for minimal-latency tracking and display for matching real and virtual worlds in head-worn displays (i.e., opitical see-through glasses). The system includes a display module, a rendering module, and a processing module. This also offers a new method of reducing latency that takes advantage of the principles of bufferless input/output and “minimal-latency” processing throughout all main components of an AR system, i.e., tracking, rendering, and display. The method calculates a user- perceived image, calculates a desired image, calculates an error image, identifies an error portion, and updates a portion of a projected image. The systems and/or methods have the potential to minimize lag-induced registration errors, which are the main effect of high latency in current systems. This technology can be implemented in software in combination with hardware and/or firmware. In addition to education benefits, societal benefits include more hand-eye coordination and augmented imagery anywhere the user looks. The approach can also benefit research, as it is useful for spatial AR and handheld AR devices that rely on low-latency visual feedback in response to moving objects and gestures.Advantages:•',\n",
       "  'From Motion to Photons in 80 Microseconds: Towards Minimal Latency for Virtual and Augmented Reality Sign In or Purchase',\n",
       "  'http://ieeexplore.ieee.org/document/7383304/?arnumber=7383304',\n",
       "  'Henry Fuchs',\n",
       "  'http://technologies.unc.edu/inventors/18584909_henry-fuchs',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2017/0345398',\n",
       "  '#14-0139'),\n",
       " ('Cloud-Scale Image Compression through Redundancy Reduction',\n",
       "  'An efficient cloud-scale digital image compression scheme has been developed for use in cloud image storage systems that leverages pixel-wise redundancy between images to minimize each photo’s memory footprint. This novel image compression technique takes full advantage of redundant image data in the cloud by independently compressing each newly uploaded image with its GIST nearest neighbor taken from a representative set of uncompressed images, and thereby efficiently reuses image content which is already stored server-side.Advantages:• Allows online photo sharing websites to significantly reduce their storage requirements• Scales to accommodate large datasets/large-scale image compression• Highly parallelizable for cloud computing•',\n",
       "  'Cloud-Scale Image Compression Through Content Deduplication',\n",
       "  'http://www.cs.unc.edu/~jmf/publications/PerraFrahmBMVC2014.pdf',\n",
       "  'Jan-Michael Frahm',\n",
       "  'http://technologies.unc.edu/inventors/18584908_jan-michael-frahm',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2017/0195678',\n",
       "  '#14-0142'),\n",
       " ('IMAGIN: High-definition High-Dynamic-Range Camera Sensor',\n",
       "  'A novel image sensing architecture has been developed that boosts the dynamic range as well as the definition of camera images. The innovation lies not in the design of the photodetector (sensor), but in the data encoding and the communication and processing architecture. Tradeoffs between frame rates, electronic shutter speeds, dark current and bright saturation are optimized for various target applications, with enhancements such as Regions Of Interest (ROI) for higher frame rates, and composition of multiple frames with varying exposure times for improved dynamic range. The methods improve the process of data acquisition from a spatially distributed array of analog continuous time sensors. In general, these methods can be applied to any collection of spatially distinct positive-definite continuous-time continuous-level signal sources, the desired outputs of which are to be discretely digitized representations of their respective time integrals.Advantages:•',\n",
       "  'Nouvant',\n",
       "  'https://www.nouvant.com',\n",
       "  'Montek Singh',\n",
       "  'http://technologies.unc.edu/inventors/18584907_montek-singh',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent Pending US 2017/0126991',\n",
       "  '#14-0143'),\n",
       " ('Plasmid: Mutant FabI Selection Marker',\n",
       "  '',\n",
       "  'A Novel Selection Marker for Efficient DNA Cloning and Recombineering in E. coli',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed/23437314',\n",
       "  'Terry Magnuson',\n",
       "  'http://technologies.unc.edu/inventors/18584905_terry-magnuson',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  'http://technologies.unc.edu/managers/363_tangible-property',\n",
       "  'Tangible Property  919.966.3929',\n",
       "  '#13-0024'),\n",
       " ('Optical See-Through Head Worn Display Using Multiple Light Attenuating Layers',\n",
       "  'New optical see-through glasses have been developed that integrate virtual imagery with high visual fidelity into a compact slim display that supports a wide field of view. The use of multiple imaging masking layers allows for simultaneous viewing of real-world objects and virtual objects that can be implemented for several purposes in the realm of augmented reality. Companies engaged in augmented reality could develop the current design for use in a variety of purposes, such as telepresence, simulation and training, and navigation.Advantages:Likely the only see-through device to support all of the following qualities:• Wide field of view• Compact design• Multiple simultaneous focal distances•',\n",
       "  'Computational augmented reality eyeglasses',\n",
       "  'http://ieeexplore.ieee.org/document/6671761/?arnumber=6671761',\n",
       "  'Andrew Maimone',\n",
       "  'http://technologies.unc.edu/inventors/18584900_andrew-maimone',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,858,721',\n",
       "  '#13-0039'),\n",
       " ('A Synthetic Route to Pactamycin Amenable to Analog Preparation',\n",
       "  'A key intermediate has been developed in a short, asymmetric total synthesis of pactamycin that is amenable to analog preparation. Pactamycin is a natural product that demonstrates potent anti-tumor, anti-microbial, and anti-viral activities, but its development as a drug candidate is hindered by its high cytotoxicity. Recent pactamycin analogues derived from genetic engineering techniques show reduced toxicities, but genetic engineering approaches to generate pactamycin analogues are limited in flexibility and diversity. Conversely, an efficient chemical approach offers the potential for greater scope in the creation of pactamycin analogues. The cyclopentenone core intermediate is prepared from intramolecular aldol condensation of the claimed aldehyde precursor. This intermediate has been used to synthesize pactamycin.Advantages:• Modular total synthesis is 15 steps from commercially available starting materials•',\n",
       "  'Enantioselective synthesis of pactamycin, a complex antitumor antibiotic.',\n",
       "  'https://www.ncbi.nlm.nih.gov/pubmed?term=((chapel%20hill%5BAffiliation%5D)%20AND%20pactamycin)%20AND%20%22science%22%5BJournal%5D',\n",
       "  'Jeffrey Johnson',\n",
       "  'http://technologies.unc.edu/inventors/18584899_jeffrey-johnson',\n",
       "  'John Rainwater Commercialization Manager 919.445.9371',\n",
       "  'http://technologies.unc.edu/managers/365_john-rainwater',\n",
       "  'Pactamycin',\n",
       "  '#13-0041'),\n",
       " ('Combating Device Theft With User Notarization',\n",
       "  'An anti-theft process for personal mobile devices often vulnerable to theft or loss. Utilizing video chat and a remote “notary” who visually and verbally authenticates the owner of the device, this system would prevent the distribution of personal information to the wrong hands and could provide extra security measures for processes such as mobile banking transactions or communicating healthcare information.Advantages:• Mobile device anti-theft technology•',\n",
       "  'Social Security: Combating Device Theft With Community-Based Video Notarization',\n",
       "  'http://www.cs.unc.edu/techreports/13-003.pdf',\n",
       "  'Michael Reiter',\n",
       "  'http://technologies.unc.edu/inventors/18584898_michael-reiter',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,660,995',\n",
       "  '#13-0042'),\n",
       " ('REALMS (Registration Efficiency and Accuracy through Learning Metric on Shape): A Fast, Interpolative Method for 2D/3D Deformable Image Registration',\n",
       "  'A real-time method for visualizing tumors in the body, allowing for the most accurate and direct delivery of radiation treatment. This approach minimizes the indirect treatment of healthy tissue that can occur as the body moves during respiration and could significantly improve the outcome for patients with terminal prognoses, such as lung cancer.Advantages:• REALMS significantly improves the margin of error that occurs with current 2D/3D deformable image registration methods•',\n",
       "  'Real-Time 2D/3D Deformable Registration Using Metric Learning',\n",
       "  'http://link.springer.com/chapter/10.1007/978-3-642-36620-8_1',\n",
       "  'Chen-Rui Chou',\n",
       "  'http://technologies.unc.edu/inventors/18584897_chen-rui-chou',\n",
       "  'Peter Liao Commercialization Manager 919.843.5028',\n",
       "  'http://technologies.unc.edu/managers/358_peter-liao',\n",
       "  'US Patent 9,495,746',\n",
       "  '#13-0043')]"
      ]
     },
     "execution_count": 595,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 536,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200"
      ]
     },
     "execution_count": 536,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Applying a tabular structure"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 537,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "df = pd.DataFrame(data, columns=['pub_title', \n",
    "                                 'pub_description', \n",
    "                                 'related_pub_title', \n",
    "                                 'related_pub_link',\n",
    "                                'research_inventor',\n",
    "                                'research_inventor_link',\n",
    "                                'managed_by',\n",
    "                                'managed_by_link',\n",
    "                                'patent_protection',\n",
    "                                'technology_number'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 538,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pub_title</th>\n",
       "      <th>pub_description</th>\n",
       "      <th>related_pub_title</th>\n",
       "      <th>related_pub_link</th>\n",
       "      <th>research_inventor</th>\n",
       "      <th>research_inventor_link</th>\n",
       "      <th>managed_by</th>\n",
       "      <th>managed_by_link</th>\n",
       "      <th>patent_protection</th>\n",
       "      <th>technology_number</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Reconstructing Detailed Textured Surface Model...</td>\n",
       "      <td>A method has been developed for constructing a...</td>\n",
       "      <td>Missed Colonic Surface Area at Colonoscopy Can...</td>\n",
       "      <td>https://www.sciencedirect.com/science/article/...</td>\n",
       "      <td>Stephen Pizer</td>\n",
       "      <td>http://technologies.unc.edu/inventors/18585179...</td>\n",
       "      <td>Peter Liao Commercialization Manager 919.843.5028</td>\n",
       "      <td>http://technologies.unc.edu/managers/358_peter...</td>\n",
       "      <td>US Patent Pending</td>\n",
       "      <td>#18-0149</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Crosslinked Hyperbranched Poly(aryletherketone...</td>\n",
       "      <td>Gas separation techniques currently use energy...</td>\n",
       "      <td>Nouvant</td>\n",
       "      <td>https://www.nouvant.com</td>\n",
       "      <td>Theo Dingemans</td>\n",
       "      <td>http://technologies.unc.edu/inventors/18585261...</td>\n",
       "      <td>John Rainwater Commercialization Manager 919.4...</td>\n",
       "      <td>http://technologies.unc.edu/managers/365_john-...</td>\n",
       "      <td>Provisional Patent Application Filed</td>\n",
       "      <td>#19-0022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Microwave Synthesis of Polymeric Nanoparticles...</td>\n",
       "      <td>The use of nanoparticles in enhanced delivery ...</td>\n",
       "      <td>Zapped assembly of polymeric (ZAP) nanoparticl...</td>\n",
       "      <td>https://pubs.rsc.org/en/content/articlelanding...</td>\n",
       "      <td>Matthew Parrott</td>\n",
       "      <td>http://technologies.unc.edu/inventors/18585138...</td>\n",
       "      <td>John Rainwater Commercialization Manager 919.4...</td>\n",
       "      <td>http://technologies.unc.edu/managers/365_john-...</td>\n",
       "      <td>Provisional Patent Application Filed</td>\n",
       "      <td>#17-0081</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Gamma Secretase Inhibitors Attenuate Vascular ...</td>\n",
       "      <td>Gamma secretase inhibitors (GSI) have been det...</td>\n",
       "      <td>Notch signaling pathway is a potential therape...</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pubmed/30573741</td>\n",
       "      <td>Julie Blatt</td>\n",
       "      <td>http://technologies.unc.edu/inventors/18584997...</td>\n",
       "      <td>Jackie Quay Director 919.966.3929</td>\n",
       "      <td>http://technologies.unc.edu/managers/370_jacki...</td>\n",
       "      <td>Provisional Patent Application Filed</td>\n",
       "      <td>#16-0192</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Recombinant Antigens for Differential Serologi...</td>\n",
       "      <td>Two novel antigens have been developed for the...</td>\n",
       "      <td>Development of Envelope Protein Antigens To Se...</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pubmed/29263206</td>\n",
       "      <td>Aravinda Desilva</td>\n",
       "      <td>http://technologies.unc.edu/inventors/18585233...</td>\n",
       "      <td>Kyle Bartholomew</td>\n",
       "      <td>http://technologies.unc.edu/managers/447_kyle-...</td>\n",
       "      <td>Provisional Patent Application Filed</td>\n",
       "      <td>#18-0017</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           pub_title  \\\n",
       "0  Reconstructing Detailed Textured Surface Model...   \n",
       "1  Crosslinked Hyperbranched Poly(aryletherketone...   \n",
       "2  Microwave Synthesis of Polymeric Nanoparticles...   \n",
       "3  Gamma Secretase Inhibitors Attenuate Vascular ...   \n",
       "4  Recombinant Antigens for Differential Serologi...   \n",
       "\n",
       "                                     pub_description  \\\n",
       "0  A method has been developed for constructing a...   \n",
       "1  Gas separation techniques currently use energy...   \n",
       "2  The use of nanoparticles in enhanced delivery ...   \n",
       "3  Gamma secretase inhibitors (GSI) have been det...   \n",
       "4  Two novel antigens have been developed for the...   \n",
       "\n",
       "                                   related_pub_title  \\\n",
       "0  Missed Colonic Surface Area at Colonoscopy Can...   \n",
       "1                                            Nouvant   \n",
       "2  Zapped assembly of polymeric (ZAP) nanoparticl...   \n",
       "3  Notch signaling pathway is a potential therape...   \n",
       "4  Development of Envelope Protein Antigens To Se...   \n",
       "\n",
       "                                    related_pub_link research_inventor  \\\n",
       "0  https://www.sciencedirect.com/science/article/...     Stephen Pizer   \n",
       "1                            https://www.nouvant.com    Theo Dingemans   \n",
       "2  https://pubs.rsc.org/en/content/articlelanding...   Matthew Parrott   \n",
       "3       https://www.ncbi.nlm.nih.gov/pubmed/30573741       Julie Blatt   \n",
       "4       https://www.ncbi.nlm.nih.gov/pubmed/29263206  Aravinda Desilva   \n",
       "\n",
       "                              research_inventor_link  \\\n",
       "0  http://technologies.unc.edu/inventors/18585179...   \n",
       "1  http://technologies.unc.edu/inventors/18585261...   \n",
       "2  http://technologies.unc.edu/inventors/18585138...   \n",
       "3  http://technologies.unc.edu/inventors/18584997...   \n",
       "4  http://technologies.unc.edu/inventors/18585233...   \n",
       "\n",
       "                                          managed_by  \\\n",
       "0  Peter Liao Commercialization Manager 919.843.5028   \n",
       "1  John Rainwater Commercialization Manager 919.4...   \n",
       "2  John Rainwater Commercialization Manager 919.4...   \n",
       "3                  Jackie Quay Director 919.966.3929   \n",
       "4                                 Kyle Bartholomew     \n",
       "\n",
       "                                     managed_by_link  \\\n",
       "0  http://technologies.unc.edu/managers/358_peter...   \n",
       "1  http://technologies.unc.edu/managers/365_john-...   \n",
       "2  http://technologies.unc.edu/managers/365_john-...   \n",
       "3  http://technologies.unc.edu/managers/370_jacki...   \n",
       "4  http://technologies.unc.edu/managers/447_kyle-...   \n",
       "\n",
       "                       patent_protection technology_number  \n",
       "0                      US Patent Pending          #18-0149  \n",
       "1  Provisional Patent Application Filed           #19-0022  \n",
       "2  Provisional Patent Application Filed           #17-0081  \n",
       "3  Provisional Patent Application Filed           #16-0192  \n",
       "4  Provisional Patent Application Filed           #18-0017  "
      ]
     },
     "execution_count": 538,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Export the dataset to CSV"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 539,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('publication.csv', index=False, encoding='utf-8')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
